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EPIDEMIOLOGY 
Chronic hepatitis C virus (HCV) infection is a major global public health problem, with recent estimates 
suggesting that 64–103 million people are infected worldwide.1 Moreover, it is thought to be 
responsible for over 350,000 deaths each year and is the predominant reason for liver transplantation 
in the Western world.2 The prevalence of HCV infection, however, shows a substantial geographical 
variation. Worldwide, Egypt, Mongolia and Cameroon have the highest prevalence of more than 
20%.2 In Europe the prevalence of HCV infection varies from 0.1 to 6.0%, with the highest occurrence 
in Southern and Eastern Europe.3 The Netherlands represents a country in which HCV infection is not 
frequently observed. A recently performed epidemiological study indicated that the seroprevalence 
of anti-HCV antibodies was 0.2%, around the lowest in the world.4 Nevertheless, this would mean 
that almost 40,000 inhabitants of the Netherlands have been in contact with the HCV, leading to 
approximately 30,000 Dutch patients with a chronic HCV infection. First-generation migrants from 
HCV-endemic countries and injecting drug users (IDU) form important risk groups in the Netherlands.5 
6 Furthermore, there was an increasing prevalence among HIV-positive men who have sex with men 
before 2010, but this appeared to level off in the years after.7
THE HEPATITIS C VIRUS 
From the mid 1970’s it was known that transfusion-associated hepatitis did often not concur with 
serological markers against the hepatitis A or B viruses.8 9 This so called non-A, non-B hepatitis was 
sporadically found in absence of blood transfusion or receipt of other blood products as well.10 In 
1989, after many years of research, dr. Michael Houghton and colleagues isolated and characterized 
the viral agent thought to be the predominant cause of hepatitis following blood transfusion.11 This 
pathogen was designated to be the HCV. Later, nearly all cases with non-A non-B post-transfusion 
hepatitis were shown to be attributable to HCV infection.12 
Hepatitis C virus is a small enveloped virus of approximately 55–65 nanometers in size and is a 
member of the genus Hepacivirus, belonging to the Flaviviridae family. It contains a single-stranded 
RNA genome of positive polarity. This genome is approximately 9600 nucleotides in length and consists 
of a highly conserved 59 untranslated region, followed by a single open reading frame that encodes a 
polyprotein of 3010 to 3033 amino acids. Cellular and viral proteases cleave this large protein into ten 
smaller viral gene products: three structural proteins (core, E1, and E2); an ion channel (p7); and six 
nonstructural proteins (NS2, NS3A, NS4A, NS4B, NS5A, and NS5B) (Figure i.1). Structural proteins are 
required for assembly and are used for the determination of the seven main HCV genotypes (and sub 
genotypes).13 The p7 and NS2 protease are required for the release of infectious particles. The other 
nonstructural proteins (NS3A, NS4A, NS4B, NS5A, and NS5B) are closely involved in HCV replication.14 
NS3 and its cofactor NS4A form a stable heterodimeric complex, which cleaves the HCV polyprotein 
at four sites. NS4B is the presumed central organizer of the HCV replicase complex and a main inducer 
of intracellular membrane rearrangements. The NS5A protein is essential for RNA replication and 
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assembly of infectious virus particles. The RNA-dependent NS5B protein is the RNA polymerase 
catalyzing the amplification of the viral RNA genome.14 15 Figure i.2 shows the entry of HCV into the 
hepatocytes, as well as its life cycle and replication process.15 In addition, several host factors have 
been involved in the HCV life cycle. These include epidermal growth factor receptor (EGFR) and ephrin 
receptor A2 (EphA2), which are two receptor tyrosine kinases that have recently been identified as 
HCV entry factors.16 Cyclophilin A (CypA), another host factor, is a protein that is involved in the 
replication of HCV by binding to the NS5A protein of all HCV genotypes.17 Apolipoprotein E (apoE) is a 
component of lipoviral particles, which is involved in the HCV infection of hepatocytes.18
Although HCV might be present in extrahepatic tissues such as bone marrow and lymphocytes, 
hepatocytes form the primary host cells in which the virus replicates extremely fast.19 A possible 
explanation for the hepatotropicity of HCV might be the distinct set of microRNAs, which are small 
non-coding regulatory RNAs, which are expressed by hepatocytes. Possibly the most important host 
factor, microRNA-122 (miR-122), is the most abundant hepatocyte-derived microRNA, and actually 
constitutes about 70% of the total microRNA population in the liver.20-23 As other tissues showed no or 
Figure i.1 | The hepatitis C virus (HCV) genome
The hepatitis C virus (HCV) genome encoding three structural proteins and seven non-structural proteins. The 
direct-acting antivirals are listed below the proteins and include the NS3/4A (or protease) inhibitors, the NS5A 
inhibitors, and the NS5B polymerase inhibitors (both nucleosides and non-nucleosides). The direct-acting 
antivirals approved by the US Food and Drug Administration and the European Medicines Agency are highlighted 
in bold.
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only minor expression of miR-122, this microRNA can be considered liver-specific.20 22 23 Importantly, 
miR-122 seems to be essential for HCV RNA stability and propagation.24 25 By binding to two closely 
spaced target sites in the highly conserved 5’UTR of the HCV genome, miR-122 is thought to protect 
the HCV genome from nucleolytic degradation and/or from host innate immune responses.25-27 
Each infected hepatocyte is estimated to produce around fifty viral particles a day, leading to a 
total daily production of 1012 new viruses in an HCV-infected liver.28 As the virus mutates quickly due to 
the high error rate of the viral RNA-dependent RNA polymerase, patients are considered to be infected 
with a HCV quasispecies of genetic variants.29 Seven HCV genotypes have been identified, which differ 
by 30-35% of the nucleotide sites over the complete genome and are further subdivided into various 
subtypes.30 31 The HCV genotypes are not equally distributed around the globe. In the Western world 
HCV genotype 1 is most prevalent, while HCV genotype 2 and 3 are the predominant variants in Asia. 
In Egypt HCV genotype 4 exists almost exclusively. Other HCV genotypes are less frequently found 
and originate from South Africa (HCV genotype 5), South East Asia (HCV genotype 6) and Central 
Africa (HCV genotype 7). Because the HCV genotypes may have different clinical consequences and 
treatment outcomes, it is relevant to know with which HCV genotype a patient is infected. 
Figure i.2 | Life cycle of the hepatitis C virus
Adapted from Feeney et al.26 Schematic overview of the life cycle of the hepatitis C virus (HCV). In order to 
enter the hepatocyte, HCV interacts with co-receptors, resulting in its endocytosis. Then the virus fuses with the 
endosome and uncoats its RNA. Host ribosomes translate the RNA into a polyprotein, which is cleaved by host 
and virally encoded proteases into the three structural and seven non-structural proteins. The non-structural 
proteins form a complex on a “membranous web” that replicates HCV RNA. The Golgi assembles the HCV RNA with 
viral structural proteins, leading to the formation of infectious viral particles, which are exocytosed from the cell. © 
2015 BMJ Publishing Group Ltd. All rights reserved.
Processed on: 27-10-2016
505957-L-bw-Maan
General introduction | 11
NATURAL COURSE OF HCV INFECTION
In the Western world, the transmission of HCV has declined substantially over the last two decades and 
the currently reported incidence rates of acute HCV infection are below 1 per 100,000 individuals.32-34 
This incidence might be underestimated, however, because diagnosing HCV infection in the acute 
phase, i.e. the first 6 months of infection, remains a clinical challenge as the majority of patients are 
asymptomatic.35 36 Already 1 to 3 weeks after exposure, HCV RNA can be detected in the circulation 
and this represents the first manifestation of the disease.37 38 Anti-HCV antibody seroconversion 
usually takes several weeks longer. Spontaneous resolution of HCV infection may occur within 3-4 
months after acquisition of the virus. Based on a systematic review of longitudinal studies 1 in every 
4 patients with acute HCV infection is expected to have self-limiting disease, but reported rates of 
spontaneous clearance vary from 10% to more than 50%.39 40 
If serum HCV RNA is still detectable six months after exposure, spontaneous clearance is unlikely 
to follow and patients are considered to have chronic HCV infection.41 Around 75% of patients who 
acquired HCV are thought to develop a chronic infection. Most patients who are referred for active 
HCV infection are diagnosed in this chronic phase. Patients may present with non-specific symptoms, 
although also chronic HCV infection often remains asymptomatic. As a consequence, the majority of 
patients are currently unaware that they are chronically infected with HCV.42 Nevertheless, various 
degrees of hepatic fibrosis may be present among these patients. Development of hepatic fibrosis 
or even cirrhosis represents the predominant consequences of chronic HCV infection and negatively 
impacts clinical outcomes among patients with this disease. 
Chronic HCV-infected patients may experience various non-specific symptoms such as fatigue, 
nausea, abdominal or musculoskeletal pain, loss of weight and pruritus. More specific liver-related 
manifestations are mostly restricted to patients with end-stage cirrhosis, and include variceal 
bleeding, ascites, jaundice and hepatic encephalopathy. Often, symptoms can be attributed to the 
presence of extrahepatic manifestations, which are reported in up to 74% of patients.43 Extrahepatic 
manifestations include mixed cryoglobulinemia vasculitis, lymphoproliferative disorders such as B-cell 
non-Hodgkin lymphoma, renal disease, type II diabetes mellitus, porphyria cutanea tarda and lichen 
planus. Depression, irritability, malaise and other neuropsychiatric symptoms have been observed 
among these patients as well, with depression being most frequently reported.44 Importantly, the 
extrahepatic symptoms and manifestations may impact morbidity, treatment opportunities as well 
as mortality.45 
Of all symptoms, fatigue is most frequently reported. Although fatigue can have a variety of 
physical and psychological causes, it has indeed been associated with chronic HCV infection. A recent 
study among 401 patients with chronic HCV genotype 1 infection indicated that approximately 
50% expe rienced fatigue.46 Patients with cirrhosis had fatigue more frequently and of more severe 
intensity, as was reported by a previous study as well.47 Fatigue should not be underestimated as 
it has a major impact on the health-related quality of life. The health-related quality of life is often 
impaired patients with chronic HCV infection, even in case of asymptomatic disease or normal 
aminotransferase levels.47 48
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Patients with chronic HCV infection often have low grade hepatic inflammation, which may be 
evidenced through liver biopsy or suggested by elevations of the serum aminotransferases. Although 
the ALT level is often raised to approximately one to three times the upper limit of normal, many 
patients with chronic hepatitis C infection have normal ALT levels. Together with the absence of 
(liver-specific) symptoms this certainly challenges us to diagnose HCV infection. Frequently, patients 
are diagnosed with chronic HCV infection because routine blood tests showed signs of hepatitis. 
The chronic inflammatory activities in the liver, as a response to the continuous presence of HCV, 
stimulate fibrogenesis by activation of hepatic stellate cells. These activated cells transdifferentiate 
to myofibroblasts and produce many extracellular matrix components as well as mediators leading 
to accumulation of these proteins.49 Therefore, chronic HCV infection is often accompanied by the 
development of hepatic fibrosis. The degree of fibrosis, i.e. the stage of liver disease, is determined 
according to semi-quantitative histopathological scoring systems, of which the METAVIR and Ishak 
classification are most frequently used.50 51 In both classifications cirrhosis is the most advanced 
stage, which can be considered as the general end-stage of many chronic liver diseases. In case of 
cirrhosis the normal architecture of the liver parenchyma is completely compromised. Cirrhosis is 
characterized by nodules of regenerating hepatocytes which are surrounded by fibrotic septa. These 
septa may be vascularized and can stretch between portal areas or between the portal areas and the 
central veins. Especially the porto-caval septa are relevant in the pathophysiology of cirrhosis as these 
can form anastomoses between efferent and afferent vessels.52 53 Next to the clinical implications 
of shunting of blood, by which the functionally active hepatocytes are bypassed, this also leads to 
relative hypoxemia of the liver parenchyma resulting in further liver injury and neovascularization.54 
The vascular abnormalities within a cirrhotic liver are indeed thought to have an important role in the 
development of the clinical sequelae of chronic HCV infection. Presence of cirrhosis surely impedes 
the prognosis of patients with this disease.55 56 Next to the manifestations of liver failure (also called 
decompensated cirrhosis), patients with HCV-induced cirrhosis are in danger of hepatocellular 
carcinoma (HCC). Both liver failure and HCC, which are rarely seen in absence of cirrhosis, may result in 
the need for liver transplantation or liver-related mortality. A recent meta-analysis indicated patients 
with chronic HCV infection and advanced hepatic fibrosis have an overall annual risk of 2.9% to 
develop liver failure, 3.2% to progress to HCC and 2.7% to die of liver-related causes.57 Although these 
rates were based on nonresponders to interferon-based therapy, they are likely to be representative 
of the natural history of untreated chronic hepatitis C. Indeed, the earlier interferon-based treatments 
which did not lead to viral clearance had no impact on the natural course of the disease.55 58-60 
It should be considered, though, that not all patients with chronic HCV infection show progression 
of hepatic fibrosis. Accurate data regarding the natural history of HCV-induced fibrosis progression 
and the occurrence of its clinical complications are difficult to obtain. Studies are subject to selection 
bias as diagnosing chronic HCV infection favors symptomatic patients who utilize medical resources. 
Other relevant issues include the high prevalence of co-factors which may already cause liver damage 
by themselves, such as alcohol abuse or co-infection with the hepatitis B virus (HBV) or HIV, and the 
uncertainty regarding the moment of HCV acquisition. Nevertheless, it has been estimated that 
approximately 16% of the patients will establish cirrhosis within 20 years of HCV infection.61 Because 
fibrosis progression may accelerate over time, however, the number of patients which will progress to 
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cirrhosis might be higher as estimated in the earlier natural history studies. Importantly, because the 
majority of Western patients with chronic HCV infection are thought to have acquired their infection 
in the 1960s and ´70s, the proportion of patients with HCV-induced cirrhosis is rapidly rising.62 63
ANTIVIRAL THERAPY FOR HCV INFECTION 
Unmatched progress in the treatment of chronic HCV infection has been made over the last two 
decades. Interferon monotherapy was the first approved antiviral treatment for non-A, non-B 
hepatitis. Now, for the last two years, direct-acting antivirals (DAAs) have replaced interferon-based 
therapy completely. 
Mechanism of action of antiviral therapy
Although still not fully elucidated, interferon alfa is thought to induce a large number of genes (called 
interferon-stimulated genes) with antiviral properties, leading to a multi-faceted attack on the virus. 
In addition, it also has some direct antiviral actions as well as important interactions with the adaptive 
and innate immune responses.64 Standard interferon was administered subcutaneously three times 
a week. Since the beginning of the 21st century, however, polyethylene glycol-modified (pegylated) 
interferon is used. Pegylated interferon is more stable as compared to standard interferon and has a 
longer half-life which allows once weekly dosing.65
Ribavirin is a guanosine analogue with activity against several RNA and DNA viruses. Different 
hypotheses regarding its mechanism of action have been proposed, of which the theory of lethal 
mutagenesis seems most reasonable.64 It has been part of the standard-of-care in the treatment of 
chronic HCV infection since 1998. 
Over the last decades, major advances in the understanding of the HCV life cycle resulted in 
the development of DAAs for the treatment of HCV infection.66 Multiple classes of DAAs have been 
developed which interact with various nonstructural viral proteins and thereby target different steps 
in the replication of HCV RNA. The three main DAA groups concern the NS3/4A protease inhibitors, 
the NS5B polymerase inhibitors and the NS5A inhibitors. In general, treatment with DAAs increases 
the virological efficacy of antiviral regimens and allows shortening pegylated interferon treatment 
duration. In fact, more recent DAA treatment regimens with a high barrier to resistance showed 
to be able to eradicate the chronic HCV infection without the need for pegylated interferon. The 
development of highly effective interferon-free therapy for chronic HCV infection should be regarded 
as one of the most important milestones in hepatology, and perhaps even in overall medicine, of the 
21st century.
Protease inhibitors target the NS3/4A serine protease and thereby inhibit the cleavage of this 
protein and thus HCV replication.15 Current approved “-previrs” include telaprevir, boceprevir, 
simeprevir, paritaprevir and grazoprevir (Figure i.1). The NS5A inhibitors, also known as “-asvirs”, target 
another nonstructural protein and block the replication of HCV RNA at the stage of membranous web 
biogenesis.67 So far, daclatasvir, ledipasvir, ombitasvir, velpatasvir and elbasvir have been approved 
(Figure i.1). Both NS3/4A protease inhibitors and NS5A inhibitors have very potent antiviral activity 
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but exhibit a low barrier to viral resistance. The NS5B inhibitors, or “-buvirs”, can be divided into two 
main classes: nucleos(t)ide inhibitors and non-nucleotide inhibitors (Figure i.1). By binding to the 
active site of the NS5B RNA-dependent RNA polymerase, nucleos(t)ide inhibitors (e.g., sofosbuvir) 
cause premature chain termination. The non-nucleotide inhibitors (e.g., dasabuvir) bind outside the 
active site, causing a conformational change, and thereby decrease the polymerase activity of the 
enzyme.15
Rationale for antiviral therapy for chronic HCV infection 
The development of hepatic fibrosis is probably the most common indication to initiate antiviral 
treatment for chronic HCV infection. Antiviral therapy might indeed be postponed among patients 
with chronic HCV infection who do not seem to developed hepatic fibrosis. In fact, some patients may 
never need to be treated as they will not develop clinical complications of their chronic HCV infection. 
However, extrahepatic symptoms and manifestations of chronic HCV infection, which can reduce 
the health-related quality of life, may represent another relevant reason to initiate antiviral therapy. 
Furthermore, some patients might choose to be treated out of fear for further HCV transmission. 
Nowadays, antiviral therapy for chronic HCV infection is considered successful in case sustained 
virological response (SVR) is attained. This virological endpoint is defined as HCV RNA negativity in 
the circulation 24 weeks following cessation of therapy. Importantly, SVR showed to have a long-term 
durability.68 Because virological relapse is already extremely rare in case a patient is HCV RNA negative 
at 12 weeks following the end of therapy, the post-treatment follow-up duration was shortened to 
this time point in order to determine sustained response rates in more recent clinical trials.69 
While we rely on SVR to determine treatment success, achievement of SVR should not be 
considered as the primary goal of antiviral therapy. Rather, we treat patients to improve their health-
related quality of life and to prevent HCV-related morbidity and mortality. Therefore, it is important 
that there is an increasing body of evidence which suggests that antiviral therapy resulting in SVR 
also benefits the patients from a clinical point of view. Eradication of HCV was shown to decrease 
the frequency and severity of fatigue, and increase the quality of life.46 70-72 Histological studies 
showed that patients who attained SVR had regression of hepatic fibrosis, even in case cirrhosis was 
established prior to treatment initiation.73 The regression of fibrosis following antiviral therapy among 
patients with HCV-induced cirrhosis has been related to improved clinical outcome.74 Following SVR, 
the hepatic venous pressure gradient was found to decline as well.75-78 Multiple large cohort studies 
with extensive follow-up duration among patients with chronic HCV infection and advanced liver 
disease indicated a strong and independent association between SVR and reduced incidence of liver 
failure, hepatocellular carcinoma and liver-related death.75 79-81 More important, recent data showed 
that there was an association between SVR and all-cause mortality, the most definite and robust 
clinical endpoint].81-84 Additional analyses among patients with compensated advanced liver disease 
who attained SVR, showed that they even had a similar life expectancy compared to a matched 
general population.85 86
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Antiviral therapy for acute HCV infection 
Early monotherapy with 24 weeks of pegylated interferon in patients with acute HCV infection showed 
to prevent chronicity in 71 to 98%, depending on treatment adherence.87 The efficacy was found to 
decline when antiviral therapy was initiated longer after HCV exposure, so that early treatment may 
be advised.88 However, immediate therapy may result in overtreatment of those patients who might 
also spontaneously resolve their HCV infection.87 89 A 12-week delay from the moment of exposure, to 
evaluate natural HCV RNA kinetics among those with symptomatic acute HCV infection, has therefore 
been suggested.90-92 The recent results of the Hep-Net Acute HCV III study from Germany, in which 107 
patients with symptomatic acute HCV infection were randomized to receive 24 weeks of pegylated 
interferon immediately or after 12 weeks with the addition of ribavirin, confirmed the effectiveness of 
such a delayed treatment strategy as long as proper adherence during follow-up and treatment can 
be assured (90% and 93% with undetectable HCV RNA after 60 weeks, respectively).93 However, as was 
found in this study, compliance might be difficult in the specific population with acute HCV infection 
in the Western world. The timing of antiviral therapy thus remains subject to debate and the preferred 
strategy should probably be determined on an individual basis.
There is insufficient data to generally recommend the use of ribavirin for acute HCV infection. 
Santantonio et al. performed a randomized trial in 130 patients with acute HCV infection.94 All 
patients started therapy by week 12 after onset and were randomized to receive 12 or 24 weeks of 
pegylated interferon monotherapy, or 12 weeks of pegylated interferon and ribavirin. There was 
no difference in SVR rate between any of these three regimens, demonstrating that 12 weeks of 
pegylated interferon might be sufficient to treat acute HCV infection. A non-randomized trial in which 
HIV-infected patients with newly acquired HCV infection were treated with pegylated interferon 
and ribavirin did suggest, however, that ribavirin improved the early HCV RNA decline.95 This was 
particularly seen among those patients who were expected to have a longer duration of infection. 
In some cases, when treatment is initiated after more than 12 weeks of onset, adding ribavirin to 
pegylated interferon to treat acute HCV infection might therefore be considered. 
A relevant issue which does not necessarily promote the treatment of acute HCV infection 
concerns the possibility of re-infection due to continuous risk behavior, for instance among IDU and 
HIV-infected men who have sex with men.96 Even more important is the current availability of highly 
effective interferon-free regimens. Recently, data from the Hep-Net Acute HCV IV study from Germany 
showed that six weeks of antiviral therapy with ledispasvir and sofosbuvir resulted in a virological 
response in all 20 patients with HCV genotype 1.97 Although these results are promising, it could be 
questioned whether treatment in these patients should be deferred and physicians should wait until 
chronic HCV infection has been established. As the price of DAAs is an important issue, overtreatment 
should be prevented. Especially when these patients could be easily treated with highly effective and 
safe treatment regimens once they have established a chronic infection. Cost-effectiveness studies 
are needed in order to conclude on the timing of antiviral therapy for acute HCV infection. 
Interferon-based antiviral therapy for chronic HCV infection 
Jay H. Hoofnagle was the first who described the treatment of so called chronic non-A, non-B 
hepatitis.98 Ten patients were treated with standard interferon in different doses, frequencies and 
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duration. As HCV was still not identified, this study assessed the response to therapy by measuring 
ALT activity rather than HCV RNA levels. Next to ALT normalization, standard interferon therapy 
indeed showed potential to eradicate the viral infection. However, the virological efficacy of this early 
treatment strategy was poor with only about 10% of treated patients attaining SVR.99 The SVR rate 
even declined to 2% among patients with HCV genotype 1 infection and advanced hepatic fibrosis, 
which are probably the most well-known factors associated with a poor virological response to 
interferon-based antiviral therapy.100 
In 1994 Brillanti et al. showed that adding ribavirin to interferon could be beneficial for patients 
with chronic HCV infection.101 While monotherapy with ribavirin did not result in substantial HCV RNA 
declines, this drug did seem to prevent virological relapse when added to interferon or pegylated 
interferon therapy.99 102 103 Pegylated interferon instead of standard interferon further increased the 
virological efficacy of antiviral therapy. A 48-week regimen of pegylated interferon and ribavirin 
resulted in SVR in about 60% of patients.104-106 This combination therapy was optimized during the first 
decade of this century with different treatment durations and response-guided therapy, depending 
on host and viral factors which were associated with virological responses. Still, among those with 
HCV genotype 1 infection and advanced hepatic fibrosis, cure rates with pegylated interferon and 
ribavirin remained limited. Only 35% of this difficult-to-treat population was able to attain SVR with 
this combination regimen.107 Pegylated interferon and ribavirin treatment duration depended on 
HCV genotype, the stage of liver disease and the on-treatment HCV RNA kinetics, but largely varied 
between 24 or 48 weeks. 
Unfortunately, interferon-based therapy is accompanied by numerous adverse effects, including 
fatigue, flu-like symptoms, hair loss, gastro-intestinal symptoms, headaches, dermatological abnor-
malities and neuropsychological symptoms such as concentration difficulties, depression and irrita-
bility.108 These symptoms further deteriorate the health-related quality of life of HCV-infected patients 
and interfere with patients’ ability to perform daily activities.109 Furthermore, interferon-based 
therapy causes bone marrow suppression so that neutropenia, thrombocytopenia and anemia may 
develop. It should be realized, of course, that also ribavirin therapy is associated with adverse events, 
of which the induction of (hemolytic) anemia is probably the most well-known. Treatment-induced 
anemia might even necessitate ribavirin dose reductions, erythropoietin therapy or recurrent blood 
transfusions. 
Especially the hematological abnormalities represent important limitations of pegylated inter-
feron therapy, as they are common causes for dose reductions due to fear of severe infections or 
bleedings. 110 Interferon dose reductions, however, negatively impact the virological efficacy of anti-
viral therapy.111 112 Moreover, patients with advanced liver disease are often excluded from interferon-
based therapy in case they already present with thrombocytopenia at baseline as a result of portal 
hypertension and/or reduced thrombopoietin production.113 Based on the limited association 
between treatment-induced cytopenia and clinically relevant infections or bleedings, it has been 
suggested that current guidelines with respect to pegylated interferon dose reductions may be too 
strict.114 115 However, limited data is available among patients with advanced liver disease, while these 
are the patients with the highest risk of infections and bleedings. Taken together, the limited virological 
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efficacy and substantial side effects associated with (pegylated) interferon-based treatment urged 
physicians to carefully consider initiation of antiviral treatment in each individual patient. 
Interferon-based triple therapy for chronic HCV infection 
As a result of the growing understanding of the HCV life cycle, ciluprevir (BILN-2061) was the first 
HCV protease inhibitor which advanced into clinical trials.116 Although development of the drug was 
stopped due to toxicity in animals, studies showed the antiviral potential of protease inhibitors. This 
eventually led to the approval of two NS3/4A protease inhibitors in 2011, telaprevir and boceprevir, 
representing the first class of DAAs in clinical practice.117 118 Although these drugs were a major 
advance for the treatment of chronic HCV infection and their efficacy was higher than dual therapy 
with pegylated interferon and ribavirin, they had several limitations.119 These included the following: 
not very effective against HCV genotypes other than HCV genotype 1; treatment became more com-
plex with various dosing schedules, durations, and stopping rules; the pill burden was large; the 
rates of resistance-associated variants (RAVs) were high; and there were many potential drug-drug 
interactions. Moreover, pegylated interferon and ribavirin remained a necessity, and these first triple 
therapy regimens only increased the side effects of antiviral treatment.120 121 Overall, SVR rates with the 
addition of telaprevir or boceprevir were around 70%, which was markedly higher as compared to the 
50% with pegylated interferon and ribavirin among patients with HCV genotype 1 infection.122-126 Still, 
these response rates were largely dependent on the degree of hepatic fibrosis, as SVR rates decreased 
to approximately 50% among those patients with cirrhosis. In this subgroup, caution with telaprevir 
or boceprevir triple therapy was advised as the first real-world experiences in France indicated many 
severe side effects, especially in case of low platelets counts and/or low albumin levels.121 Due to 
the further improvement and development of DAAs, the use of these drugs is not recommended 
anymore in the Western world. 
From a second wave of first-generation NS3/4A protease inhibitors, only simeprevir was approved 
by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) for the treatment 
of chronic HCV infection.127 Although still in combination with pegylated interferon and ribavirin, 
simeprevir improved tolerability considerably as it could be dosed once daily. Clinical trials which 
assessed the combination of simeprevir, pegylated interferon and ribavirin showed that around 
80% of treatment-naïve patients with HCV genotype 1 infection attained SVR.128 129 Importantly, the 
majority (around 90%) of these patients could be treated with only 24 weeks of pegylated interferon 
and ribavirin. As with the first-generation protease inhibitors, the SVR rate among patients who had 
relapsed after a prior pegylated interferon-based treatment course was not inferior to that among 
treatment-naïve patients, while treatment was markedly less successful among those with a prior 
null-response (reduction of less than 2 log10 in HCV RNA after 12 weeks of therapy).130 131 Among 
patients chronically infected with HCV genotype 4, against which simeprevir is active as well, similar 
SVR results have been obtained.132 However, a new dilemma arose, which is still subject to an ongoing 
discussion: should baseline RAVs be assessed? It was found that among ~50% of the patients with 
HCV genotype 1a the highly fit Q80K variant was present. Patients with this variant who received a 
triple therapy regimen including simeprevir, pegylated interferon and ribavirin, achieved SVR rates 
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that were similar to those patients who received dual therapy with pegylated interferon and ribavirin. 
It was therefore recommended to test for this variant when treatment was considered for patients 
with HCV genotype 1a.
Interferon-free treatment regimens for chronic HCV infection 
Lok et al. were the first to describe an interferon-free regimen including a protease inhibitor, (asuna-
previr) and an NS5A inhibitor (daclatasvir).133 Four of the 11 patients with HCV genotype 1 (subtype 
1a: 9 patients; subtype 1b: 2 patients) treated with this regimen for 24 weeks achieved SVR. Later on 
it was found that this regimen was much more effective in Japan, with SVR rates up to 90%, due to 
the fact that all patients in the Japanese study were infected with HCV genotype 1b. Currently, this 
regimen is approved in Japan. 
Even greater strides in the treatment of chronic HCV infection have been made by the development 
of sofosbuvir, which is a nucleotide NS5B inhibitor with activity against all HCV genotypes and a high 
barrier to resistance.134 Addition of sofosbuvir to only 12 weeks of pegylated interferon and ribavirin 
therapy showed SVR rates around 90% among both treatment-naïve patients with HCV genotype 1, 4, 
5 or 6 infection as well as treatment-naïve and treatment-experienced patients with HCV genotype 2 
or 3 infection.135-137 Even in case of compensated cirrhosis, 80% of patients were able to eradicate their 
chronic HCV infection with this short triple regimen. The first robust data on interferon-free treatment 
with sofosbuvir were derived from patients with HCV genotype 2 and 3 infection. A 12 week regimen 
of sofosbuvir and ribavirin resulted in SVR rates above 90% among those with HCV genotype 2 
infection.137-139 At first, patients with HCV genotype 3 infection showed less optimal results with this 
combination. By extending the treatment duration to 24 weeks, however, the SVR rate increased to 
85% in this group of patients as well.138 For interferon-experienced HCV genotype 3-infected patients 
with cirrhosis this sofosbuvir and ribavirin combination therapy was not very effective. Small studies 
suggested that inclusion of pegylated interferon might be useful, leading to the Boson trial. Patients 
with HCV genotype 3, including ~30% cirrhotic patients, were randomized to receive 16 or 24 weeks 
of sofosbuvir and ribavirin, or 12 weeks of sofosbuvir, pegylated interferon and ribavirin. Although 24 
weeks of dual therapy was superior to 16 weeks, it was less effective than 12 weeks of triple therapy. 
Among cirrhotic patients the benefit of adding pegylated interferon was most evident as SVR rates 
increased from 82% to 91% for naïve patients and from 76% to 86% for patients who were treatment-
experienced.140 At the cost of side effects, addition of pegylated interferon certainly increases the 
virological efficacy among all patients with HCV genotype 3. Although sofosbuvir was first approved 
in combination with pegylated interferon and/ or ribavirin, it has proven to be highly effective in 
combination with one or two DAAs from other classes, and is now mainly used as part of interferon-
free regimens.   
Most recent studies indicated that combining sofosbuvir with other DAAs, either as dual or 
triple therapy, is likely to represent a much more attractive alternative to optimize the virological 
efficacy as well as the safety profile of antiviral therapy. Daclatasvir was the first NS5A inhibitor that 
was evaluated in combination with sofosbuvir for the treatment of HCV genotype 1. In this phase II 
trial, patients received 12 or 24 weeks of therapy with or without the addition of ribavirin. From the 
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126 patients included, only three patients were counted as non-SVR since they were lost to follow-
up.141 In the COSMOS trial, simeprevir was the first protease inhibitor combined with sofosbuvir for 
12 or 24 weeks with or without ribavirin. Despite having not more than 30 patients per treatment 
arm, this phase II trial led to the use of this regimen after both agents were approved for its use with 
pegylated interferon and ribavirin.142 In phase III trials this regimen was evaluated for 8 to 12 weeks in 
patients without cirrhosis and 12 weeks for those with cirrhosis.143 144 Again, the baseline Q80K variant 
was an important predictor of response for patients with HCV genotype 1a. The OPTIMIST-1 showed 
that among non-cirrhotic patients who were treated for 8 weeks the Q80K variant was associated 
with a lower SVR rate of 73% while 84% of the patients without this variant achieved SVR. However, 
extending the treatment duration to 12 weeks could overcome this difference with SVR rates of 
96-9% for all patients.144 The OPTIMIST-2, including solely patients with cirrhosis, also showed the 
importance of this variant. Presence of the Q80K variant led to an SVR rate of 74%, while 92% of the 
patients without this variant achieved SVR.143 These studies show that once a regimen is shortened or 
initiated in a population that is difficult to cure, baseline RAVs become more important. Prolongation 
of treatment or the addition of ribavirin can possibly be a solution.
These promising results led to the studies of sofosbuvir combined with ledipasvir, another NS5A 
inhibitor. This first single-tablet regimen is very potent, but less pangenotypic than the combination 
of sofosbuvir and daclatasvir. The combination has been studied for the duration of 8-24 weeks with 
and without the addition of ribavirin.145-147 For both treatment-naïve and treatment-experienced 
patients with HCV genotype 1, there was no difference in treatment duration. Furthermore, there 
was no additional benefit when ribavirin was added. However, since only a few patients with cirrhosis 
were included, these trials were not powered to conclude on an optimal regimen for treatment-
experienced cirrhotic patients. In the ION-2 trial, 82-86% of the treatment-experienced patients with 
cirrhosis achieved SVR after 12 weeks of therapy with or without ribavirin, whereas this rate was 100% 
for both 24-week arms.145 148 A subsequent trial, including cirrhotic patients who were treatment-
experienced, randomized patients to receive either 12 weeks of sofosbuvir-ledipasvir and ribavirin or 
24 weeks of sofosbuvir-ledipasvir without ribavirin. With 77 and 78 patients in the two arms, this study 
suggested that a 12-week regimen with the addition of ribavirin is similar to extending sofosbuvir-
ledipasvir therapy to 24 weeks, since the SVR rates were 96% and 97%, respectively.149 For the first 
time in the history of chronic HCV infection, patients with decompensated cirrhosis could be included 
in clinical trials. The SOLAR-1 and SOLAR-2 trials evaluated 12 and 24 weeks of sofosbuvir-ledipasvir 
and ribavirin. Even in this population with advanced cirrhosis, SVR rates were close to 90%, with no 
difference between 12 or 24 weeks of therapy.150 151
The first regimen that combined drugs from all three classes included paritaprevir (protease 
inhibitor that is ritonavir-boosted), ombitasvir (NS5A inhibitor) and dasabuvir (non-nucleotide NS5B 
inhibitor).152-157 This 12-week regimen is highly effective against HCV genotype 1b, with SVR rates 
of 95-100% irrespective of the patients’ profile. For patients with HCV genotype 1a, SVR rates were 
90-97% and depended on the addition of ribavirin. Moreover, the duration of 24 weeks has been 
recommended for patients with cirrhosis and HCV genotype 1a. Again, regimens with a low barrier 
to resistance benefit from extending duration and/ or the addition of ribavirin. Pockros et al. assessed 
Processed on: 27-10-2016
505957-L-bw-Maan
20   |   General introduction
the efficacy of this regimen in patients with HCV genotype 1 and end-stage renal disease. Although 
the number of included patients was limited, 12 weeks of triple therapy with paritaprevir/ritonavir, 
ombitasvir and dasabuvir with or without ribavirin resulted in an SVR rate of 90%.158
The development of second-generation protease inhibitors has increased the physicians’ choice 
for the treatment of HCV genotype 1 even more. Recently, grazoprevir (protease inhibitor) and elbas-
vir (NS5A inhibitor) have been approved for the treatment of HCV genotype 1 and 4.159 The advan tage 
of this second-generation protease inhibitor is that it has a higher barrier to resistance compared to 
the first-generation protease inhibitors. A recent trial showed that this co-formulation plus ribavirin 
for 12 weeks resulted in an SVR rate of 96% in patients who had previously failed therapy with pegy-
lated interferon ribavirin in addition to telaprevir, boceprevir or simeprevir.160 The regimen is also 
highly effective for treatment-naïve and treatment-experienced patients, with different regimens 
recommended for HCV genotype 1a and 1b.161 Moreover, it was shown to have an excellent efficacy 
in patients with renal failure.162 This study is the largest study in this specific population so far and 
resulted in an SVR rate of 99%.     
Due to the fact that HCV genotype 1 is most prevalent in the Western world, clinical trials mainly 
focused on the development of treatment regimens for this genotype. In the era of pegylated 
interferon and ribavirin, HCV genotype 1 and 4 were placed in the same group when treatment deci-
sions, like dosage and duration were concerned. Most DAAs that are active against HCV genotype 
1 are also active against HCV genotype 4. Although not extensive assessed in clinical trials, the 
combination of simeprevir and sofosbuvir, sofosbuvir and ledipasvir, paritaprevir and ombitasvir 
without the addition of dasabuvir and grazoprevir-elbasvir have shown to be effective against HCV 
genotype 4. Subsequently, clinical guidelines recommend the use of these regimens for patients with 
HCV genotype 4.35 36 
For patients with HCV genotype 2, the combination of sofosbuvir and ribavirin is very effective. 
However, if there is a contra-indication for ribavirin, these patients can be treated with sofosbuvir 
and daclatasvir for 12 weeks. For HCV genotype 3, the combination of sofosbuvir and daclatasvir was 
also evaluated. In non-cirrhotic patients, 12 weeks of this combination resulted in an SVR rate of 96%. 
When this regimen was initiated in patients with cirrhosis, only 63% of patients achieved SVR.163 These 
disappointing results led to the small ALLY 3+ study, including patients with HCV genotype 3 and 
advanced hepatic fibrosis.164 Patients were randomized to receive sofosbuvir and daclatasvir plus riba-
virin for 12 or 16 weeks and resulted in SVR rates of 83 to 89%, respectively. However, the small sample 
size makes it difficult to draw strong conclusions or to distinguish the preferred duration. Additional 
data from the French compassionate use program, including mostly cirrhotic patients, showed that 24 
weeks of sofosbuvir and daclatasvir with or without ribavirin led to SVR rates above 80%.165 When the 
effectiveness was assessed according to the Child Pugh score, patients with Child Pugh A achieved 
SVR rates of 85% or higher. Again, these data should be interpreted with some caution, as patients 
were not randomized and treatment regimen as well as duration were decided at the discretion of the 
treating physician.  
In the near future, pangenotypic regimens will be approved, which will simplify treatment 
decisions considerably. The combination of sofosbuvir and velpatasvir will probably be the first pan-
geno typic regimen and has shown excellent efficacy in phase III trials.166-168 With this combination, 
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the use of ribavirin is redundant and even patients with decompensated cirrhosis can be effectively 
treated. However, the treatment of HCV genotype 3 remains a challenge.
Since the first approval of interferon-free regimens, there is an increasing amount of data on real-
world experiences. Both small retrospective cohort studies as well as large registries report on the 
outcome of antiviral treatment for chronic HCV infection. In contrast to the first real-world data on 
telaprevir and boceprevir, no major concerns were raised from these studies. As patients in these real-
world registries did not have to fulfill strict inclusion criteria, effectiveness was not as high as in phase 
III trials, but were still proven to be very effective.169 Although these DAAs were very well tolerated and 
generally had a good safety profile, reports on possible hepatotoxicity have emerged in patients with 
decompensated cirrhosis.170 171 Moreover, drug-drug interactions always need to be assessed since it 
can cause important side effects as was seen for sofosbuvir and amiodarone.172 173 In general, treatment 
with DAAs is very safe in non-cirrhotic patients and patients with compensated cirrhosis. Most pro - 
blems occur in patients with decompensated cirrhosis, who were often withheld from antiviral 
treatment in the era of pegylated interferon and ribavirin. Whether these adverse events could be 
attributed to the toxic effect of drugs or whether it is part of the patient’s natural history is not always 
clear and remains matter of debate. Likewise, the occurrence of hepatic decompensation during 
antiviral treatment has been reported for several treatment regimens, leading the FDA to discourage 
the use of dasabuvir, ombitasvir, and paritaprevir/ritonavir for patients with decompensated liver 
disease.174 Also, because of the real-world safety issues which were encountered with the first-
generation protease inhibitors telaprevir and boceprevir among patients with cirrhosis and low 
platelets or low albumin levels, one could argue that protease inhibitors may not represent an ideal 
class of DAAs for those with the most severe cirrhosis.121 
The near future will tell us whether the use of DAAs is always justified and whether no important 
safety issues will change our perspective on timing of antiviral therapy. As longer follow-up will be 
available for patients with decompensated cirrhosis, there may be a subgroup identified that does 
not really benefit from antiviral therapy before liver transplantation. Furthermore, there were some 
early observations in small cohorts of patients that reported early tumor recurrence in patients with 
HCV-related HCC who underwent interferon-free antiviral therapy.175 176 Pol, however, did not observe 
an increased risk of HCC recurrence after DAA treatment in three distinct prospective cohorts.177 These 
unexpected findings will probably dominate HCV research during the upcoming years.         
SCOPE AND AIMS OF THIS THESIS 
Clearly, the development of antiviral therapy has moved at an incredible pace during the 3 years 
following the first proof-of-concept that chronic HCV infection could be eradicated without pegylated 
interferon.133 The implementation of interferon-free treatment regimens has broadened the horizon for 
patients with chronic HCV infection tremendously. Within a timeframe of 5 years, important treatment 
developments resulted in near-perfect SVR rates, even among patients with the most advanced liver 
disease. As successful antiviral therapy may be lifesaving, these developments were long awaited. 
Some hurdles have to be taken, however, before the health burden of this chronic disease can truly 
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be reduced. For instance, the access to DAAs needs to be broadened so that patients can be treated 
regardless of the severity of hepatic fibrosis. Reducing the costs of these drugs probably remains a 
key factor before this goal can be achieved. Pegylated interferon and ribavirin therapy is therefore 
likely to remain an important treatment option for many countries. As developments are still ongoing, 
prices will hopefully fall as a result of mutual competition. Also, it is important to increase the number 
of patients who are diagnosed, as the majority of patients are currently unaware of their chronic viral 
hepatitis. Nevertheless, we have seen a true paradigm shift regarding the treatment of chronic HCV 
infection. For patients affected by this virus the nearby future has never looked more promising.  
This thesis focuses on the tolerability and outcome of antiviral treatment for patients with chronic 
HCV infection. First, in order to optimize interferon-based treatment regimens for patients with 
advanced hepatic fibrosis, the need for dose reductions because of interferon-induced thrombocyto-
penia or neutropenia was assessed in relation to the occurrence of on-treatment bleeding episodes 
and infections. Next, the association of functional variants in the inosine triphosphatase (ITPA) gene 
and hematological side effects during interferon-based regimens were evaluated. In order to see 
which patients would be considered for interferon-free treatment regimens, the epidemiological 
changes in patient and disease characteristics of patients referred to a tertiary center were assessed. 
As these interferon-free regimens rouse a broad discussion on the costs of antiviral therapy, the costs 
of interferon-based treatment were assessed among patients with advanced hepatic fibrosis. Next, 
the safety and effectiveness of interferon-free regimens were assessed in patients with compensated 
and decompensated cirrhosis as well as in patients with HCV genotype 3 specifically. Finally, the 
occurrence of renal impairment during sofosbuvir-based antiviral therapy was reported. 
Aims 
The aims of this thesis were to assess: 
1. the association between interferon-induced thrombocytopenia and bleeding episodes as well 
as the association between interferon-induced neutropenia and infections among patients with 
chronic HCV infection and advanced hepatic fibrosis. 
2. the association between the functional ITPA variants and hematological side effects during 
antiviral therapy with pegylated interferon and ribavirin
3. the epidemiological changes in patient and disease characteristics among individuals with 
chronic HCV infection
4. the direct medical costs during interferon-based antiviral treatment and the costs per SVR 
among patients with advanced hepatic fibrosis
5. safety and effectiveness of DAA-therapy in patients with cirrhosis and HCV genotype 3
6. the occurrence of renal impairment during sofosbuvir-based antiviral therapy 
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Effect of thrombocytopenia on treatment 
tolerability and outcome in patients with chronic 
HCV infection and advanced hepatic fibrosis
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ABSTRACT 
Background & Aims 
Pegylated interferon is still the backbone of hepatitis C treatment and may cause thrombocytopenia, 
leading to dose reductions, early discontinuation, and eventually worse clinical outcome. We assessed 
associations between interferon-induced thrombocytopenia and bleeding complications, interferon 
dose reductions, early treatment discontinuation, as well as SVR and long-term clinical outcome.
Methods
All consecutive patients with chronic HCV infection and biopsy-proven advanced hepatic fibrosis 
(Ishak 4–6) who initiated interferon-based therapy between 1990 and 2003 in 5 large hepatology 
units in Europe and Canada were included.
Results
Overall, 859 treatments were administered to 546 patients. Baseline platelets (in 109/L) were normal 
(≥150) in 394 (46%) treatments; thrombocytopenia was moderate (75–149) in 324 (38%) and severe 
(<75) in 53 (6%) treatments. Thrombocytopenia-induced interferon dose reductions occurred in 3 
(1%); 46 (16%), and 15 (30%) treatments respectively (p <0.001); interferon was discontinued due 
to thrombocytopenia in 1 (<1%), 8 (3%), and in 8 (16%) treatments respectively (p <0.001). In total, 
104 bleeding events were reported during 53 treatments. Only two severe bleeding complications 
occurred. Multivariate analysis showed that cirrhosis and a platelet count below 50 were associated 
with on-treatment bleeding. Within thrombocytopenic patients, patients attaining SVR had a lower 
occurrence of liver failure (p <0.001), hepatocellular carcinoma (p <0.001), liver related death or liver 
transplantation (p <0.001), and all-cause mortality (p = 0.001) compared to patients without SVR.
Conclusions
Even in thrombocytopenic patients with chronic HCV infection and advanced hepatic fibrosis, on-
treatment bleedings are generally mild. SVR was associated with a marked reduction in cirrhosis-
related morbidity and mortality, especially in patients with baseline thrombocytopenia.
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INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a major cause of cirrhosis, hepatocellular carcinoma (HCC), 
and end-stage liver disease.178 Cirrhosis and portal hypertension lead to splenomegaly and subsequent 
thrombocytopenia (platelet count <150x109/L) by the sequestration of platelets. Thrombopoietin is 
produced by the liver and production decreases with impaired synthetic function, which contributes 
to a reduced platelet count as well. In addition, virus-induced thrombocytopathy and bone marrow 
suppression are described as potential mechanisms.113 179-181 Therefore, thrombocytopenia is a fre-
quent manifestation in chronic liver disease and serves as an indicator of disease severity.182
Sustained virological response (SVR), i.e., HCV RNA negativity in blood six months after cessation 
of antiviral therapy, is the goal of antiviral therapy, with important clinical implications. Patients with 
advanced hepatic fibrosis who achieve SVR have lower liver-related and all-cause mortality as well 
as a reduced risk of hepatocellular carcinoma.79-81 Current therapy involves pegylated interferon alfa 
(PegIFN) and ribavirin (RBV). This combination treatment leads to SVR in 10–44% of patients with 
compensated cirrhosis and HCV genotype 1 or 4 infection, compared to 33–72% among those with 
HCV genotype 2 or 3.107 Unfortunately, treatment with PegIFN and RBV is associated with many side 
effects. One of the major side effects is the induction or aggravation of thrombocytopenia. Especially 
among patients with cirrhosis this frequently necessitates dose reductions, which lead to reduced 
treatment efficacy.111 112
Recently, telaprevir or boceprevir is added to the treatment regimen for HCV genotype 1 infection. 
Although the addition of a protease inhibitor increased the SVR rate for those patients with HCV 
genotype 1 and advanced liver disease, cure rates remain poor.122-126 Furthermore, real-world data 
have shown that triple therapy was associated with a high risk of severe on-treatment complications 
including infection, liver failure, and even death among patients with cirrhosis, especially for those 
with low platelets (≤100x109/L) or serum albumin <35 g/L.183
Current guidelines advise to reduce the dose of PegIFN when platelet counts fall below 50x109/L 
and to stop treatment when platelet counts fall below 25x109/L.35 36 As a result patients with 
platelet counts below 75x109/L are often excluded from antiviral therapy or have to stop treatment 
prematurely.35 36 However, patients with thrombocytopenia are those with most advanced liver 
disease, who are most likely to have a clinical benefit from successful antiviral treatment.79-81 184 Under 
the assumption that the risk of disease progression outweighs the risk of interferon-induced adverse 
events, some clinicians do treat patients with chronic HCV infection and severe thrombocytopenia. 
Currently, little is known about the safety, antiviral efficacy or long-term clinical outcome of antiviral 
therapy among these patients.
The primary aim of this study was to assess the association between thrombocytopenia and 
interferon dose reductions, early treatment discontinuation and bleeding complications among 
patients with chronic HCV infection and bridging fibrosis or cirrhosis. The secondary aim was to assess 
the SVR rates and long-term clinical outcome among patients having bridging fibrosis or cirrhosis, 
with or without thrombocytopenia.
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PATIENTS AND METHODS
Patients
The study is based on all patients included in our previously described international, multicenter co-
hort from 5 large hepatology units in Europe and Canada.81 185 This cohort included all consecutive 
patients with chronic HCV infection who started an interferon-based treatment between 1990 and 
2003 and had histological proof of bridging fibrosis or cirrhosis (Ishak fibrosis score 4–6). Patients 
co-infected with human immunodeficiency virus (HIV) or hepatitis B virus (HBV) and patients with 
a history of decom pensated liver disease were excluded. All charts were re-reviewed by a single 
investigator (RM) in order to collect detailed data on platelet counts, PegIFN and/or RBV dose 
reductions or treatment cessation, and bleeding episodes during antiviral treatment.
Thrombocytopenia was defined as a platelet count below 150x109/L; moderate thrombocyto-
penia was defined as a platelet count of 75–149x109/L and severe thrombocytopenia as a platelet 
count below 75x109/L.36 186 The platelet count closest to the start of therapy was considered as 
baseline platelet count, not exceeding six months before treatment. A bleeding episode was defined 
as severe if it resulted in hospital admission, requirement of blood transfusion, permanent disability, 
or death. All other bleedings were defined as mild. Episodes of bleeding were registered if bleeding 
was reported by the patient or if the patient was referred for further analysis because of bleeding.
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and 
the principles of Good Clinical Practice. The study protocol was reviewed and approved by the ethics 
committee in the center of the primary investigators, which was the Erasmus MC University Medical 
Center in Rotterdam, the Netherlands. Ethical approval in the participating centers was obtained 
according to the local regulations. According to the standards of the local ethics committees, written 
informed consent was obtained from patients in an earlier phase.81 185
Outcome
The primary outcome measures were thrombocytopenia-induced interferon (IFN) dose reductions, 
early treatment discontinuation, and bleeding complications during antiviral therapy. Secondary 
outcome measures were SVR and clinical events, such as liver failure, HCC, and (liver-related) mortality 
or liver transplantation. Follow-up started 24 weeks after the end of treatment, so that SVR status 
could be assessed at the start of follow-up.
Liver failure was defined as an episode of either ascites confirmed by ultrasonography, variceal 
bleeding, jaundice or overt hepatic encephalopathy. The diagnosis of HCC was based on histological 
confirmation or two coincident imaging techniques (computed tomography, magnetic resonance 
imaging, or contrast-enhanced ultrasonography), showing a focal lesion of more than two cm with 
arterial-phase enhancement or one imaging technique showing a focal lesion of more than two cm 
with arterial-phase enhancement in combination with the presence of an α-fetoprotein level of more 
than 400 ng/ml.187
Liver transplantation and liver-related death were analyzed as a combined endpoint. Death 
caused by liver failure, primary liver malignancy, or variceal bleeding was considered liver related. 
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Death due to extrahepatic malignancy, cardiovascular or cerebrovascular events, or other causes was 
consi dered as not liver related. The cause of death was determined by the treating physician.
Statistical analyses
Continuous variables were summarized as median (interquartile range [IQR]) and categorical varia-
bles as frequencies (percentages). Comparisons between groups were performed using the v2 test 
for categorical variables or the Mann-Whitney U test for comparing medians. Data were adjusted for 
multiple testing.
Treatments were classified according to the baseline platelet count (normal platelets, moderate 
thrombo cytopenia, and severe thrombocytopenia) as well as according to the fibrosis state (bridging 
fibrosis and cirrhosis). To take into account multiple measurements of platelet counts per patient 
during treatment, a repeated measurement model with a random intercept and slope was applied. 
In order not to force linearity, restricted cubic splines were used to model the dynamics of platelet 
counts during treatment for different groups.
Kaplan-Meier methods and log-rank test were used to analyze the time to reach a platelet count 
of <50x109/L during treatment. 
Logistic regression techniques, adjusting for multiple measurement within a patient, were used to 
analyze the association of platelet counts measured during therapy with a succeeding on-treatment 
bleeding event.
Dose reductions and early treatment discontinuation were assessed in treatments for which 
detailed data regarding the treatment period were available.
Logistic regression was used to analyze which of the baseline characteristics were associated 
with attaining SVR after the last registered treatment. Platelet count at baseline was analyzed as a 
dichotomous variable, using the cut-off value of <150x109/L. Age, sex, treatment naïve, and variables 
with a p value of ≤0.2 in univariate analyses were included in multivariate analyses. 
The cumulative incidence of liver failure, HCC and (liver-related) mortality after the last registered 
treatment were assessed using the Kaplan-Meier method. The log-rank test was applied to compare 
different groups of patients based on SVR-status and baseline platelet count at the last treatment. 
Since PegIFN is still the backbone of hepatitis C treatment, sensitivity analyses were done among 
patients treated with PegIFN for the association of platelet counts with on-treatment bleeding 
and SVR.
A p value <0.05 was considered statistically significant and all statistical tests were two-tailed. IBM 
SPSS 20.0.0.1 statistical package (SPSS, Inc., Chicago, IL) and SAS 9.3 were used.
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RESULTS
Patients
Overall, 546 patients with chronic HCV infection and bridging fibrosis or cirrhosis who started 
interferon-based therapy between 1990 and 2003 were included. Of the 421 (77%) patients without 
SVR, 215 patients received at least one subsequent antiviral treatment regimen. Overall, 859 treatment 
courses were registered. 
In 377 of 859 (44%) treatments thrombocytopenia was present at baseline. Thrombocytopenia 
was moderate in 324 of 377 (86%) treatments and severe in 53 of 377 (14%) treatments (Table 1.1.1). 
For 88 (10%) treatments there was no platelet count available within 6 months prior to treatment 
initiation (Supplementary Fig. 1.1.1).
Dynamics of platelet counts during treatment
The dynamics of the platelet counts during treatment are illustrated in Fig. 1.1.1. The group with 
severe thrombocytopenia reached a platelet count <50x109/L more often as well as in an earlier phase 
of treat ment compared to the group with moderate thrombocytopenia and the group with normal 
platelets (median time until the first visit with a platelet count <50x109/L was respectively 1, 24, and 
46 weeks, all p <0.001) (Supplementary Fig. 1.1.2). The platelet count dropped below 50x109/L during 
3 (<1%) of 357 treatments among patients with normal platelet count prior to treatment, during 78 
(25%) of the 310 treatments in patients with moderate baseline thrombocytopenia and in 37 (73%) of 
51 treatments among patients with severe thrombocytopenia (p <0.001, Fig. 1.1.2).
Effect of thrombocytopenia on interferon dose 
Dose reductions and early treatment discontinuation could be assessed in 684 (89%) and 720 (93%) 
treatments, respectively. In 3 (1%) of 338 treatments among those with normal platelet count, 46 (16%) 
of 296 treatments among patients with moderate thrombocytopenia and in 15 (30%) of 50 treatments 
among patients with severe thrombocytopenia prior to therapy, thrombocytopenia was the main 
reason for at least one (peg)interferon dose reduction (p <0.001, Fig. 1.1.2). In univariate analysis, the 
use of PegIFN was associated with the occurrence of dose reductions due to thrombocytopenia (OR 
2.16, 95%CI 1.25–3.72, p = 0.006).
Treatment was prematurely discontinued due to thrombocytopenia in 1 (<1%) of 354 treatments 
among patients with normal platelet count, 8 (3%) of 314 treatments among those with moderate 
baseline thrombocytopenia, and 8 (15%) of 52 treatments among patients with severe baseline 
thrombocytopenia (p <0.001, Fig. 1.1.2).
Effect of thrombocytopenia on safety and bleeding complications
In total, 109 (13%) of the 859 treatment courses had at least one visit with anemia. The occurrence of 
anemia was significantly different between treatment courses among patients with a normal platelet 
count and patients with baseline thrombocytopenia (33/394 (8.4%) vs. 76/377 (20.2%), p <0.001). 
Further safety details are shown in Table 1.1.2.
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Table 1.1.1 | Baseline characteristics according to baseline platelet count
Variable
Treatments with 
normal platelets 
(n=294)
Treatments with 
moderate TCP (n=324)
Treatments with severe 
TCP (n = 53)
Male 281 (71%) 222 (69%) 37 (70%) 
Age, in years┼ 48 (42-55) 51 (45-58) 51 (44-59) 
BMI, in kg/m2 26.1 (23.5-29.0) 26.6 (23.7-29.4) 26.8 (23.7-31.3) 
HCV genotype 
1 
2
3
4
Other/unknown 
267 (68%)
33 (8%)
64 (16%)
16 (4%)
14 (4%) 
212 (65%) 
22 (7%) 
55 (17%) 
16 (5%) 
19 (6%) 
38 (72%)
5 (9%)
4 (8%)
3 (6%) 
3 (6%) 
Treatment naïve 212 (54%) 192 (59%) 26 (49%) 
Cirrhosis#┼* 259 (66%) 271 (84%) 51 (96%) 
Fibrosis score 
Ishak 4 
Ishak 5 
Ishak 6 
135 (34%) 
81 (21%) 
178 (45%) 
53 (16%) 
57 (18%) 
214 (66%) 
2 (4%) 
5 (9%) 
46 (87%) 
Platelet count, in 109/L#┼* 197 (174-231) 115 (95-135) 63 (55-69) 
Albumin, in g/L#┼* 43 (40-45) 41 (37-43) 37 (34-41) 
Bilirubin, in μmol/L#┼* 12 (9-15) 14 (11-20) 22 (14-33) 
AST/ALT ratio┼* 0.68 (0.55-0.84) 0.78 (0.60-1.0) 0.89 (0.68-1.1) 
Treatment with PegIFN/
RBV 
184 (47%) 151 (47%) 23 (43%) 
Treatment duration, in 
weeks 
29 (21-48) 25 (17-48) 24 (14-47) 
Alcohol abuse ever 94 (24%) 74 (23%) 8 (15%) 
Diabetes mellitus┼ 39 (10%) 60 (19%) 8 (15%) 
Abbreviations: TCP, thrombocytopenia; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; PegIFN, pegylated interferon; RBV, ribavirin. 
a. Medians are presented as number, (IQR, interquartile range). 
b. Numbers are presented as n, (percentage of the whole group). 
c. Variables that were significantly different among two groups were marked with # for moderate vs. 
severe thrombocytopenia, ┼ for moderate thrombocytopenia vs. normal platelets and ⁄ for severe 
thrombocytopenia vs. normal platelets. 
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Figure 1.1.1 | Dynamics of the platelet counts during treatment 
(A) Shows the dynamics of platelet counts during treatment among patients with normal platelet count, 
moderate thrombocytopenia and severe thrombocytopenia at baseline. (B) Shows the dynamics of platelet 
counts during treatment among patients with bridging fibrosis and cirrhosis.
Figure 1.1.2 | Primary endpoints
Platelet count <50x109/L, dose reductions due to thrombocytopenia, early treatment discontinuation due to 
thrombocytopenia, and on-treatment bleeding, according to baseline platelet count.
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Bleeding complications could be assessed in 678 (88%) treatments for which detailed data 
regarding the treatment period were available. In total, 104 bleeding events were registered during 
53 treatments in 48 patients. Details on bleedings are shown in Table 1.1.3. Eleven (11%) of 104 
bleedings required treatment or further diagnostic procedures; sigmoidoscopy, gastroscopy, or 
consultation of another specialist. At least one bleeding episode occurred in 15 (4%) of 338 treatments 
in patients with a normal platelet count, in 30 (10%) of the 292 treatments in patients with moderate 
thrombocytopenia, and in 8 (17%) of 48 treatments in patients with severe thrombocytopenia (p 
<0.001, Fig. 1.1.2). 
Two bleeding complications were severe. Both were esophageal variceal hemorrhage requiring 
hospital admission and transfusion. Nevertheless, treatment was not discontinued in these two cases. 
Fatal bleedings did not occur. All other bleeding episodes were mild and included gingival bleeding 
(n = 19), hematuria (n = 14), and epistaxis (n = 45). 
In multivariate analysis adjusted for age and gender, the presence of cirrhosis (OR 4.6, 95%CI 
1.6–13.9, p = 0.006), and a platelet count <50x109/L at the previous visit (OR 5.4, 95%CI 2.8–10.5, p 
<0.001) were independently associated with the occurrence of on-treatment bleeding (Table 1.1.4). 
As a sensitivity analysis, only those patients treated with PegIFN were considered, showing that a 
platelet count <50x109/L remained independently associated with the occurrence of on-treatment 
bleeding (OR 4.5, 95%CI 2.3–9.0 p <0.001, Table 1.1.4). 
Table 1.1.2 | Adverse events during treatment
Reason
Treatments with normal/ 
unknown platelets 
(n=392)
Treatments with TCP 
(n=361)
Discontinuation
Hematological side effects
Severe infection
Decompensation
Other side effects/ events (psychiatric, 
cardiac or not specified)
9 (2.5%)
6 (1.7%)
5 (1.4%)
14 (3.9%)
2 (0.5%)
1 (0.3%)
none
13 (3.3%)
Admission
Bleeding (decompensation)
Severe infection
Transfusion
Adverse events 
2 (0.6%)
14 (3.9%)
None
7 (1.9%)
None
10 (2.6%)
4 (1.0%)
6 (1.5%)
Abbreviations: TCP, thrombocytopenia
a. Numbers are presented as n, (percentage of the total amount of treatment courses)
b. Reasons for admission defined as adverse events, included a ruptured ovary cyst, stroke, renal 
impairment, atriumfibrillation, chest pain (no diagnosis), abdominal pain (no diagnosis), pleural 
effusion, decompensation cordis and hematological side effects
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Effect of thrombocytopenia on SVR
In total, 193 (35%) of 546 patients attained SVR. Details on SVR rates are shown in Table 1.1.5. To 
assess the association between platelet counts and virological response, only the last treatment that 
a patient received was considered. 
Of 394 treatments that were started in patients with a normal baseline platelet count, 113 (29%) 
resulted in SVR. This differed significantly from the group with baseline thrombocytopenia, in which 
70 (19%) of the 377 treatments resulted in SVR (p = 0.001). Within the group of patients with baseline 
thrombocytopenia, there was no difference in SVR rates between those with moderate and those 
with severe thrombocytopenia: 61 (19%) of 324 treatments in patients with moderate baseline 
thrombocytopenia and 9 (17%) of 53 treatments in patients with severe baseline thrombocytopenia 
(p = 0.749). 
Thrombocytopenia prior to treatment was inversely associated with SVR (OR 0.41 95%CI 0.28–
0.60 p <0.001). In multivariate analysis, adjusting for age, gender, cirrhosis, baseline diabetes mellitus, 
HCV genotype, AST/ALT ratio, treatment year, type of therapy, and treatment naivety, baseline 
thrombocytopenia was an independent negative predictor of SVR (OR 0.49, 95%CI 0.31–0.76 p = 
0.002, Table 1.1.6). As a sensitivity analysis, only those patients treated with PegIFN were considered, 
showing that baseline thrombocytopenia remained an independent negative predictor of SVR (OR 
0.45, 95%CI 0.27–0.77 p = 0.004, Table 1.1.6).
Effect of thrombocytopenia on long-term clinical outcome
Liver failure, HCC, liver-related death, and all-cause mortality occurred less often among patients 
who attained SVR compared to patients who did not attain SVR within the group of patients with 
normal platelets and the group of patients with baseline thrombocytopenia (Fig. 1.1.3). Among the 
Table 1.1.3 | Details on bleedings
Type of bleeding
Treatments with 
normal platelets 
(n=338)
Treatments with  
moderate TCP 
(n=292)
Treatments with severe 
TCP 
(n=48)
Major
Variceal bleeding None 2 (3.3%) None
Minor
Epistaxis
Gingival
Hematuria
Vaginal
Rectal
Hemoptoe
Other
12 (48%)
3 (12%)
4 (16%)
5 (20%)
None
1 (4%)
None
31 (51%)
13 (21%)
4 (6.6%)
4 (6.6%)
4 (6.6%)
2 (3.3%)
Skin (1.6%)
7 (39%)
2 (11%)
6 (33%)
None
2 (11%)
None
Subconjunctival (5.6%)
Total 25 61 18
Abbreviations: TCP, thrombocytopenia
a. Numbers are presented as n, (percentage of the total amount of bleedings)
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patients who did not attain SVR, liver failure, HCC, liver-related death, and all-cause mortality occurred 
significantly more often in patients with thrombocytopenia compared to the patients with normal 
platelets at baseline. In contrast, the difference in cumulative occurrence of liver failure, HCC, liver-
related death, and all-cause mortality among the patients with SVR was not statistically significant 
between those with and without thrombocytopenia.
DISCUSSION
This large cohort study describes the course of antiviral treatment and post-treatment clinical 
outcome among patients with chronic HCV infection and advanced liver disease, including those 
with moderate and severe thrombocytopenia. These data are unique since severe thrombocytopenia 
normally is a contraindication for interferon-based therapy in randomized controlled trials in patients 
with chronic HCV infection. Severe thrombocytopenia was found to be the reason to refrain from 
interferon-based antiviral therapy in approximately 4% of patients with chronic HCV infection, mainly 
patients with advanced liver disease.188 Importantly, the proportion of patients with chronic HCV 
infection and cirrhosis is rapidly rising.63
In the present study, almost one third of patients with severe thrombocytopenia needed at 
least one dose reduction due to thrombocytopenia and treatment was discontinued prematurely in 
16%. Dose reductions and early treatment discontinuation were less frequent among patients with 
Figure 1.1.3 | Kaplan-Meier curves showing the occurrence of long-term outcome after the last treatment 
based on SVR-status and baseline platelet count 
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Figure 1.1.3 | Continued
(A) Occurrence of liver failure over time. p=0.001 for SVR vs. no SVR within patients with normal PLT; p<0.001 for 
SVR vs. no SVR within patients with TCP; p<0.001 for TCP vs. normal PLT within non-responding patients; and 
p=0.606 for TCP vs. normal PLT within patients attaining SVR. (B) Occurrence of HCC over time. p=0.008 for SVR 
vs. no SVR within patients with normal PLT; p<0.001 for SVR vs. no SVR within patients with TCP; p<0.001 for TCP 
vs. normal PLT within non-responding patients; and p=0.079 for TCP vs. normal PLT within patients attaining SVR. 
(C) Occurrence of liver-related death or liver transplantation over time. p=0.008 for SVR vs. no SVR within patients 
with normal PLT; p<0.001 for SVR vs. no SVR within patients with TCP; p<0.001 for TCP vs. normal PLT within non-
responding patients; and p=0.332 for TCP vs. normal PLT within patients attaining SVR. (D) Occurrence of all-cause 
mortality over time. p=0.032 for SVR vs. no SVR within patients with normal PLT; p=0.001 for SVR vs. no SVR within 
patients with TCP; p<0.001 for TCP vs. normal PLT within non-responding patients; and p=0.260 for TCP vs. normal 
PLT within patients attaining SVR. TCP, thrombocytopenia; PLT, platelets; SVR, sustained virological response. 
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moderate thrombocytopenia, in line with findings from earlier studies that excluded patients with 
platelets below 75x109/L.100 189
The registration trials of PegIFN showed lower rates of dose modifications (<10%) due to 
thrombocytopenia, probably because they included few patients with bridging fibrosis or cirrhosis 
and no patients with a platelet count below 90x109/L.104-106 In a previous single-center study among 
321 patients with chronic HCV infection, including 68 patients with cirrhosis, doses of 12 patients (4%) 
were reduced and antiviral treatment was discontinued in two patients because of thrombocytopenia. 
Twenty-four patients in that study were also included in the present study, due to its center and an 
overlapping inclusion period.115
Although cirrhosis and low platelet count were associated with on-treatment bleeding, our data 
confirm that treatment of patients with on-treatment platelet counts below 50x109/L is generally 
safe.115 Even in this cohort, including only patients with advanced liver disease, bleedings were 
relatively rare and mostly mild. Moreover, the two severe (variceal) bleedings observed might also 
have occurred in the natural course of advanced liver disease, independent of antiviral therapy.55
Although several interferon-free regimens are currently under development, pegylated interferon 
is still the backbone of antiviral treatment that is used in patients today. Awaiting further treatment 
developments is often not an option for patients with cirrhosis as they have a 1–5% annual risk of 
developing HCC; 3–6% of hepatic decompensation; and 2–4% of death.190 Despite established 
cirrhosis, attaining SVR may reduce these risks and improve prognosis in terms of liver-related death 
and all-cause mortality.79-81 We showed that clinical disease progression or death was more common 
in non-responders with thrombocytopenia than in non-responders with normal platelet counts, 
which suggests that thrombocytopenia predicts worse clinical outcome. Moreover, clinical disease 
progression or death was less common among thrombocytopenic patients who had attained SVR, in 
line with previous results from this cohort.81 185 Thus, successful therapy may outweigh the side-effects 
of treatment in patients with advanced liver disease.
It is hard to detangle whether thrombocytopenia is responsible for lower SVR rates rather than 
serving as a marker for more severe disease and portal hypertension, thus defining a more difficult to 
treat patient population.191 192 In general, dose reductions will compromise treatment efficacy as seen 
in patients with HCV genotype 1 infection.111 112 If dose reductions due to thrombocytopenia could 
be avoided, either by using platelet growth factors or by applying less strict stopping rules, SVR rates 
might be expected to increase. Importantly, the two severe bleedings that occurred in our cohort 
were variceal bleedings, which are caused by portal hypertension rather than thrombocytopenia per 
se, and the relevance of dose reductions because of thrombocytopenia in this setting may therefore 
be questionable. Still, only two studies, the ENABLE-1 and ENABLE-2 study, showed improvement 
in SVR rates after interventions to improve the degree of thrombocytopenia, probably due to low 
sample sizes in other studies.193-195 Eltrombopag enabled treatment initiation and improved treatment 
efficacy when compared with placebo. On the other hand, eltrombopag was associated with 
decompensation and thromboembolic complications, which warrants monitoring of safety of this 
treatment on the long term.193
One limitation of the study is selection bias, since the patients were all treated in tertiary centers. 
However, the strength of our study is that all consecutive patients have been included, even those 
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with severe thrombocytopenia who would not be eligible for treatment in randomized trials. A 
limitation of this approach is that there is heterogeneity in the treatments that have been admin-
istered, varying from interferon monotherapy in the past to combination therapy with PegIFN and 
RBV in more recent years. Due to the retrospective nature of the study, we depended on the patient 
charts for reporting of bleeding episodes. In this way, clinically insignificant bleedings such as minor 
hematomas or skin bleedings that may be expected to occur during severe thrombocytopenia are 
possibly underreported.
Currently, the standard triple therapy for chronic HCV genotype 1 is PegIFN and RBV, with 
telaprevir or boceprevir. This therapy was registered in 2012 and consequently long term follow-up 
data were not available at the time of this study. In general, triple therapy leads to higher SVR rates. 
In the registration trials, telaprevir or boceprevir did not seem associated with higher occurrence of 
on-treatment thrombocytopenia.122-126 A recent report from the French early access program for use 
of protease inhibitors in patients with HCV-induced cirrhosis showed platelet counts below 50x109/L 
in 13% of the patients treated with telaprevir, PegIFN, and RBV and in 6% of the patients treated with 
boceprevir, PegIFN, and RBV.183 These results indicate that in the era of triple therapy we should still be 
aware that treatment-induced declines in platelet counts are likely to occur.
In conclusion, thrombocytopenia was an important cause for dose reductions and for treatment 
discontinuation in patients with chronic HCV infection and bridging fibrosis or cirrhosis treated 
with interferon-based regimens. Cirrhosis and a platelet count below 50x109/L were associated with 
on-treatment bleedings, which were mostly mild. SVR was associated with a marked reduction in 
cirrhosis-related morbidity and mortality, especially in patients with baseline thrombocytopenia.
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SUPPLEMENTARY FIGURES
Supplementary Figure 1.1.1 | Overview of baseline platelet counts, dose reductions, and early treatment 
discontinuation during the treatments.
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Supplementary Figure 1.1.2 | Kaplan-Meier curve showing the occurrence of a platelet count below 50x109/L 
during treatments started in patients with normal platelet count, moderate thrombocytopenia and severe 
thrombocytopenia at baseline. Ten patients had a platelet count below 50x109/L at baseline.
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DEAR EDITOR:
Afdhal et al found that eltrombopag increased platelet count in thrombocytopenic (<75x109/L) 
patients with chronic HCV infection and advanced fibrosis and cirrhosis.193 By using eltrombopag they 
achieved increased rates of sustained virological response (SVR) in patients that would otherwise be 
ineligible to begin or maintain antiviral therapy. Both ENABLE-1 and ENABLE-2 are well designed trials 
and the results seem encouraging; yet, several aspects do require some attention.
Both trials had an initiation phase using eltrombopag to increase platelet count above the thres-
hold for treatment initiation (ENABLE-1: 90x109/L, using pegylated interferon α [PegIFN]-2a and 
ENABLE-2: 100x109/L, using PegIFN-2b). Afterwards patients were randomized to eltrombopag or 
placebo during the whole course of antiviral treatment. As the authors acknowledge in the discussion, 
the placebo group is not representative for the real-life setting since the investigators were instructed 
to follow the current local product labels for dose  reductions and discontinuations. In many 
centers, treating physicians are applying less strict rules when dose reductions or discontinuations 
are considered. Data on the efficacy in such centers is needed, in order to be able to assess the 
incremental benefit of eltrombopag on SVR rates. Moreover, no discrimination is made between the 
reasons for the PegIFN induced dose reductions. In the light of eltrombopag, only the avoidance of 
dose reductions due to thrombocytopenia seems essential.
The risk of bleeding during PegIFN induced thrombocytopenia has never been fully elucidated. 
We previously showed that the risk of bleeding during PegIFN and ribavirin treatment is associated 
with cirrhosis and a platelet count below 50x109/L. However, these bleedings were mild and mostly 
not clinically relevant.115 One could therefore question whether, with eltrombopag, we are not 
merely treating the physician’s fear for bleeding than a real clinical problem. Even in a large cohort 
of 546 patients with advanced hepatic fibrosis, we found that the risk of bleeding is generally mild 
during treatment with interferon-based regimens, also among patients with interferon-induced 
thrombocytopenia.196
Regarding side-effects, the safety of eltrombopag remains a concern, as the rates of hepatic de-
com pensation and thromboembolic events were significantly higher in the group receiving eltrom-
bopag. This is in line with a previous study of eltrombopag.197 Moreover, by allowing patients with 
severe thrombocytopenia to undergo antiviral treatment, the risk of hepatic decompensation is 
considerably increased, as Hezode et al showed in a cohort of cirrhotic patients treated with triple 
therapy.183 Especially when the full dose of PegIFN is maintained, this risk is substantial. This also raises 
the question whether we will be able to safely use eltrombopag in patients undergoing triple therapy.
In our opinion, eltrombopag is a potent agent for treating thrombocytopenia, thereby allowing 
antiviral treatment. However, more data are needed to determine whether the side effects outweigh 
the benefit on SVR rates and bleeding risk of thrombocytopenic patients during triple therapy.
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ABSTRACT 
Background & Aims 
Pegylated interferon-based treatment is still the backbone of current hepatitis C therapy and is 
associated with bone marrow suppression and an increased risk of infections. The aim of this retro-
spective cohort study was to assess the risk of infections during interferon-based treatment among 
patients with chronic hepatitis C virus (HCV) infection and advanced hepatic fibrosis and its relation 
to treatment-induced neutropenia.
Methods
This cohort study included all consecutive patients with chronic HCV infection and biopsy-proven 
bridging fibrosis or cirrhosis (Ishak 4–6) who started treatment between 1990 and 2003 in five large 
hepatology units in Europe and Canada. Neutrophil counts between 500–749/μL and below 500/μL 
were considered as moderate and severe neutropenia, respectively.
Results
This study included 723 interferon-based treatments, administered to 490 patients. In total, 113 
infect ions were reported during 88 (12%) treatments, of which 24 (21%) were considered severe. 
Only one patient was found to have moderate neutropenia and three patients were found to have 
severe neutropenia at the visit before the infection. Three hundred and twelve (99.7%) visits with 
moderate neutropenia and 44 (93.6%) visits with severe neutropenia were not followed by an 
infection. Multivariable analysis showed that cirrhosis (odds ratio [OR] 2.85, 95% confidence interval 
[CI] 1.38–5.90, p = 0.005) and severe neutropenia at the previous visit (OR 5.42, 95% CI 1.34–22.0, p = 
0.018) were associated with the occurrence of infection, while moderate neutropenia was not. Among 
a subgroup of patients treated with pegylated interferon, severe neutropenia was not significantly 
associated (OR 1.63, 95% CI 0.19–14.2, p = 0.660).
Conclusions
In this large cohort of patients with bridging fibrosis and cirrhosis, infections during interferon-
based therapy were generally mild. Severe interferon-induced neutropenia rarely occurred, but was 
associated with on-treatment infection. Moderate neutropenia was not associated with infection, 
suggesting that current dose reduction guidelines might be too strict.
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INTRODUCTION
Hepatitis C virus (HCV) infection is a major cause of cirrhosis, hepatocellular carcinoma, and end-
stage liver disease.178 It has been estimated that by 2030, 45% of the US patients chronically infected 
with HCV will have cirrhosis.63 Today, antiviral treatment efficacy among patients with cirrhosis is 
unsatisfactory.107 122 126
Although it is expected that even in this difficult-to-treat subgroup of patients, the sustained 
virological response (SVR) rates will improve substantially by using interferon-free regimes,142 145 156 
pegylated interferon (PegIFN) and ribavirin (RBV) are still the backbone of antiviral therapy in most 
countries. In fact, due to the high costs of the new direct-acting antivirals (DAAs), PegIFN and RBV 
might remain the primary treatment option for many patients with chronic HCV infection around the 
globe. Treatment with PegIFN is, however, associated with major side effects, of which bone marrow 
suppression and subsequent neutropenia is one of the most frequently reported. Out of concern for 
infections, product labels and guidelines currently advise physicians to reduce the dose of PegIFN 
when neutrophil counts drop below 750/μL and to stop PegIFN when neutrophil counts drop 
below 500/μL.35 36 This is largely based on prior  experiences in oncology, where patients receiving 
chemotherapy showed an increased risk of infection when neutrophil counts dropped below 500/μL, 
with the greatest risk below 100/μL.198 While patients undergoing interferon-based therapy are indeed 
more susceptible to bacterial and fungal infections, prior studies did not find these to be related to the 
treatment-induced neutropenia.114 199-201 Especially because interferon dose adjustments compromise 
antiviral treatment efficacy for patients with chronic HCV infection, it was suggested that the current 
guidelines regarding dose reductions might be too strict.111 112 
However, whereas patients with cirrhosis are considered to be immunocompromised and thus at 
the highest risk of infections, data regarding the relation between neutropenia and infections during 
interferon-based antiviral therapy within this population are scarce.
PATIENTS AND METHODS
Patients
The current study is based on all patients included in our previously described international, multi-
center cohort.81 This cohort included all consecutive patients from five large hepatology units in 
Europe and Canada, who had chronic HCV infection and started an interferon-based treatment 
between 1990 and 2003. They all had histological proof of bridging fibrosis (Ishak fibrosis score 4) or 
cirrhosis (Ishak fibrosis score 5 or 6).51 Patients co-infected with the human immunodeficiency virus or 
the hepatitis B virus were excluded, as well as patients with a history of decompensated liver disease. 
For the current study, all consecutive treatment courses with available on-treatment data, including 
assessment of infection and laboratory results, were included.
All charts were re-reviewed by a single investigator (RM) in order to collect detailed baseline and 
on-treatment data. Data were obtained on patient characteristics (age, gender, body mass index), 
severity of liver disease (Ishak fibrosis score), presence of diabetes mellitus (DM), severe alcohol 
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use, and antiviral treatment (type of medication, treatment period, previous and current virological 
response). Furthermore, laboratory data (neutrophil count, platelet count, hemoglobin, albumin, 
bilirubin, aspartate aminotransferase, alanine aminotransferase, and glucose) and virology data (HCV 
genotype, HCV-RNA, and anti-hepatitis B core antigen) were collected. The period within 6 months 
before treatment was considered as baseline. During antiviral treatment, all (Peg)IFN and/or RBV 
dose reductions or treatment cessations were collected as well as all infectious episodes and all other 
adverse events.
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and 
the principles of Good Clinical Practice. The study protocol was reviewed and approved by the ethics 
committee in the center of the primary investigators, which was the Erasmus Medical Center in 
Rotterdam, the Netherlands. Ethical approval in the participating centers was obtained according to 
the local regulations.
Outcome measures
The primary outcome measure was the occurrence of infections during antiviral therapy or within 2 
weeks after treatment cessation. Secondary outcome measures were on-treatment neutropenia and 
the severity of infections. 
Neutrophil counts from 500/μL to 749/μL were defined as moderate neutropenia, since interferon 
dose reductions are advised at these levels. Neutrophil counts below 500/μL were considered as 
severe neutropenia. DM at baseline was defined by an elevated fasting glucose (>6.1 mmol/L), a 
positive glucose tolerance test, or if patients were using anti-diabetic medication.
Infections were considered as all the episodes of clinically suspected infection according to the 
treating physician, when antibiotic therapy was prescribed or when there was evidence of an infection 
(radiology, positive culture). Severe infections were defined as infections resulting in death, hospital 
admission, or treatment discontinuation. All other infections were defined as mild. 
Statistical analyses
Continuous variables were summarized as median (interquartile range [IQR]) and categorical variables 
as frequencies (percentages). Comparisons between groups were performed using χ2 test for cate-
gorical variables or the Mann–Whitney U-test for continuous variables.
The dynamics of neutrophil counts during treatment for different groups were studied with a 
repeated measurement model. A restricted cubic spline was fitted per group, and to take into account 
multiple measurements per patient during treatment, a model with random intercept and slope was 
applied. 
Logistic regression was used to assess which baseline factors were associated with the occurrence 
of infections during antiviral therapy. Age, sex, cirrhosis, DM, and variables with a p value of ≤0.2 in 
univariable analyses were included in multivariable analyses. Adjusting for multiple measurements 
within a patient, the association between on-treatment neutrophil counts and succeeding infectious 
events was assessed. By using a backward stepwise method, we selected the variables significantly 
associated with infections and included these in the final model. Akaike’s Information Criteria were 
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used to select the best model. A sensitivity analysis was performed among only those patients treated 
with PegIFN-based regimens, since standard interferon is not used nowadays. 
The cumulative incidence of infections was assessed using the Kaplan–Meier method. The log-
rank test was applied to compare patients with bridging fibrosis and cirrhosis. 
A p value <0.05 was considered statistically significant and all statistical tests were two tailed. 
The significance level of interactions was set at 0.01 in order to correct for multiple testing. 81 PASW 
statistics 21.0 for Windows (SPSS, IBM, Armonk, NY, USA) and SAS 9.3 (SAS Institute, Cary, NC, USA) 
were used.
RESULTS
Patients
Overall, 546 patients with chronic HCV infection and bridging fibrosis or cirrhosis started interferon-
based antiviral therapy between 1990 and 2003. In 490 (90%) patients, detailed on-treatment data 
were available to assess the occurrence of infections during at least one interferon-based regimen. 
Of the 361 (74%) patients without SVR, 174 received at least one subsequent antiviral treatment 
regimen. Overall, 723 treatment courses could be included in the analyses. Table 2.1 summarizes the 
baseline characteristics of the patients at their first included treatment. Median age was 49 years (IQR 
43–56), 336 (69%) patients were male, and 372 (76%) presented with cirrhosis.
Neutropenia and dose of interferon
The median neutrophil count prior to the start of all treatment courses was 3000/μL (IQR 2400–3900). 
Median time between visits was 2 weeks (IQR 1–4 weeks). During therapy, the median neutrophil 
count decreased to a nadir of 1200/μL (IQR 800–1700) in a median time of 11 weeks (IQR 4–22). Patients 
receiving PegIFN had a lower median nadir neutrophil count as compared with patients receiving 
standard interferon (1000/μL [IQR 700–1400] vs 1400/μL [IQR 1000–2000], p <0.001), whereas baseline 
neutrophil counts did not differ between these groups (p = 0.729). Figure 2.1 shows the course of 
neutrophil counts during treatment. During 88 (12%) treatment courses moderate neutropenia 
occurred at least once, and during 23 (3%) treatment courses, severe neutropenia occurred at least 
once. Because of neutropenia, the (Peg)IFN dose was reduced during 58 (8%) treatment courses and 
3 (<1%) treatments were discontinued. 
Infections
In total, 113 infections were reported during 88 (12%) treatments among 81 (17%) patients. Table 2.2 
summarizes the type of infections. Dermatological infections were most common (24%), followed 
by upper respiratory tract infections (20%) and urinary tract infections (18%). None of the patients 
were diagnosed with spontaneous bacterial peritonitis during treatment. Median time until the first 
infection was 12 weeks (IQR 6–24). Time until infection was not significantly different for mild or 
severe infections (p = 0.648). Twenty-four infections among 23 (3.2%) patients were defined as severe. 
Treatment was discontinued due to infection in seven patients, and 23 hospital admissions due to 
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Table 2.1 | Baseline characteristics at first registered treatment
Variable (missing cases [%]) 
Patients
(n=490)
Male 336 (69%) 
Age, in years 49 (43–56)
BMI, in kg/m2 * 26.5 (23.7–29.4)
HCV genotype
1
2
3
4
Other/ unknown
316 (65%)
46 (9%)
79 (16%)
23 (5%)
26 (5%)
Treatment naïve 397 (81%)
Cirrhosis 372 (76%)
Fibrosis score 
Ishak 4
Ishak 5
Ishak 6
118 (24%)
98 (20%)
274 (56%)
Neutrophil count per µL * 3040 (2500–3900)
Platelet count, in 109/L 146 (108–197)
Albumin, in g/L * 42 (39–44)
Bilirubin, in μmol/L * 13 (10–19)
Treatment with PegIFN 201 (41%)
Treatment duration, in weeks 26 (21–48)
Diabetes mellitus 64 (13%)
Alcohol abuse ever * 109 (22%)
Abbreviations: PegIFN ; pegylated interferon
a. Medians are presented as number, (IQR, interquartile range). Numbers are presented as n, (percentage of the 
whole group)
b. Variables with an asterisk (*) had ≥10% missing values
Processed on: 27-10-2016
505957-L-bw-Maan
Neutropenia and infections during interferon-based treatment   |   55
2
Table 2.2 | Type of infections
Type of infection n (%) Severe infection (%)c
Urinary tract 20 (18%) 3 (3%)
Upper respiratory tract 22 (20%) 2 (2%)
Pulmonary 15 (13%) 6 (5%)
Dermatological 27 (24%) 8 (7%)
Gastrointestinal 3 (3%) 2 (2%)
Oral 12 (11%) 1 (1%)
Otherb 14 (12%) 2 (2%)
Total 113 (100%) 24 (21%)
a Data presented as number, (percentage of the total number of infections)
b Other infections included a case of endocarditis (severe), dental and eye infections
c Severe infection was defined as infection requiring hospital admission or treatment discontinuation 
Figure 2.1 | Dynamics of the neutrophil counts during treatment
Panel A shows the dynamics of neutrophil counts among all patients. Panel B shows the dynamics of neutrophil 
counts among patients with bridging fibrosis and cirrhosis. Panel C shows the dynamics of neutrophil counts 
among patients treated with standard interferon and pegylated interferon (p<.001). 
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an infection were reported. The median duration of  admission was 9 days (IQR 3–12). None of the 
patients died as a result of an on-treatment infection. During 92 (81%) of the infections, antibiotic 
therapy was prescribed.
Neutropenia and infections
Eleven patients (1.5%) had a baseline neutrophil count below 1500/μL, of which 10 patients had a 
grade 2 neutropenia (i.e. neutrophil count <1500/μL) and only one patient had a grade 3 neutro-
penia (i.e. neutrophil count <1000/μL). Three of these patients needed a dose reduction due to 
neutropenia, of which one patient discontinued due to side effects, and one of these patients needed 
dose reductions due to thrombocytopenia. In only one patient, an infection was reported, which 
was severe. This patient required hospital admission for 23 days due to a Staphylococcus aureus 
bacteremia following cellulitis. The infection resolved with intravenous antibiotics, while interferon 
and RBV were continued. 
For 81 infections (72%), the neutrophil count at the visit prior to the infection was available. 
Median neutrophil count at the visit prior to an infection was 1740/μL (IQR 1300–2650). The median 
Table 2.3 | Logistic regression analysis for infection
Variable
Univariable
OR (95% CI) p value
Multivariable
OR (95% CI) p value
Multivariable 
(PegIFN onlyc) 
OR (95% CI) p value
Age 1.02 (1.00-1.04) 0.075 1.02 (0.99-1.05) 0.296 1.02 (0.99-1.06) 0.218
Female gender 1.58 (1.01-2.47) 0.044 1.67 (0.95-2.94) 0.077 1.03 (0.52-2.10) 0.913
BMI 1.03 (0.98-1.07) 0.263
Cirrhosis at baseline 2.14 (1.19-3.85) 0.011 2.85 (1.38-5.90) 0.005 3.22 (1.16-8.95) 0.025
DM at baseline 1.58 (0.96-2.59) 0.073 1.48 (0.78-2.81) 0.224 1.17 (0.53-2.56) 0.694
Weeks on treatment 1.01 (1.00-1.02) 0.032 1.01 (0.99-1.02) 0.322
Type of interferon 
(PegIFN vs standard 
interferon)
1.38 (0.88-2.16) 0.155 0.80 (0.45-1.41) 0.435
Moderate neutropenia 
at previous visit (500-
749/µL)
0.19 (0.03-1.40) 0.103
Severe neutropenia at 
previous visit (<500/µL)
4.25 (1.21-14.9) 0.024 5.42 (1.34-22.0) 0.018 1.63 (0.19-14.2) 0.660
Platelet count ≤ 100 * 
109/L
0.86 (0.49-1.50) 0.589
Albumin < 35 g/L 1.36 (0.59-3.15) 0.471
Abbreviations: BMI, body mass index; DM, Diabetes mellitus; PegIFN, pegylated interferon
a. All analyses were corrected for multiple measurements within a patient
b. PegIFN based therapy, including 25 treatments with PegIFN monotherapy
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neutrophil count at the previous visit was not different for mild and severe infections (p = 0.399). 
Only one patient was found to have moderate neutropenia (neutrophil count of 690/μL) and three 
patients were found to have severe neutropenia (neutrophil counts of 300/μL, 330/μL, and 390/μL) at 
the visit before the infection. Three hundred and twelve (99.7%) visits with moderate neutropenia and 
44 (93.6%) visits with severe neutropenia were not followed by an infection. Patients who underwent 
a dose reduction of (Peg)IFN did not experience less infections, compared with patients who did not 
undergo a dose reduction (10.8% vs 10.6%, p = 1.00). During nine treatment courses, dose reductions 
were performed after an infection was reported.
Table 2.3 summarizes the results of univariable logistic analysis, which showed that female gender 
(odds ratio [OR] 1.58, 95% confidence interval [CI] 1.01–2.47, p = 0.044), the presence of cirrhosis (OR 
2.14, 95% CI 1.19–3.85, p = 0.011), and number of weeks on treatment (OR 1.01, 95% CI 1.00–1.02, p 
= 0.032) were significantly associated with infection. While moderate neutropenia at the visit prior to 
infection was not significantly associated (OR 0.19, 95% CI 0.03–1.40, p = 0.103) with infection, severe 
neutropenia at the previous visit was (OR 4.25, 95% CI 1.21–14.9, p = 0.024).
Multivariable logistic analyses, adjusted for age, gender, DM, number of weeks on treatment, and 
type of interferon showed that cirrhosis (OR 2.85, 95% CI 1.38–5.90, p = 0.005) and severe neutro penia 
at the visit prior to the infection (OR 5.42, 95% CI 1.34–22.0, p = 0.018) were independently associated 
with infections. The interaction terms between the variables in the final model were not statistically 
significant. In a sensitivity analysis including only the 356 (49%) PegIFN-based treatment courses 
among 292 patients, during which 71 infections were reported, severe neutropenia at the visit prior 
Table 2.4 | Logistic regression analysis for severe infectionc
Variable# Univariable
OR (95% CI) p value
Multivariable
OR (95% CI) p value
Age 1.01 (0.97-1.06) 0.572 1.00 (0.95-1.05) 0.942
Female gender 3.63 (1.41-9.34) 0.008 3.94 (1.54-10.1) 0.004
BMI 0.98 (0.87-1.11) 0.759
Cirrhosis at baseline 1.47 (0.50-4.36) 0.484 1.23 (0.40-3.77) 0.721
DM at baseline 3.04 (1.29-7.20) 0.011 3.84 (1.52-9.70) 0.004
Weeks on treatment 0.89 (0.72-1.10) 0.280
Type of interferon (PegIFN vs standard 
interferon)
0.80 (0.34-1.87) 0.600
Platelet count ≤ 100 * 109/L 1.52 (0.58-4.00) 0.396
Albumin < 35 g/L 2.45 (0.69-8.65) 0.164
Abbreviations: BMI, body mass index; PegIFN, pegylated interferon
a. All analyses were corrected for multiple measurements within a patient
b. Severe infections were defined as infections were treatment was discontinued or when admission was 
needed 
c. There were too few cases with moderate (n=1) or severe (n=1) neutropenia and severe infection to include 
these variables in the analysis.
Processed on: 27-10-2016
505957-L-bw-Maan
58   |   Chapter 2
to infection was not significantly associated (OR 1.63, 95% CI 0.19–14.2, p = 0.660). In this analysis, 
cirrhosis (OR 3.22, 95% CI 1.16–8.95, p = 0.025) was the only factor associated with infection. Table 
2.4 shows the variables associated with severe infection during antiviral treatment. After adjustment 
for age and cirrhosis, female gender (OR 3.94, 95% CI 1.54–10.1, p = 0.004) and DM (OR 3.84, 95% CI 
1.52–9.70, p = 0.004) were associated with the occurrence of severe infections. Figure 2.2 illustrated 
the infection rates according to the presence of cirrhosis or DM.
DISCUSSION
In this large cohort study, infections which occurred during interferon-based antiviral therapy were 
generally mild. The percentage of 12% of treatment courses complicated by infections is in line 
with previous studies reporting an infection rate of 4–23%.114 200 202 203 Moderate (Peg)IFN-induced 
neutropenia was not associated with infection, whereas severe neutropenia was. However, a sensi-
tivity analysis among patients treated with PegIFN could not confirm this. Furthermore, approximately 
94% of the visits of patients with severe neutropenia were not followed by an infection. Cirrhosis and 
diabetes were important risk factors for the occurrence and severity of infection. 
This real-life study was not limited by strict interferon dose modification rules which are used in 
clinical trials and thereby allows for assessment of lower neutrophil counts in relation to infections. 
Severe neutropenia occurred during only 3% of antiviral treatment regimens, and only four (17%) 
of these treatment courses with severe neutropenia were complicated by an infection. When only 
Figure 2.2 | The bars represent the percentage of treatments with at least one mild or severe infection among 
specific subgroups of patients based on the presence of cirrhosis and diabetes mellitus. Fifteen infections were 
reported among patients that had both cirrhosis and diabetes mellitus, of which 10 were mild infections and 5 
were severe infections.  
Processed on: 27-10-2016
505957-L-bw-Maan
Neutropenia and infections during interferon-based treatment   |   59
2
PegIFN-based regimens were considered, the association between severe neutropenia and occur-
rence of infections was not statistically significant. This is in line with the findings of Antonini et 
al.202 who showed that neither the presence nor duration of neutropenia was associated with the 
occurrence of infections among 319 chronic HCV-infected patients treated with PegIFN and RBV. This 
was confirmed by another retrospective study among 321 patients treated with PegIFN and RBV, as 
also in this study, on-treatment neutropenia and its duration were not associated with infectious 
episodes.114 The Individualized Dosing Efficacy versus Flat Dosing to Assess Optimal Pegylated 
Interferon Therapy (IDEAL) study is the largest clinical study to date, which prospectively assessed the 
role of PegIFN-induced cytopenias on the occurrence of infections.203 Again, no association between 
nadir neutrophil count and occurrence of infection was found. The authors did report, however, that 
the nadir lymphocyte count was associated with infectious episodes. Because the nadir lymphocyte 
count was analyzed rather than the lymphocyte count at the most recent visit prior to infection, it 
remains difficult to determine causality and to translate this finding into clinical recommendations 
with respect to the dose of PegIFN. In our cohort, lymphocyte counts were not available as these are 
not collected during antiviral therapy in daily practice. 
In contrast to our cohort, the above described studies included a relatively low number of 
patients with advanced fibrosis (11–30%) and did not show results for this subgroup specifically. We 
found that patients with cirrhosis more frequently experienced infections during interferon-based 
therapy as compared with those with bridging fibrosis. Roomer et al.114 also described a higher rate of 
infectious episodes among the 68 (21%) patients with cirrhosis included in their study, and from other 
cohorts, similar results were obtained with odds ratios ranging from 2.7 to 4.9.114 199-201 Triple therapy 
regimens with DAAs were not included in our study and often reduce treatment duration to 12 or 
24 weeks.130 135 137 Shortened PegIFN therapy could prevent infections, as we found a linear infection 
rate during treatment with a median of 12 weeks from initiation of therapy to the occurrence of an 
infection (Supplementary Fig. 2.1). However, first real-world data regarding the addition of telaprevir 
or boceprevir to PegIFN and RBV therapy indicate a substantially elevated risk of severe infections 
among patients with cirrhosis, likely because patients with advanced cirrhosis who would have met 
stopping rules with PegIFN and RBV alone were able to achieve viral suppression and stay on therapy 
longer, thus increasing their risk of infection.121 Cirrhosis is considered an immunocompromised 
state that may lead to a variety of infections, also outside of the scope of interferon-based therapy.204 
Transla tional studies have suggested that patients with cirrhosis have impaired neutrophil function, 
limiting the first immunological defense against bacterial pathogens.205 206
As this cohort study included solely patients treated with an interferon-based regimen, it lacks 
a control group of untreated cirrhotic patients. However, a previous study among cirrhotic patients 
awaiting liver transplantation found that there was a higher incidence of infections in the group that 
was treated with PegIFN and RBV compared with the matched control group that did not receive 
treatment, respectively 13 events and 2 events (p = 0.012).207 This study indicated that PegIFN-based 
antiviral treatment increases the risk of bacterial infections in a cirrhotic population. Although ap-
parently not through a reduction in neutrophil counts, infectious episodes are more frequently 
en coun tered during the use of interferon-based therapy. The mechanisms for this association are, 
however, not well understood. It has been hypothesized that PegIFN alters neutrophil function, 
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but limited data are available.208 Others have suggested that PegIFN boosts other factors among 
cirrhotic patients which facilitate infections, such as bacterial translocation, dysfunction of the reti-
cu loendothelial system, and reduction of serum and ascitic fluid complement levels.209 Thus, an 
impaired function of the immune system might be responsible for the increased infection rate during 
interferon-based therapy. 
Current recommendations regarding PegIFN dose reductions are based on experience among 
cancer patients receiving chemotherapy.198 In this situation, however, other mechanisms such as 
mucosal damage and hampered organ function caused by the underlying disease play important 
roles in the susceptibility for infections as well. Dose reductions due to neutropenia may need to 
be carefully considered as long as the neutrophil counts remain stable between 500 and 750/μL. 
Dose reductions reduce the chance to attain SVR, which is likely to affect clinical outcome.111 112 210 
A study among African American and Caucasian American patients, in whom dose reductions were 
not undertaken until the neutrophil count dropped below 500/μL, did not report a higher rate of 
infections than expected.211 Our study further suggests that dose reductions could not prevent 
infectious episodes during antiviral therapy as the number of patients who underwent a dose 
reduction of (Peg)IFN did not experience less infections (10.8% vs 10.6%). This should be interpreted 
with caution as dose reductions were at the discretion of the treating physicians and the number of 
infections could be higher if these dose reductions were not applied. The treating physicians could 
have applied dose reductions only to those patients that had a higher initial risk for infectious events. 
Due to its retrospective character, one could not really conclude that reductions of IFN could not 
affect the occurrence of infections. Ideally, one would design a randomized controlled trial with one 
group of patients undergoing dose reductions and the other group continuing the dose despite low 
neutrophil counts (or other hematological adverse events). Such studies are however hardly feasible. 
One could also debate whether dose reductions were performed too late. Unfortunately we were 
unable to assess this issue. Dose reductions were not performed according to the guidelines, making 
it impossible to conclude on timing of dose reductions. Furthermore, dose reductions were also 
performed for other reasons than neutropenia. 
Our finding of an association between DM and more severe infection was not unexpected. Higher 
infection rates among diabetic patients could be explained by vascular insufficiency, depressed 
leucocyte, and natural killer cell function, as well as impaired antioxidant systems involved in 
antibacterial activity.212 213 Others have previously shown that the risk of infections during PegIFN-
based therapy was around twofold to threefold higher among patients with chronic HCV infection 
and DM.114 201
The association of female gender and the occurrence of severe infection was also seen in the 
largest prospective study that assessed the risk for infections during antiviral treatment.203 In this 
study, they found an increased incidence of urinary tract infections and Candida infections, partly 
explaining the finding. Furthermore, they also found an increased incidence of respiratory tract 
infections among women. This was also the case in our study, where more women required hospital 
admission due to respiratory tract infections. There was no higher incidence of infections of the 
urinary tract. Although the underlying mechanism of our findings is not clear, clinicians should be 
aware of a possible increased risk for severe infection among women treated with PegIFN and RBV. 
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A limitation of our study is that, due to its retrospective character, not all infections may have 
been reported. However, it is unlikely that severe infections, which are clinically most relevant, 
were missed. Also, there was heterogeneity in the treatment regimens administered, varying from 
interferon monotherapy to combination therapy with PegIFN and RBV. Because neutrophil counts 
showed deeper declines with PegIFN, a sensitivity analysis was performed including only PegIFN-
containing regimens. 
In conclusion, patients with chronic HCV infection and bridging fibrosis and cirrhosis undergoing 
interferon-based therapy experience generally mild infections. Patients with cirrhosis are at elevated 
risk of interferon-associated infections, and among patients with DM, the course of infection seems to 
be more severe, indicating these groups should be carefully monitored. Although on-treatment severe 
neutropenia (<500/μL) might be associated with an elevated risk of infection, such deep declines in 
neutrophils do not frequently occur during PegIFN-based therapy. Furthermore this finding could 
not be confirmed among a subgroup of patients treated with PegIFN, which is used in current daily 
practice. Moderate neutropenia was not associated with an increased infection rate, suggesting that 
dose reductions due to neutropenia may need to be carefully considered as long as the neutrophil 
counts remain stable between 500 and 750/μL. Current guidelines regarding PegIFN dose reductions 
might be too strict and may unnecessarily compromise the virological efficacy of interferon-based 
therapy.
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Supplementary Figure 2.1 | Kaplan-Meier curve showing the occurrence of infection within the first 30 weeks of 
treatment within two groups based on the presence of cirrhosis.
SUPPLEMENTARY FIGURE
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ABSTRACT 
Background & Aims 
Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the 
protection from early ribavirin (RBV)-induced hemolytic anemia among patients with chronic hepa-
titis C virus (HCV) infection. The aim of the present study was to investigate the association between 
the functional ITPA variants and hematological side effects during antiviral therapy with pegylated 
interferon (PegIFN) and RBV.
Methods
This cohort study included all consecutive Caucasian patients treated for chronic HCV in fec tion with 
PegIFN and RBV between 2000 and 2009 for whom a serum sample was available for genetic testing. 
The predicted inosine triphosphate pyrophosphatase (ITPase) activity was based on the genotypes of 
the SNPs rs1127354 and rs7270101. Decline in hemoglobin (Hb) during antiviral therapy, as well as 
dose reductions, blood transfusions and use of erythropoietin were assessed.
Results
In total, 213 patients were included. The predicted ITPase activity was normal among 152 (71%) 
patients; 61 (29%) patients had ITPase deficiency. By multivariable linear regression, RBV dose in mg 
per kilogram (Beta 0.09, 95%CI 0.04–0.13, p <0.001) and normal ITPase activity (Beta 0.89, 95%CI 0.64–
1.14, p <0.001) were associated with more Hb decline at week 4 of treatment. Patients with normal 
ITPase activity underwent more dose adjustments of RBV than patients with ITPase deficiency (19 
(13%) vs 1 (2%), p = 0.014) and received erythropoietin more frequently (12 (8%) vs 0 (0%), p = 0.024).
Conclusions
Genetic variants in the ITPA gene protected against RBV treatment-induced anemia among Caucasian 
patients with chronic HCV infection. Patients with normal ITPase activity underwent more dose 
reductions of RBV and received erythropoietin more frequently. 
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INTRODUCTION
Currently, there is a changing paradigm in the treatment of chronic hepatitis C virus (HCV) infection. 
Although it is expected that the efficacy and safety of antiviral therapy improves considerably with 
the introduction of direct acting antivirals (DAAs), the high costs may limit the availability of these 
new drugs. Therefore, pegylated interferon (PegIFN) and ribavirin (RBV) containing regimens are 
likely to remain important treatment options in many countries around the world, also in high-
income countries. Furthermore, some studies showed that the addition of RBV to DAAs could be 
beneficial in selected cases.146 155 Unfortunately, PegIFN and RBV are associated with many side 
effects, including cyto penias. These cytopenias occur frequently and are the most important reasons 
for dose reductions.110 214 As these dose reductions compromise treatment efficacy,111 112 it is of great 
importance to select patients who are at greatest risk for these hematological side effects. These 
patients may benefit from strategies to optimize treatment adherence, such as early administration of 
supportive hematopoietic growth factors.
Recently, two genetic polymorphisms in the inosine triphosphatase (ITPA) gene on chromo-
some 20 were shown to be associated with protection against early RBV-induced hemolytic anemia 
during therapy with PegIFN and RBV.215 The first polymorphism concerns a missense variant in exon 2 
(rs1127354), the second concerns a splicing-altering single nucleotide polymorphism (SNP) in intron 
2 (rs7270101). These two functional variants cause ITPase deficiency, subsequently preventing the 
depletion of erythrocyte adenosine triphosphate (ATP) and oxidative damage on the erythrocyte 
membrane.216 Although ITPase deficiency is protective against anemia, it has been associated with 
a greater decline in platelet count during PegIFN and RBV therapy.217 218 It has been suggested that 
patients with normal ITPase activity have a higher chance to develop thrombocytosis in reaction to 
the decline in hemoglobin (Hb). Although the exact mechanisms for this reactive thrombocytosis have 
not been completely elucidated, the increased stimulation of megakaryocyte-erythroid progenitor 
cells by erythropoietin (EPO) production is thought to be of major importance.219 220 
The association of the ITPA variants with the occurrence of RBV-induced hemolytic anemia 
has been previously assessed.217 218 221 222 However, these studies were based on patients included 
in randomized controlled trials with strict inclusion criteria and dosing rules. It can be questioned 
whether these findings also apply for the general patient population treated with PegIFN and RBV 
in field practice, where dose reductions are less strictly applied. Therefore, the aim of this study was 
to investigate the relationships between functional ITPA variants and hematological side effects of 
PegIFN and RBV therapy in routine daily practice. Secondly, the relations between these genetic 
polymorphisms and the occurrence of PegIFN and RBV dose reductions, administration of EPO and 
blood transfusions and virological response to antiviral therapy was analyzed.
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PATIENTS AND METHODS
Patients
All Caucasian patients of whom a blood sample was available for genetic testing were included from 
our previously described cohort, which includes all consecutive patients with chronic HCV infection 
who were treated with PegIFN alfa-2a or -2b and RBV between 2000 and 2009 in our center.114 115 
The inclusion and exclusion criteria for this study are described elsewhere.114 115 Briefly, patients were 
included if they were treated with PegIFN and RBV between 2000 and 2009. Patients treated with 
conventional interferon and patients co-infected with human immunodeficiency virus or the hepatitis 
B virus were excluded. In order to prevent confounding by ethnic origin, only Caucasian patients were 
included in the present study. 
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and 
the principles of Good Clinical Practice. The ethical review board of the Erasmus Medical Center, 
Rotterdam, The Netherlands approved this study as it was considered to be a low-risk study using 
retrospective and anonymized patient data. Written informed consent was obtained from each 
patient for storage of serum samples.
Data acquisition
We obtained baseline data on gender, age, race, body mass index, METAVIR score, HCV genotype, 
previous interferon-based treatment, platelet count, absolute neutrophil counts, Hb, bilirubin and 
albumin concentration, glucose levels, presence of hemophilia and use of anticoagulants and anti-
platelet therapy, diabetes mellitus (DM), history of heroin use and/or smoking. 
During therapy all patients visited the outpatient clinic in one to six weeks intervals. At every visit 
blood tests were performed and patients were assessed for dose reductions and discontinuation of 
antiviral therapy. Among patients who were treated within a standard of care protocol, PegIFN and 
RBV dose reductions were made at the discretion of the treating physician. Patient characteristics such 
as age, physical condition, virological response, comorbidities and side effects of antiviral therapy 
were taken into account when considering a dose reduction. All study protocols of the clinical trials 
stated that dose reductions should be made according to product labels. However, these guidelines 
were not applied in some patients, due to the expected decrease of antiviral efficacy. Therefore these 
patients were treated at the discretion of the treating physician as well. The use of blood transfusion 
and EPO were also registered.
Endpoints
The primary endpoint was the decline in Hb (mmol/L) and platelet count (x109/L) which was assessed 
at week 4 (+/-7 days). This time point was chosen in order to limit the influence of dose reductions 
on these hematological outcomes.215 A clinically significant decline in Hb was defined as a decrease 
of at least 3.0 g/dL (1.86 mmol/L) or an absolute value lower than 10 g/dL (6.21 mmol/L). These 
thresholds were also used in other studies on ITPase deficiency.221-223 Anemia was defined according 
to the thresholds used by the World Health Organization; for women a Hb concentration below 7.45 
mmol/L and for men below 8.1 mmol/L were used as cut-off. Thrombocytopenia was defined as a 
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platelet count below 150x109/L. A clinical relevant thrombocytopenia was defined as a platelet count 
below 50x109/L, since current guidelines advise to reduce the dose of PegIFN when platelet counts 
fall below 50x109/L.35 
As a secondary endpoint, the decline in Hb and platelet counts were also assessed at week 8 and 
12 (+/-7 days) of antiviral therapy, as well as the nadir values of these parameters. 
Sustained virological response (SVR) was defined as HCV RNA negativity in blood six months after 
cessation of antiviral therapy. Dose reductions of RBV and PegIFN, as well as the administration of EPO 
and blood transfusion, were considered as clinical endpoints.
Genotyping methods
Serum samples stored at -20° or -80° Celsius were used for DNA extraction and genotyping proce-
dures, which were carried out centrally at LGC genomics. Purified genomic DNA of  ≥5 ng was used for 
genotyping. Genotypes were assigned using all of the data from the study simultaneously. Genotype 
sequences were derived from NCBI. Genetic analyses were performed at the polymorphic sites 
rs12979860 (19:39248147, near IL28B, also known as interferon-λ3), rs1127354 (20:3213196, ITPA–1) 
and rs7270101 (20:3213247, ITPA–2). The IL28B SNP rs12979860 was chosen, since it best describes the 
association with sustained SVR for all genotypes.224-226 Linkage disequilibrium and Hardy-Weinberg 
equilibrium (HWE) were tested for these SNPs using SNAP and OEGE.227
Predicted ITPase activity
As freshly acquired erythrocytes were lacking in order to directly measure ITPase activity, the 
predicted ITPase activity was based on genotypes of both ITPA–1 and ITPA–2 as is determined by 
previous analyses.228 229 Patients with normal ITPase activity (i.e. 100%) were defined as patients with 
the combined presence of CC-genotype and AA-genotype for rs1127354 and rs7270101 respectively 
(Supplementary Table 3.1). Patients with less than 100% ITPase activity were defined as patients with 
ITPase deficiency (non-CC-genotype and non-AA-genotype for rs1127354 and rs7270101 respectively, 
Supplementary Table 3.1).
Statistical Analysis
Continuous variables were summarized as median (interquartile range [IQR]) and categorical varia-
bles as frequencies (percentages). Comparisons between groups were performed using X2 test for 
categorical variables or the Mann-Whitney U test for comparing medians. The genetic association 
analyses for ITPA and IL28B polymorphisms consisted of a dominant genetic model (CC- and AA-
genotype vs non-CC- and non-AA-genotype for ITPA and CC-genotype vs non-CC genotype for 
IL28B).222 230 Linear regression analysis determined which variables were associated with the absolute 
decline in Hb and platelet count at week 4. Logistic regression was performed to determine which 
variables were associated with a clinically significant Hb decline at week 4, SVR and virological relapse. 
For decline in Hb and platelet count, a sensitivity analysis was performed which excluded patients 
whom were treated with a high PegIFN dose induction regimen. Age, sex and variables with a p value 
of ≤0.2 in univariable analyses were included in multivariable analyses. All final models were created 
by using a backward stepwise method, in order to select the variables that were significantly and 
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independently associated. Potential confounding was checked. All statistical tests were two-tailed, 
and p <0.05 was considered to be statistically significant. The significance level of interactions was set 
at 0.01 in order to correct for multiple testing. SPSS version 21.0 (SPSS, Chicago, IL) was used.
RESULTS
Patients
In total, 321 consecutive patients with chronic HCV infection were treated with PegIFN and RBV be-
tween 2000 and 2009, of which 256 were Caucasian. Two hundred thirteen (83%) of these patients, 
who had a sample available for genetic testing and could be genotyped for both ITPA polymorphisms, 
were included in the current analyses (Supplementary Figure 3.1). Median age was 45 years (IQR 39–
50), 145 (68%) were male, 105 (49%) had HCV genotype 1, and 39 (18%) had cirrhosis. Of the included 
patients, 140 were treated within a standard of care protocol. The remaining 73 patients were treated 
within clinical studies: 61 patients participated in three clinical trials and received a standard of care 
with PegIFN alfa-2a (180μg/week) or -2b (1.5μg/kg/week) plus weight based RBV. The remaining 12 
patients received a PegIFN induction regimen with either PegIFN alfa-2a (270–360 μg/week) for 24 
weeks or PegIFN alfa-2b (2.0–3.0 μg/kg/week) for 24 weeks followed by 48 weeks of PegIFN and daily 
weight-based ribavirin.
Genotyping
The majority of patients were homozygous carriers of the major allele for ITPA–1 (rs1127354 C) and 
ITPA–2 (rs7270101 A), respectively 200 (89%) and 170 (76%) patients. The minor allele frequency 
(MAF) was 0.04 for ITPA–1 (rs1127354 A) and 0.13 for ITPA–2 (rs7270101 C). Eighty-two of the patients 
(36%) had the favorable IL28B genotype (rs12979860 CC); MAF was 0.39 (rs12979860 T). All SNPs were 
in HWE and not in linkage disequilibrium (r2 ≤0.012). The call rates were 96% (217/226), 98% (221/226) 
and 96% (217/226), for ITPA–1, ITPA–2 and IL28B respectively. 
Supplementary Table 1 shows the distribution of the predicted ITPase activity according to the 
genotype of ITPA–1 and ITPA–2. In total, 152 (71%) patients had normal ITPase activity and 61 (29%) 
patients had ITPase deficiency. Baseline characteristics were compared between patients with normal 
ITPase activity and patients with ITPase deficiency (Table 3.1).
ITPase deficiency and on-treatment hemoglobin concentration
In total, 182 (85%) patients experienced at least one episode of anemia during antiviral treatment 
and in 157 (74%) patients a clinically significant decline in Hb was reported. At baseline, median Hb 
concentration was 9.2 mmol/L (IQR 8.7–9.9) for patients with normal ITPase activity and 9.3 mmol/L 
(IQR 8.7–9.9) for patients with ITPase deficiency (p = 0.793). At treatment weeks 4, 8 and 12, median Hb 
concentration was significantly lower among patients with normal ITPase activity (p <0.001 for all time 
points, Figure 3.1A). The nadir median Hb concentration was lower for patients with normal ITPase 
activity compared to patients with ITPase deficiency, respectively 6.6 mmol/L (IQR 5.8–7.2) and 7.2 
mmol/L (IQR 6.6–8.1, p <0.001). Furthermore, patients with ITPase deficiency had a lower occurrence 
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Table 3.1 | Baseline characteristics
Baseline variables
Total
N=213
Normal ITPase 
activity
n=152
ITPase deficiency
n=61 p-value
Age 45 (39-50) 44 (38–49) 46 (40-54) 0.25
Male 145 (68%) 100 (66%) 45 (74%) 0.26
BMI in kg/m2 c 26.0 (23.7-28.1) 25.8 (23.3–28.0) 26.4 (24.1-30.3) 0.13
HCV Genotype 
1
2
3
4
105 (49%)
19 (9%)
76 (36%)
13 (6%)
76 (50%)
11 (7%)
53 (35%)
12 (8%)
29 (48%)
8 (13%)
23 (38%)
1 (2%)
0.20
Histology/ elastography 
METAVIR score d
F0-1
F2
F3
F4
69 (32%)
67 (32%)
20 (9%)
39 (18%)
54 (38%)
46 (33%)
16 (11%)
25 (18%)
15 (28%)
21 (39%)
4 (7%)
14 (26%)
0.47
Hemoglobin, in mmol/L
     Anemia e
9.3 (8.7-9.9)
8 (4%)
9.2 (8.7–9.9)
5 (3%)
9.3 (8.7-9.9)
3 (5%)
0.79
0.57
Platelet count, in platelet x109/L
     Thrombocytopenia e
197 (152-234)
48 (23%)
198 (154–234)
31 (20%)
191 (145-241)
17 (28%)
0.38
0.24
Absolute neutrophil count, in 
cells/µL c
3200 (2500-4200) 3400 (2700–4400) 2800 (2300-3500) 0.022
Albumin, in g/L 44 (42-46) 44 (42–46) 44 (42-45) 0.22
Bilirubin, in µmol/L 10 (7-13) 10 (7–13) 10 (7-14) 0.75
Prothrombin time, in seconds 12.4 (11.7-13.2) 12.4 (11.7–13.2) 12.5 (11.8-13.5) 0.76
AST/ALT ratio c 0.73 (0.54-1.0) 0.74 (0.55-0.98) 0.72 (0.52-1.0) 0.91
Gamma-gt, in IU/L c 62 (33-118) 62 (33-111) 63 (39-150) 0.29
Creatinin, in mmol/L c 71 (63-80) 71 (63-80) 70 (67-76) 0.57
HCV RNA load < 800,000 IU/mL c 60 (28%) 35 (26%) 25 (46%) 0.007
Use of anticoagulants 7 (3%) 4 (3%) 3 (5%) 0.40
Presence of haemophilia 11 (5%) 8 (5%) 3 (5%) 0.92
Presence of DM 12 (6%) 11 (7%) 1 (2%) 0.11
Smoking 129 (61%) 92 (66%) 37 (69%) 0.71
History of IV drug use 121 (57%) 82 (55%) 39 (66%) 0.15
Peginterferon alfa-2a 151 (71%) 112 (74%) 39 (64%) 0.16
Peginterferon induction regimen 12 (6%) 10 (7%) 2 (3%) 0.36
Dose of RBV, in mg/kg 13.2 (11.8-14.5) 13.5 (12.0–14.6) 12.8 (10.3–14.1) 0.036
Abbreviations: ITPase, inosine triphosphaye pyrophosphatase; BMI, body mass index; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; DM, diabetes mellitus; IV, intravenous; RBV, ribavirin
a. Medians are presented as number (IQR). Numbers are presented as n, (percentage of whole group)
b. Variables with a ‘c’ were missing in ≥ 10%
c. Liver biopsy or elastography was available in 195 patients
d. Anemia was defined as a Hb concentration below 8.1 mmol/L for men and below 7.45 mmol/L for women, 
thrombocytopenia was defined as a platelet count below 150x109/L
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Table 3.2 | Univariable and multivariable linear regression analysis for absolute Hb decline at week 4 
Baseline variables
Univariable
Beta (95% CI) p-value
Multivariable
Beta (95% CI) p-value
Age, per year 0.05 (-0.09-0.02) 0.473 0.04 (-0.01-0.02) 0.535
Female gender -0.09 (-0.38-0.20) 0.545 0.24 (-0.03-0.50) 0.086
Cirrhosis 0.09 (-0.26-0.44) 0.628
DM -0.01 (-0.60-0.59) 0.984
BMI -0.01 (-0.05-0.02) 0.490
Platelet count, per 10x109/L -0.02 (-0.04-0.00) 0.115 -0.02 (-0.04- -0.00) 0.022
Hemoglobin, per mmol/L 0.36 (0.21-0.52) <0.001 0.44 (0.29-0.59) <0.001
Peg 2b vs Peg 2a -0.08 (-0.38-0.22) 0.583
Induction therapy 0.37 (-0.20-0.94) 0.203
RBV dose, per mg/kg 0.11 (0.05-0.16) <0.001 0.09 (0.04-0.13) <0.001
Treatment naïve 0.05 (-0.31-0.42) 0.776
Presence of hemophilia 0.44 (-0.21-1.09) 0.184
Use of anticoagulants -0.26 (-1.00-0.48) 0.490
HCV Genotype (2/3 vs 1/4) -0.38 (-0.65- -0.11) 0.006
IL28B (CC vs CT/TT) -0.12 (-0.40-0.17) 0.422
ITPA-1 (CC vs CA/AA) 1.02 (0.52-1.51) <0.001
ITPA-2 (AA vs AC/CC) 0.81 (0.50-1.12) <0.001
Normal ITPase activity 0.93 (0.66-1.21) <0.001 0.89 (0.64-1.14) <0.001
Abbreviations: DM, diabetes mellitus; BMI, body mass index; RBV, ribavirin; IL28B, interleukin-28B; ITPA, inosine 
triphosphatase; ITPase, inosine triphosphaye pyrophosphatase
a. The final model was created by using a backward stepwise method. Confounding was checked. 
Figure 3.1 | Median hemoglobin and platelet count
Median hemoglobin (A) and platelet count (B) at baseline, at week 4, 8 and 12 and the nadir hemoglobin and 
platelet count during treatment. Dashed line represents the patients with ITPase deficiency and the black line 
represents patients with normal ITPase activity. Abbreviations: ITPase, inosine triphosphaye pyrophosphatase.
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of a clinically significant decline in Hb as compared to patients without ITPase deficiency at week 4, 8 
and 12 (p <0.001 for all timepoints, Supplementary Figure 3.2). 
Multivariable linear regression analysis showed that baseline platelet count (Beta -0.02, 95% CI 
-0.04–-0.00, p = 0.022), baseline Hb concentration (Beta 0.44, 95% CI 0.29–0.59, p <0.001), RBV dose 
per kilogram body weight (Beta 0.09, 95% CI 0.04–0.13, p <0.001) and normal ITPase activity (Beta 
0.89, 95% CI 0.64–1.14, p <0.001) were associated with the absolute decline in Hb concentration at 
week 4 of treatment (Table 3.2). The interaction terms between the variables in the final model were 
not statistically significant. Also in a sensitivity analysis for which patients with a PegIFN induction 
regimen were excluded the presence of normal ITPase activity was associated with the occurrence of 
a significant decline in Hb concentration at week 4 (Beta 0.91, 95% CI 0.65–1.18, p <0.001). 
In multivariable logistic regression analysis, the occurrence of a significant decline, as a 
dichotomous variable, was associated with baseline Hb concentration (OR 2.31, 95% CI 1.47– 3.64, p 
<0.001), RBV dose per kilogram body weight (OR 1.41, 95% CI 1.19–1.67, p <0.001) and normal ITPase 
activity (OR 11.5, 95% CI 4.24–31.1, p <0.001) (Supplementary Table 3.2). Again, in a sensitivity analysis 
among patients without a PegIFN induction regimen, the presence of normal ITPase activity was 
associated with the occurrence of a significant decline in Hb concentration at week 4 (OR 13.4, 95% 
CI 4.61–39.0, p <0.001).
ITPase deficiency and on-treatment platelet counts
Median platelet count was only significantly higher at week 4 of treatment among patients with 
normal ITPase activity compared to patients with ITPase deficiency (144x109/L, (IQR 103– 196) vs 
132x109/L, (IQR 99–160); p = 0.040, Figure 3.1B). At least one episode of thrombocytopenia was 
present among 166 (78%) patients, of which 22 (10%) had a platelet count below 50x109/L. Only ten 
(5%) patients experienced a platelet count below 50x109/L at week 4 of treatment. The occurrence of 
a platelet count below 50x109/L among patients with normal ITPase  activity (4%) and patients with 
ITPase deficiency (7%) was comparable (p = 0.418). When the whole treatment period was taken into 
account, the occurrence of a platelet count below 50x109/L was still similar between patients with 
normal ITPase activity and ITPase deficiency (11% vs 10%, respectively, p = 0.881). 
In multivariable linear regression analysis, adjusted for Hb decline, baseline platelet count 
(per 10x109/L, Beta 2.55, 95%CI 1.73–3.38, p <0.001) and cumulative dose of PegIFN (per 100 mcg, 
Beta 4.86, 95%CI 2.75–6.98, p <0.001) were associated with more decline in platelet count at week 
4, whereas the presence of normal ITPase activity (Beta -18.5, 95%CI -29.7–-7.31, p = 0.001) was 
significantly associated with less decline in platelet count at week 4 (Table 3.3). When patients with a 
PegIFN induction regimen were excluded, presence of normal ITPase activity was still associated with 
less decline in platelet count (Beta -16.5, 95%CI -27.6–-5.33, p = 0.004).
ITPase deficiency, dose reductions, EPO and blood transfusions
In total, 20 (9%) patients underwent at least one dose reduction of RBV and 44 (21%) patients at least 
one dose reduction of PegIFN. At least one blood transfusion was given to 27 (13%) patients and 12 
(6%) patients received at least one dose of EPO. Nineteen (13%) patients with normal ITPase activity 
underwent at least one dose reduction of RBV, whereas one (2%) patient with ITPase deficiency 
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underwent at least one dose reduction (p = 0.014, Figure 3.2). The dose of PegIFN was reduced among 
36 (24%) patients with normal ITPase activity and among eight (13%) patients with ITPase deficiency 
(p = 0.085). Blood transfusion and EPO were administered to 23 (15%) and twelve (8%) patients with 
normal ITPase; and to 4 (7%) and none (0%) of the patients with ITPase deficiency (p = 0.089 and p = 
0.024, respectively).
ITPase deficiency and virological response
In total, 123 (58%) patients attained SVR, 45 (21%) patients had a virological relapse and 43 (20%) 
were non-responder. Two patients, who were both HCV RNA negative at the end of treatment, were 
lost to follow-up before being able to assess the sustainability of their virological response. Neither 
polymorphisms in the ITPA gene (ITPA–1 CC vs. CA/AA, OR 1.84 95% CI 0.66–5.15, p = 0.24; ITPA–2 AA 
vs AC/CC, OR 1.03 95% CI 0.54–1.97, p = 0.92) nor the presence of normal ITPase activity (OR 1.23, 95% 
CI 0.68–2.24, p = 0.50) were associated with SVR. In multivariable logistic regression analyses, age (per 
year, OR 0.94, 95% CI 0.90–0.98, p = 0.004), baseline gamma-glutamyltransferase (per U/L, OR 0.99, 
Table 3.3 | Univariable and multivariable linear regression analysis for absolute decline in platelet count at 
week 4 
Baseline variables
Univariable
Beta (95% CI) p-value
Multivariable
Beta (95% CI) p-value
Age, per year -0.75 (-1.35- -0.15) 0.015 -0.44 (-9.46-2.32) 0.233
Female gender 7.13 (-5.25-19.5) 0.257 6.15 (-4.69-17.0) 0.265
Cirrhosis -5.10 (-19.8-9.62) 0.495
DM -3.23 (-28.2-21.8) 0.799
BMI -0.22 (-1.71-1.28) 0.776
Platelet count, per 10x109/L 2.49 (1.60-3.37) <0.001 2.55 (1.73-3.38) <0.001
Hb, per mmol/L -1.06 (-8.04-5.92) 0.765
Hb decline, per mmol/L -7.89 (-13.8- -1.93) 0.010 -3.57 (-9.46-2.32) 0.233
Peg 2b vs Peg 2a -15.0 (-27.5- -2.43) 0.020
Induction therapy 13.9 (-10.0-37.9) 0.253
Cumulative dose of PegIFN, 
per 100 mcg
4.45 (2.12-6.78) <0.001 4.86 (2.75-6.98) <0.001
RBV dose, per mg/kg -1.21 (-3.61-1.19) 0.320
HCV Genotype (2/3 vs 1/4) 3.69 (-8.00-15.4) 0.534
IL28B (CC vs CT/TT) -5.76 (-17.9-6.40) 0.351
ITPA-1 (CC vs CA/AA) -18.2 (-39.8-3.26) 0.096
ITPA-2 (AA vs AC/CC) -9.54 (-23.4-4.33) 0.177
Normal ITPase activity -14.9 (-27.5- -2.19) 0.022 -18.5 (-29.7- -7.31) 0.001
Abbreviations: DM, diabetes mellitus; BMI, body mass index; Hb, hemoglobin; RBV, ribavirin; IL28B, interleukin-
28B; ITPA, inosine triphosphatase;  ITPase, inosine triphosphaye pyrophosphatase
a. The final model was created by using a backward stepwise method. Confounding was checked. 
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95% CI 0.99–1.00, p = 0.016), HCV genotype (2/3 vs 1/4, OR 4.26, 95% CI 1.89–9.63, p <0.001) and IL28B 
genotype (CC vs CT/TT, OR 5.06, 95% CI 2.16–11.9, p<0.001) were associated with SVR (Supplementary 
Table 3.3).
Univariable logistic regression analysis showed that the presence of normal ITPase activity was 
not significantly associated with virological relapse (OR 0.67, 95% CI 0.34–1.36, p = 0.27). Multivariable 
logistic regression analysis showed that only age (OR 1.05, 95% CI 1.01–1.10, p = 0.02) was significantly 
associated with virological relapse.
DISCUSSION
This large cohort study in a real world setting found that genetic polymorphisms in the ITPA gene, 
resulting in ITPase deficiency, were associated with less Hb decline during PegIFN and RBV therapy 
among Caucasian patients with chronic HCV infection. Patients with normal ITPase activity were at 
higher risk to undergo dose reductions of both PegIFN and RBV, receive blood transfusions and be 
administered EPO. These patients may benefit from early administration of supportive hematopoietic 
growth factors in order to improve treatment adherence. Furthermore it could be a helpful tool in the 
decision of adding RBV, which has shown to be of additional value for some IFN-free regimens.146 155 
Figure 3.2 | ITPase deficiency, dose reductions, EPO and blood transfusions 
Percentage of patients with at least one dose reduction of RBV or PegIFN, at least one blood transfusion or one 
dose of EPO during treatment. White bars represent the patients with normal ITPase activity and the black bars 
represent patients with ITPase deficiency. Abbreviations: ITPase, inosine triphosphate pyrophosphatase; RBV, 
ribavirin; PegIFN, pegylated interferon; EPO, erythropoietin.
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Patients with ITPase deficiency (27% of our cohort) experienced lower declines in Hb concen-
tration compared to patients with normal ITPase activity during the first four weeks of antiviral 
treatment. As expected, besides the presence of normal ITPase activity, RBV dose was also associated 
with a significant decline in Hb at week 4. The results of the present study confirm observations 
described in previous studies.217 221 222 More important, our study revealed that patients with normal 
ITPase activity underwent more dose adjustments for RBV (13% vs 2%), and more often EPO was 
administered (8% vs 0%). Two previous studies among patients with HCV genotype 2 and 3 found no 
association between the ITPase activity and the need for RBV dose reductions.217 222 In the first study, 
including 238 patients with HCV genotype 2 and 3, RBV dose was reduced in 35 patients (15%).222 
The presence of ITPase deficiency was not statistically associated with a lower hazard ratio (HR) for 
RBV dose reductions (HR 0.80, 95% CI 0.35–1.71, p = 0.57). This study used weight-based RBV and the 
dose was not reduced until Hb concentration fell below 5.9 mmol/L (i.e. 9.5 g/dL). The second study 
included 349 patients with HCV genotype 2 and 3, which showed that 6% of the patients did not 
receive the full planned dose of RBV. This low rate can be attributed to the use of low-dose RBV (i.e. 
800 mg/ day) and the shorter treatment duration among this patients. In contrast, and in line with our 
data, a study among solely HCV genotype 1 infected patients did describe that the presence of ITPase 
deficiency resulted in fewer RBV dose reductions.221 A high rate of RBV dose reductions was found in 
this study (47%), attributed to the fact that they included missed doses in this rate. Only four patients 
in this trial received EPO. In general, these data were based on clinical trial cohorts, solely including 
selected patients with specific HCV genotypes, different doses of RBV as well as limited use of blood 
transfusion and EPO. Furthermore these studies used strict dosing rules, instead of dose adjustments 
according to the treating physician, which is more representative for the clinical setting. Recently, 
another real-world study, also including all HCV genotypes, found that patients with ITPase deficiency 
required less RBV dose reductions and less EPO.223 In 18% of the patients with ITPase deficiency a RBV 
dose reductions was required, whereas 41% of the patients with normal ITPase activity underwent 
at least one dose reductions of RBV. However, this study used strict dosing rules as well, which is not 
an optimal reflection of daily practice. Moreover, they did not report on the ethnic background of 
patients, which is essential in genetic studies.230 
The presence of ITPase deficiency was also associated with a deeper decline in platelet count at 
week 4 of treatment, which could be explained by the absence of thrombocytosis in reaction to the 
hemolytic anemia. This is in line with previous studies which showed that reduced ITPase activity, 
which protects against RBV-induced anemia, is associated with the occurrence of treatment-induced 
thrombocytopenia.217 218 231 ITPase deficiency was not related to the occurrence of a platelet count 
below 50x109/L, but this rarely happens among patients with chronic HCV infection who are treated 
with PegIFN and RBV. Indeed, also in the current study, only 10% of patients had a platelet count 
below 50x109/L during their treatment course. Nevertheless, it could be a predictive tool among 
patients with cirrhosis, who are more prone to develop severe thrombocytopenia.196
We did not find ITPase deficiency to be associated with virological response to PegIFN and RBV, 
perhaps because of limited power in our current study. Data on the influence of ITPase activity on 
the virological response is inconclusive, probably due to the inclusion of various HCV genotypes, 
heterogeneity in treatment regimens and the various ways in which the association was analyzed. Our 
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results are in line with the largest study to date, among patients with HCV genotype 1, which did not 
show a relation between ITPase deficiency and SVR either.221 Nevertheless, it could be hypothesized 
that the higher frequency of dose reductions among patients with normal ITPase activity would 
compromise treatment efficacy, as was reported previously.111 112 However, the mechanism by which 
anemia and ITPase deficiency influence virological response is still not fully unraveled.
The clinical importance of ITPA polymorphisms in the era of regimes with DAAs could be debated. 
Although limited data is available, previous studies among patients treated with triple therapy 
including telaprevir also showed that a ITPA polymorphism (rs1127354) was associated with the 
development of on-treatment anemia.232-234 Unfortunately, these studies are solely among patients of 
Asian ancestry, and these patients are monoallellic for ITPA polymorphism rs7270101. In contrast to 
these results, the limited data available for Caucasian patients showed contrasting results.235 Among 
patients with advanced hepatic fibrosis, ITPA polymorphisms were associated with the severity of Hb 
decline at week 4, but not at week 12 of therapy. This effect was attributed to the increased plasma levels 
of RBV after the first 4 weeks of triple therapy.236 Recently, it was shown that ITPA polymorphisms were 
also associated with anemia during IFN-free therapy.237 Studies on the impact of RBV dose reductions 
among patients treated with triple therapy, including PegIFN, RBV and boceprevir, demonstrated that 
a lower dose of RBV did not affect SVR rates.238 239 Moreover, RBV dose reductions among patients with 
HCV genotype 2 and 3, treated with IFN-free regimens, also suggested no effect on SVR rates.138 139 
Nevertheless, as RBV will still be a component of IFN-free treatment regimens, ITPA polymorphisms 
can select patients who are prone to develop RBV-induced hemolytic anemia in order to apply more 
conservative and/ or earlier dose reductions or early administration of supportive agents. Secondly, it 
may be used as an additive tool to select a specific IFN-free regimen for the individual patient as not 
all regimens require addition of RBV for optimal virological efficacy. However, more data is needed in 
order to conclude on the clinical utility of these SNPs.
A limitation of this study is that RBV concentrations were not available. A previous study showed 
higher RBV concentrations at week 4 among patients with normal ITPase activity compared to patients 
with ITPase deficiency.217 This could be explained by the reduced hemolytic anemia that was present 
in the patients with ITPase deficiency, generating a larger distribution volume for the intracellular 
forms of RBV, leading to lower extracellular concentrations of RBV. On the other hand, lower plasma 
concentrations of RBV could have led to the protection against anemia. In contrast, another study 
among 546 patients showed no association between ITPase deficiency and RBV levels (p = 0.11).221 
Finally, due to the retrospective character of the study, we were not able to measure ITPase activity 
directly, as this requires freshly acquired erythrocytes. Nevertheless, classification of the predicted 
ITPase activity by combining the two genotypes has been suggested to be reliable.228 229
In conclusion, this real-world study showed that ITPase deficiency is associated with the protection 
against hemolytic anemia among Caucasian patients with chronic HCV infection who are treated with 
PegIFN and RBV. This led to less dose reductions of RBV and PegIFN as well as less administration of 
blood transfusions and EPO. Since treatment efficacy is hampered by dose reductions, patients with 
normal ITPase activity may benefit from early strategies in order to improve treatment adherence.
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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure 3.1 | Abbreviations: ITPA, inosine triphosphatase; SNP, single nucleotide polymorphism.
Supplementary Figure 3.2 | Percentage of patients with a clinically significant decline in Hb within the first 
twelve weeks. A significant decline was defined as a decrease of at least 1.86 mmol/L (3.0 g/dL) or an absolute 
value lower than 6.21 mmol/L (10 g/dL). White bars represent the patients with normal ITPase activity and the 
black bars represent patients with ITPase deficiency. Abbreviations: Hb, hemoglobin; ITPase, inosine triphosphate 
pyrophosphatase.
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Supplementary Table 3.1 | Predicted ITPase activity according to genotype of ITPA-1 and ITPA-2
ITPA-1 genotype a ITPA-2 genotype a
Predicted ITPase 
activity (%) a
ITPase 
deficient a
Distribution within 
cohort n (%)
Wild type (CC) Wild type (AA) 100 No 152 (67%)
Wild type (CC) Heterozygote (AC) 60 Yes 40 (18%)
Wild type (CC) Homozygote (CC) 30 Yes 5 (2.2%)
Heterozygote (CA) Wild type (AA) 25 Yes 12 (5.3%)
Heterozygote (CA) Heterozygote (AC) 10 Yes 4 (1.8%)
Homozygote (AA) Wild type (AA) <5 Yes (0%)
Abbreviations: ITPase, inosine triphosphate pyrophosphatase; ITPA, inosine triphosphatase 
Supplementary Table 3.2 | Univariable and multivariable logistic regression analysis for significant hemoglobin 
decline at week 4 
Baseline variable
Univariable Multivariable c
OR (95% CI) a p-value OR (95% CI) a p-value
Age, per year 1.01 (0.98-1.04) 0.49 1.00 (0.96-1.04) 0.95
Female gender 0.74 (0.40-1.36) 0.33 1.07 (0.47-2.44) 0.87
Cirrhosis 1.43 (0.70-2.90) 0.33
DM a 1.06 (0.33-3.47) 0.92
BMI a 0.98 (0.91-1.05) 0.55
Platelet count, per 10x109/L 0.98 (0.93-1.02) 0.31
Hb, per mmol/L a 1.69 (1.18-2.42) 0.004 2.32 (1.48-3.65) <0.001
PegIFN 2a vs PegIFN 2b a 1.29 (0.69-2.39) 0.42
PegIFN induction regimen a 2.17 (0.67-7.10) 0.198
RBV dose, per mg/kg a 1.31 (1.14-1.50) <0.001 1.41 (1.19-1.67) <0.001
Treatment naïve 0.58 (0.28-1.20) 0.143
Presence of hemophilia 2.32 (0.63-8.48) 0.204
Use of anticoagulants 0.58 (0.11-3.07) 0.52
HCV Genotype (2/3 vs 1/4) a 0.36 (0.20-0.65) 0.001 0.58 (0.27-1.22) 0.15
IL28B (CC vs CT/TT) a 0.99 (0.55-1.76) 0.96
ITPA-1 (CC vs CA/AA) a, b
ITPA-2 (AA vs AC/CC) a 6.42 (2.58-16.0) <0.001
Normal ITPase activity a 9.72 (3.93-24.0) <0.001 12.1 (4.48-32.8) <0.001
Abbreviations: CI, confidence interval; DM, diabetes mellitus; BMI, body mass index; Hb, hemoglobin; PegIFN, 
pegylated interferon; RBV, ribavirin; HCV, hepatitis C virus; IL28B, interleukin-28B; ITPA, inosine triphosphatase; 
ITPase, inosine triphosphaye pyrophosphatase
a. Within the CA/AA genotype no significant decline in Hb occurred
b. The final model was created by using a backward stepwise method. Confounding was checked. 
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Supplementary Table 3.3 | Univariable and multivariable logistic regression analysis for SVR 
Baseline variable
Univariable Multivariable b
OR (95% CI) a p-value OR (95% CI) a p-value
Age, per year 0.93 (0.90-0.96) <0.001 0.93 (0.89-0.98) 0.002
Female gender 1.85 (1.01-3.38) 0.046
Cirrhosis 0.29 (0.14-0.61) 0.001 0.38 (0.13-1.1) 0.07
DM a 0.35 (0.10-1.18) 0.090 0.54 (0.08-3.5) 0.51
BMI a 0.95 (0.88-1.01) 0.12
Gamma-glutamyltransferase, 
per U/L
0.99 (0.98-0.99) <0.001 0.99 (0.99-1.00) 0.004
Baseline platelet count (per 
10x109/L)
1.08 (1.03-1.14) 0.002
HCV Genotype  2/3 vs 1/4 a 7.44 (3.91-14.2) <0.001 4.55 (2.02-10.2) <0.001
PegIFN 2a vs PegIFN 2b a 0.98 (0.54-1.79) 0.95
Treatment naïve 1.78 (0.87-3.64) 0.11
HCV RNA < 800,000 IU/mL a 1.55 (0.83-2.91) 0.17
IL28B (CC vs CT/TT) a 4.04 (2.15-7.59) <0.001 4.20 (1.85-9.55) 0.001
Significant Hb decline at 
week 4 a
0.50 (0.28-0.88) 0.017
ITPA-1 CC vs CA/AA a 1.84 (0.66-5.15) 0.24
ITPA-2 AA vs AC/CC a 1.03 (0.54-1.97) 0.92
Normal ITPase activity a 1.23 (0.68-2.24) 0.50
Abbreviations: SVR, sustained virological response; CI, confidence interval; DM, diabetes mellitus; BMI, body mass 
index; HCV, hepatitis C virus; PegIFN, pegylated interferon; IL28B, interleukin-28B; Hb, hemoglobin; ITPA, inosine 
triphosphatase;  ITPase, inosine triphosphaye pyrophosphatase
c. The final model was created by using a backward stepwise method. Confounding was checked. 
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ABSTRACT 
Background & Aims 
Patients with chronic hepatitis C virus (HCV) infection may develop cirrhosis with portal hypertension, 
reflected by decreased platelet count and splenomegaly. This retrospective cohort study aimed to 
assess changes in platelet counts after antiviral therapy among chronic HCV-infected patients with 
advanced fibrosis.
Methods
Platelet counts and spleen sizes were recorded in an international cohort of patients with Ishak 4–6 
fibrosis who started antiviral therapy between 1990 and 2003. Last measured platelet counts and 
spleen sizes were compared with their pre-treatment values (within 6 months prior to the start of 
therapy). All registered platelet count measurements from 24-week following cessation of antiviral 
therapy were included in repeated measurement analyses.
Results
This study included 464 patients; 353 (76%) had cirrhosis and 187 (40%) attained sustained virological 
response (SVR). Among patients with SVR, median platelet count, increased by 35×109/L (IQR 7–62, 
p <0.001). In comparison, patients without SVR showed a median decline of 17×109/L (IQR 5–47, p 
<0.001). In a subgroup of 209 patients, median decrease in spleen size was 1.0 cm (IQR 0.3–2.0) for 
patients with SVR, while median spleen size increased with 0.6 cm (IQR 0.1–2.0, p <0.001) among those 
without SVR. The changes in spleen size and platelet count were significantly correlated (R=0.41, p 
<0.001).
Conclusions
Among chronic HCV-infected patients with advanced hepatic fibrosis, the platelet counts improved 
following SVR and the change in platelets correlated with the change in spleen size following antiviral 
therapy. These results suggest that HCV eradication leads to reduced portal pressure.
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INTRODUCTION
The continuous inflammation in livers of patients with chronic hepatitis C virus (HCV) infection may 
cause hepatic fibrogenesis. Progression of this process may eventually lead to cirrhosis, at which stage 
patients have an unfavorable prognosis due to the elevated risk of hepatocellular carcinoma (HCC) 
and liver failure.55 In one of the largest studies on the fibrosis progression rate, dating back to 1997, 
it was estimated that 33% of patients with chronic HCV infection develop cirrhosis within 20 years.178 
However, the number of patients who develop cirrhosis could be higher over a longer period of time 
as fibrosis development may not be linear. In fact, as the population with chronic hepatitis C is aging, 
it is expected that the incidence of HCV-related cirrhosis will increase during the upcoming years.63
The treatment of chronic HCV infection improved enormously during the last two decades. Even 
in case of advanced hepatic fibrosis, sustained virological response (SVR) rates over 90% can be 
achieved with combination regimens of direct-acting antiviral agents.142 145 146 156 240 Several studies 
showed that hepatic fibrosis can regress once HCV is eradicated as causative agent of liver injury, 
also among patients with advanced hepatic fibrosis.74 241-247 However, these studies are limited by a 
short follow-up duration or low number of patients with cirrhosis. Also, there is significant sampling 
error with respect to percutaneous liver biopsy, which remains an invasive procedure with potentially 
severe complications so that repeated assessments of liver histology are often not feasible.247-249 The 
longitudinal pattern of hepatic fibrosis regression is thus difficult to study. 
The platelet count is strongly related to the degree of hepatic histopathological abnormalities 
and portal pressure, especially among those patients with bridging fibrosis or cirrhosis.250-257 Indeed, 
lower platelets have been repeatedly associated with a higher risk for cirrhosis-related morbidity and 
mortality, which supports that the platelet count is representative of the stage of liver disease.55 79-81 
Importantly, the change in platelets correlated with the change in hepatic fibrosis following antiviral 
therapy among patients with chronic HCV infection, including those who attained SVR.258 259 Changes 
in platelets thus represent a noninvasive alternative to assess the evolution of the stage of liver disease 
and portal pressure. Because splenic sequestration of blood cells as a direct result of elevated portal 
pressure causes the spleen to increase in size, splenomegaly is also considered a non-invasive marker 
of the degree of portal hypertension or presence of esophageal varices.250-252
The aim of our study was to assess the change in platelet counts following SVR in a large cohort 
of consecutively interferon-treated patients with chronic HCV infection and biopsy-proven bridging 
fibrosis or cirrhosis.
PATIENTS AND METHODS
Patients
All consecutive patients with chronic HCV infection and bridging fibrosis or cirrhosis (Ishak fibrosis 
score 4–6) who initiated interferon-based antiviral therapy between 1990 and 2003 were included 
from five large hepatogy units in Europe and Canada. The design of this retrospective cohort study 
has been described in detail previously.81 For the current study, the patients were assessed from the 
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last received interferon-based treatment course onwards. Hereby, it was prevented that interferon-
induced bone marrow suppression influenced the platelet counts during follow-up as a result of 
retreatment. Excluded were patients with a human immunodeficiency virus or hepatitis B virus co-
infection, patients who had developed HCC or liver failure prior to start of follow-up or prior to the 
first available platelet count measurement during follow-up, and patients who received long-term 
low-dose pegylated interferon maintenance therapy. Patients without follow-up beyond January 1st 
2010 were invited for a single visit to the outpatient clinic.
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and the 
principles of Good Clinical Practice. According to the standards of the local ethics committees, written 
informed consent was obtained from patients visiting the outpatient clinics.
Outcome measures
Pre-treatment markers of liver disease severity closest to the start of therapy were included, as long 
as these were available within 6 months before the start of antiviral therapy. All available platelet 
count measurements were registered from 24 weeks after cessation of interferon-based antiviral 
therapy. A platelet count <150×109/L was defined as thrombocytopenia. Measurements obtained 
after the diagnosis of HCC or liver failure were not considered. The diagnosis of HCC was based on 
histopathological confirmation or two coincident imaging techniques (computed tomography, mag-
netic resonance imaging, or contrast-enhanced ultrasonography) showing a focal lesion larger than 
2 cm with arterial-phase hyper-enhancement or one imaging technique showing a focal lesion larger 
than 2 cm with arterial-phase hyper-enhancement in the presence of an α-fetoprotein level greater 
than 400 ng/mL.187 Liver failure was defined as an episode of ascites, bleeding varices, jaundice, or 
overt hepatic encephalopathy. Only the first episode of liver failure was considered in case patients 
experienced multiple liver failure events. The last available spleen size measurement (in centimeters), 
as determined by radiological examination (ultrasound, computed tomography or magnetic reso-
nance imaging), was registered. Spleen sizes that were measured after initiation of treatment for HCC 
or portal hypertension were not considered, and in such cases, the last spleen size prior to these 
events was used.
Statistical analyses
Baseline characteristics were compared between patients with SVR and patients without SVR using 
the Mann-Whitney test for continuous and the chi-square test for categorical variables. To assess 
the difference in median platelet count per Ishak fibrosis scores (4, 5, or 6), the Kruskal–Wallis was 
used. Correlations were analyzed with Spearman’s rank correlation coefficient. The relation between 
baseline laboratory markers and the degree of hepatic fibrosis (Ishak 4/5 versus 6 and Ishak 4 versus 
5/6) was assessed with logistic regression and receiver operating characteristic curve analysis.
Per virological response group, the statistical significance of the change in platelets from baseline 
to the last available measurement during follow-up was assessed with the Wilcoxon signed-rank test. 
The difference in the change of platelets between patients with SVR and patients without SVR was 
assessed with the Mann- Whitney test. Per virological response group, McNemar’s test was used to 
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assess the difference in the percentage of patients with thrombocytopenia at baseline and last follow-
up. The change in spleen size was assessed accordingly.
Linear regression analysis was used to determine which baseline variables were associated with 
the change in platelets from baseline to last follow-up among the patients who attained SVR. Repeated 
measurement analyses with a random intercept and slope per patient and an unstructured covariance 
matrix were performed to analyze the evolution of platelets over time, correcting for potential non-
linearity by including the squared time to the platelet count measurement into the model. As chronic 
HCV infection and interferon therapy can influence the platelets as well, 24 weeks after cessation of 
antiviral therapy was considered as time zero in the repeated measurement analyses. 
All statistical tests were two sided, and a p value <0.05 was considered to be statistically significant. 
SPSS version 17.0.2 (SPSS Inc., Chicago, IL, USA) and SAS 9.2 PROC GENMOD (SAS institute, Cary, NC, 
USA) were used for all statistical analyses.
RESULTS
Study population
Between 1990 and 2003, 546 patients with chronic HCV infection and histological proof of advanced 
hepatic fibrosis received interferon-based antiviral therapy. Eight patients who were lost-to-follow-up 
and eight patients who developed HCC or liver failure before 24 weeks after their initial treatment 
course were excluded. Of the remaining 530 patients, 125 (24%) attained SVR, and 405 (76%) did not. 
During follow-up, 204 patients without SVR were retreated at least once, which resulted in SVR for 
another 67 patients. Among retreated patients, seven experienced a cirrhosis-related complication 
before 24 weeks following their last treatment course, 14 received long-term low-dose pegylated 
interferon maintenance therapy, and 45 had no available platelet count measurement during follow-
up. These patients were excluded as well, so that the total study cohort consisted of 464 patients: 
187 with SVR and 277 without SVR (Figure 4.1). Table 4.1 summarizes the baseline characteristics 
according to the virological response to the last antiviral treatment course.
Platelet count in relation to hepatic fibrosis 
At baseline, platelet counts were associated with histological stage of fibrosis: the median platelet 
count was 186×109/L (interquartile range [IQR] 143–226) among patients with Ishak fibrosis score 
4, 160×109/L (IQR 134–209) among patients with Ishak fibrosis score 5 and 133×109/L (IQR 92–176) 
among patients with Ishak fibrosis score 6 (p <0.001). Accordingly, the percentage of patients with 
thrombocytopenia increased with higher Ishak fibrosis score (31%, 40%, and 60% for Ishak fibrosis 
score 4, 5, and 6, respectively, p <0.001). The platelet count could largely discriminate patients with 
Ishak fibrosis score 4/5 from those with Ishak 6 (area under the curve [AUC] 0.70, 95% confidence 
interval [CI] 0.65–0.75, p <0.001). The AUC of the platelet count was similar to differentiate between 
Ishak 4 and 5/6 (AUC = 0.69, 95% CI 0.63–0.74, p <0.001). The discriminating abilities of bilirubin, 
albumin, or the ratio between the aspartate and alanine aminotransferase were lower (AUCs ranging 
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Figure 4.1 | Study flow chart
Abbreviations: HCC; hepatocellular carcinoma, SVR; sustained virological response, PegIFN; pegylated interferon
Table 4.1 | Baseline characteristics according to virological response
Overall
(n = 464)
With SVR
(n = 187)
Without SVR
(n = 277) p value
Age, years 51 (44-57) 49 (44-57) 51 (44-58) 0.071
Male, n/total (%) 321/464 (69) 137/187 (73) 184/277 (66) 0.118
BMI, kg/m2 a 25.9 (23.4-28.7) 25.6 (23.1-28.6) 26.1 (23.8-29.0) 0.135
Fibrosis score, n/total (%) 0.429
      - Ishak 4 111/464 (24) 50/187 (27) 61/277 (22)
      - Ishak 5 91/464 (20) 33/187 (18) 58/277 (21)
      - Ishak 6 262/464 (56) 104/187 (55) 158/277 (57)
HCV genotype, n/total (%) <0.001
      - 1 300/440 (68) 93/179 (52) 207/261 (79)
      - 2 42/440 (10) 32/179 (18) 10/261 (4)
      - 3 79/440 (18) 46/179 (26) 33/261 (13)
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Table 4.1 | Continued
Overall
(n = 464)
With SVR
(n = 187)
Without SVR
(n = 277) p value
      - 4 15/440 (3) 6/179 (3) 9/261 (3)
    - Other 4/440 (1) 2/179 (1) 2/261 (1)
Type of treatment, n/total (%) <0.001
      - IFN mono 70/464 (15) 9/187 (5) 61/277 (22)
      - IFN and RBV  110/464 (24) 49/187 (26) 61/277 (22)
      - PegIFN mono 12/464 (3) 4/187 (2) 8/277 (3)
      - PegIFN and RBV 253/464 (54) 118/187 (63) 135/277 (49)
      - ConsensusIFN (+/- RBV) 11/464 (2) 2/187 (1) 9/277 (3)
      - PegIFN and RBV and PI 8/464 (2) 5/187 (3) 3/277 (1)
Laboratory markers of liver disease 
severity b
      - Platelet count, x109/L 150 (112-199) 162 (132-205) 142 (100-191) <0.001
      - Albumin, g/L 42 (39-44) 42 (40-44) 41 (38-44) 0.016
      - Bilirubin, μmol/L 13 (10-18) 12 (9-15) 14 (10-19) <0.001
      - AST/ALT ratio 0.73 (0.59-0.92) 0.68 (0.55-0.82) 0.76 (0.62-0.97) <0.001
Spleen size, cm 12.5 (11.0-14.3) 12.0 (10.6-13.8) 12.9 (11.2-14.8) 0.012
Treatment naïve, n/total (%) 267/464 (58) 109/187 (58) 158/277 (57) 0.789
Year treatment started 2001 (1998-2003) 2002 (2000-2003) 2001 (1998-2003) 0.003
Treatment duration, weeks 31 (22-48) 48 (25-49) 24 (16-48) <0.001
Diabetes mellitus, n/total (%) 71/464 (15) 20/187 (11) 51/277 (18) 0.024
History of severe alcohol use, n/total 
(%) c
100/437 (23) 38/180 (21) 62/257 (24) 0.460
AntiHBc positivity, n/total (%) 168/364 (46) 63/141 (45) 105/223 (47) 0.654
Data are presented as median (interquartile range), unless otherwise noted. Abbreviations: BMI; Body Mass Index, 
HCV; Hepatitis C Virus, IFN; interferon, PegIFN; pegylated interferon, AST; Aspartate aminotransferase, ALT; Alanine 
aminotransferase, antiHBc; anti-hepatitis B core antigen, PI; protease inhibitor. 
a. BMI was missing in 24 (13%) patients with SVR, and 61 (22%) patients without SVR.
b. Platelet count was missing in 9 (5%) patients with SVR and 29 (10%) patients without SVR. Albumin was 
missing in 13 (7%) patients with SVR and 48 (17%) patients without SVR. Total bilirubin was missing in 14 
(7%) patients with SVR and 36 (13%) patients without SVR. The AST/ALT ratio was missing in 15 (8%) patients 
with SVR and 37 (15%) patients without SVR. The spleen size was missing in 88 (47%) patients with SVR and 
130 (47%) patients without SVR.
c. Severe alcohol use was defined as the use of more than 50 gram of alcohol per day.
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from 0.56 to 0.62). Logistic regression analyses indicated that the platelet count was the only objective 
laboratory marker of liver disease severity that had an independent statistically significant association 
with the baseline stage of hepatic fibrosis (Table 4.2).
Changes in platelets following antiviral therapy
During the follow-up, which started 24 weeks post-treatment, 3387 platelet count measurements 
were registered. The median interval between platelet count measurements was 0.45 years (IQR 0.13–
0.79), which differed between patients with SVR (0.54 years, IQR 0.28–1.02) and patients without SVR 
(0.31 years, IQR 0.12– 0.61, p <0.001). The last available platelet counts were measured after a median 
of 5.7 (IQR 2.1–7.6) years among patients with SVR and after 4.4 (IQR 1.9–7.1) years among patients 
without SVR (p = 0.111). The median last platelet count was 198×109/L (IQR 166–248) in the group 
with SVR and 113×109/L (IQR 73–167) in the group without SVR (p <0.001). In 426 patients, a platelet 
count measurement was available both at baseline as well as during follow-up. Among those with 
SVR, 44 (62%) of the patients with thrombocytopenia at baseline showed a normal platelet count at 
the time of the last measurement (p <0.001), while only 2 (2%) patients with SVR and normal platelets 
at baseline had thrombocytopenia at the final measurement (Table 4.3). The platelet counts in these 
patients were 122×109/L and 134×109/L at the end of follow-up, respectively. Among patients without 
SVR, 47 (43%) patients changed from a normal platelet count at baseline to thrombocytopenia at the 
end of follow-up (p <0.001), while 14 (10%) patients with thrombocytopenia at baseline had normal 
platelet counts at the time of the last measurement. From baseline to the last available measurement, 
the platelet count showed a median increase of 35×109/L (IQR 7–62) among the patients with SVR 
Table 4.2 | Logistic regression analyses for the stage of hepatic fibrosis
Ishak score 4 versus 5/6
Univariate analyses Multivariate analyses
OR 95%CI p value OR 95%CI p value
Age, per year 1.05 1.02-1.07 <0.001 1.05 1.02-1.08 0.003
Males 1.17 0.74-1.84 0.511 - - -
BMI, per kg/m2 1.07 1.00-1.13 0.036 1.05 0.98-1.11 0.150
HCV genotype 3 1.53 0.89-2.63 0.121 - - -
Laboratory data
- Platelet count, per 10x109/L 0.92 0.89-0.96 <0.001 0.93 0.89-0.97 0.001
- Albumin, per g/L 0.94 0.89-0.99 0.012 0.98 0.91-1.05 0.505
- Bilirubin, per μmol/L 1.04 1.00-1.07 0.037 1.00 0.97-1.04 0.817
- AST/ALT ratio, per 0.1 1.01 0.96-1.06 0.713 - - -
Diabetes mellitus 1.66 0.86-3.21 0.135 - - -
History of severe alcohol use 1.17 0.70-1.94 0.546 - - -
AntiHBc positivity 0.93 0.57-1.51 0.760 - - -
Abbreviations: ALT; Alanine aminotransferase, AST; Aspartate aminotransferase, BMI; Body mass index, HCV; 
hepatitis C virus, CI; Confidence interval, OR; Odds Ratio. 
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and a median decrease of 17×109/L (IQR 5–47) among patients without SVR (p <0.001; for the paired 
analyses within each response group as well as for the comparison between both response groups).
Linear regression analyses were performed to assess which factors were associated with improvement 
of platelets following SVR (Table 4.4). Higher body mass index (BMI) was negatively associated with the 
change in the platelet count (β =1.59, standard error 0.78, p = 0.043). These analyses were corrected 
for the baseline platelet count and the time from SVR to the last platelet count measurement.
Repeated measurement analyses showed a gradual and almost linear increase in platelets 
beyond the moment of SVR, while the platelet counts further declined among those patients who 
did not attain SVR (p <0.001; for the change within each response group as well as for the comparison 
between both response groups) (Figure 4.2).
Spleen size 
Spleen sizes were available within 6 months prior to initiation of antiviral therapy in 99 (53%) patients 
with SVR and 147 (53%) patients without SVR. The median baseline spleen size was 12.0 cm (IQR 
10.6–13.8) among those patients who would later achieve SVR and 12.9 (IQR 11.2–14.8) among those 
without subsequent SVR (p = 0.012). The median spleen sizes were 11 cm (IQR 9.8–12.6), 12.5 cm (IQR 
11.4–14.0) and 13.0 cm (IQR 11.4–15.0) among patients with Ishak 4, 5, and 6 fibrosis, respectively (p 
<0.001). The AUC to discriminate Ishak 4/5 from Ishak 6 fibrosis using the spleen size was 0.65 (95%CI 
0.58–0.72, p <0.001) and 0.74 (95%CI 0.66–0.81, p <0.001) to discriminate Ishak 4 from Ishak 5/6. At 
baseline, the spleen size was significantly correlated to the platelet count (R =0.44, p <0.001).
Table 4.3 | Thrombocytopenia at baseline versus follow-up
Patients with SVR Last platelets <150 Last platelets ≥150 total
Baseline platelets <150 27 (38%) 44 (62%) 71
Baseline platelets ≥150 2 (2%) 105 (98%) 107
total 29 (16%) 149 (84%) 178
McNemar’s test: p<0.001
Patients without SVR Last platelets <150 Last platelets ≥150 total
Baseline platelets <150 124 (90%) 14 (10%) 138
Baseline platelets ≥150 47 (43%) 63 (57%) 110
total 171 (69%) 77 (31%) 248
McNemar’s test: p<0.001
Included in these analyses were all 426 patients (178 with SVR and 248 without SVR) who had both a platelet 
count measurement at baseline and a platelet count measurement during follow-up available. The grey-shaded 
cells indicate the groups of patients who showed a change in platelet count category from baseline to the last 
measurement during follow-up. Platelets are measured in x109/L.
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In 145 (78%) patients with SVR and 235 (85%) of patients without SVR, a spleen size was registered 
during follow-up. The last median spleen size was 10.4 cm (IQR 9.5–12.0) among patients with SVR 
versus 13.6 cm (IQR 11.6–16.0) among patients without SVR (p <0.001). Paired data on pre-treatment 
and end-of-follow-up spleen sizes were available in 209 (45%) patients. Among patients with SVR the 
spleen size showed a median decrease of 1.0 cm (IQR 0.3–2.0) and among patients without SVR the 
spleen size showed a median increase of 0.6 cm (IQR 0.1–2.0) from baseline to the last measurement 
(p <0.001; for the paired analyses within each response group as well as for the comparison between 
both response groups). The change in spleen size was statistically significantly correlated with the 
change in platelet count (R =0.41, p <0.001).
DISCUSSION
With this study, we showed that the platelet counts improved following eradication of chronic HCV 
infection among patients with bridging fibrosis or cirrhosis. With a repeated measurement analysis 
Figure 4.2 | Evolution of platelet counts according to virological response
Repeated measurement analyses with a random intercept and slope per patient and an unstructured covariance 
matrix were performed to analyze the evolution of platelets over time, correcting for potential non-linearity by 
including the squared time to the platelet count measurement into the model. The mean and 95% confidence 
interval (dotted line) are presented for patients with sustained virological response (SVR) and patients without 
SVR. Twenty-four weeks after cessation of antiviral therapy was considered as time 0. The statistical significance 
refers to both the change within the group with SVR, the change within the group without SVR as well as the 
difference between both virological response groups.
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including over 3000 platelet count evaluations, a rather linear increase in platelets was observed from 
the moment of SVR onwards. In contrast, patients who did not attain SVR showed a further decline. 
The increase in platelets continued for many years after SVR, suggesting that the histopathological 
abnormalities and portal pressure gradually improve among chronic HCV-infected patients with 
advanced liver disease who were successfully treated. This was further substantiated by the reduction 
in spleen size among the patients who had attained SVR. 
Four previous studies have assessed the change in platelets after SVR among Western patients 
with chronic HCV infection.80 242 260 261 George et al. followed 150 patients with interferon-induced 
clearance of their chronic HCV infection for 5 years.242 In this study, the mean pre-treatment platelet 
count (232×109/L) did not significantly differ from the mean last measured platelet count during 
follow-up (235×109/L). However, only 16 (11%) patients with cirrhosis were included in this study, 
at which stage platelet counts are most affected. Although limited by the inclusion of only 10 (10%) 
patients with cirrhosis as well, another follow-up study did show that the mean platelets significantly 
increased from 209×109/L at baseline to 239×109/L at the final follow-up (which ranged from 1 to 
22 years after successful therapy) among 100 patients with SVR.261 The change in platelets following 
Table 4.4 | Linear regression analyses for the change in platelets among patients with SVR a
SVR patients
Univariate analyses Multivariate analyses
β b SE p value β b SE p value
Age, per year 0.36 0.35 0.307 - - -
Males -3.88 7.46 0.603 - - -
BMI, per kg/m2 -1.75 0.83 0.037 -1.59 0.78 0.043
Ishak score 4 vs. 5/6 -1.90 7.37 0.797 - - -
HCV genotype 3 0.81 7.80 0.917 - - -
Laboratory markers at baseline
    - Platelet count, per 10x109/L -1.43 0.53 0.007 -1.84 0.05 0.001
    - Albumin, per g/L -0.44 0.83 0.596 - - -
    - Bilirubin, per μmol/L 0.10 0.46 0.835 - - -
    - AST/ALT ratio, per 0.1 -1.51 1.13 0.183 - - -
Diabetes mellitus 16.78 10.65 0.117 - - -
History of severe alcohol use -9.62 8.27 0.246 - - -
Time to last platelet count, per 
year
3.46 0.92 <0.001 3.37 0.99 0.001
AntiHBc positivity 13.11 7.87 0.098 - - -
Abbreviations: ALT; Alanine aminotransferase, AST; Aspartate aminotransferase, BMI; Body mass index, HCV; 
hepatitis C virus, SE; Standard error. 
a. The unstandardized coefficients are reported.
b. The β indicates that for each unit increase of the predictor variable, the change in platelets will increase (in 
case of a positive β) or decrease (in case of a negative β) by β units. So, when specified to our multivariate 
analysis above, for every 1 kg/m2 increase in BMI at baseline, the change in platelets will be 1.59 x109/L 
lower. 
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antiviral therapy was also assessed in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis 
(HALT-C) trial, which only included patients with at least Ishak F3 fibrosis.80 In contrast to both earlier 
described studies, a control group without SVR was included. As compared with pre-treatment levels, 
the mean platelet count was already significantly increased at the time SVR was attained (24 weeks 
after cessation of therapy). An additional post-hoc assessment among the patients with SVR after 
approximately 5 years of follow-up indicated that the platelet counts further increased with time. In 
line with our findings, the platelet counts declined among patients without SVR.
With repeated measurement analyses including all platelet count assessments during follow-up, 
we have showed the evolution of platelets according to the virological response following antiviral 
therapy among patients with bridging fibrosis or cirrhosis in more detail. Pre-treatment platelet 
counts were not included in these analyses as we started the follow-up at the time of SVR. This is 
important, because other mechanisms than splenic sequestration as a result of elevated portal 
pressure may reduce the platelet counts among patients with chronic HCV infection as well, such 
as reduced thrombopoietin (TPO) production, HCV-mediated bone marrow suppression and the 
presence of autoantibodies, causing chronic immune thrombocytopenic purpura.113 At the time of 
SVR, when HCV has been suppressed for more than 6 months, bone marrow suppression due to 
HCV or interferon-based therapy should no longer be of influence.115 196 Increasing TPO levels could 
continue to be relevant for the rise of platelets after SVR, because the production of TPO has been 
negatively correlated with the degree of hepatic fibrosis.262 263 In this case, regression of hepatic 
fibrosis and improvement of liver function would thus remain the underlying cause for the improved 
platelet counts. Nevertheless, lowering of portal pressure and reversal of splenomegaly is likely to 
remain a predominant reason for the increase in platelets once HCV is eradicated as cause of liver 
injury. Indeed, the change in platelets and change in spleen size were correlated in our study, which 
has not been shown by any of the previous studies. A limitation of the current study, however, is that 
data on baseline spleen size were available in only a limited number of the included patients, also 
because we restricted the baseline period to 6 months prior to the start of antiviral therapy. 
Another interesting result of our study was that higher BMI was negatively associated with the 
increase in platelet counts among the patients with SVR. Currently, risk factors for disease progression 
following viral eradication remain largely unknown. Our finding might be explained by the presence 
of hepatic steatosis and inflammation among patients with high BMI.264 265 Although data on the 
presence of steatosis is lacking in our cohort, its association with higher BMI is well known.266 To what 
extend these or other aspects of the metabolic syndrome may impact the clinical course of cirrhosis 
after patients have cleared their chronic HCV infection requires further study. For now, life-style 
modifications to reduce obesity may be advocated. 267
Despite the limitations of percutaneous liver biopsy (ethical concerns regarding multiple mea-
sure ments and the subjective character of hepatic fibrosis assessment), the impact of antiviral therapy 
on liver histology among patients with chronic HCV infection has been studied. 73 241 242 246 247 The 
largest study to date included almost 700 patients with at least METAVIR F2 fibrosis at baseline from 4 
randomized controlled trials.246 Even though all patients were biopsied already 24 weeks after cessation 
of antiviral therapy, patients with SVR showed regression of hepatic fibrosis while patients without 
SVR had rather stable liver disease, with median estimated annual METAVIR fibrosis progression rates 
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of -0.591 and 0, respectively. However, 24 weeks after cessation of antiviral therapy might be too 
early to assess the true impact of successful antiviral therapy on liver histology. Indeed, a prior study 
including 183 patients with various degrees of HCV-induced hepatic fibrosis and SVR indicated that 
regression of hepatic fibrosis takes time, as the regression of fibrosis was more pronounced in case 
of longer post-SVR follow-up.247 Our data, showing the continued increase in platelets for many years 
after SVR, is in line with this finding. A recent histological study including patients with HCV-related 
cirrhosis and SVR showed that 23 (61%) patients had a reduction of the METAVIR F4 fibrosis score in 
their liver biopsy obtained after a median of approximately 5 years following treatment cessation.241 
Interestingly, even though the METAVIR F4 score was not reduced in the remaining 15 (39%) patients, 
morphometric analyses indicated that their total liver collagen content was still significantly reduced. 
Because the semi-quantitative hepatic fibrosis scores, by which regression of hepatic fibrosis has been 
largely assessed so far, may thus be somewhat too crude, objective and continuous variables for the 
assessment of changes in hepatic fibrosis are relevant to fully appreciate the impact of SVR on liver 
disease severity. As the change in platelets has been linked to the change in hepatic fibrosis, the 
platelet count represents an easily accessible biomarker to assess histological improvement.258 259 We 
remained with the platelet count as outcome measure in our study because many other laboratory-
based non-invasive fibrosis markers showed a poor accuracy for hepatic fibrosis assessment among 
patients with SVR.268 Perhaps, this is explained by the fact that most include parameters of hepatic 
inflammation, which is also affected by viral eradication. Regression of hepatic fibrosis, especially in 
case of cirrhosis, was recently shown to be clinically relevant. In a pivotal study by Mallet et al., clinical 
outcome was superior among chronic HCV-infected patients with cirrhosis who showed a substantial 
reduction of their post-treatment METAVIR score as compared with patients who did not regress.74 
In addition, other large cohort studies have indicated that SVR was also associated with a reduced 
occurrence of liver failure, HCC and mortality among patients with advanced liver disease.75 79-83 
Only a few studies have directly measured the hepatic venous pressure gradient (HVPG) before and 
after antiviral therapy.77 78 269 All included only a small number of patients, but showed that SVR was 
significantly associated with a reduction in HVPG, which remains one of the best validated surrogate 
markers in hepatology. Our finding of a decrease in spleen size following SVR in a large group of 
patients with bridging fibrosis or cirrhosis further substantiates the reduction of portal pressure once 
the chronic HCV infection is eradicated. 
In conclusion, the platelet counts gradually increased, and the spleen size decreased following 
achievement of SVR among chronic HCV-infected patients with bridging fibrosis or cirrhosis. This 
suggests that successful antiviral therapy leads to a reduction in portal pressure, probably because 
of regression of the histopathological abnormalities, which have resulted from long-term liver injury 
due to chronic HCV infection.
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ABSTRACT 
Background & Aims 
As the field of antiviral therapy for chronic HCV infection is rapidly evolving, this study aimed to assess 
the epidemiological changes in patient and disease characteristics among individuals with chronic 
HCV infection.
Methods
This study included all consecutive patients with chronic HCV monoinfection who were referred 
between 1990 and 2013 to the Erasmus MC University Medical Center Rotterdam, a large tertiary 
center in the Netherlands. To identify trends over time, the study population was divided into six 
equal eras based on date of first visit to the outpatient clinic.
Results
A total of 1,779 patients were diagnosed with chronic HCV infection. Mean age increased over time 
from 43.6 (SD 13.8) years to 51.7 (SD 11.2) years (p <0.001). The number of patients who were referred 
with cirrhosis increased over time, from 31 (25%) patients in Era 1 to 118 (42%) patients in Era 6 (p 
<0.001), respectively. More patients were referred with HCV genotype 1a and 3 in the last era, with 
27 (48.2%) and 15 (14.0%) patients in Era 1 and 58 (54.2%) and 60 (21.8%) patients in Era 6 (p <0.001 
both), respectively. The vast majority of patients (69.5%) were born between 1950 to 1975, with 62.5% 
of the patients being born between 1945 and 1965.
Conclusions
The HCV-infected population is ageing and is more often referred with severe liver disease. This study 
stresses the importance of urgently implementing national HCV screening programs in order to be 
able to decrease the future burden of chronic HCV infection in the Netherlands.
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INTRODUCTION
Chronic infection with HCV is a major public health problem. The estimated prevalence of chronic 
HCV infection globally is 2–3%, with a high geographical variation.270-272 Recently, it has been 
estimated that in the Netherlands around 22,000 individuals have a chronic HCV infection, of whom 
12,000 have a known diagnosis.4 In the Western world HCV genotype 1 is most common, while 
HCV genotype 6 is the predominant variant in Southeast Asia. In the Netherlands, HCV genotype 
1 is the most prevalent (50%), followed by HCV genotype 3 (30%) and subsequently HCV genotype 
2 and 4 (both approximately 10%).5 13 The result of the continuous presence of HCV is a chronic 
inflammatory activity in the liver, causing progressive fibrosis and ultimately cirrhosis. Fortunately, 
the disease is characterized by a slow progression and not all patients with chronic HCV infection 
show progression of hepatic fibrosis. However, once cirrhosis is established, patients have an annual 
risk of approximately 3% of developing hepatic decompensation as well as hepatocellular carcinoma 
(HCC).61 273-277 Early detection and successful treatment could reduce this risk and slow down the 
development of cirrhosis and HCC. 
Since the discovery of HCV in 1989 and the implementation of blood screening tests shortly 
thereafter, there has been a significant reduction in the transmission of the virus.11 278-281 In the US, it 
has been identified that the majority of HCV patients were infected between the 1960s and 1970s. 
As cirrhosis is slowly developed, many infected people remain undetected so far. Consequently, due 
to ageing of this HCV-infected population, approximately 25% of the US patients with chronic HCV 
infection are expected to have cirrhosis. This proportion is likely to increase to 45% by the year 2030.63 
Birth cohort screening could identify these patients in an earlier stage of disease. Early detection 
could prevent morbidity and mortality due to chronic HCV infection. Therefore, in the US, birth cohort 
screening has recently been recommended for people born between 1945–1965, since more than 
75% of HCV patients in the US are born during these years.282-284 So far, a screening program has not 
been implemented in the Netherlands. This can be attributed to the low prevalence, which ranges 
from 0.13% to 0.22%.4 6 285 From a public health perspective it might be important to implement 
screening programs when there is an increase in newly referred patients with a more advanced stage 
of the disease. These patients do benefit from successful antiviral treatment as it may avoid or reduce 
cirrhosis-related complications and improve the overall survival.81 However, as Koh et al.261 suggested, 
the greatest benefit from successful antiviral treatment may be in patients without cirrhosis. 
In 2011, it was estimated that in the Netherlands 900 patients were treated annually.4 With the 
introduction of very safe and effective interferon (IFN)- and ribavirin (RBV)-free antiviral treatment, 
it is expected that more patients can be treated. Currently, sofosbuvir, simeprevir and daclatasvir are 
being reimbursed by Dutch insurance companies for the treatment of patients with chronic HCV 
infection and bridging fibrosis or cirrhosis. As a pan-genotypic antiviral regimen has not yet been 
introduced in daily care, current antiviral treatment is still genotype-specific.
Recently, data was published on the present and future burden of chronic HCV infection in the 
Netherlands based on historical data.4 286 287 In 2013, the prevalence of cirrhosis among the patients 
with chronic HCV infection was 11%, of whom 1.3% had decompensated cirrhosis. The rate of both 
HCC and liver-related mortality was 0.5%. Additional data on the trends in patient and disease 
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characteristics from the last 23 years are important for Dutch health policy makers to be informed 
about the shifting trends in the patient population with chronic HCV infection. This also provides 
information on the patients that will be considered for IFN-free therapy. Moreover, it could help 
deciding on the implementation of efficient screening programs in the Netherlands. Therefore, the 
aim of this study was to assess the epidemiological trends in patient and disease characteristics over 
time among individuals with chronic HCV infection that were newly referred to a tertiary center in the 
Netherlands from 1990 to 2013.
PATIENTS AND METHODS
Study population and data collection
This study included all consecutive patients with chronic HCV infection who were referred between 
1990 and 2013 to the Erasmus MC University Medical Center Rotterdam (EMC), a large tertiary center 
in the Netherlands. The EMC is considered to have the largest viral hepatitis unit in the country and is 
an important referral center for the surrounding hospitals. In addition, it has the largest unit for liver 
transplantation in the country. All charts were reviewed by two investigators in order to collect detailed 
data on patient and disease characteristics and treatment history at their first visit to our clinic. Patients 
were included if they had detectable HCV RNA by polymerase chain reaction (PCR). Patients who were 
coinfected with HIV or HBV were excluded, as well as patients who underwent a liver transplantation 
before referral.288-290 Baseline characteristics included the date of birth, gender, ethnicity, body mass 
index (kg/m2), HCV genotype and subtype, treatment history, probable mode of transmission, history 
of/or current alcohol abuse (≥50 g/day), diabetes mellitus and other comorbidities. Ethnicity was 
categorized as Caucasian, Black, Asian or Mediterranean. The probable mode of transmission was 
determined by the presence of risk factors such as intravenous drug use (IDU), blood transfusion or 
tattoos. The laboratory data that were obtained included alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), albumin and platelet count. The AST/ALT ratio, AST to platelet ratio index 
(APRI) and FIB-4 index were calculated from AST, ALT, platelet count and age at time of referral. To 
assess the severity of liver disease, detailed information was obtained on liver biopsy, transient 
elastography, ultrasound and/or clinical (liver) history. Liver biopsy was taken as a golden standard 
and a METAVIR score of F4 was considered as cirrhosis.50 When there was no liver biopsy performed, 
results of transient elastography were assessed, in which a liver stiffness of 12.5 kilopascals or higher 
was considered as cirrhosis.291 If data on liver biopsy or transient elastography was not available, 
ultrasound reports and clinical history were assessed in order to determine whether cirrhosis was 
likely to be present. Clinical cirrhosis was defined as an episode of decompensated cirrhosis (that is, 
ascites, spontaneous bacterial peritonitis, icterus, overt hepatic encephalopathy or variceal bleeding) 
or the presence of esophagus varices during gastroscopy. The cutoff values that were used to define 
cirrhosis were AST/ALT ratio ≥1.00, APRI>2.00 and FIB-4 index >3.25.292-294 The study was conducted 
in accordance with the guidelines of the Declaration of Helsinki and the principles of Good Clinical 
Practice. The study was considered to be a low-risk study using retrospective and anonymized patient 
data. Ethical approval was obtained from the local ethics committee.
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Virology
Information on amplification of RNA was obtained from results of polymerase chain reaction (PCR), 
to determine if RNA genome was detectable. The following tests were used: Roche Cobas AmpliPrep/
Cobas Amplicor HCV (Roche, Pleasanton, CA, USA) test version 2.0 with limit of detection (LOD)=100 
IU/ml (from 01-01-2000 to 01-10-2008), Roche Cobas AmpliPrep/Cobas Taqman HCV test version 
1.0 with LOD=15 IU/ml and limit of quantification (LOQ)=43 IU/ml (from 01-10-2008 to 15-03-2012), 
Roche Cobas AmpliPrep/Cobas TaqMan HCV test version 2.0 with LOD=LOQ=15 IU/ ml (from 15-03-
2012 to present). Before 2000, multiple assays were used for testing HCV RNA, including outsourced 
assays. The HCV genotype was determined by sequential analyses. Supplementary Table 5.1 shows 
information on all the tests.
Statistical analyses
Descriptive analyses were conducted to determine means, medians and proportions of baseline 
patient characteristics. Pearson X2 test was used for the comparison of dichotomous or categorical 
variables and Mann–Whitney U-test, Student’s t-test or ANOVA was used for the comparison of conti-
nuous variables. To identify trends over calendar time in patient characteristics, the study population 
was divided in six eras based on date of first visit at the Hepatology Unit of the EMC. In order to obtain 
equal eras, a 4-year range was applied: Era 1 (1990–1993), Era 2 (1994–1997), Era 3 (1998–2001), Era 4 
(2002–2005), Era 5 (2006–2009) and Era 6 (2010–2013). Linear trend test (ANOVA or Mantel–Haenszel 
X2 for trend) was performed to assess differences in proportions or means across the six eras. To assess 
whether there was a birth year cohort in our study, we applied two time frames from earlier studies 
that described a birth year cohort for the Netherlands (1950–1975) and a US birth year cohort (1945–
1965).261 284 All statistical tests were two-tailed and p <0.05 was considered statistically significant. 
Statistical analyses were performed in SPSS for windows, version 21.0 (IBM, Armonk, NY, USA).
RESULTS
Baseline characteristics
Between 1990 and 2013 a total of 1,971 patients with chronic HCV infection were referred to the 
Department of Hepatology at the EMC. Patients coinfected with HIV or HBV and patients who 
underwent liver transplantation before referral (n=192) were excluded. In total, 1,779 patients were 
included in the current analyses. Table 5.1 presents an overview of baseline characteristics of the 
study population. In this population, 1,210 (68.0%) patients were male and mean age was 46.5 years 
(SD 11.7). Cirrhosis was present among 459 patients (26.2%). The presence of cirrhosis was biopsy-
proven in 174 (37.9%) patients and diagnosed by transient elastography in 97 (21.1%) patients. The 
remaining patients with cirrhosis were diagnosed by ultrasound (38.6%) or by the presence of a 
clinical cirrhotic event (2.4%). Figure 5.1 presents the number of patients born per birth year. The vast 
majority of patients (69.5%) were born between 1950 to 1975, with 62.5% of the patients being born 
between 1945 and 1965. 
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Table 5.1 | Baseline characteristics at time of referral
Baseline variables Total (N=1,779)
Age, in years 46.5 (11.7)
Male 1,210 (68.0%)
HCV genotype
     1
           Subtype 1a
 Subtype 1b
 Unknown subtype
      2
      3
      4
      Otherb
      Unknown
915 (51.4%)
            239 (26.1%)
  300 (32.8%)
  376 (41.1%)
192 (10.8%)
414 (23.3%)
132 (7.4%)
12 (0.7%)
114 (6.4%)
Cirrhosis 459 (22.8%)
Diabetes mellitus 170 (9.6%)
Ethnicity
     Caucasian
     Black
     Mediterranean
     Asian
1,238 (69.6%)
219 (12.3%)
229 (12.9%)
72 (4.0%)
Mode of infection
     Blood transfusion
     IDU
     Tattoo
     medical procedures
     Positive partner
     Multiple risk factors
     Unknown
280 (15.7%)
727 (40.9%)
43 (2.4%)
76 (4.3%)
24 (1.3%)
44 (2.5%)
585 (32.9%)
Alcohol abuses
     Yes
             Active
             In past
     No
     Unknown
525 (29.5%)
        299 (57.0%)
        226 (43.0%)
1,041 (58.5%)
213 (12.0%)
Treatment experienced 294 (16.5%)
BMI, kg/m2 24.9 (22.2-28.2)
Albumin, in g/L 44 (40-46)
Platelet count, x109/L 186 (127-237)
AST/ALT ratio 0.77 (0.58-1.06)
APRI 0.99 (0.50-2.27)
FIB-4 Index 1.62 (0.93-3.81)
Abbreviations: HCV, hepatitis C virus; IDU, intravenous drug use; BMI, body mass index; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; APRI, AST to platelet ratio index
a. Continuous variables are presented as mean (standard deviation) or median (interquartile range);  
dichotomous variables are presented as n, (percentage of whole group) 
b. Other genotypes included HCV genotype 5 and 6 or double genotypes
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Demographics
Mean age at first visit increased over time (Table 5.2), from 43.6 (SD 13.8) years in Era 1 to 51.7 (SD 11.2) 
years in Era 6 (p <0.001). When the percentage of patients with an age of 50 or higher was considered, 
it increased from 32.5% in the first era to 66.2% in the last era (p <0.001). Most patients were male, 
but this percentage did not change over time (p = 0.780), ranging from 66.6% to 69.5%. There was no 
statistically significant trend for ethnicity among the patients (p = 0.654); 1,238 (70.4%) patients were 
Caucasian.
Mode of transmission
There were significant changes in mode of infection during the six different eras (p = 0.003). Among 
patients that were infected via blood transfusion, a significant decrease in percentage was observed, 
from 39 (31.2%) patients in Era 1 to 47 (16.4%) patients in Era 6 (p <0.001). In contrast, the number of 
patients infected through IDU significantly increased over time, from 34 (27.2%) patients in Era 1 to 
100 (35.0%) patients in Era 6 (p = 0.036), with even higher percentages in Era 3, 4 and 5, respectively 
46.6, 44.0 and 48.2%. Figure 5.2 shows that IDU was most frequent mode of infection (61.4%) among 
patients with HCV genotype 3, and to a lesser extent among patients with HCV genotype 1, 2 and 4 
(respectively 39.8%, 17.0% and 29.5%).
HCV genotype
HCV genotype 1 was predominant in all time periods, and the distribution of HCV genotypes did not 
differ significantly among the various eras (p = 0.474). Nevertheless, there was a decrease observed 
among patients with genotype 2 (from 20.6% to 6.9%) and an increase among patients with genotype 
3 (from 14.0% to 21.8%). 
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Figure 5.1 | Birth year of the patients that were included in the study
The shaded area shows that 69.5% of the referred patients were born between 1950 and 1975. The dashed lines 
mark the period between 1945 and 1965 in which 62.5% of the patients that were referred were born.
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Among patients with an available subtype for HCV genotype 1, a significant linear trend was 
observed, with a shift in predominant subtype. In Era 1, 27 (48.2%) patients had subtype 1a and 
29 (51.8%) patients had subtype 1b. This was significantly different from Era 6, in which 58 (54.2%) 
patients were diagnosed with subtype 1a and 49 (45.8%) patients were diagnosed with subtype 1b 
(p = 0.001).
Treatment experience
In Era 1, only 7 (5.6%) patients that were referred were treatment-experienced. The percentage of 
patients that were treatment experienced gradually increased to 22.0% in the last era (p = 0.001). A 
major increase of treatment-experienced patients was seen among patients with cirrhosis at baseline 
(10.0% in Era 1 to 32.2% in Era 6; p = 0.012). This increase was less pronounced, and not statistically 
significant, among patients without cirrhosis (from 4.2% to 14.6%, respectively; p = 0.873).
Severity of liver disease
There was an increase seen in number of patients with cirrhosis at first visit, from 31 patients (24.6%) 
in Era 1 to 118 patients (41.7%) in Era 6 (p <0.001). When considering the group of patients with an 
age below 50, there was no increase observed among patients diagnosed with cirrhosis (18.8% in 
Era 1 and 19.8% in Era 6; p = 0.223). In contrast, there was a significant increase among patients aged 
50 or higher (from 50.0% to 67.3%; p <0.001). Table 5.3 presents the median AST/ALT ratio, APRI and 
FIB-4 index that were calculated among the patients over the six eras. These markers increased from 
respectively 0.59 (0.48–0.76), 0.69 (0.38–1.79) and 1.07 (0.69–2.63) in the first era to 0.92 (0.72–1.26), 
1.06 (0.57–2.71) and 2.22 (1.25–5.01) in the last era (p <0.001 for all). When using the cutoff values for 
the presence of cirrhosis, the percentage of patients that were defined as cirrhotic patients by the 
non-invasive markers gradually increased (p <0.001 for all).
Figure 5.2 | The mode of infection among patients with HCV genotype 1 to 4
White bars represent the patients that were infected due to a blood transfusion. Grey bars represent the patients 
that were infected due to IDU. The black bars represent all other modes of infection, including tattoo, medical 
pro ce dures, positive partner, multiple risk factors or unknown mode of infection. Abbreviations: IDU, intravenous 
drug use.
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DISCUSSION
This study showed the epidemiological trends among 1,779 patients with chronic HCV infection that 
were newly referred to a large hepatology unit in a tertiary center in the Netherlands. There was a 
significant increase in mean age over the succeeding time periods, showing that the population with 
chronic HCV infection is ageing. The proportion of newly referred patients who were diagnosed with 
cirrhosis increased over time. The majority of patients were infected with HCV genotype 1, and there 
was an increasing number of patients with HCV genotype 1a and 3.
In our study population there was a significant increase in the age of patients at time of referral, 
from 43.6 years to 51.7 years. This finding is in line with a recent study that was performed in the US, 
also showing an increase in mean age (from 45 to 56 years) among patients who were referred to a 
tertiary liver center.295 In fact, it is a cohort of patients that were probably infected a few decades ago, 
in the peak incidence years. As ageing of the population will continue, treatment of elderly patients 
will increase. Innes et al.296 showed that non-cirrhotic patients aged 60 or older have the lowest benefit 
of achieving sustained virological response (SVR) to prevent liver failure and liver-related death. In the 
past, IFN-based antiviral treatment was being withheld among older patients, due to increased risk 
for side effects and reduced efficacy. As the new direct-acting antivirals (DAAs) were shown to have 
no safety issues, physicians will not be hampered in applying these regimens to the elderly. However, 
as the costs of these IFN-free regimens are high, it could be questioned whether the application of 
these strategies will be cost-effective in this growing subgroup. Therefore, as our study underlines, we 
need to assess the clinical relevance of antiviral therapy for chronic HCV infection among the elderly. 
There might be a threshold in age, when patients with advanced hepatic disease will have less clinical 
benefit from successful antiviral therapy as there will be a higher burden of non-liver-related diseases.
In all six eras, HCV genotype 1 was the predominant genotype. Historically, HCV genotype 
1 had the lowest response rates to antiviral therapy with pegylated IFN and ribavirin.106 With the 
introduction of the first generation protease inhibitors these response rates increased but were still 
suboptimal.122 126 Among those patients with HCV genotype 1, the incidence of subtype 1a increased 
compared to subtype 1b. This increase of subtype 1a was also observed in Belgium and the US.295 297 A 
possible explanation of this finding could be that the response rates of triple therapy with telaprevir 
and boceprevir were higher among patients with subtype 1b, due to the lower rate of drug-resistant 
variants.298 Even with the newer IFN-free DAA-regimens, differences in SVR rates between genotype 
1a and 1b remain relevant.128 129 145 156 157 Another, maybe more important finding, is the increase of 
HCV genotype 3. Although it was not statistically significant, probably due to the lack of power, it 
has major clinical implications. First, it was found that HCV genotype 3 was associated with disease 
progression for both severity of liver disease as well as clinical outcome.299 Second, treatment of HCV 
genotype 3 seems to be the most challenging in the era of IFN-free regimens, when treatment efficacy 
is concerned.138 163
In the last era (2010–2013), the number of patients with cirrhosis at their first visit was high (41.7%). 
First, this finding may be explained by the reduced transmission rate after the discovery of HCV, leading 
to the ageing of a cohort of patients that has been infected with the virus in the peak incidence 
years and consequently an increase of patients presenting with cirrhosis.300 Second, late referral to 
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our center could have contributed to the large number of patients with cirrhosis, who were more 
difficult to treat in the era of IFN-based treatment. Third, the slow course of the disease is responsible 
for the late diagnosis of the infection. However, the high rate of patients with cirrhosis should be 
interpreted with care, since it might be subject to selection bias as patients with significant disease 
are those who are seeking medical care and will be referred to a tertiary center as they are considered 
difficult to treat. In a recent study among more than 14,000 patients, late diagnosis of chronic HCV 
infection was associated with more hospitalization (59% versus 35%) and death (33% versus 9%), 
with a median time of 4.8 years from initial HCV diagnosis until death.301 In France, an observational 
multicenter study showed an increase in number of newly referred patients with cirrhosis with 7.4% 
of the patients in 1995, 10.4% in 2001 and 16.1% in 2010. Even though an increase was observed, 
this percentage in France was lower than in the current study.302 This is probably due to the fact that, 
in contrast to the Netherlands as well as many other countries in Europe, France has been actively 
screening and treating patients over the last two decades. This might have led to more patients being 
cured in an earlier phase of disease.303 With the combination of multiple DAAs, it is expected that more 
patients, regardless of the presence of cirrhosis, will achieve SVR in the near future. Although, there is 
a reduced risk for developing clinical complications of cirrhosis among patients who attained SVR, the 
risk cannot be fully eliminated.81 82 Therefore, these patients will continue to be included in intensive 
surveillance programs.
It is interesting to note that 70% of all patients were born between 1950 to 1975. This is in line 
with recent published data showing that 72% of the HCV population in the Netherlands was born 
between 1950–1975.286 Another recent study that was performed in the US found a birth year cohort 
of 1945 to 1965 in which 75% of the patients were born, which is higher than the 63% in the present 
study.283 The wider range in the Netherlands might be due to variability in risk factors between the 
countries and different time of introduction of the virus. In the US, the prevalence in the 1945 to 
1965 birth year cohort was 3× higher (3.5%) compared to the prevalence in the general population.304 
Since it was shown that US birth cohort screening is cost-effective from a minimum prevalence of 
0.84%, screening of patients born between 1945 and 1965 is recommended.285 When screening is 
concerned, it has to be noted that regulation of health-care systems differs per country and therefore 
these findings concerning cost-effectiveness of HCV screening cannot directly be extrapolated to 
the Dutch health-care system. Since we found an increasing number of patients that were referred 
with more advanced disease, probably the point is reached at which urgent screening is warranted. 
Due to the low prevalence in the Netherlands, it is a country where chronic HCV infection could be 
fully eradicated. As this study showed that 70% of the patients were born between 1950 and 1975, 
those people could be included in screening programs. In addition, first-generation migrants could 
be screened, since it was found that these patients account for many infections.6 In order to prevent 
the development of cirrhosis among patients with chronic HCV infection and identify the patients 
in an early stage of disease, it is of utmost importance to implement effective screening programs. 
Especially, since we now have very efficient treatment regimens.
A salient strength of the current study was the large sample size of 1,779 chronic HCV patients, 
which ensured an adequate power. Furthermore, by including consecutive patients from 1990 to 
2013, epidemiological trends from the discovery of the virus to the present time could be accurately 
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assessed. Nevertheless, the study also has some limitations. First, retrospective data were used, which 
resulted in missing variables as data was not gathered for the purpose of research. Using data of a 
tertiary center might have caused selection bias resulting in the overrepresentation of difficult to treat 
patients, like patients with advanced liver disease. Finally, cirrhosis was diagnosed in heterogeneous 
ways. Nevertheless, we performed sensitivity analyses, including solely patients that were diagnosed 
by biopsy or transient elastography, showing comparable results (data not shown). Non-invasive 
fibrosis markers showed the same trends, assuring us that these results were legitimate.
In conclusion, the HCV-infected population in the Netherlands is ageing and more often referred 
with severe liver disease. This stresses the importance of urgently implementing national HCV 
screening programs in order to be able to decrease the future burden of chronic HCV infection in 
the Netherlands.
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SUPPLEMENTARY TABLE
Supplementary Table 5.1 | HCV RNA tests that have been used
Date Test
Quantitative/qualitative HCV 
RNA test
Before 2000 Multiple assays, including outsourced assays 
01-01-2000 to 01-10-2008 Roche Cobas AmpliPrep/cobas Amplicator HCV test version 2.0
LOD: 100 IU/mL
01-10-2008 to 15-03-2012 Roche Cobas AmpliPrep/cobas Taqman HCV test version 1.0
LOD: 15 IU/mL; LOQ: 43 IU/mL
15-03-2012 to present Roche Cobas Ampli/Prep/cobas Taqman HCV test version 2.0
LOD=LOQ= 15 IU/mL
Sequential tests
~ to 08-08-2005 Sanger sequencing on 5’UTR
08-08-2005 to 10-12-2003 Sanger sequencing on NS5-gen
10-12-2003 to 16-07-2007 Versant HCV genotype version 1.0 assay (LiPA)
16-07-2007 to present Versant HCV genotype version 2.0 assay (LiPA)
Abbreviations: LOD, limit of detection; LOQ, limit of quantification
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ABSTRACT 
Background & Aims 
Very potent direct acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection were 
recently introduced into daily clinical practice. Currently, treatment uptake is hampered by their 
high costs, eliciting prioritization of treatment. We aimed to evaluate the direct medical costs during 
interferon (IFN)-based antiviral treatment and the costs per sustained virological response (SVR) 
among patients with advanced hepatic fibrosis.
Methods
This retrospective cohort study included all consecutive patients with chronic HCV infection and 
biopsy-proven bridging fibrosis or cirrhosis (Ishak 4-6) treated with IFN-based regimens in five hepa-
tology units of tertiary care centers in Europe and Canada. Direct medical costs, expressed in 2013 
Euros, during therapy were assessed. The components of care were quantified by three distinct 
categories: treatment, safety/ monitoring and complications. Cost per SVR was calculated by dividing 
the mean cost by the SVR rate. 
Results
In total, 672 interferon-based treatments administered to 455 patients were included. Total medical 
costs per patient were averaged to €14,559 (95%CI, €13,323-€15,836). The mean cost per SVR was 
€38,514 (95%CI, €35,244-€41,892). The costs per SVR were €26,105 (95%CI, €23,068-€29,296) for 
patients with a normal platelet count and €50,907 (95%CI, €44,151-€59,612) for patients with thrombo-
cytopenia, with the costs per SVR of €74,961 (95%CI, €55,463-€103,541) among those patients with a 
platelet count below 100x109/L.
Conclusions
Due to the lower SVR rates, the cost per SVR of IFN-based treatment increased when patients with 
more advanced liver disease were treated. Additional costs of IFN-free therapy could be limited 
among these patients.
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INTRODUCTION
The burden of chronic hepatitis C virus (HCV) infection is expected to increase over the next years.305 
Today, it is the leading cause of chronic liver disease, hepatocellular carcinoma (HCC) and the most 
common indication for liver transplantation in the Western world.41 178 It has been estimated in the 
United States that by 2030, 45% of the HCV population will have cirrhosis, which may be reflected 
by the development of thrombocytopenia.63 113 Indeed, even though the pathophysiology of 
thrombocytopenia is thought to be multifactorial, it appears to be largely related to the severity of 
liver disease.180 181 Since the number of patients with cirrhosis will increase, it can be expected that 
the prevalence of those with thrombocytopenia will increase as well.306 It could be questioned to 
what extent the presence of thrombocytopenia reflects a functional problem which causes on-
treatment safety issues such as bleeding complications, or whether it is merely serving as a marker for 
more severe liver disease with portal hypertension. Nevertheless, thrombocytopenia defines a more 
difficult to cure patient population, who are in urgent need of successful antiviral therapy.191 192
Until now, treatment for chronic HCV infection consisted of pegylated interferon (PegIFN)-based 
regimens leading to suboptimal sustained virological response (SVR) rates and important safety 
issues, especially among patients with advanced liver disease.107 These side effects frequently neces-
sitate dose reductions or treatment discontinuation, leading to reduced treatment efficacy.111 112 The 
recent discovery of direct-acting antivirals (DAAs) has revolutionized treatment for patients with 
chronic HCV infection. With interferon-free therapy even cirrhotic patients have very high chances of 
attaining SVR.145 156
Unfortunately, the costs of DAAs are very high and this currently limits the availability of these 
drugs for the majority of patients worldwide. Also in wealthy countries it is deemed necessary to 
prioritize DAA treatment, in order to reduce the budget impact. Because patients with cirrhosis, 
especially in case of thrombocytopenia, are at highest risk of cirrhosis-related complications, these 
patients are treated first. Indeed, they have most direct clinical benefits of the highly effective IFN-free 
treat ment regimens.196 307 In light of the discussion on costs and availability of IFN-free therapy it is 
noteworthy that there have only been a limited number of real-world economic studies published. 
The true cost of IFN-based therapy applied to a population with advanced hepatic disease is thus 
largely unknown. For this reason we aimed to investigate the real-world healthcare costs per SVR 
for patients with advanced hepatic fibrosis in Europe and Canada that were treated with IFN-based 
regimens.
PATIENTS AND METHODS
Study population
In this cohort all consecutive patients from five large hepatology units in Europe (the Netherlands, 
Germany and Switzerland) and Canada, who had chronic HCV infection, histological proof of bridging 
fibrosis or cirrhosis (Ishak fibrosis score 4-6) and started an interferon-based treatment between 1990 
and 2003 were included.81 For the current study, all consecutive treatment courses with available on-
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treatment clinical data were assessed. Cases for whom data were available for less than three visits 
during the course of therapy, the respective treatment course was not considered.
The charts of all included patients were re-reviewed by a single investigator (RM) in order to collect 
detailed information at baseline and during treatment. Details on the data that were collected were 
described previously.196 308 The period within six months before treatment was considered as baseline.
Components of care, from initiation of therapy until 24 weeks after stopping treatment (i.e. 
the moment when SVR could be assessed), were quantified by three distinct categories: treatment, 
safety-monitoring and complications. Total medical costs attributable to each cost component were 
calculated. Laboratory costs were based on a detailed inventory of the resource use of patient charts. 
Costs of hospitalization (inpatient care episode) were calculated as the per diem prices multiplied by 
the length of stay. Outpatient costs were assigned based on visits to the hospital. Specialist fees are 
(all-)inclusive in the unit costs of outpatient or inpatient visits.
A list of major unit prices and their sources, as well as the profile of the health care systems for each 
country, are presented in Supplementary Tables 6.1 and 6.2.309-315  All medical costs were expressed in 
2013 Euros, using publicly available currency exchange rates. Where necessary, costs were adjusted 
to 2013 prices using consumer price index.309 Costs were presented with mean, median, standard 
deviation, standard error and 95% confidence intervals.
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and 
the principles of Good Clinical Practice. The study protocol was reviewed and approved by the ethics 
committee in the center of the primary investigators, which was the Erasmus Medical Center in Rotter-
dam, the Netherlands. Ethical approval in the participating centers was obtained according to the 
local regulations.81 185
Objectives
The primary objective was to assess direct medical costs during antiviral therapy among patients with 
bridging fibrosis or cirrhosis and to assess the cost per SVR. Secondary objectives were the assess-
ment of medical costs in the five different centers as well as in the four different countries and for 
different components during treatment. To assess the role of the severity of liver disease, the direct 
medical costs and cost per SVR were also assessed according to the presence of bridging fibrosis or 
cirrhosis (Ishak 4 vs Ishak 5-6) and for three different categories based on the baseline platelet count (a 
valid marker of the severity of liver disease). A platelet count ≥150x109/L was considered as a normal 
platelet count; a platelet count <150x109/L as thrombocytopenia and a platelet count < 100x109/L as 
a severe thrombocytopenia.
Definitions
Three major components were defined to display the total costs. Treatment costs were based on the 
total dose of (Peg)IFN and RBV, taking into account all dose adjustments for one of these compounds. 
The costs of safety monitoring included the costs for all laboratory tests, visits to day clinic, admis sions 
to the hospital, referrals to others physicians and additional diagnostic procedures for reasons other 
than an infection, bleeding episode or another adverse event. The costs of complications contained 
costs for hospital admission, diagnostic procedures, referrals to others physicians and treatment for 
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an infection, bleeding episode or another adverse event. On-treatment resource utilization was pre-
sen ted for the whole treatment period of each individual patient.
Statistical analyses
Continuous variables were summarized as median (interquartile range [IQR]) and categorical variables 
as frequencies (percentages). Mean costs were estimated separately for disease-related components. 
Total costs were calculated per patient. Standard error and 95% confidence interval of the mean were 
calculated by means of bootstrapping the cost results with 1000 bootstrap samples. Comparisons 
between groups were performed using X2 test for categorical variables or the Mann-Whitney U test 
for continuous variables. The costs per SVR were calculated by using the following formula: costs per 
SVR = mean cost per patient * (1/SVR rate). A p value <0.05 was considered statistically significant and 
all statistical tests were two-tailed. PASW statistics 22.0 for Windows (SPSS, IBM, Armonk, New York, 
USA) was used.
Sensitivity Analysis
One-way deterministic sensitivity analysis was performed to determine the influence of components 
of care on medical costs. In addition, the SVR rate of the study population was varied over a range of 
± 50% when the costs per SVR were calculated.
RESULTS
Patients
In total, 546 patients with chronic HCV infection and bridging fibrosis or cirrhosis started IFN-based 
antiviral therapy between 1990 and 2003. In 672 (78%) of the 859 treatment courses among these 
patients detailed on-treatment data were available to assess the occurrence of bleeding, infection 
and laboratory tests. These treatment courses were registered among 455 patients. Of the 334 (73%) 
patients without SVR after their treatment of inclusion, 169 patients received at least one subsequent 
antiviral treatment regimen. Table 6.1 summarizes the baseline characteristics of the patients at their 
first included treatment. In order to compare the baseline characteristics according to the presence 
of thrombocytopenia, these data were also shown in Table 6.1. Median age was 48 years (IQR 43-
56), 317 (70%) patients were male and 346 (76%) presented with cirrhosis (Ishak 5 or 6). At the first 
registered treatment, platelet count was available for 432 (95%) patients. Baseline thrombocytopenia 
was present among 226 (52%) patients, of whom 87 (38%) had a platelet count below 100x109/L.
On-treatment resource utilization
Fourteen (7%) patients with a normal platelet count experienced 28 bleeding episodes in total, 
for which none received treatment for the bleeding. Among patients with thrombocytopenia, 34 
(15%) patients experienced 76 bleeding episodes, for which 9 (26%) required treatment. Seven teen 
(20%) patients and 37 bleeding episodes were reported among patients with a platelet count below 
100x109/L, of which 4 (24%) needed treatment. The number of infections that were experienced by 
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Table 6.1 | Baseline characteristics according to the presence of thrombocytopenia at the first registered 
treatment course
Variable
Total
(N=455)
Treatments with 
normal platelets
(n=206)
Treatments with TCP
(n=226) p value
Male 317 (70%) 146 (71%) 154 (68%) 0.538
Age, in years 48 (43–56) 47 (42–55) 50 (44–57) 0.009
BMI, in kg/m2 26.6 (23.8–29.4) 26.2 (23.4–29.0) 26.8 (24.1–29.8) 0.149
Center
Rotterdam
Toronto
Hannover
Homburg 
Bern
63 (14%)
210 (46%)
93 (20%)
15 (3%)
74 (16%)
21 (10%)
118 (57%)
32 (16%)
7 (3%)
28 (14%)
41 (18%)
88 (39%)
52 (23%)
5 (2%)
40 (18%)
0.002
HCV genotype
1
2
3
4
5 or 6
310 (68%)
45 (10%)
75 (17%)
21 (5%)
4 (1%)
139 (68%)
26 (13%)
32 (16%)
9 (4%)
-
154 (68%)
18 (8%)
38 (17%)
12 (5%)
4 (2%)
0.282
Treatment naïve 367 (81%) 168 (82%) 180 (80%) 0.617
Cirrhosis 346 (76%) 134 (65%) 196 (87%) <0.001
Fibrosis score 
Ishak 4
Ishak 5
Ishak 6
109 (24%)
93 (20%)
253 (56%)
72 (35%)
45 (22%)
89 (43%)
30 (13%)
42 (19%)
154 (68%)
<0.001
Platelet count, in 109/L 147 (109–197) 198 (174–225) 111 (89-132) <0.001
Albumin, in g/L 42 (39–44) 43 (41–45) 40 (37–43) <0.001
Bilirubin, in μmol/L 13 (10–19) 12 (9–15) 15 (11–23) <0.001
AST/ALT ratio 0.70 (0.57–0.91) 0.67 (0.52–0.80) 0.78 (0.62–1.02) <0.001
Treatment with PegIFN* 204 (45%) 97 (47%) 102 (45%) 0.684
Alcohol abuse everd 103 (24%) 49 (25%) 52 (25%) 0.929
Diabetes mellitus 58 (13%) 24 (12%) 34 (15%) 0.301
Abbreviations: TCP, thrombocytopenia; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; PegIFN, pegylated interferon;
a. Medians are presented as number, (IQR, interquartile range)
b. Numbers are presented as n, (percentage of the whole group)
c. * Including respectively 10 and 4 treatment courses with PegIFN monotherapy for patients with normal 
platelets and TCP
d. Missing in 37 patients
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the patients with a normal platelet count, thrombocytopenia or platelet count below 100x109/L, were 
46 (among 34 (17%) patients), 58 (among 42 (19%) patients) and 11 (among 9 (10%) patients), respec-
tively. Antibiotics were prescribed for 43 (93%), 45 (78%) and 9 (82%) of the infections, and 8 (17%), 12 
(21%) and 6 (55%) of the infections were considered severe. Six patients (3%) with a normal platelet 
count underwent 9 radiological procedures and 13 (6%) patients needed a hospital admission during 
therapy. Twenty (9%) patients with thrombocytopenia underwent 31 radiological procedures and 26 
(12%) patients were admitted to the hospital during therapy. For the patients with a platelet count 
below 100x109/L, 11 (13%) patients underwent 20 radiological procedures and 13 (15%) patients 
need a hospital admission. When laboratory assessments were considered, patients with a normal 
platelet count had a mean of 3.5 lab values that were determined per week, whereas patients with 
thrombocytopenia and with a platelet count below 100x109/L had a mean of 4.9 and 6.7 lab values 
determined per week, respectively.
Treatment duration and dose reductions
Median treatment duration was 34 weeks (IQR 19-48) for patients with bridging fibrosis and 26 weeks 
(IQR 21-48) for patients with cirrhosis (p = 0.878). At least one dose reduction of IFN was applied in 
24.7% of the treatments among patients with bridging fibrosis and in 33.7% of the treatments among 
patients with cirrhosis (p = 0.028). Treatment was discontinued in 32.4% of the treatments given to 
patients with bridging fibrosis and in 38.1% of the treatments among cirrhotic patients (p = 0.177). 
Side effects were the reason for treatment discontinuation in 18.2% and 29.3% of the discontinuations 
among patients with bridging fibrosis and cirrhosis, respectively (p = 0.100).
The median duration per treatment was 31 weeks (IQR 21-48) for patients with a normal platelet 
count and 26 weeks (IQR 20-48) for patients with thrombocytopenia (p = 0.507), also including 
patients with a platelet count below 100x109/L whom received treatment for a median of 24 weeks 
(IQR 16-48). The dose of IFN was reduced in 24.1% of treatments among patients with a normal platelet 
count and in 40.6% of treatments among patients with a thrombocytopenia (p <0.001). Treatment 
was discontinued in 33.4% of the treatments among patients with a normal platelet count, including 
22.1% of these discontinuations due to side effects. Among patients with thrombocytopenia, 40.0% 
of the treatments were discontinued, of which 32.8% were due to side effects (p = 0.088 and p = 
0.071, respectively). For patients with a platelet count below 100x109/L, in 51.4% of the treatments at 
least one dose reduction was applied as well as early treatment discontinuation. Almost half of the 
discontinuations were due to side effects (48%).
Costs during treatment
Total medical costs per patient were averaged to €14,559 (95% CI €13,323-€15,836). Table 6.1 depicts 
country-specific mean costs per patient with their respected sums. The highest average costs per 
patient were in Switzerland (€18,777 (95%CI €14,608-€25,226)). The lowest average cost per patient 
was in Germany (€11,388 (95%CI €9,377-€13,757)). The mean per patient costs in the Netherlands and 
Canada were comparable, €15,520 (95%CI €13,122-€17,983) and €14,414 (95%CI €12,887-€16,113), 
respectively (Table 6.2). Figure 6.1 shows country-specific costs (per patient) for all medical com-
ponents (treatment, safety-monitoring, complications). The most influential cost driver was the anti-
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Table 6.2 | Medical costs per country
Country Medical costs Standard error
Bootstapa
95% Confidence Interval
Lower Upper
The Netherlands Number of patients
Sum of costs
Mean of costs
Standard deviation
63
€977.779,00
€15.520,30
€9.604,45
€1.249,25
€971,33
€13.121,74
€7.601,23
€17.983,75
€11.382,00
Canada Number of patients
Sum of costs
Mean of costs
Standard deviation
210
€3.026.964,00
€14.414,11
€12.075,46
€828,00
€1.078,24
€12.887,77
€10.074,07
€16.113,13
€14.248,22
Germany Number of patients
Sum of costs
Mean of costs
Standard deviation
108
€1.229.995,00
€11.388,84
€11.231,37
€1.117,93
€957,72
€9.377,48
€9.285,58
€13.757,87
€12.969,94
Switzerland Number of patients
Sum of costs
Mean of costs
Standard deviation
74
€1.389.559,00
€18.777,82
€23.470,06
€2.676,13
€8.491,23
€14.608,86
€10.293,84
€25.226,37
€36.689,81
a. Bootstrap results are based on 1000 samples
Figure 6.1 | Medical costs of key components of care per country per patient
Mean medical costs in 2013 Euro of the key components of care per country per patient. These key components 
included treatment, safety-monitoring and complications. The last four bars represent the total mean medical 
costs. 
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viral therapy component (in particular (Peg)IFN), with a mean cost of €9,579 (95%CI €8,722-€10,408). 
Costs of safety-monitoring and complications during antiviral treatment were € 3,198 (95%CI €2,973-
€3,454) and €1,176 (95%CI €505-€2,206), respectively. Figure 6.2 shows results by means of a tornado 
diagram when key medical components were varied in one-way sensitivity analysis.
Costs by severity of liver disease
In total, 346 (76%) patients presented with cirrhosis at the first registered treatment. The remaining 
109 (24%) patients had histological proof of bridging fibrosis. The mean costs per patient according to 
Ishak score 4 and Ishak score 5-6 were €15,346 (95%CI €13,327-€17,626) and €14,311 (95% CI €12,930-
€15,894), respectively (Table 6.3).
The mean costs among patients with and without thrombocytopenia were €14,416 (95%CI 
€12,503-€16,598) and €12,419 (95% CI €10,974-€13,937), respectively (Table 6.4). The analyses among 
patients with platelet count below 100x109/L showed comparable results (€13,786 (95%CI €10,200-
€19,042).
Figure 6.2 | Tornado diagram showing one-way sensitivity analysis
Tornado diagram showing one-way sensitivity analysis for the medical costs for all countries. The components of 
these costs are defined below the figure. 
T I  Costs of (peg)interferon
S-M I Costs of visits 
C II Costs due to an infection 
S-M II Costs of laboratory assessments during treatment
T II Costs of ribavirin
C III Costs due to admissions for adverse events, other than an infection or bleeding
C I Costs due to a bleeding
S-M III Costs due to admissions per protocol 
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Table 6.3 | Medical costs for patients according to the platelet count
Country Medical costs Standard error
Bootstapa
95% Confidence Interval
Lower Upper
Normal platelet 
count (≥150x109/L)
Number of patients
Sum of costs
Mean of costs
Standard deviation
206
€2.558.314,00
€12.418,89
€10.677,34
€763,31
€814,22
€10.902,75
€9.096,20
€13.986,88
€12.310,23
Thrombocytopenia 
(<150x109/L)
Number of patients
Sum of costs
Mean of costs
Standard deviation
226
€3.258.156,00
€14.416,62
€16.223,66
€1.060,18
€3.945,55
€12.503,21
€10.100,82
€16.598,63
€23.385,11
Severe 
Thrombocytopenia 
(<100x109/L)
Number of patients
Sum of costs
Mean of costs
Standard deviation
88
€1.213.166,00
€13.785,98
€21.770,30
€2.325,09
€8.156,54
€10.200,16
€8.964,83
€19.042,14
€34.385,86
Thrombocytopenia 
with SVR 
(<150x109/L)
Number of patients
Sum of costs
Mean of costs
Standard deviation
64
€1.211.576,00
€18.930,88
€23.998,97
€2.868,68
€9.715,90
€14.354,62
€7.320,03
€24.919,52
€38.487,99
Abbreviations: SVR, sustained virological response
a. Bootstrap results are based on 1000 samples 
 
Table 6.4 | Medical costs according to the presence of bridging fibrosis and cirrhosis
Country Medical costs Standard error
Bootstrapa
95% Confidence Interval
Lower Upper
Bridging fibrosis 
(Ishak score 4)
Number of patients
Sum of costs
Mean of costs
Standard deviation
109
€1.672.683,00
€15.345,72
€11.655,84
€1.074,51
€934,06
€13.327,90
€9.590,22
€17.625,57
€13.411,27
Cirrhosis
(Ishak score 5/6)
Number of patients
Sum of costs
Mean of costs
Standard deviation
346
€4.951.614,00
€14.311,02
€14.998,31
€722,20
€2.829,15
€12.930,57
€10.631,60
€15.894,47
€20.491,02
a. Bootstrap results are based on 1000 samples
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Costs per SVR
The SVR rate of the overall population was 38% (172/455). The mean cost per SVR was €38,514 (95%CI, 
€35,244-€41,892). One-way sensitivity analysis revealed that when the SVR rate varied (±50%), mean 
costs ranged from €25,746 (95%CI, €23,496-€27,928) to €77,027 (95%CI, €70,488-€83,783) (Table 6.5).
The SVR rate was 46% (50/109) among patients with bridging fibrosis and 35% (122/346) among 
patients with cirrhosis (p = 0.046). The mean costs per SVR were €33,454 (95%CI €29,053-€38,425) for 
patients with bridging fibrosis, whereas the costs per SVR were €40,587 (95%CI, €36,670-€45,076) for 
patients with cirrhosis.
Again, when one-way sensitivity analysis was performed with the SVR rate varied (±50%), mean 
costs ranged from €22,303 (95%CI, €19,369-€25,616) to €66,909 (95%CI, €58,106-€76,849) among 
patients with bridging fibrosis. Similarly, when SVR rate among patients with cirrhosis varied (±50%), 
mean costs ranged from €27,058 (95%CI, €24,447- €30,051) to €81,174 (95% CI, €73,341-€90,153), 
respectively (Table 6.5).
For patients with an available platelet count at baseline, the SVR rates were 28% (64/226) among 
patients with thrombocytopenia and 48% (98/206) among patients with a normal platelet count (p 
< 0.001). The mean cost per SVR was €50,907 (95%CI, €44,151-€58,612) for patients with thrombo-
cytopenia, whereas the mean cost per SVR was €26,105 (95%CI, €23,068-€29,296) for patients with 
a normal platelet count. For patients with a platelet count below 100x109/L, the SVR rate was 18% 
(16/87). Within this specific group, the mean cost per SVR was €74,961 (95%CI, €55,463-€103,541).
One-way sensitivity analysis revealed that when SVR rate among patients with thrombocytopenia 
varied (±50%), mean costs ranged from €33,938 (95%CI, €29,434-€39,074) to €101,813 (95%CI, 
€88,302-€117,223). Similarly, when SVR rate among patients without thrombocytopenia varied 
(±50%), mean costs ranged from €17,403 (95%CI €15,379-€19,530) to €52,210 (95% CI, €46,136-
€58,592), respec tively. For patients with a platelet count below 100*109/L, costs per SVR ranged from 
€49,974 (95%CI €36,975-€69,027) to €149,923 (95%CI €110,925-€207,082) (Table 6.5).
Table 6.5 also shows these data according to the following baseline characteristics: the use of con-
ven tional IFN and PegIFN; having HCV genotype 1/4 and HCV genotype 2/3; being treatment naïve 
and treatment experienced.
DISCUSSION
Our study quantified real-world healthcare costs of IFN-based treatment among patients with advanced 
hepatic fibrosis who were treated in the Netherlands, Germany, Switzerland and Canada. Although 
the direct medical costs did not differ among the patients with more severe thrombocytopenia, the 
cost per SVR was higher among patients with lower platelet count. This could be attributed to the 
lower SVR rate of IFN-based treatment among these patients.
As antiviral therapy, rather than the costs for management of adverse events, was the most 
influential cost driver in this study, it is not unexpected that the costs during treatment were not 
higher among patients with more severe liver disease. First, patients with more severe liver disease 
were treated for a shorter period as antiviral treatment is prematurely discontinued in case of an 
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Table 6.5 | Costs per SVR according to baseline variables
Subgroup
Mean costs (95% 
confidence interval) SVR rate
Costs per SVR (95% 
confidence interval)
Mean costs per 
SVR when SVR rate 
varied (± 50%)
Total population €14,559 
(€13,323-€15,836)
172/455 
(38%)
€38,514 
(€35,244-€41,892)
€25,746 - €77,027 
Severity of liver disease
Bridging fibrosis €15,346 
(€13,327-€17,626) 
50/109 
(46%)
€33,454 
(€29,053-€38,425)
€22,303 - €66,909 
Cirrhosis €14,311 
(€12,930-€15,894)
122/346 
(35%)
€40,587 
(€36,670-€45,076)
€27,058 - €81,174
Baseline platelet count
Normal platelet 
count
€12,419 
(€10,974-€13,937)
98/206 
(48%)
€26,105 
(€23,068-€29,296)
€17,403 - €52,210
Thrombocytopenia €14,416 
(€12,503-€16,598)
64/226 
(28%)
€50,907 
(€44,151-€58,612) 
€33,938 - €101,813 
Platelet count 
<100x109/L
€13,786 
(€10,200-€19,042
16/87 
(18%)
€74,961 
(€55,463-€103,541)
€49,974 - €149,923 
Type of interferon used
Conventional 
interferon
€12,754 
(€11,265-€14,242)
74/251 
(30%)
€43,260 
(€38,210-€48,307)
€28,840 - €86,520
Pegylated interferon €16,780 
(€14,534-€19,026)
98/204 
(48%)
€34,930 
(€30,254-€39,605)
€23,287 - €69,860
HCV genotype
HCV genotype 1/4 €14,824 
(€13,488-€16,159)
100/335 
(30%)
€49,660 (€45,185-
€54,133)
€33,107 - €99,321
HCV genotype 2/3 €14,222 
(€10,806-€17,638)
72/120 
(60%)
€23,703 (€24,013-
€29,397)
€15,802 - €47,407
Previous treatment response
Naive €14,092 
(€12,600-€15,585)
143/367 
(39%)
€36,166 (€32,337-
€39,998)
€24,111 - €72,332
Experienced €16,505 
(€13,850-€19,159)
29/88 
(33%)
€50,084 (€42,028-
€58,138)
€33,389 - €100,168
Abbreviations: SVR, sustained virological response; HCV, hepatitis C virus
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insufficient virological response. Second, out of fear of bleeding and infection, dose reductions are 
often applied when platelet and neutrophil counts drop substantially. Although previous studies 
showed that on-treatment platelet counts below 50x109/L were associated with the risk of bleeding 
among patients undergoing IFN-based treatment, these bleeding episodes were generally without 
major clinical complications, and thereby do not generate more healthcare costs.115 196 On-treatment 
infections were generally mild as well.308
In a previous study, the diagnosis of thrombocytopenia among patients with chronic HCV infec-
tion was associated with increased medical resource utilization ($37,924 vs $12,174, p <0.001).316 
However, this study cannot be truly compared to our study as they included patients with various 
stages of disease and assessed resource utilization in general, instead of on-treatment costs. The 
increased medical resource utilization among these patients could be attributed to the stage of liver 
disease rather than the presence of thrombocytopenia as thrombocytopenia is associated with the 
severity of liver disease.182 Patients with thrombocytopenia and cirrhosis, which represent a more 
diseased population, are indeed at higher risk to develop hepatic decompensation, HCC and liver 
transplantation, which increases their medical resource utilization.75 79-81 191 317
More important was our finding that the costs per SVR were higher among patients with throm-
bo cytopenia compared to patients with a normal platelet count, especially among those who had a 
platelet count below 100x109/L. This can be predominantly attributed to the lower SVR rates among 
these patients. In line with this finding were the mean costs per SVR for other subgroups that are 
associated with a hampered treatment response, i.e. patients treated with conventional IFN, HCV 
genotype 1/4 and those whom are treatment experienced. As the costs per SVR for patients with a 
platelet count below 100x109/L were high, it would be interesting to compare these to the real-world 
costs per SVR with IFN-free therapy. One could argue, that the additional costs of IFN-free antiviral 
therapy will be less than expected for patients with more severe liver disease. Especially, when one 
would take into account the important safety issues that are associated with IFN-based therapy 
among patients with low platelet counts. Phase 3 studies showed high SVR rates around 95% and 
negligible safety issues with IFN-free regimens, which could result in lower costs per SVR. Moreover, 
these high SVR rates prevent patients from necessitating re-treatment, which would generate even 
higher costs.
A recent study assessing the costs per SVR in a cohort of patients that were treated with triple 
therapy (telaprevir-based) showed that the median cost per SVR was $189,338.318 These costs were 
much higher than what we found. First, this study included only 52 (35%) patients with advanced 
hepatic fibrosis, leading to more patients completing the full therapy of 48 weeks. Second, triple 
therapy with telaprevir is more expensive than dual therapy. Third, only including patients with 
HCV geno type 1, result again in a longer treatment duration and a reduced antiviral efficacy, when 
compared to patients with HCV genotypes 2 and 3. Moreover first real-world data on triple therapy, 
showed much more safety concerns than dual therapy, which would increase the costs for the 
manage ment of adverse events even further.121 In our study, treatment efficacy was limited among 
patients with a platelet count below 100x109/L, and as a result these patients had the highest costs 
per SVR (€74,961 (95%CI €55,463-€103,541). Jonk et al. performed a comparable analysis among 
patients with HCV genotype 1 and 2 that were treated with PegIFN and RBV. They found that the costs 
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per SVR were $47,324, with higher costs per SVR among HCV genotype 1 patients ($63,448) compared 
to patients with HCV genotype 2 ($25,152).319
Our study has some limitations. The time span of the patient accrual does not cover important 
treatment advances such as the introduction of the first generation DAAs. Due to its retrospective 
character, another limitation is missing data. When comparing baseline variables between patients 
that were included and excluded in the study (Supplementary Table 6.3), more data was missing 
for treatment courses applied earlier during the period of inclusion. However, this may in fact make 
the included patients more representative of the current HCV population. Lastly, costs for over-the-
counter medications, reduced productivity at work and quality of life were not included in this study 
and could have an influence on the economic burden of antiviral treatment. However, the study was 
not conducted for this purpose. When considering these costs for interferon-free regimens, recent 
data showed that both work productivity, as well as health-related quality of life improved during and 
after successful antiviral treatment.320 321 This is in contrast with the results during IFN-based regimens, 
for both dual and triple therapy.322 323
A salient strength is that the study was conducted as a multi-country, multi-center study in which 
healthcare utilization and costs were quantified in four countries, located in two continents. Moreover 
the study included a large cohort of patients, who had histological evidence of advanced liver disease. 
For the presence of thrombocytopenia, readily available lab results were used rather than the ICD-9 
codes that are commonly used, which makes the diagnosis very reliable.
The cost per SVR was high among patients with advanced liver disease. Taking into account the 
possible risks of IFN-based treatment, as well as the high chance of necessitating re-treatment, the 
additional costs per SVR of the highly-effective and well-tolerated IFN-free regimens could be limited, 
especially in the specific subset of patients with most advanced liver disease who are in urgent need 
of successful antiviral therapy.
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SUPPLEMENTARY TABLES
Supplementary Table 6.1 | Unit costs and their sources for each country 
Unit costs/ 
country (2013)
The 
Netherlands Canada
Germany
SwitzerlandHannover Homburg
Antiviral 
treatment
Interferon €20.22/6 MU $218.76/18 MU €20.22/6 MU €20.22/6 MU 415.90/25 MU
Pegylated 
interferon
(Dutch price) (Dutch price)
     2a €184.97/180 mcg $478.70/180 mcg €295.87/180 mcg €295.87/180 mcg 333.65/180 mcg
     2b €184.98/100 mcg $467.46/120 mcg €288.23/100 mcg €288.23/100 mcg 338.31/100 mcg
Ribavirin €2.94/200 mg $1.48/200 mg €5.98/200 mg €5.98/200 mg 7.16/200 mg
Laboratory tests
Albumin € 1.81 $2.59 € 3.30 € 1.75 CHF 2.50
Bilirubin € 1.81 $2.59 € 0.88 € 4.08 CHF 3.20
yGT € 2.10 $2.59 € 0.88 € 2.33 CHF 2.50
AST € 2.10 $2.59 € 0.88 € 2.33 CHF 2.50
ALT € 2.25 $2.59 € 0.88 € 2.33 CHF 2.50
Creatinine € 1.96 $2.59 € 0.88 € 2.33 CHF 2.50
Glucose € 1.00 $2.59 € 0.88 € 2.33 CHF 2.50
Hemoglobin € 1.81
$8.27
(hematology)
€ 2.10
(hematology)
€ 3.50
(Hematology) CHF 10.00 
(hematology)
Platelets € 1.81
Leucocytes € 1.81
Neutrophils € 1.81 € 1.17
PT/ Quick € 4.73 $6.20
Together with 
PT
€ 1.75 € 2.91 CHF 6.00
Together with 
PT
INR € 11.32 € 1.75 € 2.91
HCV RNA € 120.13 $105.64 € 66.30 € 145.72 CHF180
Radiology
X-ray € 51.64 $32.65 € 53.77 € 27.26 CHF 100.26
CT Thorax €248,16 $64.95 € 370.00 € 187.27 CHF 284.62
Ultrasound 
abdomen
€ 73.92 $81.95 € 100.00 € 14.30 CHF 150.00
CT abdomen € 211.64 $86.60 € 470.00 € 187.27 CHF 284.12
Ultrasound 
extremity
€ 73.92 $44.20 € 80.00 € 44.20 CHF 120.00
Endoscopy
Gastroscopy € 91.38 $125.10 € 600.00 € 199.76 CHF 345.49
Colonoscopy € 407.91 $197.20 € 800.00 € 201.94 CHF 453.80
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Unit costs/ 
country (2013)
The 
Netherlands Canada
Germany
SwitzerlandHannover Homburg
Visits
Outpatient clinic € 273.00 $157.00 € 60.00 € 30.60 CHF 200.00
Consultation € 140.00 $157.00 € 60.00 € 30.60 CHF 200.00
Admission (1 day) € 626.16 $2,657 € 600.00 € 600.00 CHF 3840.00
Antibiotics
Mean costs/ week € 31.03 $22.88 € 58.09 € 8.91 CHF 218.88
Sources / 
References
- Dutch 
Healthcare 
Authority314
- The National 
Healthcare 
Institute313
- Ontario 
schedule of 
Benefits – 
Physician  and 
laboratory 
services
- Ontario 
Drug Benefit 
Formulary/ 
Comparative 
Drug Index
- Management 
of chronic 
hepatitis B: 
Consensus 
guidelines315
- MHH list for 
hospital-based 
costs and 
medication
- Internal list 
from Saarland 
University 
Hospital
- The Swiss 
Compendium312
Supplementary Table 6.1 | Continued
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Supplementary Table 6.2 | Profile of health care system per country310
The Netherlands The Netherlands has statutory health insurance system, with universally-mandated 
private insurance (of national exchange). The Dutch government regulates and subsidizes 
insurance. Public financing consists earmarked payroll tax, community-rated insurance 
premiums and general tax revenue. Private plans provide statutory benefits while 85% 
of the population buy complementary coverage for benefits excluded from statutory 
package. Children are exempt from cost-sharing and there are premium subsidies for 
low-income. 
Switzerland Switzerland has statutory health insurance system, with universally mandated private 
insurance (of regional exchange). There is federal legislation on health insurance, with 
cantonal (state) government responsible for provider supervision, capacity planning, 
and financing through subsidies. Switzerland has community-rated insurance premiums 
and general tax revenue. Private plans provide universal core benefits; some people 
buy complementary (services not covered by statutory insurance) and supplementary 
(improved amenities and access). The copayment exemptions are for <19-year-olds. 
Income-related premium assistance is 30%. 
Germany Germany has statutory health insurance system, with 131 competing SHI insurers 
(“sickness funds” in national exchange). People with high income can opt out for private 
coverage. Public financing consists employer/employee earmarked payroll tax and 
general tax revenue. 11% of the population opt out from statutory insurance and buy 
private substitutive coverage. Some complementary (minor benefit exclusions from 
statutory scheme, copayments) and supplementary coverage (for improved amenities). 
The caps on cost-sharing include 2% of household income and 1% of income for 
chronically ill. Children and adolescents <18 years of age are exempt.
Canada Canada has regionally administered universal public insurance program that plans and 
funds (mainly private) provision. Public financing consists provincial/federal general tax 
revenue. 67% of the population buy private complementary coverage for non-covered 
benefits (e.g., private rooms in hospitals, drugs, dental care, optometry). There is no cost-
sharing for publicly covered services. The protection for low-income people from cost of 
prescription drugs varies by region.
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Supplementary Table 6.3 | Baseline characteristics at the first registered treatment of patients included 
and excluded in the analyses
Variable
Patients included in 
analyses
(n=455)
Patients excluded 
from analyses
(n=91) p value 
Male 317 (70%) 59 (65%) 0.363
Age, in years 48 (43–56) 48 (42–57) 0.746
BMI, in kg/m2 26.6 (23.8–29.4) 25.1 (23.6–29.5) 0.288
Center
Rotterdam
Toronto
Hannover
Homburg 
Bern
63 (14%)
210 (46%)
93 (20%)
15 (3%)
74 (16%)
1 (1%)
34 (37%)
25 (28%)
13 (14%)
18 (20%)
<0.001
HCV genotype
1
2
3
4
5 or 6
310 (68%)
45 (10%)
75 (17%)
21 (5%)
4 (1%)
39 (65%)
5 (8%)
15 (25%)
1 (2%)
-
0.547
Treatment naïve 367 (81%) 85 (93%) 0.003
Cirrhosis 346 (76%) 60 (66%) 0.044
Fibrosis score 
Ishak 4
Ishak 5
Ishak 6
109 (24%)
93 (20%)
253 (56%)
31 (34%)
11 (12%)
49 (54%)
0.054
Platelet count, in 109/L 147 (109–197) 159 (101-203) 0.755
Albumin, in g/L 42 (39–44) 40 (36–44) 0.166
Bilirubin, in μmol/L 13 (10–19) 13 (9–17) 0.369
AST/ALT ratio 0.70 (0.57–0.91) 0.74 (0.57–0.92) 0.508
Treatment with PegIFN* 204 (45%) 20 (22%) <0.001
Alcohol abuse everd 103 (24%) 18 (23%) 0.823
Diabetes mellitus 58 (13%) 11 (12%) 0.863
Abbreviations: BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PegIFN, 
pegylated interferon;
a. Medians are presented as number, (IQR, interquartile range)
b. Numbers are presented as n, (percentage of the whole group)
c. * Including respectively 10 and 4 treatment courses with PegIFN monotherapy for patients with normal 
platelets and TCP
d. Missing in 37 patients
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chapter 7
Safety and effectiveness of DAA-based 
therapy for the treatment of patients with 
chronic HCV infection and cirrhosis
Processed on: 27-10-2016
505957-L-bw-Maan
134   |   Chapter 7
ABSTRACT 
Background & Aims 
Direct-acting antivirals (DAAs) have revolutionized treatment for patients with chronic hepatitis C 
virus (HCV) infection, leading to a high rates of sustained virological response. This study assessed 
the real-world safety and effectiveness of DAA-based antiviral therapy for the treatment of cirrhotic 
patients with chronic HCV infection.
Methods
This international, multicenter cohort study included all consecutive patients with chronic HCV 
infection and cirrhosis who underwent antiviral therapy with second-generation DAAs. Data on all 
patients were analyzed to assess treatment response. Predictors of hepatic decompensation during 
antiviral therapy were assessed using Cox proportional hazards regression analyses.
Results
Until June 2015, 433 cirrhotic patients with chronic HCV infection started DAA-based treatment. Their 
mean age was 57.8 (±8.7) years, 277 (64.0%) patients were male, and 114 (26.3%) had a Child–Pugh 
(CP) score of B/C cirrhosis. The sustained virological response rate at 12 weeks was similar among 
patients with a CP score of A (261 of 304 [85.9%]) and a CP score of B/C (83 of 101 [82.2%]; p = 0.37). 
A baseline albumin level less than 35 g/L (hazard ratio [HR], 3.11; 95% confidence interval [CI], 1.23–
7.84; p = 0.005), baseline MELD score of 14 or higher (HR, 1.63; 95% CI, 1.03–2.61; p = 0.037), and 
HCV genotype 3 (HR, 2.05; 95% CI, 1.09–3.88; p = 0.033) were associated independently with hepatic 
decompensation during antiviral treatment among patients with a CP score of B/C.
Conclusions
This large cohort study showed that therapy is safe and effective in patients with compensated (CP 
score of A) cirrhosis. For patients with decompensated (CP score of B/C) cirrhosis, albumin level less 
than 35 g/L, MELD score of 14 or greater, and HCV genotype 3 are important risk factors for hepatic 
decompensation during DAA-based treatment. Therefore, these patients require close monitoring 
during antiviral therapy or treatment should be deferred until after transplantation.
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INTRODUCTION
Chronic hepatitis C virus (HCV) infection continues to be a major global public health problem, with 
recent estimates suggesting that 64 to 103 million people are infected worldwide.1 Continuous inflam-
matory activity in the liver may lead to hepatic fibrosis, which eventually may progress to cirrhosis, 
putting patients at risk for hepatic decompensation and hepatocellular carcinoma (HCC).274 Con-
sequently, chronic HCV infection is still the leading indication for liver transplantation in the Western 
world.13 Although the prevalence of HCV infection is decreasing, it is estimated that the disease burden 
of chronic HCV will increase as the infected population ages, leading to an increasing incidence of 
cirrhosis and its complications.63 Successful viral eradication (sustained virological response [SVR]) is 
associated with a reduced incidence in mortality and morbidity among patients with cirrhosis.81
The discovery of oral direct-acting antivirals (DAAs) has revolutionized treatment for chronic 
HCV infection. Within multiple phase 3 studies, shorter and better tolerated therapies without 
pegy lated interferon alfa (PegIFN) have been reported to lead to SVR rates as high as 80% to 100% 
among patients with compensated cirrhosis.143 145 156 Moreover, given the excellent safety profile of 
the new regimens, physicians have increasing confidence that patients with hepatic decompensation 
can be treated safely. However, case reports and small case series have reported patients with 
cirrhosis who experienced worsening of hepatic decompensation during therapy.170 171 324 Under - 
standing who is at risk for liver-related complications will be critical to help clinicians identify which 
patients require closer monitoring and which patients potentially should be left untreated until after 
liver transplantation.
This study aimed to assess the safety and effectiveness of DAA-based regimens for the treatment 
of cirrhotic patients with chronic HCV infection. Patients with compensated cirrhosis were compared 
with patients with decompensated cirrhosis.
PATIENTS AND METHODS
Study Population and Design
This international cohort study included all consecutive patients with chronic HCV infection and 
cirrhosis from 4 academic, tertiary care, referral centers including 2 in Canada (Toronto Centre for Liver 
Disease and Gastrointestinal Research Institute Vancouver), 1 in Germany (Hannover Medical School), 
and 1 in The Netherlands (Erasmus MC, University Medical Center Rotterdam). All patients received 
DAA-based antiviral therapy. The specific regimen was at the discretion of the treating physician. 
Patients enrolled in phase II/III clinical trials were excluded, as well as patients who underwent liver 
transplantation before antiviral therapy was initiated. All charts were reviewed by a single investigator 
to obtain details on demographics, virological, and clinical data. 
The protocol was conducted in accordance with the Declaration of Helsinki and Good Clinical 
Practice and was reviewed and approved by each local ethics review board.
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Definitions
Cirrhosis. The presence of cirrhosis was based on the results of liver biopsy or transient elastography. 
Pretreatment liver biopsy showing cirrhosis, defined as a METAVIR score of F4, was considered the 
gold standard.50 When no liver biopsy was performed, a liver stiffness value of 13.0 kPa or greater was 
considered as cirrhosis.325 If liver biopsy or transient elastography resulted in a METAVIR score of less 
than F4, patients were considered cirrhotic if they had at least 2 of the following: esophageal varices; 
platelet count less than 140x109/L; a nodular liver, signs of portal hypertension, or ascites on imaging; 
noninvasive serum panels compatible with stage 4 fibrosis (FIB-4 >3.25 or FibroTest ≥0.75).293 326
Hepatic decompensation. The criteria for hepatic decompensation were as follows: (1) new-onset 
variceal bleeding, ascites, jaundice leading to hospital admission, or hepatic encephalopathy in 
patients who had never experienced hepatic decompensation; (2) if patients experienced worsening 
of existing hepatic decompensation (ie, required increased dose of diuretics, addition of rifaximin 
for pre-existing hepatic encephalopathy, or hospital admission for a decompensation event); or (3) 
if patients experienced a new decompensation event other than that already present at the start of 
antiviral therapy.
Serious adverse events. Adverse events were considered as follows: (1) comprised hepatic 
decompensation as described earlier, (2) required hospitalization, (3) resulted in discontinuation 
of HCV therapy, or (4) resulted in death. Virological response was measured 12 or 24 weeks after 
cessation of antiviral therapy. HCV RNA was measured using the COBAS AmpliPrep/COBAS TaqMan, 
version 2 (lower limit of detection, 15 IU/mL) (Roche, Pleasanton, CA) or the RealTime HCV assay (lower 
limit of quantification, 12 IU/mL) (Abbott Molecular, Des Plaines, IL) according to the manufacturer’s 
instructions.
Statistical Analysis
Data are presented as means with ±SD, medians with interquartile range, or as proportions. For 
comparisons of patients with Child–Pugh (CP) score of A vs a CP score of B/C, the Student t test, chi-
square, Pearson correlation, or their nonparametric equivalents were used. 
For analysis of adverse events, all patients who started therapy were included. Cox proportional 
hazards regression analyses were used to assess factors associated with the occurrence of hepatic 
decompensation from the start of therapy until 12 weeks after cessation. Patients were censored at 
the 12-week SVR (SVR12) assessment or at death/liver transplantation. Because patients could ex-
perience more than 1 event, all events that occurred in a given patient were included in the analyses 
and time to subsequent decompensation as well as factors associated with more than 1 episode of 
decompensation were assessed. Analyses were stratified by the number of events that the patient 
experienced (ie, at risk for first event, at risk for second event, third event, and so forth). Interaction 
terms between patient characteristics and event strata (first event, second event, and so forth) were 
studied to determine whether different factors were associated with the first or second event. All factors 
with a P value of .2 or less in univariable analyses as well as clinical factors known to be important, 
such as model for end-stage liver disease (MELD) score, age, and sex, were included in multivariable 
Cox models. By using a backward stepwise method, after exclusion of collinear variables, variables 
significantly associated with outcome were included in the final model. Results are presented as a 
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hazard ratio (HR) and the 95% confidence interval (95% CI). For any laboratory para meter associated 
with outcome as a continuous variable, dichotomous thresholds also were evaluated to potentially 
improve clinical utility. 
For the effectiveness analysis, a per-protocol analysis was performed, including all patients who 
completed therapy and had complete follow-up data. A second analysis was performed including 
all patients, regardless of treatment duration, and including patients who were lost to follow-up 
evaluation or died as non-SVR. 
A p value less than .05 was considered statistically significant and all statistical tests were 2-tailed. 
The significance level of interactions was set at 0.01 to correct for multiple testing. PASW statistics 21.0 
for Windows (SPSS, IBM, Armonk, NY) was used.
RESULTS
Patient Characteristics
Between January 1, 2014, and July 1, 2015, there were 433 cirrhotic patients who started treatment 
with a DAA-based regimen. Demographic features are summarized in Table 7.1. Ascites was the most 
common prior decompensation event (105 [84%] patients). Supplementary Table 7.1 shows the 
treatment regimens used. In total, 238 (55.0%) of the treatments included ribavirin (RBV) and 130 
(30.0%) included a protease inhibitor (PI). Patients with a CP score of A were treated more often with 
a regimen including a PI (107 of 319; 33.5%) compared with those with a CP score of B/C (23 of 114, 
20.2%; p = .008). There was no difference in use of RBV among these subgroups (172 of 319 [53.9%] vs 
66 of 114 [57.9%]; p = .464).
Adverse Events
In total, 104 (24.0%) patients reported 164 serious adverse events (SAEs) (Supplementary Table 7.2). 
Among patients with a CP score of A, 50 (13.2%) reported at least 1 SAE compared with 53 (46.5%) 
patients with a CP score of B/C (p <.001). There were 2 cases of suspected treatment-induced hepato-
toxicity. Both patients (1 receiving sofosbuvir [SOF]/simeprevir [SMV] and 1 receiving SOF/RBV) had 
an increase in direct bilirubin level with no other precipitating cause. Five (1.2%) patients underwent 
liver transplantation between initiation of antiviral therapy and assessment of SVR12; 2 patients for 
HCC (5 and 10 weeks after stopping therapy); 2 patients for hepatic decompensation, including 1 
patient with suspected drug-induced liver injury at week 10 of treatment and 1 patient received a 
transplant for both HCC and hepatic decompensation (8 weeks after stopping therapy). Four patients 
had undetectable HCV RNA at the time of transplantation and achieved SVR. Only 1 patient, who had 
a detectable viral load of less than 15 IU/mL at the time of transplantation, relapsed after transplant. 
Six (1.4%) patients (1 CP score of A, 3 CP scores of B, and 2 CP scores of C) died between starting 
therapy and SVR12. Five deaths were liver-related (2 from acute-on chronic hepatic decompensation 
as a result of pneumonia, 1 from deteriorating liver function caused by suspected drug-induced liver 
injury, 1 from multi-organ failure after esophageal variceal bleeding, and 1 from cryoglobulinemia 
and end-stage liver failure in the absence of a clear precipitating event). The non–liver-related death 
occurred as a result of a motor vehicle accident 2 weeks after cessation of therapy. 
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Table 7.1 | Baseline characteristics according to Child Pugh score (A vs. B/C)
Baseline variable
Child Pugh A 
(n=319)
Child Pugh B/C
(n=114)
Total
(N=433) p value
Male sex 206 (64.6%) 71 (62.3%) 277 (64.0%) 0.661
Age, in years
     ≥65 years
58.0 (± 8.6)
57 (17.9%)
57.1 (± 9.3)
22 (19.3%)
57.8 (± 8.7)
79 (18.2%)
0.334
0.734
BMI, kg/m2 b 27.3 (± 4.9) 27.5 (± 5.5) 27.4 (± 5.1) 0.672
Caucasian
Black
Asian
Other/unknown
268 (84.0%)
2 (0.6%)
15 (4.7%)
34 (10.7%)
93 (81.6%)
2 (1.8%)
4 (3.5%)
15 (13.2%)
361 (83.4%)
4 (0.9%)
19 (4.4%)
49 (11.3%)
0.583
Treatment history 
Naïve
Experienced
     IFN-based failures
     DAA failures
104 (32.6%)
67 (58.8%)
157 (73.0%)
58 (27.0%)
47 (41.2%)
67 (58.8%)
59 (88.1%)
8 (11.9%)
151 (34.9%)
282 (65.1%)
216 (76.6%)
66 (23.4%)
0.097
Prior decompensation 36 (11.3%) 89 (78.1%) 125 (28.9%) <0.001
Child Pugh score
A
       B
       C
319 (100.0%)
105 (92.1%)
9 (7.8%)
319 (73.7%)
105 (24.2%)
9 (2.1%)
MELD score
       0-9
       10-15
       16-21
       Unknown
8 (6-20)
244 (76.5%)
67 (21.0%)
3 (0.9%)
5 (1.6%)
13 (6-20)
19 (16.7%)
79 (69.3%)
16 (14.0%)
-
9 (6-20)
264 (61.0%)
146 (33.7%)
19 (4.4%)
4 (0.9%)
<0.001
HCV Genotype
       1a
       1b
       1 (unspecified)
       2
       3
       4
       5
       Mixed genotype
143 (44.8%)
90 (28.2%)
7 (2.2%)
11 (3.4%)
50 (15.7%)
10 (3.1%)
0 (0.0%)
8 (2.5%)
33 (28.9%)
38 (33.3%)
3 (2.6%)
6 (5.3%)
23 (20.2%)
6 (5.3%)
1 (0.9%)
4 (2.6%)
176 (40.6%)
128 (29.6%)
10 (2.3%)
17 (3.9%)
73 (16.9%)
16 (3.7%)
1 (0.2%)
12 (2.8%)
0.105
Platelet count, x109/L 108 (16-599) 75 (14-734) 98 (14-734) <0.001
Albumin, in g/L 37.9 (± 4.7) 31.1 (± 5.2) 36.1 (± 5.7) <0.001
Bilirubin, in mmol/L 14 (3-76) 33 (3-100) 17 (3-100) <0.001
Creatinine, in umol/L 70 (36-500) 71 (43-193) 70 (36-500) 0.296
Comorbidities
     Diabetes mellitus
     Alcohol abuseb
     HIV coinfection
74 (23.2%)
57 (31.8%)
4 (2.2%)
24 (21.1%)
32 (38.1%)
1 (1.2%)
98 (22.6%)
89 (33.8%)
5 (1.9%)
0.639
0.318
0.620
Abbreviations: BMI, body mass index; HCV, hepatitis C virus; IFN, interferon; DAA, direct-acting antivirals; HIV, 
human immunodeficiency virus
a. Continuous variables are presented as mean (±SD) or median (range); categorical variables are presented as 
n (%). P values correspond to the comparison of patients with Child-Pugh A vs Child-Pugh B/C.
b. BMI was missing in 15% of the patients; alcohol abuse was missing in 40% of the patients; alcohol abuse was 
defined as either a history of alcohol abuse or a current use of more than 21 units per week. 
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An SAE was reported during 63 (22.3%) treatments that included RBV compared with 32 (16.4%) 
treatments without RBV (p = .012). Overall, there was no difference in the occurrence of SAEs between 
regimens that included a PI compared with those that did not (PI, 25 of 130 [19.2%] vs no PI, 70 of 303 
[23.1%]; p = .37). In patients with a CP score of B/C cirrhosis, 14 of 23 (60.9%) patients receiving a PI 
reported at least 1 SAE compared with 39 of 91 (42.9%) of patients not receiving a PI (p = .12). 
Of the 32 patients treated with an IFN-containing regimen, 30 (93.8%) patients had a CP score 
of A and 2 had CP scores of B/C cirrhosis. Only 1 patient discontinued treatment early owing to side 
effects. Six (18.8%) patients experienced at least 1 SAE, including hepatic decompensation (ascites, 
n = 1), liver transplantation for HCC (n = 1), anemia (n = 1), recurrent gingival bleeding (n = 2), and 
hypokalemia (n = 1).
Hepatic Decompensation
Fifty (11.5%) of the 433 patients experienced at least 1 hepatic decompensation event during or within 
12 weeks after therapy with a median time to the first decompensation event of 8 weeks (range, 
0–36 wk). Nineteen patients experienced more than 1 decompensation event, leading to a total of 
90 events in 50 patients. Of these, 50 (55.6%) events comprised worsening of pre-existing hepatic 
decompensation, 26 (28.9%) new events in the presence of existing hepatic decompensation, and 14 
(15.6%) de novo events in patients without a history of decompensation (Supplementary Figure 7.1). 
The most common decompensation event was ascites, either new-onset (10.0%) or worsening ascites 
(38.9%). Five (5.6%) patients experienced recurrent variceal bleeding. Of the 50 patients with an event, 
33 (66%) required at least 1 hospital admission for decompensation. In 8 (14%) patients, treatment 
was discontinued, however, 2 patients still achieved SVR. In total, 8 (14%) of these 50 patients died (5 
before SVR12 was assessed and 3 after having achieved SVR12).
Univariable Cox regression showed that baseline characteristics associated with an increased 
risk of first hepatic decompensation included the following: treatment-naive status (vs treatment-
experienced: HR, 1.84; 95% CI, 1.06–3.21; p = .034), HCV genotype 3 (vs non–genotype 3: HR, 2.42; 95% 
CI, 1.35–4.36; p = .005), a CP score of B/C (vs a CP score of A: HR, 18.1; 95% CI, 8.51 to infinity; p <.001), 
albumin level less than 35 g/L (HR, 5.89; 95% CI, 3.19–10.9; p <.001), bilirubin level of 40 mmol/L or 
greater (HR, 7.35; 95% CI, 4.16–13.0; p <.001), MELD score of 14 or greater (HR, 8.28; 95% CI, 4.74–14.5; p 
<.001), and platelet count less than 100x109/L (HR, 2.72; 95% CI, 1.49–5.13; p = .001). In a multivariable 
Cox model, HCV genotype 3 (vs non–genotype 3: HR, 2.08; 95% CI, 1.16–3.74; p = .020), a CP score of 
B/C (vs a CP score of A: HR, 12.63; 95% CI, 5.57 to infinity; p <.001), and albumin level less than 35 g/L 
(HR, 2.03; 95% CI, 1.05–3.93; p = .026) were associated independently with the occurrence of the first 
decompensation event during treatment (Table 7.2). Because MELD score and CP score were highly 
collinear, CP score could be replaced by a MELD score of 14 or higher (HR, 4.68; 95% CI, 2.60–8.42; p 
<.001). A sensitivity analysis, excluding patients treated with an IFN-based regimen, did not affect the 
model (data not shown). Because CP score was a very strong factor, the analyses were repeated for 
a CP score of A and a CP score of B/C as separate groups. Univariable Cox regression among patients 
with a CP score of A showed that only a history of hepatic decompensation was associated with on-
treatment hepatic decompensation (HR, 13.42; 95% CI, 3.21 to infinity; p <.001). Among a CP score 
of B/C patients, HCV genotype 3, albumin level less than 35 g/L, and MELD score of 14 or higher 
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Table 7.2 | Cox Proportional Hazards Regression Analyses for Hepatic Decompensation among all patients
Baseline variable
Univariable Multivariable
HR (95% CI)
p value
likelihood 
ratio HR (95% CI)
p value
likelihood 
ratio
Age 1.002 (0.977-1.028) 0.867
Age ≥ 65 1.001 (0.568-1.765) 0.997
Male gender 1.043 (0.663-1.639) 0.856
Treatment naïve
     For 1st event
     For subsequent event 
1.839 (1.055-3.205)
0.994 (0.524-1.888)
0.034
0.986
RBV-based 0.911 (0.597-1.392) 0.667
PI-based 0.998 (0.599-1.665) 0.995
HCV genotype 3
     For 1st event
     For subsequent event 
2.424 (1.347-4.364)
0.678 (0.331-1.389)
0.005
0.277
2.080 (1.156-3.744)
0.584 (0.283-1.202)
0.020
0.134
Child Pugh B/C vs A
     For 1st event
     For subsequent eventa 
18.139 (8.509-∞)
-
<0.001
-
12.628 (5.570-∞)
-
<0.001
-
Albumin 0.879 (0.848-0.911) <0.001
Albumin <35 g/L
     For 1st event
     For subsequent event
5.894 (3.187-10.900)
7.345 (0.993-∞)
<0.001
0.007
2.030 (1.047-3.934)
4.581 (0.594-∞)
0.026
0.070
Bilirubin 1.031 (1.021-1.042) <0.001
Bilirubin ≥40 μmol/L
     For 1st event
     For subsequent event
7.345 (4.162-12.963)
0.937 (0.499-1.759)
<0.001
0.839
Creatinine 1.004 (0.999-1.009) 0.184
MELD score 1.241 (1.169-1.317) <0.001
MELD score ≥14
     For 1st event
     For subsequent event
8.279 (4.741-14.458)
1.634 (0.823-3.241)
<0.001
0.152
4.675 (2.596-8.422)b 
1.266 (0.632-2.538)
<0.001
0.502
Platelet count 0.996 (0.992-1.000) 0.061
Platelet count <100x109/L
     For 1st event
     For subsequent event
2.724 (1.448-5.126)
1.052 (0.530-2.090)
0.001
0.884
Abbreviations: HR, hazards ratio; CI, confidence interval; RBV, ribavirin; PI, protease inhibitor; HCV, hepatitis C virus
a. There were no subsequent events among patients with CP A.
b. Model if Child Pugh was replaced by MELD score ≥14; HR presented for HCV genotype 3 and albumin <35 
g/L were adapted from the model including Child Pugh
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Figure 7.1 | Kaplan Meier curves showing the occurrence of hepatic decompensation from start of therapy 
to SVR12 for 4 important baseline factors
Straight lines represent the first event; dotted lines represent subsequent events. Among patients with Child Pugh 
A, there were no subsequent events. Abbreviations: HCV, hepatitis C virus 
24-week cumulative incidence for first event
Panel A Child Pugh A 1.9% (95%CI 0.3-3.5) 
Child Pugh B/C 34.5% (95%CI 25.7-43.3) 
Panel B MELD score <14 5.3% (95%CI 2.9-7.7)
MELD score ≥14 39.4% (95%CI 27.6-51.2) 
Panel C Albumin ≥35 g/L 3.4% (95%CI 1.2-5.6) 
Albumin <35 g/L 22.2% (95%CI 15.7-28.7) 
Panel D HCV genotype non-3 8.7% (95%CI 5.8-11.6) 
HCV genotype 3 19.2% (95%CI 10.2-28.2)
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were associated independently with the occurrence of decompensation (Table 7.3). There was a trend 
toward increasing risk of decompensation with PI use in CP score B/C patients (HR, 1.60; 95% CI, 0.90–
2.85; p = .12). Figure 7.1 shows the occurrence of first and subsequent decompensation by CP score, 
MELD score, albumin level, and the presence of HCV genotype 3.
Treatment Response
Per-protocol analysis showed that 344 (84.9%) of 405 patients achieved SVR12. Of patients who did 
not attain SVR12, 60 (98.4%) relapsed and 1 (1.6%) had a partial response. When including all patients, 
350 (80.8%) patients achieved SVR12, 63 (14.5%) relapsed, 3 had a partial response, 6 patients died, 
and 11 patients were lost to follow-up evaluation, including 3 patients with undetectable HCV RNA 
levels 4 weeks after cessation of therapy and 6 patients with undetectable HCV RNA levels at the end 
of treatment. The SVR12 rate was similar among patients with a CP score of A (261 of 304 [85.9%]) 
and a CP score of B/C (83 of 101 [82.2%]; p = .37) in per-protocol analysis, however, there was a trend 
toward better response rates among patients with a CP score of A compared with a CP score of B/C 
cirrhosis when all patients were considered (CP score A, 264 of 319 [82.8%] vs CP score B/C, 86 of 114 
[75.4%]; p = .088).
Excluding regimens in which RBV is considered standard of care (ie, DAA/PegIFN/RBV and SOF/
RBV), the addition of RBV did not influence SVR12. The SVR12 rate was 94.8% (92 of 97) for regimens 
with RBV compared with 93.0% (172 of 185) for regimens without RBV (p = .54). Only HCV genotype 
was associated significantly with treatment response because SVR12 was 70.6% (48 of 68) among 
patients with HCV genotype 3 compared with 87.8% (296 of 337) among patients with other 
genotypes (p <.001). Among patients with HCV genotype 1, SVR was 89.0% (202 of 227) for a CP 
score of A cirrhosis and 83.1% (54 of 65) for a CP score of B/C cirrhosis (p = .20). Thirty-six (72.0%) of 
50 patients who experienced hepatic decompensation achieved SVR12, compared with 314 of 383 
(82.0%) patients without decompensation during therapy (p = .092). Supplementary Tables 7.3 and 
7.4 show SVR12 rates (full-case analysis) stratified by treatment regimen/duration, HCV genotype, 
treatment experience, and CP score at baseline. Figure 7.2 shows the changes in MELD score according 
to CP score and treatment response. 
Table 7.4 shows the cumulative incidence of hepatic decompensation and SVR according to 
the presence of any combination of the 3 factors at baseline (HCV genotype 3, albumin level <35, 
and MELD score ≥14). As noted, in patients with all 3 baseline predictors of decompensation, the 
probability of decompensation was higher than that of achieving SVR, whereas for patients with 0 or 
even 1 factor, SVR was much more likely than decompensation.
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Table 7.3 | Cox Proportional Hazards Regression Analyses for Hepatic Decompensation among patients 
with Child Pugh B/C
Baseline variable
Univariable Multivariable
HR (95% CI)
p value
likelihood 
ratio HR (95% CI)
p value 
likelihood 
ratio
Age 1.005 (0.980-1.032) 0.680
Age ≥ 65 0.897 (0.489-1.646) 0.722
Male gender 1.089 (0.678-1.750) 0.723
Treatment naïve
     For 1st event
     For subsequent event 
1.704 (0.929-3.127)
0.921 (0.486-1.748)
0.086
0.801
RBV-based 0.835 (0.535-1.304) 0.431
PI-based 1.583 (0.931-2.691) 0.102 1.598 (0.897-2.848) 0.120
HCV genotype 3
     For 1st event
     For subsequent event 
2.210 (1.173-4.161)
0.651 (0.318-1.331)
0.019
0.228
2.054 (1.088-3.878)
0.685 (0.321-1.459)
0.033
0.320
Albumin 0.939 (0.900-0.980) 0.004
Albumin <35 g/L
     For 1st event
     For subsequent event
3.338 (1.189-9.372)
3.182 (0.428-∞)
0.007
0.174
3.107 (1.232-7.837)
3.257 (0.420-∞)
0.005
0.182
Bilirubin 1.010 (0.998-1.022) 0.113
Bilirubin ≥40 μmol/L
     For 1st event
     For subsequent event
1.868 (1.016-3.432)
0.792 (0.422-1.483)
0.047
0.464
Creatinine 1.007 (0.999-1.016) 0.122
MELD score 1.097 (1.021-1.178) 0.012
MELD score ≥14
     For 1st event
     For subsequent event
1.843 (1.159-2.930)
1.333 (0.678-2.621)
0.009
0.398
1.634 (1.025-2.606)
1.289 (0.647-2.570)
0.037
0.466
Platelet count 1.001 (0.998-1.004) 0.696
Platelet count <100x109/L
     For 1st event
     For subsequent event
0.966 (0.485-1.921)
1.074 (0.541-2.134)
0.921
0.837
Abbreviations: HR, hazards ratio; CI, confidence interval; RBV, ribavirin; PI, protease inhibitor; HCV, hepatitis C virus
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Figure 7.2 | Change in MELD score at SVR12 visit for all patients and patients with Child Pugh B/C
Patients who underwent liver transplantation, died or were lost to follow-up were not included. Panel A shows 
changes in MELD score for patients who achieved SVR and panel B shows changes in MELD score for patients 
who did not attain SVR. Grey bars represent improvement of MELD score and black bars represent worsening of 
MELD score. The asterisk (*) represents the number of patients (%) with a significant change in MELD score (i.e. ≥ 
2 points).
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Table 7.4 | Cumulative incidence of hepatic decompensation and SVR12 rate according to three risk factors
24 week cumulative incidence (95% CI) 
hepatic decompensation 
(first event)
SVR12 rateb
(%)
0 factor N
No factor 212 3.3% (0.9-5.7) 182/212 (85.6%)
1 factor
HCV genotype 3
Yes 73 19.2% (10.2-28.2) 48/73 (65.8%)
No 360 8.7% (5.8-11.6) 302/360 (83.9%)
Albumin <35 g/La
     Yes 163 22.2% (15.7-28.7) 124/163 (76.1%)
     No 269 3.4% (1.2-5.6) 225/269 (83.6%)
MELD score ≥14a
     Yes 66 39.4% (27.6-51.2) 54/66 (81.8%)
     No 362 5.3% (2.9-7.7) 292/362 (80.7%)
Any factor 217 17.6% (12.5-22.7) 165/217 (76.0%)
2 factors
HCV genotype 3 +          
     Albumin <35 g/L 28 46.4% (28.0-64.8) 16/28 (57.1%)
     MELD score ≥14 15 60.0% (35.3-84.7) 11/15 (73.3%)
Albumin <35 g/L +  
     MELD score ≥14 54 46.3% (33.0-59.6) 42/54 (77.8%)
Any two factors 73 39.7% (28.5-50.9) 53/73 (72.6%)
3 factors
HCV genotype 3 + 
Albumin <35 g/L + MELD score ≥14 12 75.0% (50.5-99.5) 8/12 (66.7%)
Abbreviations: CI, confidence interval; SVR, sustained virological response; HCV, hepatitis C virus
a. MELD score at baseline was missing for 5 patients; albumin at baseline was missing for 1 patient
b. SVR12 rates were presented as full case analysis
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DISCUSSION
This large multicenter cohort study assessed real-world safety and the effectiveness of DAA regimens 
in HCV patients with cirrhosis. Patients with a CP score of A cirrhosis tolerated therapy well, with 
only 8 patients (2.5%) experiencing an episode of decompensation. In contrast, decompensating 
events occurred in 36.8% of patients with a CP score of B/C and were associated with 3 specific risk 
factors: HCV genotype 3, serum albumin level less than 35 g/L, and a MELD score of 14 or higher. 
The overall SVR12 rates were lower than those reported in clinical trials, especially for patients with 
decompensated cirrhosis and patients with HCV genotype 3. 
Hepatic decompensation during DAA therapy occurred in 11.5% of patients. More than 50% 
of these events comprised worsening of pre-existing (stable) hepatic decompensation and the 
remainder were new events, mostly in patients who already had experienced another decompensation 
event. De novo decompensation in a patient with previously well-compensated cirrhosis was rare, 
accounting for 14 episodes. Among patients with a CP score of B/C at baseline, factors predictive 
of decompensation were baseline albumin level less than 35 g/L, a MELD score of 14 or higher, and 
infection with HCV genotype 3. The importance of albumin also was highlighted in a recent study 
by Foster et al.327 They found that albumin level less than 35 g/L was associated with an increased 
risk of “harm” during therapy, defined as an increase in MELD score by 2 or more points, and/or the 
occurrence of any serious adverse event. Albumin level was particularly important in patients older 
than age 65, a trend that we did not observe.327 Although serum albumin is a well-known parameter of 
liver synthetic function, it is not clear why it is specifically more useful in predicting adverse outcomes 
in patients treated with DAAs. Beyond reflecting hepatocyte protein synthesis, a low albumin level 
may worsen complications of portal hypertension such as ascites, and albumin may have a specific 
role in reducing the risk of infection, a major precipitant for hepatic decompensation.328 In the era of 
PegIFN and RBV, Dultz et al329 found that every 1-point increase in MELD score increased the risk for 
decompensation 1.56-fold. Our data, as well as those from other studies, emphasize that MELD is a 
useful predictor of safety and possibly response to IFN-free DAA-based therapy. 
Our finding that HCV genotype 3 was associated with the occurrence of hepatic decompensation 
was somewhat surprising. Genotype 3 HCV infection was associated with an accelerated course of 
fibrosis, but this is unlikely to be of major significance during the short duration of DAA therapy. 
Although more patients with HCV genotype 3 had a MELD score of 14 or higher, genotype remained 
a significant factor in multivariable analysis and an interaction with MELD was not observed. A 
simple explanation may be that the lower success of therapy for HCV genotype 3 meant that fewer 
patients with this genotype achieved SVR and more patients relapsed after therapy. However, the 
rate of decompensation was similar between patients who did and did not achieve SVR, suggesting 
that this is not the full explanation. Alternatively, the issue may be the use of SOF/RBV combination 
therapy, which was the most commonly used regimen, in part because daclatasvir was not approved 
in Canada during the study period. However, SOF and RBV also frequently were components of the 
treatment regimens administered to patients with HCV genotype non-3 (102 of 291; 35.1%) and the 
use of this combination was not associated independently with decompensation. Univariable analysis 
did not show that the use of RBV or the cumulative exposure to RBV were associated with the risk of 
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decompensation. One possible hypothesis is that the metabolism of DAAs may be different among 
patients with different genotypes. Recently, Younossi et al330 assessed the cholesterol pathway in 
patients with HCV genotypes 2 and 3 and found that the presence of HCV genotype 3 was associated 
with reduced circulation of lipids, resulting in relative hypocholesterolemia, a possible basis for 
the hampered virological response with this genotype. Whether this same pathway also could be 
involved in increasing the risk of adverse events requires further study. In addition to the safety issue, 
lower SVR rates in genotype 3 patients highlight the need for better therapy for this group of patients. 
Fortunately, multiple regimens in development, including SOF/velpatasvir, are highly active against 
genotype 3 and should be available in the near future.168 Hopefully more effective therapy for HCV 
genotype 3 also will prove to be safer than current regimens.
Cox regression analyses among patients with a CP score of B/C showed a trend toward increasing 
the risk of decompensation with the use of a protease inhibitor (HR, 1.60; 95% CI, 0.90–2.85). Upon initial 
approval of SOF/SMV, many of the most advanced patients were treated with this regimen to salvage 
them from decompensated cirrhosis. However, numerous cases of hepatotoxicity with SOF/SMV were 
reported, reinforcing that SMV is not recommended in patients with decompensated cirrhosis.127 324 331 
The issue is likely to be a class effect related to hepatic metabolism and the potential for accumulation 
of PIs in the liver of cirrhotic patients. More recently, the US Food and Drug Administration indicated 
that the use of dasabuvir, ombitasvir, and paritaprevir/ritonavir is contraindicated in patients 
with decompensated liver disease.174 Similarly, the most recently approved PI, grazoprevir, is not 
recommended in people with a CP score of B/C because of the risk of PI-induced hepatotoxicity. 
Before starting therapy, it is important to weigh the risks and benefits of antiviral treatment. For 
patients with a CP score of A cirrhosis, the risk of decompensation appears low in this study and in 
multiple clinical trials and real-world reports, suggesting that these patients can be treated safely 
and are likely to bene t from therapy. However, in patients with a CP score of B/C at baseline, there 
is clearly a risk of causing harm. By identifying 3 useful factors, physicians potentially can assess 
the risk for hepatic decompensation and weigh this risk against the chance of attaining SVR. One 
could argue that when the risk of decompensation is equal to or higher than the chance of attaining 
SVR, delaying therapy would be a better option. Recent data from patients treated after liver 
transplantation have shown excellent safety and high rates of SVR, particularly in patients treated 
early after transplantation.150 332 333 Moreover, the clinical bene t of attaining SVR in patients with a 
CP score of B/C still is unknown. Some studies have shown improvement in MELD score at 12 or 24 
weeks after the cessation of therapy,327 334 but whether small decreases in MELD score truly indicate 
clinical bene t and whether these benefits will translate into improved clinical outcomes remains to be 
seen. More data are needed urgently on long-term outcomes of decompensated cirrhosis to elucidate 
which patients benefit from successful antiviral therapy and, more importantly, which patients do not. 
Our analysis showed that therapy is safe and effective in patients with compensated CP score of A 
cirrhosis. For patients with a CP score of B/C, an albumin level less than 35 g/L, a MELD score of 14 or 
greater, and genotype 3 infection were associated with decompensation during therapy. If only 1 of 
these factors was present, the SVR rate still was approximately 75%, compared with an approximately 
20% risk of decompensation, thus favoring treatment with careful monitoring. However, when 2 or 
all 3 risk factors were present, the rate of decompensation was almost equivalent or even higher than 
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the chance of SVR, arguing that these patients would likely be better off deferring therapy until after 
transplantation. Although some of the decompensation events may be owing to the natural history 
of advanced liver disease rather than treatment itself, the high event rate and marginal benefit of pre-
transplant treatment in these patients still would argue for delaying therapy. 
This study had important limitations, including its retrospective nature and the potential for 
underreporting of decompensation events and missing data. However, it is unlikely that severe 
adverse events, which are clinically most relevant, were missed. Second, because of the heterogeneous 
regimens used, it was not possible to conclude that a specific regimen would be preferred in patients 
with decompensated cirrhosis. Finally, the limited follow-up period of 12 weeks after treatment 
allowed for assessment of only short-term benefits of therapy. In conclusion, in a large cohort of 
patients with HCV cirrhosis, SVR rates with second-generation DAAs were lower than reported in 
clinical trials. Treatment was safe and effective in patients with compensated cirrhosis. However, in 
patients with a CP score of B/C at baseline, there was a significant risk of worsening decompensation 
during therapy. An albumin level less than 35 g/L, a MELD score of 14 or higher, and HCV genotype 3 
infection are useful tools to assess the risk and benefits when antiviral treatment with DAAs is under 
consideration for patients with advanced cirrhosis.
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SUPPLEMENTARY FIGURE AND TABLES
Supplementary Figure 7.1 | Flow chart for hepatic decompensation from start of therapy to the SVR12 visit. 
In total, 50 patients experienced at least one decompensating event. In 19 (38%) patients a subsequent 
decompensating event was reported. HE, hepatic encephalopathy
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Supplementary Table 7.1 | Treatment allocation
DAA/PEG/
RBVa SOF/RBV
SOF/SMV ± 
RBV
SOF/LDV ± 
RBV
OBV/PTV/r/
DSV ± RBV
SOF/DCV ± 
RBV
Patients, n (%) 32 (7.4%) 99 (22.9%) 106 (24.5%) 115 (26.6%) 24 (5.5%) 57 (13.2%)
RBV used 32 (100.0%) 99 (100.0%) 27 (25.5%) 36 (31.3%) 20 (83.3%) 24 (42.1%)
Completed treatment 31 97 101 102 21 47
Early treatment 
discontinuation
Reason for stopping:
     Adverse event
     Decompensation
     Only RBV/PegIFN  
     Stopped
Lost to follow-up/ died
1
0
0
1
0
4
2
2
0
4
5
1
2
2
2
0
0
0
0
6
1
0
0
1
2
6
0
2
4
3
SVR 12b 23/32 
(71.9%)
57/99 
(57.6%)
95/106 
(89.6%)
101/115 
(87.8%)
22/24 
(91.7%)
52/57 
(91.2%)
Abbreviations: DAA, direct-acting antiviral; PEG, pegylated interferon α; RBV, ribavirin; SOF, sofosbuvir; SMV, 
simeprevir; LDV, ledipasvir; OBV, ombitasvir; PTV/r, paritaprevir/ritonavir; DSV, dasabuvir ; DCV, daclatasvir; SVR, 
sustained virological response
a. Including 30 treatments with SOF/PEG/RBV, 1 treatment with SIM/PEG/RBV and 1 treatment with SOF/PEG/
RBV/boceprevir
b. b. Patients who died or were lost to follow-up were included as non-SVR
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Supplementary Table 7.2 | Safety issues reported
Event
Child-Pugh A
319 patients 
Child-Pugh B/C
114 patients
Total
433 patients
SAEs
Total
At least one
2 events
> 2 events
62
49 (15.4%)
10 (3.1%)
1 (0.3%)
116
54 (47.4%)
7 (6.1%)
18 (15.8%)
178
103 (23.8%)
17 (3.9%)
19 (4.4%)
Hepatic decompensation
Variceal bleeding
Hepatic encephalopathy
Ascites
Jaundicea
8 (12.9%)
5 (62.5%)
0 (0.0%)
3 (37.5%)
0 (0.0%)
82 (71.9%)
8 (9.8%)
30 (36.6%)
41 (50.0%)
3 (3.7%)
90 (50.6%)
13 (14.4%)
30 (33.3%)
44 (48.9%)
3 (3.3%)
Other SAEs
Cardiac 
Gastrointestinal
Infection
Symptomatic anemiab
Liver transplantation
Deathc
Other
3 (4.8%)
1 (1.6%)
8 (12.9%)
14 (22.6%)
1 (1.6%)
1 (1.6%)
17 (27.4%)
0 (0.0%)
0 (0.0%)
3 (2.6%)
9 (7.9%)
4 (3.5%)
5 (4.4%)
16 (12.3%)
3 (1.7%)
1 (0.6%)
11 (6.2%)
23 (12.9%)
5 (2.8%)
6 (3.4%)
31 (17.4%) 
Laboratory adverse events
Anemia (Hb <8.0 g/dL)
Creatinine increase (>26.5 μmol/L)
5 (1.6%)
10 (3.1%)
6 (5.3%)
11 (9.6%)
11 (2.5%)
21 (4.8%)
Abbreviations: SAEs, serious adverse events; HCC, hepatocellular carcinoma; Hb, hemoglobin 
a. Jaundice was defined as an episode of a total serum bilirubin ≥ 40 μmol/L, and requiring hospital admission
b. Symptomatic anemia was defined as the presence of anemia (all grades) requiring dose reduction of RBV or 
blood transfusion
c. Causes of death included two deaths due to acute on chronic hepatic decompensation caused by 
pneumonia; two deaths due to end-stage liver disease (including one case of suspected drug induced liver 
injury); one death due to multi-organ failure after variceal bleeding; and one death due to a motor vehicle 
accident.
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Supplementary Table 7.3 | SVR12 rates for a treatment duration of 12 weeks (full case analysis)
HCV genotype
Treatment experience
No addition of RBV RBV-based regimen
TotalChild-Pugh A Child-Pugh B/C Child-Pugh A Child-Pugh B/C
DAA/PEG/
RBV
HCV genotype 1a
Naïve - - 3/4 0/1 3/5
TE - - 4/4 - 4/4
HCV genotype 1b
Naïve - - 2/3 - 2/3
TE - - 2/4 - 2/4
HCV genotype 1 no 
subtype
Naïve - - - - -
TE - - 2/2a - 2/2
HCV genotype 3
Naïve - - 1/1 - 1/1
TE - - 5/6 - 5/6
HCV genotype 4
Naïve - - 0/1 - 0/1
TE - - - - -
HCV genotype 5
Naïve - - - - -
TE - - - 1/1 1/1
20/27
SOF/RBV HCV genotype 2 
Naïve - - 3/4 2/2 5/6
TE - - 2/3 1/2 3/5
8/11
SOF/SMV HCV genotype 1a
Naïve 3/4 1/1 7/7 2/2 13/14
TE 17/20 - 12/13 1/1 30/34
HCV genotype 1b
Naïve 9/11 4/5 - - 13/16
TE 19/20b 5/6 - - 24/26
HCV genotype 1 no 
subtype
Naïve - - - - -
TE 1/1 2/3 - - 3/4
HCV genotype 4
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HCV genotype
Treatment experience
No addition of RBV RBV-based regimen
TotalChild-Pugh A Child-Pugh B/C Child-Pugh A Child-Pugh B/C
Naïve 2/2 1/1 - - 3/3
TE 1/1 1/1 - - 2/2
88/99
SOF/LDV HCV genotype 1a
Naïve 10/10 3/3c 2/2 2/3d 17/18
TE 1/2 1/1 8/9e 5/5f 15/17
HCV genotype 1b
Naïve 2/4 2/3 - 1/2 5/9
TE 1/1 - 3/3 2/2 6/6
HCV genotype 1 no 
subtype
Naïve - - - - -
TE - - 2/2 - 2/2
HCV genotype 4
Naïve 1/1 - - - 1/1
TE - - - 1/1 1/1
47/54
OBV/PTV/r/
DSV 
HCV genotype 1a
Naïve - - 6/6 1/1 7/7
TE - - - - -
HCV genotype 1b
Naïve 1/1 - 4/4 - 5/5
TE - - 4/4 0/1 4/5
HCV genotype 1 no 
subtype
Naïve - - - - -
TE 1/1 - - - 1/1
17/18
SOF/DCV HCV genotype 1a
Naïve 0/1 - 1/1 - 1/2
TE - - 3/3 1/1 4/4
HCV genotype 1b
Naïve - - 1/1 - 1/1
TE 1/1 - 2/2g - 3/3
HCV genotype 3
Supplementary Table 7.3 | Continued
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HCV genotype
Treatment experience
No addition of RBV RBV-based regimen
TotalChild-Pugh A Child-Pugh B/C Child-Pugh A Child-Pugh B/C
Naïve - - - - -
TE 1/1 - - - 1/1
HCV genotype 4
Naïve - - - - -
TE - - 1/1 1/1 2/2
12/13
Abbreviations: SVR, sustained virological response; HCV, hepatitis C virus; RBV, ribavirin; DAA, direct-acting 
antiviral; PEG, pegylated interferon α; TE, treatment experienced; SOF, sofosbuvir; SMV, simeprevir; LDV, ledipasvir; 
OBV, ombitasvir; PTV/r, paritaprevir/ritonavir; DSV, dasabuvir ; DCV, daclatasvir
a. Including one patient with HCV genotype 1 receiving 12 weeks of SOF in addition to BOC/PEG/RBV, which 
was used for 24 weeks already
b. One patient had a mixed infection with HCV genotype 1b/4, this patient achieved SVR12
c. One patient had a mixed infection with HCV genotype 1a/1b, this patient achieved SVR12
d. One patient had a mixed infection with HCV genotype 1a/2, this patient achieved SVR12
e. One patient had a mixed infection with HCV genotype 1a/1b, this patient achieved SVR12
f. One patient had a mixed infection with HCV genotype 1a/2, this patient achieved SVR12
g. This patient had a mixed infection with HCV genotype 1b/3
Supplementary Table 7.3 | Continued
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Supplementary Table 7.4 | SVR12 rates for a treatment duration of 16 or 24 weeks (full case analysis)
HCV genotype
Treatment experience
No addition of RBV RBV-based regimen Total
Child-Pugh A Child-Pugh B/CChild-Pugh A Child-Pugh B/C
DAA/PEG/
RBVc
HCV genotype 1a
Naïve - - - - -
TE - - 1/1 - 1/1
HCV genotype 1b
Naïve - - 1/1a - 1/1
TE - - 0/1 - 0/1
HCV genotype 3
Naïve - - 0/1 - 0/1
TE - - 1/1 - 1/1
3/5
SOF/RBV HCV genotype 1a
Naïve - - 0/2 - 0/2
TE - - 1/2 - 1/2
HCV genotype 1b
Naïve - - 2/4 2/2 4/6
TE - - 4/10 2/6 6/16
HCV genotype 2 
Naïve - - 2/2b 1/1b 3/3
TE - - 2/2b 0/1b 2/3
HCV genotype 3 
Naïve - - 11/17 7/12 18/29
TE - - 9/17 5/8b 14/25
HCV genotype 4 
Naïve - - 1/1 - 1/1
TE - - - 0/1 0/1
49/88
SOF/SMV HCV genotype 1a
Naïve - - - - -
TE - - 3/3 - 3/3
HCV genotype 1b
Naïve - 1/1 - - 1/1
TE 2/2 - - - 2/2
HCV genotype 4
Naïve - - - - -
TE - - 1/1 - 1/1
7/7
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HCV genotype
Treatment experience
No addition of RBV RBV-based regimen Total
Child-Pugh A Child-Pugh B/C Child-Pugh A Child-Pugh B/C
SOF/LDV HCV genotype 1a
Naïve 1/1 2/3 1/1c - 2/3
TE 25/28d 4/5e 3/3f 1/2 33/38
HCV genotype 1b
Naïve 1/1 2/2 - - 3/3
TE 7/8 6/6 - - 13/14
HCV genotype 3
Naïve - - - -
TE - - 1/1 - 1/1
54/61
OBV/PTV/r/
DSV 
HCV genotype 1a
Naïve - - - - -
TE 2/2 - 2/3 - 4/5
HCV genotype 1 no 
subtype
Naïve - - - - -
TE - - 1/1 - 1/1
5/6
SOF/DCV HCV genotype 1a
Naïve 2/2 - - 1/1 3/3
TE 13/13g 5/6 1/2 0/1 19/22
HCV genotype 1b
Naïve - - - 1/1 1/1
TE 5/5 - 1/1 1/1 7/7
HCV genotype 3
Naïve 1/1 - 1/2b - 2/3
TE - - 2/2 3/3 5/5
HCV genotype 4
Naïve - - - - -
TE 2/2 1/1 - - 3/3
40/44
Abbreviations: SVR, sustained virological response; HCV, hepatitis C virus; RBV, ribavirin; DAA, direct-acting 
antiviral; PEG, pegylated interferon α; TE, treatment experienced; SOF, sofosbuvir; SMV, simeprevir; LDV, ledipasvir; 
OBV, ombitasvir; PTV/r, paritaprevir/ritonavir; DSV, dasabuvir ; DCV, daclatasvir
a. This patient received 24 weeks of SMV/PEG/RBV 
b. 16 weeks for 6 patients with HCV genotype 2 (SOF/RBV [SVR 5/6]) and two patients with HCV genotype 3 
(SOF/RBV [SVR] and SOF/DCV/RBV [SVR])
Supplementary Table 7.4 | Continued
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c. This patient had a missing HCV genotype
d. Including two patients who had a double infection with HCV genotype 1a/2, both patients achieved SVR12
e. One patient had a mixed infection with HCV genotype 1a/1b
f. One patient had a mixed infection with HCV genotype 1a/1b
g. One patient had a mixed infection with HCV genotype 1a/1b
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ABSTRACT 
Background & Aims 
Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies 
lead to high rates of sustained virological response (SVR). However, genotype 3 (GT3) HCV remains a 
challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study reports the 
effectiveness and safety of SOF-based therapy in patients with GT3 HCV treated in clinical practice.
Methods
Hepatitis C Virus Therapeutic Registry and Research Network is an international, prospective obser-
vational study evaluating patients treated in usual clinical practice. Patients with GT3 HCV were 
analyzed to assess predictors of treatment response and adverse events using descriptive statistics 
and multivariable logistic regression.
Results
Treatment outcomes were available for 197 patients treated with SOF and ribavirin (RBV), with or 
without peginterferon, including 54% with cirrhosis and 49% who failed prior therapy. Of 178 patients 
treated with SOF/RBV, 60% achieved SVR at 12 weeks (SVR12), compared with 84% of 19 patients 
treated with SOF/peginterferon/RBV. For patients treated with SOF/RBV, the SVR12 rate was 58% in 
treatment-naive patients with cirrhosis, and 42% in those with cirrhosis who failed prior therapy. In 
noncirrhotic patients, SVR12 rates were 89% in treatment-naive and 88% in treatment-experienced 
patients. After controlling for age and sex, absence of cirrhosis (odds ratio [OR], 6.4; 95% confidence 
interval [CI], 2.78–14.74), albumin levels ≥3.2 g/dL (OR, 12.48; 95% CI, 3.86–40.33), and platelet count 
≥105 cells/µL (OR, 7.44; 95% CI, 3.51–15.78) were associated with greater odds of SVR12.
Conclusions
SVR rates were acceptable in patients with GT3 HCV without cirrhosis; however, in those with cirrhosis, 
treatment with SOF/RBV was suboptimal, highlighting the need for new therapies for this population.
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INTRODUCTION
Chronic hepatitis C virus (HCV) infection continues to be a major global public health problem, with 
recent estimates suggesting that >103 million people are infected worldwide.1 There is wide geo-
graphical variation in HCV genotype distribution; genotype 1 is most common (46%), followed by 
genotype 3 (GT3) (22%).1 Chronic infection leads to progressive liver fibrosis that may eventually lead 
to cirrhosis, putting patients at risk of liver failure and/or hepatocellular carcinoma (HCC).274-276 Several 
studies have shown that both the risk for fibrosis progression and the risk of developing HCC are 
increased among patients with HCV GT3.299 335 
Therapy for chronic HCV was originally based on interferon, and resulted in different response 
rates by genotype.107 Genotypes 2 (GT2) and 3 are relatively interferon sensitive and required shorter 
duration of therapy with lower doses of ribavirin (RBV) to achieve high rates of sustained virological 
response (SVR). Even in the interferon era, data suggested that GT3 was more difficult to cure than GT2, 
particularly in patients with established cirrhosis.336 The discovery of direct-acting antivirals (DAAs) 
has revolutionized treatment of chronic HCV infection. Sofosbuvir (SOF) is a well-tolerated nucleotide 
polymerase inhibitor with activity against all HCV genotypes. However, despite initially promising 
results, large clinical trials reported lower rates of SVR in patients with GT3 infection receiving SOF-
based therapy than with other HCV genotypes.337 
The FUSION, FISSION, and POSITRON trials showed that the combination of SOF and RBV was 
more effective and much better tolerated than pegylated interferon (peg-IFN)/ RBV in patients with 
GT2 and GT3 HCV.137 139 However, a breakdown of the results by genotype and cirrhosis status revealed 
that patients with GT3, particularly those with cirrhosis, had high rates of relapse. With extension of 
therapy to 24 weeks, the SVR rates rose to 93% in treatment-naive patients; however, in patients who 
had failed prior peg-IFN/RBV, the SVR rates were 85% without cirrhosis, but only 60% in those with 
cirrhosis.138 
Studies then evaluated adding peg-IFN to SOF/RBV for 12 weeks and showed that SVR rates 
increased to 85%, even in treatment-experienced patients with cirrhosis.140 338 Based on these results, 
guidelines recommend either a 12-week course of SOF/peg-IFN/RBV or a 24-week course of SOF/RBV 
for patients with GT3 infection.35 36 Daclatasvir (DCV), a relatively pan-genotypic NS5A inhibitor, has 
also been combined with SOF, and the combination has been recommended as an alternative therapy 
for GT3 infection.35 36 The efficacy and safety of these regimens are based on treatments administered 
to patients who fulfilled the eligibility criteria for clinical trials. Whether these results apply in daily 
clinical practice is unknown. This study reports the safety and effectiveness of 2 SOF-based regimens 
for the treatment of chronic GT3 HCV in an international, prospective observational study.
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PATIENTS AND METHODS
Study Population and Design
Hepatitis C Virus Therapeutic Registry and Research Network (HCV-TARGET) is an international, pros-
pective observational study enrolling patients from academic (n = 44) and community (n = 17) centers 
in the United States, Canada, Germany, and Israel who receive antiviral treatment for chronic HCV 
infection. Sequentially enrolled patients with no history of liver transplant or prior DAA treatment, 
≥18 years old with GT3 HCV who received treatment with SOF and RBV, with or without peg-IFN, were 
included. The treatment regimen was chosen by the treating physician. Redacted medical records 
were collected by a central team of trained coders and reviewed, and baseline and on-treatment 
demo graphic, clinical, and virological data were entered into a common, standardized database. Data 
were managed using REDCap electronic data capture tools hosted at the University of North Carolina 
at Chapel Hill and reviewed for completeness and accuracy by study monitors. Extreme or unlikely 
values were verified or resolved with additional queries.
The protocol was conducted in accordance with the Declaration of Helsinki and Good Clinical 
Practice guidelines. The protocol was approved by each local institutional review board (IRB). All 
patients provided written informed consent or an informed consent waiver was granted by the IRB 
overseeing the site.
Definitions
The following clinical definitions were applied to the study population. 
Cirrhosis. Cirrhosis was defined by an algorithm implemented for HCV-TARGET analyses.169 The 
primary indicator of cirrhosis was a liver biopsy with Metavir score F4. Patients with a liver biopsy 
reported as Metavir score F3 with at least 1 secondary indicator were also defined as having cirrhosis. 
Secondary indicators included serum fibrosis scores above thresholds for cirrhosis (FibroSure/
FibroTest, FibroSpect, Hepascore); transient elastography (Fibroscan) ≥12.5 kPa; or signs of portal 
hypertension (esophageal/gastric varices, portal gastropathy, or platelet count <140x109/L). In the 
absence of a biopsy, patients with ≥2 secondary indicators were defined as having cirrhosis.120 
Decompensated cirrhosis was defined as documented presence of current or past ascites, hepatic 
encephalopathy, spontaneous bacterial peritonitis, hepatic hydrothorax or variceal hemorrhage, or 
use of medications specifically prescribed for one of these indications. 
Adverse Event. An adverse event (AE) was defined as any reported AE regardless of the need for 
dose reduction or discontinuation of HCV therapy.
Serious Adverse Event. A serious adverse event (SAE) was defined as an AE that either required 
hospitalization or met criteria for expedited reporting per US Food and Drug Administration form 
MEDWATCH 3500.
Anemia. Anemia was reported as an AE, or documented RBV dose reduction, treatment with 
erythropoietin, or blood transfusion.
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Statistical Analyses
Demographics, baseline laboratory values, and frequencies of AEs were collected and analyzed by 
treatment regimen for the evaluable population (N = 197), which comprised patients who ended 
treatment with a known virological outcome or were confirmed to be lost to posttreatment follow-
up (counted as non– virological failures). Those lost to follow-up during treatment or who withdrew 
consent were excluded.
The per-protocol population (n = 174) comprised patients who completed treatment or ended 
treatment early due to virological failure only, and have a known virological outcome. The unadjusted 
rates of SVR were calculated for the evaluable and per-protocol populations, and multivariable 
analyses of factors associated with response and results in subgroups of interest are reported for the 
per-protocol population, including treatment history, presence of cirrhosis, and features of cirrhosis. 
Confidence intervals (CIs) of unadjusted rates were calculated using exact binomial methods.
The association between baseline covariates and SVR was estimated by logistic regression ad-
justed for age and sex for the per-protocol population. Covariates significant after adjustment for age 
and sex without significant collinearity were combined into multivariable models. Predictor variables 
were selected a priori based on consensus of clinical expertise and included well-established cova-
riates associated with SVR: treatment regimen, age, sex, race, albumin level (<3.2 g/dL, ≥3.2 g/dL), 
platelet count (<105 cells/µL, ≥105 cells/µL), creatinine clearance, total bilirubin (mg/dL), hemoglobin 
(g/dL), cirrhosis status, and history of prior antiviral treatment as well as Model for End-Stage Liver 
Disease score and history of decompensating event in patients with cirrhosis. Results are presented 
as an odds ratio (OR) with 95% CIs. Analyses were performed using SAS version 9.4 software (SAS 
Institute, Cary, North Carolina).
RESULTS
Patient Disposition
Between December 2013 and January 2015, 210 patients with GT3 HCV infection with no history of 
liver transplant or prior DAA therapy started treatment with SOF/RBV or SOF/ peg-IFN/RBV. A total of 
185 patients completed the prescribed regimen. Eighteen patients discontinued treatment early due 
to AEs [4], lack of efficacy [4], noncompliance [3], or other reasons [3] (eg, loss of insurance or planned 
surgery). Twelve patients were excluded due to loss to follow-up during treatment [4], withdrawal of 
consent [1], or ongoing posttreatment follow-up at the time of reporting [5]. 
The majority of patients (178/197 [90%]) were treated with SOF/RBV, with 87% receiving 24±2 
weeks of therapy, while 19 (10%) patients received 12 (n = 12), 16 (n = 1), or 24 (n = 5) weeks of SOF/
peg-IFN/RBV, including 1 patient who discontinued treatment at week 4. In total, 112 (57%) were 
male, 81% were white, and the mean age was 56 years (range, 27–77 years). Just under half (49%) were 
treatment experienced and 3 patients (1.5%) were coinfected with human immunodeficiency virus 
(HIV). Of 107 (54%) patients with cirrhosis, 49 (46%) had a history of prior hepatic decompensation. 
Of cirrhotic patients with complete MELD data (70%), the median baseline MELD score was 10 (range, 
6–24). MELD score was <10 in 49% (n = 37), 10–15 in 44% (n = 33), and >15 in 7% (n = 5) of patients 
with cirrhosis (Table 8.1; Supplementary Table 8.1).
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Table 8.1 | Baseline demographic and clinical characteristics of patients with G3 HCV who completed 
therapy with sofosbuvir and ribavirin +/- peginterferon
Characteristic
SOF/PEG/RBV
 (n=19)
SOF/RBV
 (n=178)
Total
(n=197)
Median age (range), yr 56.0 (33-67) 56.0 (27-77) 56.0 (27-77)
18-39
40-64
65+
3 (15.8%)
15 (78.9%)
1 (5.3%) 
19 (10.7%)
140 (78.7%)
19 (10.7%)
22 (11.2%)
155 (78.7%)
20 (10.2%)
Male sex, n (%) 13 (68.4%) 99 (55.6%) 112 (56.9%)
Race, n (%)
     White
     Black 
     Other/pending
14  (73.7%)
0   (0.0%)
5  (26.3%)
146  (82.0%)
4   (2.2%)
28  (15.7%)
160  (81.2%)
4   (2.0%)
33  (16.8%)
Hispanic ethnicity, n (%) 2  (10.5%) 15   (8.4%) 17   (8.6%)
Prior HCV treatment, n (%)
Naive
Experienced
7  (36.8%)
12  (63.2%)
94  (52.8%)
84  (47.2%)
101  (51.3%)
96  (48.7%)
Cirrhosis, n (%) 11  (57.9%) 96  (53.9%) 107  (54.3%)
History of hepatic decompensation, n (%) 3  (15.8%) 46  (25.8%) 49  (24.9%)
Baseline MELD ≥ 10 (n=75) 2 (25.0%) 36 (53.7%) 38 (50.7%)
HCV RNA (mean), log10 IU/mL 6.3 (4-7) 5.9 (0-8) 5.9 (0-8)
Median total bilirubin (range), mg/dl 0.9 (0.2-2.8) 0.7 (0.1-6.6) 0.8 (0.1-6.6)
Median albumin (range), g/dl 4.0 (2.4-5.0) 3.9 (2.3-5.0) 3.9 (2.3-5.0)
Median ALT (range), mean IU/l 74.0 (28.0-375.0) 73.0 (12.0-362.0) 73.0 (12.0-375.0)
Median platelet count (range) (x103) per µl 132 (59.0-302.0) 134 (22.0-418.0) 133 (22.0-418.0)
Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; 
peg-IFN, pegylated interferon; RBV, ribavirin; SOF, sofosbuvir
a. Data are presented as No. (%) unless otherwise indicated
Treatment Response
SVR12 was achieved by 107 of 178 (60.1%) patients treated with SOF/RBV. The reasons for virological 
failure included relapse in 50 (28%) patients, viral breakthrough in 6 patients (3.4%), and lack of efficacy 
in 1 patient (<0.5%). Fourteen patients (8%) were lost to posttreatment follow-up and were counted 
as failing treatment. Of those who received SOF/peg-IFN/RBV, 16 of 19 (84%) achieved SVR12; 1 was a 
nonresponder and 2 relapsed (Table 8.2). 
In the per-protocol population, the SVR12 rate was similar in patients without cirrhosis who 
received SOF/RBV, whether treatment naive (41/46 [89%]) or experienced (22/25 [88%]). In patients 
with cirrhosis treated with SOF/RBV, the SVR12 rate was 58% (19 of 33) in treatment-naive patients 
and fell to 42% (22 of 52) in those who had failed prior therapy (Table 8.2). In contrast, of 8 treatment-
experienced patients with cirrhosis who received SOF/peg-IFN/RBV, 7 (88%) achieved SVR12 (Table 
8.2). Overall, treatment with SOF/RBV was associated with a lower rate of SVR than treatment with 
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SOF/peg-IFN/RBV (OR, 0.25; 95% CI, .06–1.13), but the difference did not reach statistical significance 
given the few patients treated with triple therapy. After controlling for the presence of cirrhosis, 
neither treatment history nor treatment duration was associated with SVR. 
After controlling for age and sex, the absence of cirrhosis (OR, 6.4; 95% CI, 2.78–14.74), albumin 
levels of ≥3.2 g/dL (OR, 12.48; 95% CI, 3.86–40.33), and platelet count ≥105 cells/µL (OR, 7.44; 95% CI, 
3.51–15.78) were associated with greater odds of achieving SVR12, whereas male sex (OR, 0.44; 95% 
CI, .22–.86) and increasing baseline bilirubin levels (OR, 0.37; 95% CI, .22–.63) were negative predictors 
of response (Figure 8.1). 
Among patients with cirrhosis, after controlling for age and sex, patients with baseline albumin 
≥3.2 g/dL (OR, 7.13; 95% CI, 2.09–24.32) and those with platelet count ≥105 cells/µL (OR, 5.27; 95% 
CI, 1.84–15.08) were more likely to achieve SVR. Increasing baseline total bilirubin (OR, 0.43; 95% CI, 
.23–.79), baseline MELD score (OR, 0.75; 95% CI, .61–.92), and history of decompensating events (OR, 
Table 8.2 | Virological response in patients with G3 HCV who completed therapy with sofosbuvir and 
ribavirin +/- peginterferon
Treatment Regimen
SOF/PEG/RBV
 (n=19)
SOF/RBV
 (n=178)
Total
(n=197)
Overall SVR12 
(Evaluable)
16/19 (84.2%) 107/178 (60.1%) 123/197 
(62.4%)
Per Protocol SVR12 16/18 (88.9%) 104/156 (66.7%) 120/174 
(69.0%)
Non-Cirrhotic Cirrhotic Non-cirrhotic Cirrhotic
Overall SVR12 
(Evaluable)
87.5% 
(7/8)
81.8% 
(9/11)
78.1% 
(64/82)
 44.8% 
(43/96)
Per Protocol SVR12 87.5% 
(7/8)
90% 
(9/10)
88.7% 
(63/71)
48.2% 
(41/85)
TN TE TN TE TN TE TN TE
SVR12 (Evaluable) 100%
(4/4) 
 75%
(3/4)
 66.7%
(2/3)
87.5%
(7/8)
75.0%
(42/56)
84.6%
(22/26)
55.3%
(21/38)
37.9%
(22/58)
SVR12 (PP) 100%
(4/4) 
 75%
(3/4)
 100%
(2/2)
87.5%
(7/8)
89.1%
(41/46)
 88.0%
(22/25)
57.6%
(19/33)
42.3%
(22/52)
Virological failure (EP)
Breakthrough - - - - 1 1 2 2 6
Relapse - 1 - 1 7 3 12 28 52
Non-response - - 1 - - - - 1 2
Non-virological failure - - - - 6 - 3 5 14
Abbreviations: EP, evaluable population; peg-IFN, pegylated interferon; PP, per protocol; RBV, ribavirin; SOF, 
sofosbuvir; SVR12, sustained virological response at 12 weeks; TE, treatment experienced; TN, treatment naïve
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Figure 8.1 | Baseline predictors of sustained virologic response (SVR) among patients with genotype 3 hepatitis 
C virus treated with sofosbuvir (SOF) and ribavirin (RBV) with or without peginterferon with available virological 
outcomes. Factors associated with SVR are shown with an estimate of the odds ratios (ORs) with 95% confidence 
interval determined by multivariable logistic regression for each variable controlled for either age and sex**, or 
age or sex*. Abbreviations: CrCl, creatinine clearance; HGB, hemoglobin; LCL, lower confidence limit; TBIL, total 
bilirubin; UCL, upper confidence limit.
Figure 8.2 | Baseline predictors of sustained virological response (SVR) among patients with genotype 3 hepatitis 
C virus and cirrhosis treated with sofosbuvir (SOF) and ribavirin (RBV) with or without peginterferon with 
available virological outcomes. Factors associated with SVR among patients with cirrhosis are shown with an 
estimate of the odds ratios (ORs) with 95% confidence interval determined by multivariable logistic regression 
for each variable controlled for either age and sex**, or age or sex*. Abbreviations: CrCl, creatinine clearance; 
HGB, hemoglobin; LCL, lower confidence limit; MELD, Model for End-Stage Liver Disease; TBIL, total bilirubin; UCL, 
upper confidence limit.
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0.29; 95% CI, .12–.70) were each associated with a decreased likelihood of SVR (Figure 8.2). The SVR 
rate in patients treated with SOF/RBV with compensated cirrhosis was 64.8% (35/54) compared with 
36% (4/11) in those with a history of decompensated disease (p = .08). Baseline HCV RNA was not 
predictive of SVR. Week 4 HCV RNA values were available in 153 patients (81%) and although patients 
with undetectable HCV RNA by week 4 were more likely to achieve SVR, this did not reach statistical 
significance (p = .09).
Adverse Events
At least 1 AE was reported by 86% (169/197), whether treated with SOF/RBV or SOF/peg-IFN/RBV 
(Table 8.3). The most commonly reported AEs were fatigue (40%), headache (21%), and anemia (20%) 
(Table 8.3). Rash was reported in 5 (26%) patients treated with SOF/peg-IFN/RBV and 23 (13%) of 
those treated with SOF/RBV. Depression was documented in 25 (14%) patients on SOF/RBV compared 
to none on SOF/peg-IFN/RBV. In total, 11 patients experienced hepatic decompensation during 
therapy, all of whom had a prior history of decompensation (Table 8.4). Hepatic encephalopathy (n = 
10) was the most frequently reported decompensating event, followed by ascites (n = 2) and variceal 
hemorrhage (n = 2). 
Anemia was reported in 37 (21%) patients on SOF/RBV and 3 (16%) patients on SOF/peg-IFN/RBV. 
The median hemoglobin decline was 2.1 g/dL in SOF/RBV-treated patients, and 2.7 g/dL in patients 
treated with SOF/peg-IFN/RBV. Anemia led to RBV dose reduction in 33 (18.5%) and discontinuation 
in 2 (10.5%) patients. The initial RBV dose ranged from 4.6 mg/kg to 19.2 mg/kg (mean, 13.1 mg/
kg). As shown in the forest plots (Figures 8.1 and 8.2), initial RBV dose was not associated with SVR in 
those with cirrhosis but was associated with SVR in the overall population, suggesting the effect was 
greatest in those without cirrhosis. The correlation between RBV dose and SVR is shown in Figure 8.3. 
RBV dose reduction was not associated with SVR (Figure 8.1 and 8.2). Addition of erythropoietin was 
needed by 7 patients (4%) and a blood transfusion by 4 (2%) individuals, all in patients treated with 
SOF/RBV. A total of 18 SAEs were reported in 13 patients (all treated with SOF/RBV), of which 8 SAEs in 
7 patients were likely related to HCV therapy per the treating physician.
DISCUSSION
This large observational study evaluated the effectiveness and safety of 2 SOF-based therapies in 
patients with GT3 HCV infection. Although treatment was generally safe and fairly well tolerated, the 
SVR12 results were suboptimal (69%), particularly in patients with cirrhosis treated with SOF/RBV 
alone, highlighting the need for improved therapies for this population. 
As reported in clinical trials, the main determinant of outcome in GT3 infection was the presence 
of cirrhosis.137-139 Less than half (48%) of those with cirrhosis treated with SOF/ RBV achieved SVR12. 
Notably, cirrhosis was a negative predictor of response even in patients who were previously 
untreated. Although the VALENCE trial reported a 92% SVR rate in treatment- naive patients with 
cirrhosis, only 13 such patients were included in the trial.138 In this real-world study, only 19 of the 
33 (58%) treatment-naive patients with cirrhosis achieved SVR12. Whether this reflects differences 
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Table 8.3 | Adverse events, and management of anemia
Event
SOF/PEG/RBV
 (n=19)
SOF/RBV
 (n=178)
Total
(n=197)
N Patients (%) N Patients (%) N Patients (%)
Any adverse event (AE) 15 (79.0) 154 (86.5) 169 (85.8)
     Fatigue                                  8  (42.1)  70  (39.3)  78  (39.6) 
     Headache                                 4  (21.1)  38  (21.4)  42  (21.3) 
     Anemia                                  3  (15.8)  37  (20.8)  40  (20.3) 
     Insomnia                                 2  (10.5)  35  (19.7)  37  (18.8) 
     Nausea                                   1   (5.3)  33  (18.5)  34  (17.3) 
     Rash                                     5  (26.3)  23  (12.9)  28  (14.2) 
     Dyspnea                                 2  (10.5)  25  (14.0)  27  (13.7) 
     Influenza-like illness   5  (26.3)  21  (11.8)  26  (13.2) 
     Depression                               0   (0.0)  25  (14.0)  25  (12.7) 
     Dizziness                                   2  (10.5)  21  (11.8)  23  (11.7) 
     Irritability                              3  (15.8)  19  (10.7)  22  (11.2) 
     Pruritus                                 2  (10.5)  20  (11.2)  22  (11.2) 
     Decreased appetite     3  (15.8)  15   (8.4)  18   (9.1) 
     Abdominal pain   3  (15.8)  13   (7.3)  16   (8.1) 
     Asthenia                                 2  (10.5)  13   (7.3)  15   (7.6) 
     Diarrhea                                2  (10.5)  11   (6.2)  13   (6.6) 
     Muscle spasms   2  (10.5)  11   (6.2)  13   (6.6) 
     Cough                                     2  (10.5)  11   (6.2)  13   (6.6) 
Serious adverse events (18 events)b 0 (0.0) 13 (7.3) 13 (6.6)
Anemia management   
RBV dose reduction 2 (10.5) 33 (18.5) 35 (17.8)
Erythropoietin use 0 (0.0) 7 (3.9) 7 (3.6)
Blood transfusion 0 (0.0) 4 (2.2) 4 (2.0)
RBV discontinuation 0 (0.0) 1 (0.6) 1 (0.5)
Abbreviations: peg-IFN, pegylated interferon; RBV, ribavirin; SOF, sofosbuvir.
a. Data are presented as No. (%) of patients.
b. Anemia, colitis, gastrointestinal hemorrhage, esophageal varices hemorrhage, chest pain,
hepatocellular carcinoma (2), hepatic encephalopathy (4), dizziness (2), depression, psychotic
disorder, renal failure acute (2), epistaxis.
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between clinical trials and clinical practice, or inclusion of patients with more advanced disease, or 
highlights the uncertainty of drawing conclusions from the small numbers included in the trial is 
difficult to determine.
How cirrhosis affects response to therapy is not clear but is likely multifactorial.339 Data from 
patients with genotype 1 infection suggest that even in a cirrhotic liver, SOF is effectively taken up 
by hepatocytes and phosphorylated to the active compound.339 Shunting due to portal hypertension 
may affect local drug concentrations and cirrhosis has important effects on innate and adaptive 
immune function, which are likely still important for viral clearance even with potent DAA therapy.339 
Younossi and colleagues recently reported that patients with GT3 infection had lower levels of lipids 
and, specifically, lower levels of metabolites from late in the cholesterol biosynthesis pathway.330 
Although the specific mechanisms remain unclear, these findings support the hypothesis that the 
unique effects of GT3 HCV on lipid metabolism may affect responses to antiviral therapy, an effect 
that appears to be more pronounced in the presence of cirrhosis. Unfortunately, cirrhosis is important 
even when SOF is combined with other approved DAAs for GT3 infection. Only 63% of patients with 
cirrhosis achieved SVR when SOF was combined with DCV for 12 weeks.163 In the small ALLY 3+ study, 
patients with GT3 HCV and cirrhosis who received SOF/DCV plus RBV for 12 or 16 weeks achieved SVR 
rates of 83%–89%; however, the small sample size makes it difficult to draw strong conclusions or to 
distinguish the preferred duration.164 Additional data from the French compassionate use program 
showed that 24 weeks of SOF/DCV with or without RBV led to SVR rates >80% despite inclusion of 
Figure 8.3 | Correlation of probability of sustained virological response at 12 weeks (SVR12) and initial ribavirin 
(RBV) dose (by body weight [BW]; mg/kg). The impact of the initial dose of RBV is shown by estimating the 
probability of SVR according to initial RBV dose using observed SVR (circle) and observed virological failure 
(diamond), The shaded area shows the 95% confidence interval (CI) for the estimated correlation.
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some patients with decompensated disease.340 SOF/RBV plus LDV has also been evaluated in GT3 HCV. 
With the very limited activity of LDV against GT3 in vitro, it was perhaps surprising to see SVR rates as 
high as 73% in patients with cirrhosis.341 These results clearly leave room for improvement for patients 
with GT3 infection and cirrhosis. 
The disappointing outcomes with SOF/RBV therapy led to evaluation of the reintroduction of 
peg-IFN. Similar to the initial small studies evaluating this approach, the SOF/peg-IFN/ RBV regimen 
proved quite effective in this cohort, most notably in the 8 patients with cirrhosis who had failed 
prior therapy, 7 of whom achieved SVR. A randomized controlled trial comparing SOF/RBV for 16 or 
24 weeks to SOF/peg-IFN/RBV for 12 weeks in patients with GT3 HCV140 showed that the inclusion of 
peg-IFN increased response rates in all patient subgroups but most notably in those with cirrhosis, 
whether treatment naïve or experienced. Peg-IFN was well tolerated, with only 1 patient discontinuing 
treatment prematurely. Similarly, in this real-world experience, peg-IFN was well tolerated, with similar 
Table 8.4 | Details on 14 decompensation events in 11 patients during antiviral therapy 
Patient 
ID
Decompensation 
Event Regimen
Releated to 
Treatment
Timing of 
Event, wk
Past History of 
Decompensation
Treatment 
Outcome
1 Hepatic 
Encephalopathy
SOF/RBV N 8.3 Y SVR
2 Hepatic 
Encephalopathy
SOF/RBV Y 16.1 Y Relapse
3 Variceal Hemorrhage SOF/RBV N 11.7 Y Relapse
4 Hepatic 
Encephalopathy
SOF/RBV Y 4.9 Y Relapse
4 Hepatic 
Encephalopathy
SOF/RBV Y 24.4 Y Relapse
5 Variceal Hemorrhage SOF/RBV Y 0.4 Y SVR
6 Hepatic 
Encephalopathy
SOF/RBV Y 0.1 Y Relapse
7 Hepatic 
Encephalopathy
SOF/RBV Y 19.4 Y SVR
7 Hepatic 
Encephalopathy
SOF/RBV Y 16.6 Y SVR
8 Hepatic 
Encephalopathy
SOF/RBV Y 0.1 Y LTFU
8 Ascites SOF/RBV Y 9 Y LTFU
9 Hepatic 
Encephalopathy
SOF/RBV N 4.3 Y BT
10 Hepatic 
Encephalopathy
SOF/RBV Y 4.9 Y BT
11 Ascites SOF/RBV Y 13.3 Y SVR
Abbreviations: BT, breakthrough (on treatment); LTFU, lost to posttreatment follow-up; SOF/RBV, sofosbuvir/
ribavirin; SVR, sustained virological response
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rates of AEs and higher rates of SVR reported compared with SOF/ RBV alone. However, despite these 
encouraging results, SOF/ peg-IFN/RBV was prescribed to only 19 of the 197 (9.6%) patients with GT3 
who have started therapy in HCV-TARGET to date. Clearly there is a great reluctance by both clinicians 
and patients to accept interferon-based therapies. Fortunately, recent studies have shown that SOF 
combined with velpatasvir, a pangenotypic NS5A inhibitor, is highly effective for GT3 HCV infection, 
leading to SVR12 rates of 90% even in patients with cirrhosis, without the need for RBV.168 Other 
promising DAA combinations hold promise for GT3 HCV as well.342 With this in mind, although SOF/
peg-IFN/RBV may be considered for patients, particularly those with cirrhosis, waiting for approval of 
new therapies may be prudent, as it is unclear if an unsuccessful course of SOF/RBV or SOF/DCV will 
affect responses and/or access to future therapies. 
Among patients with cirrhosis, low baseline albumin and low platelet count were associated with 
much lower odds of achieving SVR12. Only 20% of patients with albumin levels <3.2 g/dL achieved 
SVR, whereas 39% with baseline platelet count <105 cells/µL achieved SVR12 with SOF/RBV. Of the 18 
patients with albumin <3.2 g/dL and platelets <105 cells/µL, only 4 (22%) achieved SVR, suggesting 
that for such individuals, waiting for availability of new multi-DAA regimens would be advisable. This 
study has some important limitations. The lack of randomization limits the ability to directly compare 
treatment groups, which is further compounded by the small number of patients who received SOF/
peg-IFN/RBV therapy. However, the results clearly demonstrate the limitations of SOF/RBV in patients 
with GT3 HCV infection and cirrhosis. In addition, by including a broader population of patients, many 
of whom may not have qualified for clinical trials, the safety and effectiveness profile provide very 
useful data for clinicians and patients.
CONCLUSIONS
This large observational, real-world study demonstrated that GT3 remains a clinical challenge. SOF/
RBV for 24 weeks resulted in low SVR rates in patients with cirrhosis, particularly those with low 
baseline albumin and platelet levels. Although high efficacy and acceptable tolerability were seen 
in patients treated with SOF/peg-IFN/RBV, the extremely low uptake of this regimen highlights the 
poor acceptance of peg-IFN among patients and clinicians. Therapies in development will hopefully 
improve outcomes for this difficult-to-cure population.
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SUPPLEMENTARY TABLE
Supplementary Table 8.1 | Disposition of patients with G3 HCV who underwent therapy with sofosbuvir and 
ribavirin +/- peginterferon
SOF PEG RBV SOF RBV Total
(N=19) (N=191) (N=210)
Started treatment             19 (100.0%) 191 (100.0%) 210 (100.0%)
     Treatment ongoing                     0   (0.0%) 1   (0.5%) 1   (0.5%)
Discontinued prematurely    1   (5.3%) 23  (12.0%) 24  (11.4%)
Adverse event 0   (0.0%) 5   (2.6%) 5   (2.4%)
Lack of efficacy        0   (0.0%) 5   (2.6%) 5   (2.4%)
Withdrawal by   subject   0   (0.0%) 1   (0.5%) 1   (0.5%)
Lost to follow up       0   (0.0%) 5   (2.6%) 5   (2.4%)
Non compliance          1   (5.3%) 3   (1.6%) 4   (1.9%)
Other 0   (0.0%) 4 (2.1%) 4   (1.9%)
 Completed treatment         18  (94.7%) 167  (87.4%) 185  (88.1%)
Lost to post-treatment follow-up      0 14 14
In post treatment follow up 0 6 6
Abbreviations: PEG, pegylated infterferon; RBV, ribavirin; SOF, sofosbuvir
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chronic hepatitis C virus infection treated with 
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ABSTRACT 
Background & Aims 
Guidelines recommend withholding sofosbuvir (SOF) in patients with an estimated glomerular filtra-
tion rate (eGFR) of less than 30 mL/min. However, little is known about the risk of renal impairment (RI) 
in patients with no renal contraindications for SOF-based treatment.
Methods
This multicenter retrospective observational study included all consecutive patients that were treated 
with SOF-based or telaprevir (TVR)/boceprevir (BOC)-based regimens at two tertiary university centers 
in North America. RI was defined as an increase of ≥0.3 mg/dL in serum creatinine level. Multivariable 
logistic regression analysis was used to identify risk factors for the occurrence of RI.
Results
In total, 426 patients were included and treated with a SOF-based regimen (n=233, 54.7%) or TVR/
BOC-based regimen (n=193, 45.3%). Among patients treated with a TVR/BOC-based regimen 34 
(18%) of 193 patients experienced RI compared to 26 (11%) of 233 patients treated with SOF-based 
regi mens (p = 0.056). Multivariable logistic regression analysis showed that the presence of ascites 
(OR 4.44, 95%CI 1.46-13.54, p = 0.009) and the use of NSAIDs (OR 4.47, 95%CI 1.32-15.19, p = 0.016) 
were associated with a risk of RI during SOF-based antiviral therapy. Creatinine levels returned to 
normal at end of follow-up in 23 (88%) of the 26 patients that experienced RI and had a creatinine 
level available during follow-up.
Conclusions
Although the risk for RI was lower than for patients treated TVR/BOC-based regimens, RI was seen 
during 11% of SOF-based regimens and was mostly reversible. Patients with ascites and patients 
using NSAIDs have an increased risk for RI during SOF-based antiviral therapy.
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INTRODUCTION
It has been estimated that 64-103 million people worldwide are chronically infected with the hepatitis 
C virus (HCV).1 The continuous inflammatory activity in the liver may lead to hepatic fibrosis and 
subsequently to cirrhosis. Although not linear, approximately 15-20% of patients with chronic HCV 
infection will develop cirrhosis within 20 years after their encounter with the virus.61 These patients 
have an increased risk of developing liver failure and hepatocellular carcinoma (HCC), associated 
with an increased mortality rate.55 However, chronic HCV infection is a multifaceted disease, which is 
not restricted to the liver. Extrahepatic manifestations, including mixed cryoglobulinemic vasculitis 
and renal disease, may occur long before cirrhosis has been established.45 Notably, the non-hepatic 
complications of HCV are clinically relevant, with a recent study documenting increased non-liver-
related mortality among patients with HCV.343  
Until 2011, physicians depended on the administration of pegylated interferon alpha (PegIFN) and 
ribavirin (RBV) for the treatment of chronic HCV infection. These regimens were suboptimal in most 
patients and were associated with important safety issues.104-106 The introduction of the first protease 
inhibitors, telaprevir (TVR) and boceprevir (BOC), for the treatment of HCV genotype 1 led to improved 
sustained virological response (SVR) rates. Although the registration trials reported a relatively benign 
renal safety profile, shortly after approval, data emerged on significant renal adverse events344 345 along 
with a more significant overall adverse event profile than that documented in the registration trials.120 
121 The approval of sofosbuvir (SOF), a very potent nucleotide analogue inhibitor of the HCV RNA-
dependent RNA polymerase, has revolutionized the treatment of chronic HCV infection. SOF is active 
against all HCV genotypes and when combined with other direct-acting antivirals (DAAs) leads to 
very high rates of SVR in most patient populations.141 147 The main active metabolite of SOF, GS331007, 
is excreted by the kidneys, and higher drug and metabolite concentrations are found in those patients 
with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 or end-stage renal disease 
(ESRD) on hemodialysis.346 Therefore, guidelines do not recommend the use of SOF in patients with 
an eGFR <30mL/min or patients with ESRD, and recommend regular monitoring of renal function in 
patients receiving SOF.35 36 The major trials examining the safety and efficacy of SOF demonstrated an 
excellent renal safety profile139 141 147, however whether this also applies in real-world clinical practice 
is currently unknown. Therefore, we aimed to examine the renal safety profile in patients treated with 
SOF-based therapies, and compared it to the profile of TVR/BOC-based antiviral therapy.
PATIENTS AND METHODS
Study population
This multicenter retrospective observational study included all consecutive patients who initiated 
treatment with a SOF-based or TVR/BOC-based regimen prior to January 31st, 2015. Patients were 
treated in the Toronto Centre for Liver Disease or the University of Arkansas for Medical Sciences. All 
included patients had available creatinine results before, during and after therapy and all creatinine 
levels were evaluated. Patients on hemodialysis or treated post-liver transplantation were excluded. 
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All charts were reviewed by five investigators (RM, SA, JSK, SMH and KDR) in order to collect detailed 
data on baseline demographics, on-treatment laboratory results and clinical events and outcome of 
therapy. 
Definitions
On-treatment RI was defined as an increase of ≥0.3 mg/dL or ≥50% in serum creatinine level when 
com pared to baseline value.347 Normalization of creatinine was considered whenever follow up 
deter minations were no more than 0.2 mg/dL from baseline. The eGFR was calculated using the 
abbre viated Modification of Diet in Renal Disease (MDRD) equation: eGFR (mL/min/1.73m2) = 186 x 
(creatinine / 88.4) -1.154 x (age) -0.203 x (0.742 if female) x (1.210 if black). The presence of cirrhosis 
was based on liver biopsy, transient elastography (kPa>13), or clinical suspicion (i.e. the presence of 
varices, ascites, hepatic encephalopathy). The Child-Turcotte-Pugh (CTP) score was used to make a 
distinc tion between compensated and decompensated cirrhosis (decompensated if CTP ≥7 points). 
An undetectable viral load 12 weeks after cessation of SOF-based therapy and 24 weeks after TVR/
BOC-based therapy was considered an SVR. The Abbott RealTime HCV assay (Abbott Molecular, Des 
Plaines, IL, USA) with a lower limit of quantification of 12 IU/mL, and Roche COBAS AmpliPrep/TaqMan 
48 HCV Test (Roche Diagnostics, Indianapolis, IN, USA) with a lower limit of quantification of 15 IU/mL, 
were used in Canada and USA, respectively.
Outcomes
The primary outcome of this study was the occurrence of RI during antiviral therapy with SOF-based 
and TVR/BOC-based regimens. Secondary outcomes included factors associated with the occurrence 
of RI, the influence of RI on attaining SVR, and the on-treatment dynamics of creatinine among 
patients who experienced RI. 
Statistical analyses
Data were presented as means with standard deviation (SD), medians with interquartile range (IQR) 
or as frequency (percentage), as appropriate. For comparisons of patients treated with SOF-based 
regimens versus TVR/BOC-based regimens, Student’s t-test, Chi-square, Pearson correlation or their 
non-parametric equivalents were used.
Univariable logistic regression analyses were used to assess factors associated with RI. All clinical 
factors of importance, including age, the presence of cirrhosis, CTP score, Model for End-stage Liver 
Disease (MELD) score, the presence of ascites, hypertension, the use of nonsteroidal anti-inflammatory 
drugs (NSAIDs), and antiviral treatment regimens were included in multivariable analyses. The original 
MELD score was used for calculations in order to avoid the flooring effect from the United Network for 
Organ Sharing (UNOS)-modified version. Results are presented with an odds ratio and 95% confidence 
intervals. The dynamics of on-treatment creatinine levels were plotted for all patients, with a special 
focus on patients who experienced RI. A p value <0.05 was considered statistically significant and 
all statistical tests were two-tailed. The significance level of interactions was set at 0.01 in order to 
correct for multiple testing. Analyses were performed using PASW statistics 21.0 for Windows (SPSS, 
IBM, Armonk, New York, USA) and R statistical software version 3.2.2 (online available).
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RESULTS
Patients
In total, 426 patients with chronic HCV infection who underwent antiviral treatment with SOF-based 
regimens (n=233, 54.7%) or TVR/BOC-based regimens (n=193, 45.3%) were included. Table 9.1 shows 
baseline characteristics according to the treatment regimen applied. Mean age was 54.7 (±9.0) years, 
253 (59.4%) patients were male and 221 (52.0%) had evidence of cirrhosis. Of those patients treated 
with a SOF-based regimen, 68 (29.2%) received SOF/simeprevir (SMV) ± RBV, 77 (33.0%) received 
SOF/PegIFN/RBV, 77 (33.0%) received SOF/RBV, and 11 (4.7%) received SOF/ledipasvir (LDV) ± RBV. A 
total of 44 patients (22.8%) received BOC/PegIFN/RBV and 149 (77.2%) patients received TVR/PegIFN/
RBV. At baseline, a higher proportion of patients treated with SOF-based regimens had evidence of 
cirrhosis, including decompensated cirrhosis, and they had higher MELD scores compared to patients 
treated with TVR/BOC-based regimens. Supplementary Table 9.1 shows baseline characteristics of the 
32 (7.5%) patients with a baseline eGFR ≤60 mL/min of whom none had a baseline eGFR <30 mL/min. 
Renal impairment
From the total cohort of 426 patients, 60 (14.1%) patients experienced a rise in creatinine ≥0.3 mg/
dL during antiviral treatment. Of these, 34 (17.6%) patients treated with TVR/BOC-based regimens 
experienced RI compared to 26 (11.2%) patients who received SOF-based regimens (p = 0.056). Table 
9.2 shows the characteristics of the patients who experienced RI and were treated with SOF-based 
antiviral therapy. Among the 13 patients with human immunodeficiency virus (HIV)/HCV coinfection, 
one (7.7%) experienced RI. Six (18.8%) of 32 patients with a baseline eGFR ≤60 mL/min experienced 
RI. When analyzing patients with an increase in creatinine ≥50%, 14 (7.3%) patients treated with TVR/
BOC-based regimens experienced RI, compared to 8 (3.4%) treated with SOF-based regimens (p = 
0.076). In order to better identify the risk factors potentially associated with RI we used the ≥0.3 mg/
dL definition for subsequent analyses. 
Univariable logistic regression analyses showed that higher age (OR 1.06, 95%CI 1.02-1.10, p = 
0.004), lower baseline eGFR (OR 0.99, 95%CI 0.97-1.00, p = 0.035), lower baseline albumin (OR 0.44, 
95%CI 0.27-0.40, p = 0.001), CTP class B/C (OR 2.26, 95%CI 1.19-4.32, p = 0.013), the presence of 
ascites (OR 3.29, 95%CI 1.73-6.22, p <0.001), hypertension (OR 2.66, 95%CI 1.52-4.65, p = 0.001), the 
use of NSAIDs (OR 2.41, 95%CI 1.02-5.69, p = 0.045) and the use of angiotensin-converting-enzyme 
inhibitors (ACE) or angiotensin II receptor antagonists (ARA) (OR 1.96, 95%CI 1.07-3.58, p = 0.029) 
were significantly associated with the occurrence of RI (Table 9.3). As the presence of ascites and the 
use of diuretics were highly collinear, only the presence of ascites was used in the model in order to 
avoid redundancy. There was a trend toward a lower risk of RI with SOF-based regimens compared to 
TVR/BOC-based regimens (OR 0.59, 95%CI 0.34-1.02, p = 0.058). When these parameters were tested 
in a multivariable logistic regression model adjusted for age and MELD score, only the presence of 
ascites (OR 4.69, 95%CI 2.10-10.5, p <0.001), hypertension (OR 2.96, 95%CI 1.58-5.55, p = 0.001), and 
the use of NSAIDs (OR 2.69, 95%CI 1.08-6.72, p = 0.034) remained independently associated with an 
increased risk for RI; whereas the use of a SOF-based regimen (OR 0.40, 95%CI 0.22-0.74, p = 0.004) was 
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Table 9.1 | Baseline characteristics according to the treatment regimen that was applied
Variable
Total
N=426
TVR/BOC-based therapy
n=193
SOF-based therapy
n=233 p value
Age 54.7 (±8.98) 54.0 (±8.85) 54.9 (±9.20) 0.62
Male sex 253 (59.4%) 120 (62.2%) 133 (57.1%) 0.29
BMI 28.7 (±6.04) 29.0 (±5.74) 28.4 (±6.26) 0.27
HCV genotype
1
2
3
4
6
355 (83.3%)
42 (9.9%)
20 (4.7%)
8 (1.9%)
1 (0.2%)
192 (99.5%)
-
-
1 (0.5%)
-
163 (70.0%)
42 (18.0%)
20 (8.6%)
7 (3.0%)
1 (0.4%)
Not 
performed
Cirrhosis 221 (51.9%) 88 (45.6%) 133 (57.3%) 0.016
CTP B/C 68 (16.0%) 23 (11.9%) 45 (19.3%) 0.040
MELD score 5.2 (±3.8) 4.7 (±3.4) 5.7 (±4.0) <0.001
Cryoglobulins (+)b 94 (25.7%) 36 (22.9%) 58 (27.8%) 0.30
Proteinuriac 60 (21.1%) 29 (22.7%) 31 (19.7%) 0.65
Diabetes mellitus 79 (18.5%) 35 (18.1%) 44 (18.9%) 0.84
Hypertension 168 (39.4%) 72 (37.3%) 96 (41.2%) 0.41
NSAIDs 30 (7.0%) 12 (6.2%) 18 (7.7%) 0.55
ACE/ARA 89 (20.9%) 36 (18.7%) 53 (22.7%) 0.30
Diuretics 101 (23.7%) 41 (21.2%) 60 (25.8%) 0.32
Creatinine 0.86 (±0.20) 0.85 (±0.21) 0.86 (±0.19) 0.42
eGFR 87.5 (±20.8) 90.0 (±22.5) 85.4 (±19.2) 0.022
Platelet count 167 (±89) 177 (±90) 159 (±87) 0.038
ALT 63 (39-100) 61 (37-103) 63 (40-100) 0.50
Abbreviations: TVR, telaprevir; BOC, boceprevir; SOF, sofosbuvir; BMI, body mass index; HCV, hepatitis c virus; 
CTP, Child-Turcotte-Pugh; MELD, Model for End-stage Liver Disease; NSAIDs, nonsteroidal anti-inflammatory 
drugs; ACE, angiotensin-converting-enzyme inhibitors; ARA, angiotensin II receptor antagonists; eGFR, estimated 
glomerular filtration rate; ALT, alanine aminotransferase
a. Data are presented as n (%), mean (±SD) or median (interquartile range), p-values are the result of Student’s 
t-test, Chi-square, Pearson correlation or their non-parametric equivalents. 
b. Missing for 60 (14.1%) patients
c. Spot or quantitative proteinuria not tested in 141 (33.1%) patients
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associated with a decreased risk (Table 9.3). There was no significant difference in incidental RI across 
the different SOF-based regimens. A sensitivity analysis, excluding patients with HIV/HCV coinfection, 
did not change the results (data not shown).
When only the patients treated with SOF-based regimens were considered, univariable analysis 
showed that baseline MELD score (OR 1.14, 95%CI 1.03-1.25, p = 0.009), the presence of ascites (OR 
5.61, 95%CI 2.38-13.24, p <0.001), the use of NSAIDs (OR 3.55, 95%CI 1.15-10.95, p = 0.027), lower 
baseline eGFR (OR 0.97, 95%CI 0.94-0.99, p = 0.003), and lower baseline albumin (OR 0.31, 95%CI 0.16-
0.60, p = 0.001) were associated with the occurrence of RI (Table 9.4). Although multivariable analysis 
was limited by the number of events, in a model adjusted for MELD score, the presence of ascites (OR 
4.44, 95%CI 1.46-13.54, p = 0.009), and the use of NSAIDs (OR 4.47, 95%CI 1.32-15.19, p = 0.016) were 
associated with increased risk of RI in patients treated with SOF-based regimens. 
Table 9.3 | Logistic regression analyses for renal impairment
Variable Univariable p value Multivariable p value
Age 1.06 (1.02-1.10) 0.004 1.03 (0.99-1.08) 0.17
Sex 0.64 (0.37-1.11) 0.11
BMI 1.04 (0.99-1.08) 0.10
Cirrhosis 1.15 (0.66-1.99) 0.62
MELD score 1.04 (0.97-1.12) 0.23 1.00 (0.92-1.09) 0.99
CTP B/C 2.26 (1.19-4.32) 0.013
Ascites 3.29 (1.73-6.22) <0.001 4.69 (2.10-10.45) <0.001
Hypertension 2.66 (1.52-4.65) 0.001 2.96 (1.58-5.55) 0.001
Diabetes mellitus 1.26 (0.64-2.46) 0.50
NSAIDs 2.41 (1.02-5.69) 0.045 2.69 (1.08-6.72) 0.034
Diuretics 3.22 (1.82-5.68) <0.001
ACE/ARA 1.96 (1.07-3.58) 0.029
Creatinine 1.01 (0.55-1.85) 0.98
eGFR 0.99 (0.97-1.00) 0.035
ALT 1.00 (0.99-1.00) 0.085
Albumin 0.44 (0.27-0.40) 0.001
SOF-based vs TVR/
BOC-based
0.59 (0.34-1.02) 0.058 0.40 (0.22-0.74) 0.004
Abbreviations: BMI, body mass index; MELD, Model for End-stage Liver Disease; CTP, Child-Turcotte-Pugh; NSAIDs, 
nonsteroidal anti-inflammatory drugs; ACE, angiotensin-converting-enzyme inhibitors; ARA, angiotensin II 
receptor antagonists; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; SOF, sofosbuvir; 
TVR, telaprevir; BOC, boceprevir
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Outcome of antiviral treatment
Among the patients treated with TVR/BOC-based regimens, 138 of the 193 (71.5%) patients achieved 
SVR. A higher SVR rate was achieved among the 233 patients treated with SOF-based regimens 
(193/233 [82.8%], p = 0.005) when compared to TVR/BOC-based regimens. There was no difference 
in SVR rate between patients that were treated with TVR-based regimens (107/150, 71.3%) and BOC-
based regimens (31/43, 72.1%, p = 0.922). Among the 60 patients who experienced RI, 45 (75.0%) 
achieved SVR, compared to 286 (78.1%) of the 366 patients that did not experience RI (p = 0.59). 
The rate of SVR among patients who experienced RI during SOF-based therapy was 69.2% (18/26) 
compared to 84.5% (175/207) among those treated with SOF who did not experience RI, p = 0.051, 
Figure 9.1). Multivariable regression analysis among patients treated with SOF-based regimens, only 
Table 9.4 | Logistic regression analyses for renal impairment among patients treated with SOF-based 
regimens
Variable Univariable p value Multivariablea p value
Age 1.02 (0.97-1.07) 0.36
Sex 0.73 (0.32-1.64) 0.44
BMI 1.03 (0.97-1.10) 0.29
Cirrhosis 1.47 (0.62-3.44) 0.38
MELD score 1.14 (1.03-1.25) 0.009 1.04 (0.92-1.18) 0.501
CTP B/C 4.18 (1.73-10.12) 0.002
Ascites 5.61 (2.38-13.24) <0.001 4.44 (1.46-13.54) 0.009
Hypertension 2.12 (0.93-4.85) 0.075
Diabetes mellitus 1.33 (0.50-3.55) 0.56
NSAIDs 3.55 (1.15-10.95) 0.027 4.47 (1.32-15.19) 0.016
Diuretics 4.06 (1.76-9.38) 0.001
ACE/ARA 1.96 (0.82-4.70) 0.13
Creatinine 1.14 (0.67-1.94) 0.64
eGFR 0.97 (0.94-0.99) 0.003
ALT 1.00 (0.99-1.01) 0.58
Albumin 0.31 (0.16-0.60) 0.001
Abbreviations: SOF, sofosbuvir; BMI, body mass index; MELD, Model for End-stage Liver Disease; CTP, Child-
Turcotte-Pugh; NSAIDs, nonsteroidal anti-inflammatory drugs; ACE, angiotensin-converting-enzyme inhibitors; 
ARA, angiotensin II receptor antagonists; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase
a. Three variables were forced into the model, because extensive multivariable analyses could not be 
performed due to the number of events (n=26)  
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including the presence of cirrhosis and RI as factors, showed that both variables were associated with 
a lower chance of attaining SVR (presence of cirrhosis: OR 0.53, 95%CI 0.25-1.11, p = 0.094; RI: OR 0.43, 
95%CI 0.17-1.09, p = 0.074). 
Dynamics of creatinine changes
The mean creatinine levels during and after antiviral treatment with TVR/BOC-based regimens (a) 
and SOF-based regimens (b) are shown in Figure 9.2 for all subjects, and in Figure 9.3 for those who 
experienced RI. The mean rise in creatinine was 0.16 (range -0.4-2.5), and differed between patients 
treated with TVR/BOC-based regimens (0.20 [range -0.1-1.3]) and those treated with SOF-based 
regimens (0.12 [range -0.4-2.5], p <0.001). Median time to RI was 9 weeks (IQR 4-16), and the mean 
maximum rise in creatinine was 0.55 mg/dL (range 0.30-2.5) for patients who experienced RI. There 
was no statistically significant difference between patients treated with TVR/BOC-based regimens 
(0.50 [range -0.3-1.3]) and those treated with SOF-based regimens (0.60 [range 0.3-2.5], p = 0.52).
Creatinine levels returned to normal at end of follow-up in 51 (86.4%) of the 59 patients who 
experienced RI and had a creatinine level available at the end of follow-up. Among those patients 
without normalization of creatinine, 3 (11.5%) were treated with a SOF-based regimen and 5 (15.2%) 
with a TVR/BOC-based regimen (see Table 9.2 for patient characteristics). In patients who experienced 
RI and had available creatinine level during follow-up, the mean difference in creatinine between 
baseline and follow-up was 0.06 mg/dL (range -0.30 – 0.90).
DISCUSSION
This multicenter study showed that RI was observed in 11% of patients treated with a SOF-based 
regimen, which was lower than the 18% observed in patients treated with TVR/BOC-based regimens. 
However, as RI was reversible in all but 3 cases, SOF-based treatment can be considered to have a good 
Figure 9.1 | SVR rates
The SVR rates according to the treatment regimen applied and for patients with (white bars) and without renal 
impairment (grey bars).
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Figure 9.2 | Dynamics of creatinine for all patients
Panel A shows the mean creatinine level (and standard error) at baseline, during and after TVR/BOC-based 
antiviral therapy. The asterisks (*) indicate the mean creatinine level for patients at week 24 and 36 who were 
treated for 48 weeks. Panel B shows the mean creatinine level (and standard error) at baseline, during and after 
SOF-based antiviral therapy. The asterisks (*) indicate the mean creatinine level for patients at week 12 who were 
treated for 24 weeks. 
Figure 9.3 | Dynamics of creatinine for patients experiencing renal impairment
Panel A shows the mean creatinine level (and standard error) at baseline, during and after TVR/BOC-based 
antiviral therapy. The asterisks (*) indicate the mean creatinine level for patients at week 24 and 36 who were 
treated for 48 weeks. Panel B shows the mean creatinine level (and standard error) at baseline, during and after 
SOF-based antiviral therapy. The asterisks (*) indicate the mean creatinine level at week 12 for patients who were 
treated for 24 weeks. 
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renal safety profile. Patients with ascites, hypertension and those who use NSAIDs had an increased 
risk of RI during antiviral therapy. Among patients treated with SOF-based regimens, those with 
advanced liver disease, particularly those with decompensated cirrhosis (ascites), had an increased 
risk for RI.
The large phase 3 trials with SOF-based antiviral therapy did not report on the occurrence of RI as an 
important safety issue.148 346 Large clinical trials often include a very selected patient population, which 
is not always representative of the broad population of patients with chronic HCV infection. Recently, 
some studies have reported on the safety and effectiveness of SOF-based therapy among patients 
with impaired renal function (eGFR <30mL/min), with notably heterogeneous results. Bhamidimarri 
et al. reported on 15 patients with ESRD (both pre-dialysis and on dialysis) who underwent treatment 
with half-dose SOF and SMV. During the treatment period no major adverse events were reported and 
87% of the patients achieved SVR.348 A report from the US included seventeen patients with advanced 
renal disease who received full-dose SOF in addition to SMV. Fifteen of these patients were on dialysis 
and two were pre-dialysis. All patients achieved SVR, there were no specific severe adverse events and 
none of the patients needed a dose reduction during therapy.349 Recently, Desnoyer et al. reported on 
careful pharmacokinetics in 12 patients with renal disease who underwent treatment with different 
SOF-based regimens. All patients were on hemodialysis and received either daily full-dose SOF or full-
dose SOF given three times a week after dialysis. Ten (83.3%) of the 12 patients achieved SVR, including 
all 7 who received daily full-dose SOF and no major adverse events were reported.350 Notably, the 
GS331007 metabolite did not accumulate beyond the first days of treatment and 53% was removed 
by dialysis. Although these three small studies did not report major safety issues, detailed information 
on creatinine levels during treatment was not discussed. Recently, data on the safety and efficacy of 
SOF-based regimens among 73 patients with an eGFR ≤45 ml/min/1.73m2 were reported from the 
HCV-TARGET registry.351 Although they used only chart review rather than objective evidence of RI, 
they found that the presence of impaired renal function (eGFR ≤45 ml/min/1.73m2) at baseline and a 
lower baseline hemoglobin level were associated with a higher risk for RI during SOF-based therapy. 
Renal outcomes after discontinuation of SOF were not reported. Worsening renal function occurred 
in 2% of all patients, but was higher among patients with an eGFR ≤45 ml/min/1.73m2 (15%), a high 
proportion of whom were post-transplant (49%). This study even reported one death among the 
group of patients with impaired renal function; a liver transplant recipient died due to worsening of 
renal failure and hepatic decompensation. There was no statistically significant difference in SVR rates 
based on the baseline eGFR. In contrast, we used a robust definition of RI based on recommendations 
of the International Club of Ascites (ICA) for patients with cirrhosis347, and eliminated post-transplant 
patients and those with a baseline eGFR <30 ml/min/1.73m2 (or on hemodialysis). This strategy 
allowed us to create a homogeneous cohort with no increased risk for RI at baseline, and one that 
resembles the majority of patients treated in clinical practice throughout the world. We identified an 
incidence of on-treatment RI of 11%, which was associated with a trend toward a lower rate of SVR. It 
is likely that this finding can be explained by the fact that the patients who experienced RI and did not 
attain SVR were patients with more advanced liver disease. Indeed, 7 (87.5%) of the 8 patients who did 
not attain SVR in this group had cirrhosis, of whom 6 had decompensated cirrhosis (data not shown). 
It was not unexpected that the use of a TVR/BOC-based regimen was associated with a higher occur-
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rence of RI, as previous studies also showed that renal adverse events were not uncommon.344 345 
Although they used another definition for renal impairment, Mauss et al. showed that up to 5% of 
patients on triple therapy experienced renal insufficiency stage 3 (eGFR <60 mL/min). However, some 
authors have questioned whether the decrease in eGFR noted is clinically significant, as TVR was 
shown to inhibit drug transporter OCT2 (an organic cation transporter on the basolateral membrane 
of the tubular cell), which interacts with creatinine tubular transport.352 Thus, the rise in creatinine may 
not represent true deterioration of glomerular filtration, but a transient change in tubular excretion of 
creatinine with no associated kidney damage. Although the true nephrotoxicity of protease inhibitors 
(PIs) remains unclear, studies (including the current one) have found that the early rise in creatinine 
normalizes after the cessation of antiviral therapy in almost all individuals suggesting that renal issues 
are likely not a major issue with first generation PIs. Studies using more specific markers of glomerular 
filtration (i.e. iothalamate) before and during antiviral treatment have not been performed but would 
help clarify the true degree of renal toxicity of these agents.
New generation PIs like SMV, paritaprevir and grazoprevir are all entirely hepatically metabolized and 
thus expected to have excellent renal safety profiles.353-355 We did not find an increased frequency of 
RI in patients using SOF/SMV when compared to patients taking SOF without SMV (data not shown). 
Renal elimination of SMV and grazoprevir is negligible at <1%, and similarly, the regimen containing 
paritaprevir/ritonavir, ombitasvir and dasabuvir is minimally renally excreted (<11.3%).127 159 356 Based 
on their limited renal excretion, grazoprevir and elbasvir as well as the combination of paritaprevir/
ritonavir, ombitasvir and dasabuvir have been evaluated in patients with advanced chronic kidney 
disease or on hemodialysis showing that these agents are extremely safe and highly effective.158 162
The finding that ascites was associated with the occurrence of RI during antiviral therapy stresses 
the importance of close monitoring of patients with decompensated cirrhosis. Renal function 
gradually deteriorates due to hemodynamic changes associated with decompensated liver disease.357 
Whether our observation of impaired renal function in these patients is induced by antiviral therapy 
or whether it is related to progression of liver disease and/or its treatment, is not clear. Patients taking 
diuretics were at higher risk of RI during treatment as were patients taking NSAIDs, a class of drugs that 
are contraindicated in patients with cirrhosis due to their impairment of renal blood flow, particularly 
in the setting of portal hypertension.358 
There are some limitations of our study. Due to its retrospective character, the choice of antiviral 
regimens was made by the treating physician, however patients were treated in academic centers and 
all consecutive patients were included, limiting selection bias. Although missing data always present 
challenges, we had very low rates of missing data and do not believe that they significantly affected 
the results of our study. Given the reduced number of RI events noted in the subgroup of patients 
with SOF-based regimens, we had limited ability to do a comprehensive multivariable analysis to 
identify more factors associated with RI (i.e. hypertension). Finally, the HCV TARGET registry and 
others have suggested that patients with baseline impairment of renal function are at higher risk of 
RI during SOF-based therapy, however, we had few patients with eGFR below 60 ml/min at baseline 
and a subanalysis of this population could thus not be performed. Nevertheless, approximately 19% 
of these patients experienced RI. 
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Despite inclusion of patients with more advanced liver disease, the risk for RI was lower for patients 
treated with SOF-based regimens compared to TVR/BOC-based regimens. Although RI was seen in 
11% of the patients treated with SOF-based therapy, it was reversible in almost all cases. Patients with 
ascites and patients using NSAIDs have an increased risk for RI during SOF-based antiviral therapy. 
Monitoring of renal function and standard nephroprotective measures are suggested when using 
SOF-based regimens, particularly in patients with advanced cirrhosis and portal hypertension, or in 
those with comorbidities potentially affecting the kidneys.
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SUPPLEMENTARY TABLE
Supplementary Table 9.1 | Characteristics of the 32 patients with a baseline eGFR ≤60 mL/min
Variable N
Age 32 58.1 (±6.54)
Male sex 32 14 (43.8%)
BMI 32 27.6 (±5.75)
HCV genotype
1
2
3
4
32
28 (87.5%)
1 (3.1%)
2 (6.3%)
1 (3.1%)
Cirrhosis 32 15 (46.9%)
CTP B/C 31 7 (21.9%)
MELD score 31 10 (7-13)
Cryoglobulins (+) 29 6 (18.8%)
Diabetes mellitus 32 9 (28.1%)
Hypertension 32 16 (50.0%)
NSAIDs 32 3 (9.4%)
ACE/ARA 32 5 (15.6%)
Diuretics 32 9 (28.1%)
Creatinine 32 1.23 (±0.26)
eGFR 32 52.2 (±6.8)
Platelet count 32 206 (±127)
ALT 32 49 (33-82)
Treatment regimen
BOC/P/R
TVR/P/R
SOF/P/R
SOF/R
SOF/SMV/±R
SOF/LDV/±R
32
1 (3.1%)
11 (34.4%)
8 (25.0%)
6 (18.8%)
5 (15.6%)
1 (3.1%)
Abbreviations: eGFR, estimated glomerular filtration rate; BMI, body mass index; HCV, hepatitis c virus; CTP, 
Child-Turcotte-Pugh; MELD, Model for End-stage Liver Disease; NSAIDs, nonsteroidal anti-inflammatory 
drugs; ACE, angiotensin-converting-enzyme inhibitors; ARA, angiotensin II receptor antagonists; ALT, alanine 
aminotransferase; BOC, boceprevir; P, pegylated interferon alpha; R, ribavirin; TVR, telaprevir; SOF, sofosbuvir; SMV, 
simeprevir; LDV, ledipasvir
a. Data are presented as n (%), mean (±SD) or median (interquartile range). 
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BACKGROUND
Chronic hepatitis C virus (HCV) infection continues to be a major global public health problem. 
Although the incidence of HCV infection is declining in the West, it has been estimated that the inci-
dence of patients with HCV-induced cirrhosis will not peak until 2030.63  
With the approval of multiple direct-acting antivirals (DAAs), the therapeutic horizon has been 
broadened for patients with chronic HCV infection. After two decades with merely minor improve-
ments of interferon-based antiviral treatment regimens, current DAAs allow patients to be treated 
with high effectiveness and excellent tolerability. Until 2011, treatment of chronic HCV infection 
consisted solely of pegylated interferon and ribavirin. Almost 50% of the patients with chronic HCV 
infection were treated successfully and were considered having a sustained virological response 
(SVR) when serum HCV RNA was absent at 24 weeks after the cessation of therapy. The SVR rates 
greatly varied between patients and several viral, host and treatment factors could be used as 
predictors of successful treatment outcome.107 339 359 Once SVR is attained, patients have an improved 
long-term outcome compared to patients without SVR.75 79-82 84 This beneficial effect of SVR was best 
assessed in patients with advanced hepatic fibrosis, who are at highest risk for developing liver 
failure, hepatocellular carcinoma (HCC) and all-cause mortality. Due to one of the most important 
mile stones in hepatology, even patients with severe hepatic disease can be offered antiviral therapy. 
Interferon-based therapy was namely contra-indicated in patients with decompensated cirrhosis, due 
to the occurrence of severe adverse events, including worsening of hepatic decompensation, severe 
bacterial infections and even death.121 207 Interferon-free regimens are likely to change their future, but 
this will remain a matter of debate during the upcoming years. 
THE OLD LANDSCAPE: OPTIMIZING INTERFERON-BASED 
THERAPY
Until 2014, pegylated interferon remained the backbone of the treatment for chronic HCV infec-
tion. The first DAAs were combined with pegylated interferon and ribavirin.128 129 135 Although these 
regimens could be shortened to 12 or 24 weeks and were associated with improved SVR rates, 
interferon-induced side effects remained and some patients could not receive treatment. 
Hereafter, combinations of multiple classes of DAAs showed overwhelming SVR rates and 
excellent safety profiles. The high costs of these new drugs, however, have limited their availability. 
Indeed, also in high-income countries the access to DAAs is still subject to debate. In the Netherlands, 
partly due to the low prevalence of this disease, all patients with chronic HCV infection can be treated 
with the approved DAAs. Yet, pegylated interferon is still expected to remain a necessary treatment 
option for many patients with chronic HCV infection around the globe. Consequently, optimizing the 
use of pegylated interferon in order to maximize the chance of SVR is thus still relevant. Especially 
among patients with compensated advanced liver disease it is not an option to await the availability 
of interferon-free treatment options. 
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Interferon-associated side effects limit treatment adherence and may lead to dose reduction or 
treatment discontinuation, by which the virological efficacy of antiviral therapy is compromised.110-112 
214 Interferon-based regimens, which can be shortened to 12-24 weeks with the addition of a 
next-generation DAA, remained to have the pegylated interferon-associated side effects. The 
most commonly reported side effects are cytopenias, such as thrombocytopenia, neutropenia 
and anemia.110 214 These interferon-induced cytopenias were actually the most frequent causes of 
pegylated interferon dose reductions.104 Out of fear for bleeding episodes and infections, current 
guidelines and product labels recommend to reduce the dose of pegylated interferon when the 
platelet count drops below 50x109/L or when the absolute neutrophil count (ANC) drops below 
750/µL. Treatment is even advised to be discontinued in case of a platelet count below 25x109/L or 
a ANC below 500/µL.35 36 It has been suggested, however, that these recommendations are overly 
cautious and unnecessarily impede treatment success. 114 115 The only study which assessed the risk 
of on-treatment bleeding episodes did show a relation with interferon-induced thrombocytopenia, 
but all registered bleeding episodes were deemed minor expect for one, which actually occurred in 
a patient without thrombocytopenia.115 Although chronic HCV-infected patients are at an increased 
risk of bacterial infections during interferon-based therapy, these infections were generally mild.114 
200 203 360-362 Moreover, a relation between the infection rate and interferon-induced neutropenia has 
never been described. 
Yet, the above-cited studies included only a limited number of patients with advanced hepatic 
fibrosis. Because of an increase in portal pressure and a reduced thrombopoietin production those 
with cirrhosis are also most prone for thrombocytopenia. In fact, thrombocytopenia may already be 
present in absence of interferon-based therapy.113 As a result, cirrhosis was probably found to be a risk 
factor for bleeding episodes during pegylated interferon therapy. 115 Patients with cirrhosis, however, 
can be considered as immunocompromised and are at highest risk of infections. 204 In chapters 1a 
and 2, we have investigated the risk of bleeding episodes and infections during interferon-based 
antiviral therapy among the patients with chronic HCV infection and bridging fibrosis or cirrhosis 
(Ishak fibrosis score 4–6). This cohort study included all consecutive patients with chronic HCV 
infection who started an interferon-based treatment between 1990 and 2003. In total, 104 bleeding 
episodes were registered during 53 (8%) of the 678 interferon-based treatments which could be 
included for this endpoint. In line with the results as reported by Roomer et al., cirrhosis and a platelet 
count <50x109/L at the previous visit were significantly associated with bleeding episodes.115 How-
ever, nearly all registered bleeding episodes were considered to be minor and remained without 
serious clinical consequences. The two (2%) bleeding episodes which were considered to be severe 
both concerned variceal bleeding episodes for which the patients were hospitalized. Antiviral therapy 
was not discontinued in these patients. Considering the natural history of HCV-related cirrhosis, two 
variceal bleeding episodes in such a large cohort of patients with advanced liver disease might also 
be expected outside of the scope of interferon-based therapy. 55 In fact, both patients had a previous 
variceal bleeding episode and both had pretreatment thrombocytopenia as a measure of portal 
hypertension (89x109/L and 90x109/L respectively). In order to overcome thrombocytopenia-induced 
dose reductions of pegylated interferon as well as the fear for bleeding episodes, efforts have been 
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made in order to increase the platelet count before and during antiviral therapy by treating patients 
with eltrombopag, an oral thrombopoietin receptor agonist.193 Although, eltrombopag was shown 
to be a potent agent for treating thrombocytopenia, some important safety issues on its use during 
interferon-based antiviral therapy were addressed in chapter 1b. The rates of hepatic decompensation 
and thromboembolic events were significantly higher in the group receiving eltrombopag. By allowing 
patients with severe thrombocytopenia to undergo interferon-based therapy, the risk for hepatic 
decompensation is considerably increased. It could be questioned whether these risks outweigh the 
little benefit on SVR rates which were seen in the groups that received eltrombopag. Besides, patients 
with severe portal hypertension may not benefit from successful antiviral therapy as they are beyond 
the ‘point of no return’ and their natural history is unlikely to be reversed. 
In this same cohort, 113 infections were registered during 88 (12%) of the 723 interferon-based 
treatments. In 23 of these treatments the ANC dropped below 500/µL, but an infection was observed 
during only three of these treatments. Nevertheless, on-treatment ANC <500/µL was significantly 
associated with the occurrence of infection. However, a sensitivity analysis including only those 
regimens containing pegylated interferon could confirm this finding, which is in line with other 
studies including patients treated with pegylated interferon and ribavirin only.114 200 202 203 Importantly, 
the majority of infections which occurred during interferon-based therapy were mild, both in our 
study as well in the studies of others. As expected, we found that cirrhosis and diabetes mellitus were 
independent risk factors for on-treatment infections. 
With respect to infections and bleeding episodes, our study among patients with advanced 
liver disease confirmed that pegylated interferon-based therapy is generally safe. In case of risk 
factors such as cirrhosis or diabetes mellitus, infections and/or bleeding episodes may be expected 
more frequently. These patients should therefore to be monitored more closely. Because patients 
with advanced liver disease seem to have much to gain by attaining SVR, it may be considered to 
maintain the dose of pegylated interferon as long as the ANC and platelet counts remain above 500/
µL and 25x109/L, respectively. Although we rarely observed cytopenias below these values (the 
ANC dropped below 500/µL in 3% of treatments and the platelet counts dropped below 25x109/L 
in 2% of treatments), it should be noted that interferon dose reductions were at the discretion of the 
treating physicians. Prospective studies would obviously be warranted to validate these alternative 
recommendations, especially when regimens of 12 to 24 weeks can be used. However, considering 
the field is moving toward interferon-free therapy, these studies are unlikely to be executed.
Although not in general, ribavirin is still being used next to the DAAs to optimize the virological 
efficacy in some specific subgroups of patients. The use of ribavirin has been associated with 
hemolytic anemia and is responsible for hemoglobin declines during antiviral therapy. Two genetic 
polymorphisms in the inosine triphosphatase (ITPA) gene on chromosome 20 were shown to be 
associated with protection against early ribavirin-induced hemolytic anemia during treatment with 
pegylated interferon and ribavirin.215 As the findings on these two ITPA polymorphisms were mostly 
derived from patients who were included in randomized controlled trials, we assessed this association 
in chapter 3 for patients who were treated in daily clinical practice.217 218 221 222 In total, 213 Caucasian 
patients could be included who had a blood sample available for genetic testing. In 74% patients a 
clinically significant decline in hemoglobin was reported. Patients who were homozygous carriers 
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of the major allele of the two ITPA genes (representing normal ITPase activity) experienced deeper 
declines in hemoglobin and had a higher occurrence of clinically significant anemias. More important, 
these patients often underwent dose reductions of both ribavirin and pegylated interferon, and more 
often were administrated blood transfusions and/or erythropoietin. 
Since treatment efficacy is hampered by dose reductions, patients with normal ITPase activity may 
benefit from early strategies to maintain adequate hemoglobin levels in order to improve treatment 
adherence. These polymorphisms may also be used as an additive tool to select a specific interferon-
free regimen for the individual patient as not all regimens require addition of ribavirin for optimal 
virological efficacy. However, whether the association between ITPase activity and anemia remains in 
case of ribavirin containing interferon-free therapy needs to be assessed.
The importance of platelets was also highlighted in chapter 4. Besides an improved prognosis, 
SVR has been repeatedly associated with reductions in hepatic fibrosis and portal pressure, which 
are linked to a favorable clinical outcome.74 78 241-247 269 363-365 Evaluating liver histology or the hepatic 
venous pressure gradient requires invasive procedures, so that multiple assessments are difficult to 
accomplish. In chapter 4 we have therefore investigated the evolution of platelet counts over time 
following antiviral therapy in patients with chronic HCV infection and advanced hepatic fibrosis. 
Especially among patients with more advanced liver disease, the platelet count represents a non-
invasive and objective parameter of the degree of portal hypertension and hepatic fibrosis.253 255 
256 Previously, changes in platelet count following antiviral therapy have been linked to changes 
in hepatic fibrosis.258 259 With a repeated measurement analysis we observed a significant increase 
in platelet counts for many years following achievement of SVR, which showed to be rather linear. 
Importantly, the change in platelet count correlated with the change in spleen size, which represents 
another marker of portal pressure. These findings suggest a gradual improvement in portal pressure 
and liver histology after HCV eradication. In contrast, the platelet counts further declined during 
follow-up among patients who were not successfully treated. 
THE CHANGING LANDSCAPE
Since the discovery of HCV in 1989 and the implementation of blood screening tests shortly thereafter, 
there has been a significant reduction in the transmission of the virus.11 278-281 As fibrosis slowly 
develops, and patients may be asymptomatic or with non-specific symptoms only, many infected 
people remain undetected so far. Due to ageing of the HCV-infected population, approximately 25% 
of the US patients with chronic HCV infection are expected to have cirrhosis. This proportion is likely 
to increase to 45% by the year 2030.63 With the introduction of safe and effective interferon-free 
antiviral regimens, it is expected that more patients can be effectively treated, including those with 
advanced liver disease. 
Based on historic data, the present and future burden of chronic HCV infection in the Nether-
lands were recently modeled as well.4 286 287 Additional details on the trends in patient and disease 
characteristics from the last 2 decades are important for Dutch health policy makers to be informed 
about the shifting trends in the patient population with chronic HCV infection. This provides 
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information on the burden of patients who will be considered for interferon-free therapy during 
the upcoming years. Chapter 5 describes the epidemiological trends in patient and disease 
characteristics over time among 1779 individuals with chronic HCV infection that were newly 
referred to a tertiary care center in the Netherlands from 1990 to 2013. As expected, with a reduced 
incidence of chronic HCV infection, more recently referred patients were older and more often had 
advanced hepatic fibrosis as compared to the patients who were referred in the early years. Also, more 
patients were infected with HCV genotype 1a. This could possibly explained by the lower response 
rates of patients with chronic HCV genotype 1a compared to patients with chronic HCV genotype 
1b, especially when treated with first-generation protease inhibitors telaprevir and boceprevir.298 The 
reason for this difference between HCV genotype 1a and 1b was most likely the resistance-associated 
variants that were present at baseline or emerge during antiviral therapy.366-369 Although it was not 
statistically significant, there was also an increase in the number of patients referred with chronic HCV 
genotype 3. As this genotype is associated with a more accelerated disease progression, this finding 
is important.299 Moreover, treatment with interferon-free regimens had suboptimal efficacy among 
patients with HCV genotype 3. 
Another interesting finding was that 70% of all patients were born between 1950 and 1975. 
Although screening for chronic HCV infection has not been considered cost-effective in the Nether-
lands due to the low prevalence of the disease in light of suboptimal treatment options, this should be 
re-evaluated for specific subgroups with highest prevalence now that effective treatment regimens 
are available. An effective screening strategy could really decrease the disease burden with respect 
to both prevalence and clinical impact are concerned. At the moment, the fact that patients are 
un aware of their disease seems to represent the greatest limitation to make a real impact on HCV- 
related mortality.370
The approval of various DAAs induced an enormous debate on the price of these drugs. Currently, 
the high costs of these DAAs hamper global access. Policy makers, therefore, are forced to prioritize 
treatment to those patients who are considered to have an urgent need for successful antiviral therapy. 
This situation, however, is far from ideal, especially since patients without cirrhosis have the greatest 
benefit from successful antiviral treatment as was suggested by Koh et al.261 Since the introduction 
of DAAs there was an increasing number of studies on the cost-effectiveness of these drugs with 
different conclusions on who to treat and when to treat.371-374 In order to place the costs of DAA into 
broader perspective, chapter 6 describes the costs per SVR for patients with advanced hepatic fibrosis 
who were treated with interferon-based antiviral therapy. Patients that were included in chapter 1 
and 2, were also included in this study if detailed information was available. For the total cohort, 
the mean costs per SVR was €38,514. These costs were higher for patients with cirrhosis (€40,587) as 
compared to patients with bridging fibrosis (€33,454). When the baseline platelet count was used as 
indicator for the severity of liver disease, we found that for patients with a platelet count <100x109/L 
the mean costs per SVR were €74,961, which was substantially higher than for patients with a normal 
platelet count at baseline (€26,105). These differences can probably be attributed to the lower chance 
of attaining SVR in these subgroups, which is important since the currently approved interferon-free 
regimens seem overcome this with universal high SVR rates. Taking into account the possible risks of 
interferon-based treatment as well as the high chance of necessitating re-treatment, the additional 
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costs per SVR of the DAAs could be limited, especially among those with most severe liver disease. 
Of course, these data should be interpreted with caution and not be used to justify the high costs of 
the new drugs. In order to be able to treat more patients, these costs should be substantially reduced.
THE NEW LANDSCAPE: ANTIVIRAL THERAPY WITH DIRECT-
ACTING ANTIVIRALS
After the approval of telaprevir and boceprevir, the first DAAs, real-world studies warned the trea-
ting physicians for important safety issues, especially in patients with advanced hepatic fibrosis.120 
121 Real-world data is of utmost importance after the approval of new drugs. The efficacy and safety 
of these regimens are based on treatments administered to patients who fulfilled the eligibility 
criteria for clinical trials. In chapter 7 we assessed the safety and effectiveness of DAA-based antiviral 
therapy in patients with cirrhosis. Data from 4 large university hospitals in Canada, Germany and 
the Netherlands were combined. In total, 433 cirrhotic patients were included of whom 114 had 
evidence of decompensated cirrhosis (defined as a Child Pugh B or C). The overall SVR rate was 81% 
(350/433) and there was a trend towards a better response rate among patients with CP A compared 
to CP B/C patients (264/ 319 [82.8%] vs. 86/ 114 [75.4%], p = 0.088). More importantly, 50 (11.5%) 
patients experienced worsening or new onset of hepatic decompensation during antiviral therapy. 
Factors that were associated with the occurrence of hepatic decompensation were HCV genotype 
3 (vs non-genotype 3), Child Pugh B/C (vs Child Pugh A) and albumin <35 g/L. When Child Pugh 
score was replaced by MELD score, we found that a MELD score ≥14 was associated with hepatic 
decom pensation. When three risk factors (HCV genotype 3, albumin <35 g/L and MELD score ≥14) 
were present, the 24-week cumulative incidence for hepatic decompensation was 75.0% (50.5-99.5) 
and the chance of attaining SVR was 67%. By identifying these three parameters, physicians could 
potentially assess the risk for hepatic decompensation, which should be weighed against the chance 
of SVR. One could argue that when the risk of decompensation is more or less equal or higher than 
the chance of attaining SVR, delaying therapy would be a better option. This study also highlighted 
the importance of HCV genotype 3. Previous data has shown that HCV genotype 3 is associated with 
faster progres sion to cirrhosis, the development of HCC and overall survival.299 335 Our data shows that 
HCV genotype 3 is still relevant among patients with decompensated cirrhosis as we found that it 
has also been associated with the development/worsening of hepatic decompensation. Fortunately, 
more effective therapy for HCV genotype 3 were recently presented and reported on multiple 
combinations of further developed DAAs (sofosbuvir and velpatasvir, especially with the addition of 
GS-9857, and ABT-493 and ABT-530).168 375-377 Approval of these agents should be considered a high 
priority.
The need for more effective therapy for HCV genotype 3 was also highlighted in chapter 8. This 
study, part of the large registry HCV-TARGET, included 197 patients with HCV genotype 3, who were 
treated with sofosbuvir and ribavirin with or without the addition of pegylated interferon. Of 178 
patients treated with sofosbuvir and ribavirin, 60% achieved SVR, compared to 84% of 19 patients 
treated with sofosbuvir, pegylated interferon and ribavirin. After controlling for age and sex, absence 
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of cirrhosis, albumin levels ≥3.2 g/dl and platelet count >100x109/L were associated with greater 
odds of SVR. Although this study was not powered for this purpose, it showed that adding pegylated 
interferon to the treatment of HCV genotype 3 could increase the chance of SVR. This was also 
highlighted in a randomized controlled trial comparing sofosbuvir and ribavirin for 16 or 24 weeks 
to sofosbuvir, pegylated interferon and ribavirin for 12 weeks in patients with HCV genotype 3.378 
This study showed that the inclusion of pegylated interferon increased response rates in all patient 
subgroups, but most notably in those with cirrhosis. Among these patients the SVR rates increased 
from 82% with sofosbuvir and ribavirin for 24 weeks to 91% with sofosbuvir, pegylated interferon and 
ribavirin in treatment-naïves and from 77% to 86% in case of prior treatment-experience. Pegylated 
interferon was tolerated well with only 1 patient discontinuing treatment prematurely. Similarly, 
pegylated interferon was well tolerated with similar rates of adverse events and higher rates of 
SVR reported than with sofosbuvir and ribavirin alone. However, despite these encouraging results, 
sofosbuvir, pegylated interferon and ribavirin was prescribed to only 19 of the 197 (9.6%) patients 
with HCV genotype 3 infection who have started therapy within the HCV-TARGET to date. Clearly 
both clinicians and patients are reluctant to accept interferon-based therapies. Fortunately recent 
studies have shown that sofosbuvir combined with velpatasvir, a pan-genotypic NS5A inhibitor, is 
highly effective for chronic HCV genotype 3 infection, leading to SVR rates of 90% even in patients 
with cirrhosis. Ribavirin no longer seems to be required with this new DAA combination.168
Despite the fact that sofosbuvir is considered very safe, its use is not recommended in patients 
with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 or patients with end-stage 
renal disease. This is because the main active metabolite of sofosbuvir, GS331007, is excreted by the 
kidneys, and higher drug and metabolite concentrations are found in those patients with an estimated 
glomerular filtration rate (eGFR) <30 mL/min/1.73m2 or end-stage renal disease on hemodialysis.346 
Although the major trials examining the safety and efficacy of sofosbuvir demonstrated an excellent 
renal safety profile, it currently remains unknown whether this also applies in daily clinical practice. 
Previously, the registration trials of telaprevir and boceprevir also reported a relatively benign renal 
safety profile, while shortly after its approval data on significant renal safety toxicity emerged.344 345 
In Chapter 9 the occurrence of renal impairment was assessed during sofosbuvir-based antiviral 
therapy. This large study included 426 patients with chronic HCV infection who were treated with 
sofosbuvir-based (n=233) or telaprevir/ boceprevir-based (n=193) regimens at two tertiary university 
centers in North America. The risk for renal impairment was lower for patients treated with sofosbuvir-
based regimens compared to telaprevir/ boceprevir-based regimens. Although renal impairment was 
seen in 11% of the patients treated with sofsobuvir-based therapy, it has a good renal safety profile 
as renal impairment was reversible in almost all cases. Patients with ascites and patients using NSAIDs 
have an increased risk for renal impairment during sofosbuvir-based antiviral therapy. Monitoring of 
renal function and standard nephroprotective measures are suggested when using sofosbuvir-based 
regimens, particularly in patients with advanced cirrhosis and portal hypertension, or in those with 
comorbidities potentially affecting the kidneys. Fortunately, two regimens have shown promising 
results in patients with renal failure. Based on their limited renal excretion, grazoprevir and elbasvir 
as well as the combination of paritaprevir/ritonavir, ombitasvir and dasabuvir have been evaluated 
in patients with advanced chronic kidney disease or on hemodialysis showing that these agents are 
extremely safe and highly effective.158 162 
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CONCLUSIONS
With the approval of multiple oral DAAs, physicians now have the ability to initiate highly effective 
and very safe antiviral therapy in patients with chronic HCV infection, even in those with most 
advanced hepatic disease. Although the costs limit global access to these drugs, a recent study on 
the use of generic DAAs showed promising results.379 Until that time, pegylated interferon may be 
necessary, yet, for a shorter duration than before 2014. With the right monitoring, even patients 
with compensated cirrhosis could be safely treated with pegylated interferon. In absence of DAA 
combinations, physicians should not be too reluctant to initiate interferon-based antiviral therapy, 
especially not in patients with HCV genotype 3 who may actually benefit from this addition. Chronic 
HCV infection is par excellence a disease that needs a patient tailored approach when treatment is 
concerned. While there is almost no limitation for the use of DAAs, some patients may have no clinical 
benefit from successful antiviral therapy as the natural course of their disease cannot be reversed 
anymore. With the upcoming pangenotypic regimens, treatment decisions will be simplified, 
although this will not be the case for every patient. Close collaboration between physicians, health 
authorities and pharmaceutical companies is urgently needed to reduce the enormous burden of 
chronic HCV infection. Patients need to be diagnosed, linked to care and treated in order to eradicate 
the virus, especially now we have a cure.
Processed on: 27-10-2016
505957-L-bw-Maan
Processed on: 27-10-2016
505957-L-bw-Maan
Samenvatting
Processed on: 27-10-2016
505957-L-bw-Maan
202   |    Samenvatting
ACHTERGROND
Chronische hepatitis C virus (HCV) infectie blijft wereldwijd een belangrijk probleem voor de volks-
gezondheid. Hoewel de incidentie van chronische HCV infectie afneemt in het Westen, denkt men dat 
de incidentie van patiënten met HCV-geïnduceerde cirrose, verlittekening van de lever, pas in 2030 
zijn hoogtepunt zal bereiken.63  
Door de goedkeuring van meerdere medicijnen die direct op het virus inwerken (DAAs, direct-
acting antivirals), heeft de behandelaar van patiënten met chronische HCV infectie momenteel een zeer 
ruime keuze. Na twee decennia van slechts geringe verbeteringen van ‘de oude’ interferon-gebaseerde 
antivirale behandelingen, maken de huidige DAAs het mogelijk om patiënten te behandelen met een 
hoge effectiviteit en uitstekende verdraagbaarheid. Tot 2011 bestond de behandeling van chronische 
HCV infectie uitsluitend uit gepegyleerd interferon en ribavirine, medicijnen die het immuun 
systeem van de patiënt stimuleren het virus op te ruimen (interferon) en ervoor te zorgen dat het 
virus muteert (ribavirine). Bijna 50% van de patiënten met chronische HCV infectie werden hiermee 
succesvol behandeld. We beschouwen patiënten als genezen indien er 24 weken na het staken van 
de behandeling geen virus meer aantoonbaar is in het bloed. Dit wordt een blijvende virologische 
respons genoemd (SVR, sustained virological response). De SVR percentages varieerden aanzienlijk 
tussen patiënten en verschillende virale-, patiënt- en behandel factoren konden worden gebruikt 
als voorspellers van een succesvol behandelingsresultaat.107 339 359 Zodra SVR is bereikt, hebben 
patiënten een betere uitkomst op de lange termijn in vergelijking met patiënten zonder SVR.75 79-82 
84 Dit gunstige effect van SVR is het beste onderzocht bij patiënten met gevorderde leverfibrose, zij 
hebben namelijk het grootste risico op het ontwikkelen van leverfalen, hepatocellulair carci noom 
(HCC) en sterfte. Door een van de belangrijkste mijlpalen in de hepatologie, kunnen zelfs patiënten 
met een ernstige leveraandoening antivirale therapie ontvangen. Interferon-gebaseerde therapie 
was namelijk gecontra-indiceerd bij patiënten met gedecompenseerde levercirrose, vanwege het 
risico op ernstige bijwerkingen, waaronder verergering van leverdecompensatie, ernstige bacteriële 
infec ties en zelfs overlijden.121 207 Interferon-vrije behandelingen zullen de toekomst van patiënten 
met chronische HCV infectie waarschijnlijk veranderen, maar of dit voor iedere patiënt zo is zal de 
komende jaren een punt van discussie blijven.
HET OUDE LANDSCHAP: OPTIMALISEREN VAN INTERFERON-
GEBASEERDE THERAPIE 
Tot 2014 was gepegyleerd interferon de basis van de behandeling van chronische HCV infectie. De 
eerste DAAs werden namelijk gecombineerd met gepegyleerd interferon en ribavirine.128 129 135 Hoewel 
deze regimes konden worden ingekort tot 12 of 24 weken en een hogere kans op genezing hadden, 
bleven de interferon-geïnduceerde bijwerkingen bestaan, waardoor sommige patiënten niet konden 
worden behandeld.
Hierna volgden combinaties van meerdere soorten DAAs met een hoge kans op slagen van de 
behandeling en een uitstekend veiligheidsprofiel. De hoge kosten van deze nieuwe geneesmiddelen 
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zorgen echter voor een beperkte beschikbaarheid. Sterker nog, ook in landen met hoge inkomens is 
de beschikbaarheid van DAAs nog steeds onderwerp van discussie. In Nederland, mede door de lage 
prevalentie van deze ziekte, kunnen alle patiënten met chronische HCV infectie worden behandeld 
met de geregistreerde DAAs. Verwacht wordt dat  wereldwijd, voor veel patiënten met chronische 
HCV infectie, gepegyleerd interferon een belangrijk onderdeel van de behandeling blijft. Daarom is 
het belangrijk om optimaal gebruik te maken van gepegyleerd interferon en daardoor de kans op 
SVR te vergroten. Vooral bij patiënten met gecompenseerde levercirrose is  het geen optie om de 
beschikbaarheid van interferon-vrije behandelingsopties af te wachten.
Interferon-geassocieerde bijwerkingen beperken de therapietrouw en kunnen leiden tot dosis-
verlaging of staken van de behandeling, waarbij de kans op succesvolle behandeling in gevaar 
komt.110-112 214 Interferon-gebaseerde behandelopties kunnen worden ingekort tot 12 of 24 weken 
met de toevoeging van de nieuwe generatie DAAs. Helaas gaat dit wel gepaard met de interferon-
geassocieerde bijwerkingen. De meest voorkomende bijwerkingen zijn afwijkingen in het bloed, 
zoals trombocytopenie (lage bloedplaatjes), neutropenie (lage neutrofielen) en anemie (laag hemo-
globine).110 214 Deze interferon-geïnduceerde afwijkingen zijn de meest voorkomende oorzaken van 
dosisverlagingen van gepegyleerd interferon.104 Uit angst voor bloedingen en infecties wordt in de 
huidige richtlijnen aanbevolen om de dosering van gepegyleerd interferon te verlagen wanneer het 
aantal bloedplaatjes daalt onder 50x109/l of als het absolute aantal neutrofielen (ANC) daalt onder 750/
µl. Indien het aantal bloedplaatjes daalt beneden 25x109/l of bij een ANC lager dan 500/µl wordt zelfs 
geadviseerd de behandeling te staken.35 36 Gesuggereerd wordt dat deze adviezen te voorzichtig zijn 
en onnodig de kans op een succesvolle behandeling verlagen.114 115 De enige studie die het risico op 
bloedingen tijdens behandeling heeft geëvalueerd toonde een relatie met interferon-geïnduceerde 
trombocytopenie. Gelukkig waren alle geregistreerde bloedingen waren mild, behalve één bloeding, 
die optrad bij een patiënt zonder trombocytopenie.115 Hoewel patiënten met een chronische HCV 
infectie een verhoogd risico op bacteriële infecties hebben tijdens interferon-gebaseerde therapie, 
waren deze infecties over het algemeen mild.114 200 203 360-362 Bovendien is een relatie tussen een infectie 
en de ernst van een interferon-geïnduceerde neutropenie nooit beschreven.
Helaas includeerden de bovengenoemde studies slechts een beperkt aantal patiënten met 
ver gevorderde leverfibrose. Door een toename van portale druk en een verminderde productie 
trom bo poietine hebben patiënten met cirrose een grote kans op het ontwikkelen van thrombo-
cytopenie. Vaak hebben deze patiënten al een trombocytopenie zonder de aanwezigheid van 
interferon-gebaseerde therapie.113 Als gevolg hiervan, werd cirrose als een risicofactor voor bloe-
dingen tijdens behandeling met gepegyleerd interferon beschouwd.115 Patiënten met cirrose kunnen 
ook worden beschouwd als immuun gecompromitteerd, waardoor zij een verhoogd risico hebben 
op infecties.204 In hoofdstuk 1.1 en 2, hebben we het risico op bloedingen en infecties tijdens 
interferon-gebaseerde antivirale therapie onderzocht bij patiënten met chronische HCV infectie en 
ernstige fibrose of cirrose (Ishak fibrose score 4-6). In deze studie werden uit vijf verschillende centra 
alle patiënten met een chronische HCV infectie geïncludeerd, die hun eerste interferon-gebaseerde 
behandeling hadden ondergaan tussen 1990 en 2003. In totaal werden 678 interferon-gebaseerde 
behandelingen bekeken, waarbij in 53 (8%) behandelingen ten minste één bloeding werd geregi-
streerd. In lijn met de resultaten zoals gerapporteerd door Roomer et al., was het hebben van 
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cirrose en het hebben van bloedplaatjes onder de 50x109/l bij het vorige bezoek aan de polikliniek 
significant geassocieerd met bloedingen.115 Echter, bijna alle geregistreerde bloedingen waren mild 
en bleven zonder ernstige klinische consequenties. De twee (2%) bloedingen die als ernstig werden 
beschouwd, waren beide varices bloedingen waarvoor de patiënten werden opgenomen in het 
ziekenhuis. De antivirale therapie werd bij deze patiënten overigens niet gestopt. Aangezien onze 
studie alleen patiënten includeerde met gevorderde leverziekte, kunnen de twee varices bloedingen 
ook passen bij het natuurlijk beloop van de ziekte en hoeft het geen relatie te hebben met de 
interferon-gebaseerde therapie.55 Bovendien hadden beide patiënten een eerdere varices bloeding 
gehad en beiden hadden voorafgaand aan de behandeling trombocytopenie als maat voor portale 
hypertensie (respectievelijk 89x109/l en 90x109/l). Om ervoor te zorgen dat het aantal bloedplaatjes 
voorafgaand aan de behandeling hoog genoeg was, met als doel om dosisverlagingen en bloedingen 
te voorkomen, werd onderzocht of patiënten konden worden behandeld met eltrombopag, een orale 
trombopoietine receptoragonist.193 Hoewel werd aangetoond dat eltrombopag een krachtig middel is 
voor de behandeling van thrombocytopenie, werden een aantal belangrijke bijkomende problemen 
bij het gebruik tijdens interferon-gebaseerde antivirale therapie besproken in hoofdstuk 1b. De kans 
op het ontwikkelen van leverdecompensatie en trombo-embolische bijwerkingen was significant 
hoger in de groep die eltrombopag kreeg. Doordat patiënten met ernstige trombocytopenie langer 
behandeld werden met interferon, was het risico op hepatische decompensatie aanzienlijk toege-
nomen. Men zou zich kunnen afvragen of deze risico’s opwegen tegen het minimale voordeel met 
betrekking tot de kans op SVR bij patiënten die werden behandeld met eltrombopag. Bovendien is 
het de vraag of patiënten met ernstige portale hypertensie baat hebben bij een succesvolle antivirale 
therapie. Het is goed mogelijk dat deze patiënten voorbij een ‘point of no return’ zijn, waardoor het 
natuurlijke beloop van de ziekte niet meer kan worden omgedraaid. 
Hoofdstuk 2 laat zien dat binnen dezelfde groep patiënten als hierboven beschreven, 113 infec-
ties gerapporteerd werden tijdens 88 (12%) van de 723 interferon-gebaseerde behandelingen. In 
23 van deze behandelingen daalden de neutrofielen onder 500/µl, maar een infectie werd slechts 
bij drie van deze behandelingen waargenomen. Een ANC <500/µl bij het voorafgaande bezoek was 
wel significant geassocieerd met het optreden van een infectie. Echter, bij een analyse waarbij alleen 
patiënten werden geïncludeerd die waren behandeld met gepegyleerd interferon, kon deze associatie 
niet worden aangetoond. Dit komt overeen met eerdere studies, waarbij hetzelfde is onderzocht.114 200 
202 203 Belangrijk is dat de meeste infecties, die tijdens de behandeling met interferon optraden, mild 
waren, zowel in onze studie als in andere studies. Zoals verwacht bleek dat ook cirrose en diabetes 
mellitus onafhankelijke risicofactoren zijn voor infecties tijdens interferon-gebaseerde behandeling.
Met betrekking tot infecties en bloedingen laten onze studies zien dat bij patiënten met 
gevorderde leverziekte, gepegyleerd interferon-gebaseerde therapie over het algemeen veilig is. Bij 
risicofactoren zoals cirrose of diabetes mellitus kunnen infecties en/of bloedingen vaker voorkomen. 
Deze patiënten moeten daarom nauwlettend worden gecontroleerd tijdens de  behandeling. 
Omdat patiënten met gevorderde leverziekte veel baat hebben bij het behalen van SVR, kan worden 
overwogen om de dosis van interferon te handhaven zolang ANC en bloedplaatjes respectievelijk 
boven de 500/µl en 25x109/l zijn. Hoewel we zelden deze waarden hebben waargenomen (ANC <500/
µl in 3% van de behandelingen en de bloedplaatjes <25x109/l in 2% van de behandelingen), moet 
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worden opgemerkt dat de dosisverlagingen van interferon niet volgens een bepaald protocol werden 
toegepast, maar werden gekozen door de behandelende artsen. Prospectieve studies zouden moeten 
worden uitgevoerd om te kijken of minder strenge richtlijnen rondom de dosisverlagingen niet tot 
een groter risico op infecties en bloedingen leidt, vooral wanneer de behandelduur verkort kan 
worden tot 12 of 24 weken. Echter, gezien de snelle veranderingen waarbij interferon-vrije therapie 
de eerste keuze is, zullen deze studies waarschijnlijk nooit worden uitgevoerd.
Waarschijnlijk zal ribavirine nog steeds worden gebruikt in combinatie met DAAs om in bepaalde 
subgroepen van patiënten de virologische effectiviteit te optimaliseren. Het gebruik van ribavirine is 
geassocieerd met hemolytische anemie en is verantwoordelijk voor hemoglobine dalingen tijdens 
antivirale therapie. Genetische polymorfismen in het inosine triphosphatase (ITPA) gen op chromosoom 
20 bleken tijdens de behandeling met gepegyleerd interferon en ribavirine geassocieerd te zijn met 
de bescherming tegen vroegtijdige ribavirine-geïnduceerde hemolytische anemie.215 Aangezien de 
bevindingen over deze twee ITPA polymorfismen meestal afkomstig waren van patiënten die waren 
geïncludeerd in gerandomiseerde gecontroleerde studies, onderzochten we deze associatie in 
hoofdstuk 3 bij patiënten die in de dagelijkse klinische praktijk werden behandeld.217 218 221 222 In totaal 
konden 213 Kaukasische patiënten worden geïncludeerd, omdat zij een bloedmonster beschikbaar 
hadden voor de genetische testen. In 74% van de patiënten werd een klinisch significante daling 
van de hemoglobine gemeld. Patiënten die homozygote dragers waren van de meest voorkomende 
allel van beide ITPA genen (wat overeenkomt met een normale ITPase activiteit), ondervonden een 
diepere daling van hemoglobine en daardoor trad een klinisch significante anemie vaker op. Deze 
patiënten ondergingen ook meer dosisverlagingen van zowel ribavirine en gepegyleerd interferon 
en kregen vaker bloedtransfusies en/of erytropoëtine toegediend.
Omdat de effectiviteit van de behandeling wordt verminderd door dosisreducties kunnen pa-
tiënten met een normale ITPase activiteit profiteren van de vroege strategieën ter bevordering van 
het hemoglobinegehalte. Deze polymorfismen kunnen ook worden gebruikt als criterium om de 
keuze voor een  bepaald interferon-vrij regime voor de individuele patiënt te selecteren, aangezien 
niet alle regimes de toevoeging van ribavirine nodig hebben voor een optimaal virologisch effect. De 
vraag blijft echter wel of de associatie tussen ITPase activiteit en anemie ook wordt gevonden indien 
patiënten worden behandeld met interferon-vrij therapie in combinatie met ribavirine.
Het belang van bloedplaatjes werd opnieuw benadrukt in hoofdstuk 4. Naast een verbeterde 
prognose, is SVR herhaaldelijk geassocieerd met vermindering van leverfibrose en portale druk, welke 
verband houden met een gunstige klinische uitkomst.74 78 241-247 269 363-365 Het evalueren van verandering 
in de architectuur van de lever of de hepatische veneuze drukgradiënt vereist invasieve procedures, 
zodat het moeilijk is om meerdere keren deze uitkomsten te evalueren. In hoofdstuk 4 hebben we 
daarom het beloop van bloedplaatjes na antivirale therapie onderzocht bij patiënten met chronische 
HCV infectie en gevorderde leverfibrose. Vooral bij patiënten met gevorderde leverziekte is de hoogte 
van bloedplaatjes een niet-invasieve en objectieve parameter van de mate van portale hypertensie en 
leverfibrose.253 255 256 Eerder zijn de veranderingen in het aantal bloedplaatjes na antivirale therapie in 
verband gebracht met veranderingen in leverfibrose.258 259 Met herhaaldelijke metingen zagen we na 
enkele jaren een aanzienlijke toename van bloedplaatjes, welke lineair bleek te zijn, indien patiënten 
SVR hadden behaald,. Belangrijk is dat de verandering in het aantal thrombocyten gecorreleerd is 
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aan de verandering in miltgrootte, welke een maat is van portale druk. Deze bevindingen wijzen op 
een geleidelijke verbetering van de portal druk en leverhistologie nadat een chronische HCV infectie 
succesvol is behandeld. In tegenstelling tot bij patiënten met SVR, namen de bloedplaatjes verder af 
tijdens de follow-up bij patiënten die zonder succes werden behandeld. 
HET VERANDERENDE LANDSCHAP
Sinds de ontdekking van HCV in 1989 en de implementatie van het screenen van bloedproducten kort 
daarna, werd een significante daling van de overdracht van het virus geconstateerd.11 278-281 Aangezien 
leverfibrose zich langzaam ontwikkelt en patiënten vaak asymptomatisch zijn of niet-specifieke symp-
tomen hebben, blijven veel besmette mensen tot nu onopgemerkt. Als gevolg van veroudering van 
de HCV-geïnfecteerde populatie, wordt verwacht dat ongeveer 25% van de Amerikaanse patiënten 
met chronische HCV infectie levercirrose heeft. Dit percentage zal waarschijnlijk in de komende jaren 
verder toenemen en in 2030 tot 45% zijn gestegen.63 Met de introductie van veilige en effectieve 
interferon-vrij antivirale behandelingen, wordt verwacht dat meer patiënten effectief kunnen worden 
behandeld, zelfs patiënten met gevorderde leverziekte. 
Op basis van historische gegevens werd een model gemaakt voor de huidige en toekomstige 
ziektelast van chronische HCV infectie in Nederland.4 286 287 Aanvullende informatie over de trends 
in de patiënt- en ziektekenmerken van de laatste twee decennia is belangrijk voor de Nederlandse 
gezondheidszorg en voor beleidsmakers om te worden geïnformeerd over de veranderende trends 
in de patiëntenpopulatie met een chronische HCV infectie. Dit geeft informatie over de kenmerken 
van de patiënten die tijdens de komende jaren voor interferon-vrije therapie in aanmerking komen. 
Hoofdstuk 5 beschrijft de epidemiologische veranderingen van de patiënt- en ziektekenmerken van 
1.779 nieuwe patiënten met een chronische HCV infectie die tussen 1990 tot 2013 werden verwezen 
naar een tertiair centrum in Nederland. Zoals verwacht met een verminderde incidentie van chronische 
HCV infectie werden in de laatste jaren patiënten verwezen die ouder waren en vaker gevorderde 
leverfibrose hadden in vergelijking met de patiënten die in de eerste jaren werden verwezen. Ook 
waren de patiënten vaker besmet met HCV genotype 1a. Dit kan mogelijk verklaard worden door de 
lagere kans op genezing bij patiënten met chronische HCV genotype 1a in vergelijking met patiënten 
met chronische HCV genotype 1b, vooral bij behandeling met de eerste generatie proteaseremmers 
telaprevir en boceprevir.298 De oorzaak van dit verschil tussen HCV genotype 1a en 1b is waarschijnlijk 
de resistentie-geassocieerde varianten die aanwezig waren voorafgaand aan de behandeling of 
welke zijn ontstaan  tijdens antivirale therapie.366-369 Hoewel het niet statistisch significant was, werd 
tevens een toename van het aantal patiënten met chronische HCV genotype 3 gevonden. Aangezien 
dit genotype geassocieerd is met een snellere progressie van de ziekte, is deze bevinding erg 
belangrijk.299 Bovendien is de behandeling met interferon-vrije therapie minder effectief bij patiënten 
met HCV genotype 3.
Een andere interessante bevinding was dat 70% van alle patiënten werd geboren tussen 1950 
en 1975. Hoewel screening voor chronische HCV infectie in Nederland door de lage prevalentie van 
de ziekte en bij suboptimale behandelingen niet als kosteneffectief werd beschouwd, moet dit nu er 
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effectieve behandelingen beschikbaar zijn opnieuw worden beoordeeld voor specifieke subgroepen 
met de hoogste prevalentie. Met het oog op de prevalentie en de klinische impact van de ziekte kan 
een effectieve screening strategie de ziektelast van chronische HCV infectie echt verminderen. Om de 
HCV-gerelateerde sterfte te verminderen moeten patiënten, die nog niet op de hoogte zijn van hun 
chronische HCV infectie, worden gediagnosticeerd.370
De goedkeuring van verschillende DAAs leidde tot een discussie over de prijs van deze genees-
middelen. Op dit moment belemmeren de hoge kosten van deze DAAs wereldwijde beschikbaarheid. 
Beleidsmakers worden daarom gedwongen om prioriteit te geven aan het behandelen van patiënten 
die een dringende behoefte hebben aan succesvolle antivirale therapie. Deze situatie is echter 
verre van ideaal, vooral omdat gedacht wordt dat patiënten zonder cirrose het grootste voordeel 
van succesvolle antivirale behandeling hebben.261 Sinds de introductie van DAAs werden steeds 
meer studies verricht die de kosteneffectiviteit van deze geneesmiddelen onderzocht, waarbij 
verschillende conclusies worden gevormd over wie te behandelen en op welke moment.371-374 Om 
de kosten van DAAs in een breder perspectief te plaatsen, hebben we in hoofdstuk 6 de kosten per 
SVR bekeken bij patiënten met gevorderde hepatische fibrose die werden behandeld met interferon-
gebaseerde antivirale therapie. De patiënten die waren geïncludeerd in de studies uit hoofdstuk 1 
en 2, werden ook geïncludeerd in dit onderzoek indien gedetailleerde informatie beschikbaar was. 
Voor de totale studiegroep waren de gemiddelde kosten per SVR €38.514. Deze kosten waren hoger 
voor patiënten met cirrose in vergelijking met patiënten met ernstige fibrose. Indien de hoeveelheid 
bloedplaatjes werd gebruikt als indicator voor de ernst van de leverziekte, bleek dat voor patiënten 
met bloedplaatjes <100x109/l de gemiddelde kosten per SVR €74,961 waren, wat aanzienlijk hoger 
was dan voor patiënten met normale bloedplaatjes bij aanvang van behandeling (€26,105). Deze 
verschillen kunnen waarschijnlijk worden toegeschreven aan de lagere kans op het bereiken van 
SVR in deze subgroepen, wat belangrijk is, omdat dit bij de huidige goedgekeurde interferon-
vrije behandelingen niet het geval is vanwege hoge SVR percentages binnen alle subgroepen van 
patiënten. Rekening houdend met de mogelijke bijwerkingen van de behandeling met interferon en 
de hoge kans op herbehandeling, kunnen de extra kosten per SVR van de DAAs beperkt zijn, vooral 
voor patiënten met de meest ernstige leverziekte. Natuurlijk moeten deze gegevens met terug-
houdendheid worden geïnterpreteerd en niet worden gebruikt om de hoge kosten van de nieuwe 
geneesmiddelen te rechtvaardigen. Om wereldwijd meer patiënten te kunnen behandelen, zouden 
deze kosten aanzienlijk moeten worden verminderd.
HET NIEUWE LANDSCHAP: DIRECT-WERKENDE ANTIVIRALE MIDDELEN
Na de goedkeuring van telaprevir en boceprevir, de eerste DAAs, lieten verschillende studies zien 
dat belangrijke bijwerkingen werden gezien tijdens de behandeling, met name bij patiënten met 
gevorderde leverfibrose.120 121 Gegevens van patiënten die niet worden behandeld in gerandomiseerde 
studies zijn, na de goedkeuring van nieuwe medicijnen, van heel groot belang. De werkzaamheid en 
veiligheid van deze behandelingen zijn namelijk gebaseerd op het behandelen van patiënten die aan 
de strenge criteria voldoen. In hoofdstuk 7 onderzochten we de veiligheid en de effectiviteit van 
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DAA-gebaseerde antivirale therapie bij patiënten met cirrose. Gegevens van vier grote academische 
ziekenhuizen in Canada, Duitsland en Nederland werden gecombineerd. In totaal werden 433 
patiënten met cirrose geïncludeerd, waaronder 114 patiënten met gedecompenseerde cirrose (gede-
finieerd als een Child Pugh B of C). Het totale SVR percentage bedroeg 81% (350/433) en er was 
een trend naar een betere respons bij patiënten met CP A in vergelijking met patiënten met CP B/C 
(264/319 [82.8%] versus 86/114 [75,4% ], p = 0,088). Wat nog belangrijker was, was dat bij 50 (11,5%) 
van de patiënten leverdecompensatie of een verergering van de bestande leverdecompensatie 
optrad tijdens antivirale therapie. Factoren die waren geassocieerd met het optreden van lever-
decompensatie waren HCV genotype 3 (versus niet-genotype 3), Child Pugh B/C (vs Child Pugh A) 
en albumine <35 g/l. Wanneer Child Pugh score werd vervangen door MELD score, vonden we dat 
een MELD score ≥14 was geassocieerd met leverdecompensatie. Indien drie risicofactoren (HCV 
genotype 3, albumine <35 g / l en MELD score ≥14) aanwezig waren, was de cumulatieve incidentie 
voor leverdecompensatie tijdens de eerste 24 weken 75,0% (50,5-99,5%) terwijl de kans op het 
bereiken van SVR 67% bedroeg. Door het bepalen van deze drie parameters, kunnen artsen het 
risico op leverdecompensatie beoordelen, wat moet worden afgewogen tegen de kans op SVR. Men 
zou kunnen stellen dat, wanneer de kans op decompensatie min of meer gelijk is of hoger is dan de 
kans op het bereiken van SVR, het uitstellen van de therapie een betere optie zou zijn. Deze studie 
geeft tevens het belang van HCV genotype 3 aan. Eerdere gegevens hebben aangetoond dat HCV 
genotype 3 is geassocieerd met een snellere progressie naar cirrose, de ontwikkeling van HCC en een 
verminderde algehele overleving.299 335 Onze gegevens tonen aan dat HCV genotype 3 nog steeds 
relevant is bij patiënten met gedecompenseerde cirrose, omdat we vonden dat het ook in verband 
gebracht kon worden met de ontwikkeling of verergering van leverdecompensatie. Gelukkig werden 
de uitkomsten van meer effectieve behandelingen voor HCV genotype 3 onlangs gepresenteerd, 
waarbij meerdere combinaties van nieuwe DAAs mogelijk zijn (sofosbuvir en velpatasvir, vooral met 
de toevoeging van GS-9857 en ABT-493 en ABT-530).168 375-377 De goedkeuring van deze middelen 
moet hoge prioriteit krijgen.
De behoefte aan effectievere therapie voor HCV genotype 3 werd ook beschreven in hoofdstuk 
8. Deze studie was onderdeel van een grote registratiestudie HCV-TARGET en includeerde 197 pa-
tiënten met HCV genotype 3 die werden behandeld met sofosbuvir en ribavirine met of zonder 
toevoeging van gepegyleerd interferon. Van de 178 patiënten die met sofosbuvir en ribavirine werden 
behandeld, bereikte 60% SVR, vergeleken met 84% van de 19 patiënten behandeld met sofosbuvir, 
gepegyleerd interferon en ribavirine. Na gecorrigeerd te hebben voor leeftijd en geslacht, bleken het 
ontbreken van cirrose, albumine ≥3.2 g/dl en bloedplaatjes >100x109/l geassocieerd te zijn met een 
grotere kans op SVR. Hoewel deze studie hier niet voor was opgezet, bleek dat het toevoegen van 
gepegyleerd interferon voor de behandeling van HCV genotype 3 de kans op SVR kan verhogen. Dit 
werd ook aangetoond in een gerandomiseerde gecontroleerde trial waarbij sofosbuvir en ribavirine 
gedurende 16 of 24 weken werd vergeleken met sofosbuvir, gepegyleerd interferon en ribavirine 
gedurende 12 weken bij patiënten met HCV genotype 3.378 Deze studie toonde aan dat het toevoegen 
van gepegyleerd interferon aan sofosbuvir en ribavirine de kans op respons verhoogd binnen alle 
subgroepen, maar vooral bij patiënten met cirrose. Bij deze patiënten steeg de kans op SVR tot 82%, 
met sofosbuvir en ribavirine voor 24 weken, tot 91% met sofosbuvir, gepegyleerd interferon en 
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ribavirine bij de patiënten die niet eerder waren behandeld en van 77% tot 86% bij patiënten die 
al eerder waren behandeld. Gepegyleerd interferon werd goed verdragen en moest slechts bij één 
patiënt vroegtijdig worden gestopt. In onze studie werd hetzelfde gezien. Het aantal bijwerkingen was 
vergelijkbaar binnen de groep met en zonder gepegyleerd interferon en de SVR percentages waren 
hoger in de groep die werd behandeld met gepegyleerd interferon. Ondanks deze bemoedigende 
resultaten, werd binnen HCV-TARGET sofosbuvir, gepegyleerd interferon en ribavirine bij slechts 
19 van de 197 (9,6%) patiënten met HCV genotype 3 infectie voorgeschreven. Het is duidelijk dat 
zowel artsen als patiënten terughoudend zijn om interferon-gebaseerde therapieën te gebruiken. 
Gelukkig hebben recente studies aangetoond dat sofosbuvir in combinatie met velpatasvir, een pan-
genotypische NS5A inhibitor, zeer effectief is voor patiënten met chronische HCV genotype 3 infectie, 
waardoor SVR percentages van 90% werden gevonden, zelfs bij patiënten met cirrose. Ribavirine lijkt 
ook niet langer nodig te zijn met deze nieuwe DAA combinatie.168
Ondanks het feit dat sofosbuvir als zeer veilig wordt beschouwd, is het gebruik ervan niet aan-
bevolen bij patiënten met een geschatte glomerulaire filtratiesnelheid (eGFR) <30 ml/min/1,73m2 
of bij patiënten met eindstadium nierziekte. Dit komt omdat de belangrijkste actieve metaboliet 
van sofosbuvir, GS331007, wordt uitgescheiden door de nieren. Hierdoor worden hogere meta-
boliet concen traties gevonden bij patiënten met een geschatte glomerulaire filtratiesnelheid 
(eGFR) <30 ml/min/1.73m2 of eindstadium nierziekte die hemodialyse ondergaan.346 Hoewel de 
belang rijkste klinische studies over de veiligheid en werkzaamheid van sofosbuvir een uitstekend 
veiligheidsprofiel hebben aangetoond met betrekking tot de nier is het nog niet bekend of dat 
ook geldt in de dagelijkse klinische praktijk. Eerder meldden de registratiestudies van telaprevir en 
boceprevir ook een relatief goed renaal veiligheidsprofiel, terwijl kort na de goedkeuring belangrijke 
gegevens werden gepubliceerd over de toxiciteit van de nieren.344 345 In hoofdstuk 9 werd het 
optreden van nierfunctiestoornissen bekeken tijdens sofosbuvir-gebaseerde antivirale therapie. 
Deze grote studie omvatte 426 patiënten met chronische HCV infectie die werden behandeld met 
sofosbuvir-gebaseerde (n=233) of telaprevir/ boceprevir-gebaseerde (n=193) behandelingen in 
twee tertiaire centra in Noord-Amerika. Het risico op een nierfunctiestoornis was lager voor pa tiën-
ten die werden behandeld met sofosbuvir-gebaseerde behandeling in vergelijking met telaprevir/ 
boceprevir-gebaseerde behandeling. Hoewel nierinsufficiëntie werd waargenomen bij 11% van de 
patiënten behandeld met sofsobuvir-gebaseerde therapie, heeft het een goed renaal veiligheids-
profiel, aangezien nierinsufficiëntie in bijna alle gevallen reversibel was. Patiënten met ascites 
en patiënten die NSAID’s gebruikten, hadden een verhoogd risico op het ontwikkelen van een 
nierfunctiestoornis tijdens sofosbuvir-gebaseerde antivirale therapie. Controle van de nierfunctie en 
de standaard beschermende maatregelen voor de nieren worden aanbevolen bij het gebruik van 
sofosbuvir-gebaseerde regimes, vooral bij patiënten met gevorderde cirrose en portale hypertensie 
of bij patiënten met comorbiditeit met mogelijke gevolgen voor de nieren. Gelukkig hebben twee 
nieuwe behandelopties veelbelovende resultaten aangetoond bij patiënten met nierfalen. Op basis 
van hun beperkte renale excretie zijn grazoprevir en elbasvir en de combinatie van paritaprevir/
ritonavir, ombitasvir en dasabuvir geëvalueerd bij patiënten met gevorderde chronische nierziekte of 
hemodialyse en het blijkt dat deze middelen uiterst veilig en zeer effectief zijn.158 162 
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CONCLUSIES
Met de goedkeuring van meerdere orale DAAs hebben artsen nu de mogelijkheid om een zeer 
effectieve en een zeer veilige antivirale therapie te starten bij patiënten met chronische HCV infectie, 
zelfs bij patiënten met de meest ernstige leverziekte. Hoewel de kosten wereldwijde toegang tot 
deze geneesmiddelen momenteel beperken, heeft een recent onderzoek naar het gebruik van 
generieke DAAs veelbelovende resultaten aangetoond.379 Tot die tijd kan gepegyleerd interferon 
worden gebruikt, gelukkig met een kortere duur dan vóór 2014. Met de juiste controle kunnen zelfs 
patiënten met gecompenseerde cirrose veilig worden behandeld met gepegyleerd interferon. Indien 
nieuwe DAA combinaties niet beschikbaar zijn, kunnen artsen overwegen interferon-gebaseerde 
antivirale therapie te starten, met name bij patiënten met HCV genotype 3, die daadwerkelijk kunnen 
profiteren van deze toevoeging. Chronische HCV infectie is bij uitstek een ziekte die, wat betreft de 
behandeling, een patiënt-specifieke aanpak nodig heeft. Terwijl er bijna geen beperkingen meer 
zijn voor het gebruik van DAAs, hebben sommige patiënten wellicht geen klinisch voordeel van 
succesvolle antivirale therapie, aangezien het natuurlijke beloop van hun ziekte niet meer kan worden 
teruggedraaid. Met de aankomende pangenotypische behandelingen worden behandelingsbesluiten 
vereenvoudigd, hoewel dit niet voor elke patiënt zo zal zijn. Nauwe samenwerking tussen artsen, 
gezondheidsautoriteiten en de farmaceutische bedrijven is dringend nodig om de enorme ziektelast 
van chronische HCV infectie te verminderen. Patiënten moeten worden gediagnosticeerd, verwezen 
en behandeld, zodat het virus volledig uitgeroeid kan worden, vooral omdat we nu een goede kans 
op genezing kunnen bewerkstelligen.
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DANKWOORD
Na iets meer dan 4 jaar mag ik dan eindelijk iedereen bedanken die aan de totstandkoming van dit 
proefschrift heeft bijgedragen. Het is het onderdeel van het proefschrift dat de minste aandacht krijgt, 
maar wel het meest gelezen wordt. Bij deze wil ik mij verontschuldigen, indien ik mensen vergeet te 
bedanken die mij door de jaren heen hebben geholpen. 
Beste Harry (prof. dr. H.L.A. Janssen), dank voor alle steun die ik tijdens deze periode heb mogen 
ontvangen. Het bewaken van de grote lijnen binnen een promotietraject is jou op het lijf geschreven. 
Helaas hebben we maar een half jaar in Rotterdam samengewerkt, maar door de vele afspraken in 
binnen- en buitenland hebben we elkaar goed leren kennen. De mogelijkheden en ruimte die jij mij 
hebt gegeven, hebben ervoor gezorgd dat ik mij op zowel persoonlijk als wetenschappelijk gebied 
heb kunnen ontwikkelen. Voor mij was de periode in Toronto een geweldige ervaring en heb ik 
kunnen zien wat jij daar in korte tijd hebt opgebouwd. Graag kom ik nog eens terug! 
Beste Rob (dr. R.J. de Knegt), dank voor de afgelopen jaren. Vanaf de eerste dag dat wij elkaar ont-
moetten op een bijeenkomst in Berlijn, wist ik dat jij een zeer brede interesse hebt, die ook buiten de 
geneeskunde ligt. Hierdoor waren de besprekingen en diners altijd gezellig en zeer leerzaam. Ik hoop 
dat jij de echografie in Rotterdam nog beter op de (Europese) kaart kan zetten. Het lijkt me prachtig 
om over een aantal jaren bij jou hiervoor in de leer te gaan.
Prof. dr. U.H.W. Beuers, prof. dr. C.A.B. Boucher en prof. dr. R.A. de Man, hartelijk dank voor het plaats-
nemen in de kleine commissie en voor het beoordelen van mijn proefschrift. 
Beste prof. dr. R.A. de Man, nogmaals dank voor het in mij gestelde vertrouwen door mij op te leiden 
tot medisch-specialist Maag-, Darm- en Leverziekten. Onder uw supervisie weet ik zeker dat ik een 
goede Maag,- Darm,- en Leverarts zal worden. Beste dr. H.E. van der Wiel, bedankt dat ik mijn voor-
opleiding Interne Geneeskunde in het IJsselland ziekenhuis mag voltooien. De eerste maanden zijn 
tot nu toe een groot succes. 
Lieve Bettina (dr. B.E. Hansen), wat een gemis voor het Erasmus MC dat jij nu bent vertrokken naar 
Toronto. Ik wil je bedanken voor alle hulp en mooie momenten. Dit proefschrift had niet dezelfde 
kwaliteit gehad zonder jouw expertise. Jij bent de schakel tussen de promovendi en de stafartsen. Ik 
kom graag een keer op bezoek in Toronto!
Dear Heiner (prof. dr. H. Wedemeyer), first of all thank you for being part of the thesis defense com-
mittee. We have met each other multiple times throughout the years and it was always very pleasant, 
but also confronting (Dutch vs German football team). It was also very inspiring to see your way of 
working in Hannover during my last visit. Hopefully we will keep in touch in the future!
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Dear Jordan (dr. J.J. Feld), thank you for being part of the thesis defense committee. Your input in 
almost every chapter in this thesis was of so much value. It was an honor to work with you during my 
stay in Toronto. It was a very fruitful visit, both work-related as well as on a personal level. Maybe Jessie 
Mira and Morris will cross paths one day as well. 
Beste Bart (dr. B.J. Veldt), hartelijk dank voor jouw bijdrage aan dit proefschrift en voor het plaatsnemen 
in de commissie. De besprekingen op dinsdagochtend waren altijd zeer verhelderend. Helaas ben je 
niet meer betrokken geweest bij het laatste gedeelte van dit proefschrift, maar in Delft hebben ze 
daardoor jouw volledige aandacht gekregen. Succes met jouw verdere carrièreplannen. 
I also want to thank all the co-authors and research nurses who contributed to the papers in this thesis 
and who were all of considerable value during the data collection and writing process. 
Marion en Margriet, jullie zijn de spil van de afdeling hepatologie in Rotterdam. Dank voor jullie be-
trok kenheid en inzet bij de laatste loodjes van dit proefschrift. Maar vooral bedankt voor de gezellige 
momenten tijdens de afgelopen vier jaar. Helaas is de roddel & achterklap-app nooit echt van de 
grond gekomen. 
Heleen en Melek, jullie waren de basis van de trialpoli’s op maandagmorgen. Bedankt voor alle leuke 
momenten! Jullie waren geweldige collega’s en de patiënten hebben maar geluk met jullie! Wilma, 
steun en toeverlaat tijdens woensdagmiddag-poli. Bedankt voor de leuke samenwerking. Verder wil 
ik ook alle andere collega’s op de MDL-poli en alle research verpleegkundigen van de afgelopen jaren 
bedanken voor de prettige samenwerking. Iedereen van het Clinical Research Bureau, bedankt! Irene, 
bedankt voor de afgelopen jaren en veel succes met het najagen van jullie droom op de Antillen. 
I also want to thank the Toronto team for their hospitality and warmth during my stay. Especially 
Danie, Eli, Geraldine, Jo-Anne, Matt, Magdalena, Melissa, Orlando and Seham, thank you guys!
Uiteraard wil ik ook iedereen bedanken met wie ik menig lief en leed heb gedeeld op de befaamde 
‘dakpoli’. Zonder de geweldige activiteiten, zoals wintersporten, BDDLs, feestjes, vrijdagmiddagborrels, 
koffiemomenten en bruggenlopen zou het leven van een promovendus toch een stuk saaier zijn. 
Ik ga mij er niet aan wagen om alle namen te noteren van collega’s, want ik ben bang mensen te 
vergeten en dat verdient niemand. Wel wil ik stilstaan bij de hepa’s Heng, Wim, Lisanne (Plompen), 
Ludi en Michelle. Bedankt voor de leuke congressen en etentjes. Marjolein, voorlopig de laatste HCV 
promovenda, bedankt voor de leuke samenwerking. Na mijn verdediging heb ik alle tijd voor jouw 
projecten! Lieve Els, ouwe Feyenoord-hooligan, jouw enthousiasme en interesse zijn ongekend. 
Succes met het afronden van alles. Lieve Maren, wat hebben we een geweldige tijd gehad. Met name 
de weken in Toronto waren heel tof. Jij bent het schoolvoorbeeld van “Work hard, play harder”! Laten 
we snel weer een etentje plannen.
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Niemand kan zonder kamergenoten. Milan, wie had gedacht dat we elkaar na Wolfert op CA-419 
zouden treffen! Bedankt voor de gezelligheid en input tijdens de afgelopen jaren. Helaas hebben 
we maar kort bij elkaar op de kamer gezeten, maar de congressen hebben een hoop goed gemaakt. 
Mede dankzij jouw speurwerk, belandden we altijd op de beste feestjes! 
Lisanne (Holster), jouw gedrevenheid en werkethos werkten zeer aanstekelijk. Altijd tijd voor een 
koffie/thee-moment, waar we de meest uiteenlopende zaken bespraken. Helaas zien we elkaar niet 
zo vaak, maar daar zal snel verandering in komen als we weer samen in het EMC terechtkomen. 
Lieve Margo, de jongste telg van CA-419 (inmiddels ook ex-CA-419). Wat hebben we een mooie tijd 
gehad op de kamer, maar ook op congressen. Ik wens je veel succes met het afronden van je pro-
motie. Blijf zoals je bent!
Tot slot, lieve Eline, het orakel, wat hebben we een geweldige tijd gehad op CA-419 aka de toffe peren-
kamer. Je bent een geweldig mens en ik weet zeker dat je een hele goede huisarts gaat worden. 
Jouw organisatorisch vermogen en betrokkenheid zijn ongeëvenaard. Wat hebben we een hoop 
meegemaakt in de afgelopen jaren. Bedankt dat je er altijd voor me was.
Collega’s uit het IJsselland Ziekenhuis, YSL Masters, in korte tijd voel ik mij al helemaal thuis bij jullie. 
Vanaf nu heb ik meer tijd voor die vrijdagmiddagborrel, zodat we niet alleen maar koffie met elkaar 
drinken. 
Willem Pieter, wat geweldig dat jij, ongeveer een jaar na jouw eigen grote dag, nu achter mij plaats-
neemt. Vanaf dag één wist ik dat ik niet alleen een nieuwe collega had, maar ook een nieuwe dierbare 
vriend. Bedankt voor alle geweldige momenten tot nu toe. Ik weet zeker dat er nog veel meer mooie 
momenten gaan volgen, ook samen met onze kleine mannen. 
Ad, jouw invloed en drive zijn aanstekelijk en hebben een hele grote rol gespeeld bij de ontwikkeling 
van dit proefschrift. Mijn dank is ontzettend groot, je bent een geweldige en unieke vent en ik weet 
zeker dat we de basis hebben gelegd voor een prachtige toekomst, zowel op zakelijk als privé gebied. 
Onze gedeelde passie, ambitie en humor staat centraal in onze vriendschap. Vanzelfsprekend sta jij 
vandaag achter mij.   
BVV six, cinq, quattro, dank voor alle uren van relativering en ontspanning. Ik beloof dat jullie de rest 
van dit seizoen de ‘oude Maan’ weer te zien krijgen. ‘Dakterrastriviantje’, bedankt voor jullie interesse 
in de ‘vergeten ziekte’. De avondjes triviant, waarbij soms niet alle laatjes zich openden, zorgden voor 
de nodige uurtjes vermaak. Laten we snel weer een nieuwe avond plannen! 
Lieve vrienden, bedankt voor alle interesse tijdens de afgelopen jaren. Jullie zijn geweldig! Lieve 
Jeroen, onze onvoorwaardelijke vriendschap heeft ons al veel gebracht. Ik ben trots op je en jouw 
succes inspireert mij enorm. De gesprekken tijdens onze vele lunches zorgden voor een welkome 
afleiding tijdens mijn promotie. Lieve Bob, jij bent het voorbeeld dat je met genoeg discipline kan 
bereiken wat je wilt. Onze vriendschap is mij zeer dierbaar. De week dat jullie in Toronto waren was 
geweldig! Lieve Koen, ook al zien we elkaar niet meer op regelmatige basis, de basis die wij in het 
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verleden hebben gelegd zorgt ervoor dat we nog steeds mooie momenten kunnen delen. Lieve 
Joost, de uurtjes boksen en gezellige avondjes op de Witte de With waren geweldig. Ik beloof weer 
meer tijd vrij te maken voor deze belangrijke momenten. Lieve Rick, wat hebben we al veel mooie 
dingen meegemaakt, van vakken vullen tot voetballen. Jouw eeuwige vrolijkheid is een voorbeeld 
voor iedereen. 
Lieve Niek en Nique, wat ben ik blij dat we zulke goede vrienden zijn! Tot nu toe hebben we veel 
mooie herinneringen kunnen maken en ik weet zeker dat er nog veel meer mooie herinneringen 
gaan volgen. Het was een hele eer om jullie grote dag te regelen en ik kijk er naar uit dat jullie dit in 
2017 voor ons kunnen doen. Lieve Hadewych, het moment dat je mij kwam uitzwaaien op Schiphol 
vergeet ik nooit meer. Je bent een schat!
Dear Canadian family, thank you so much for all the great moments during my visits to Toronto. I 
would never considered going to Toronto if you wouldn’t be around. Thank you, for the great interest 
in my work and for taking care of me. I am sure we will visit Toronto some day! 
Lieve familie, bedankt voor al jullie interesse in mijn werkzaamheden. Lieve opa Frans en oma Wip, 
ook al kunnen jullie vandaag niet meer aanwezig zijn, ik weet zeker dat jullie, net als bij de uitreiking 
van mijn artsenbul, heel trots geweest zouden zijn. Bedankt voor alle liefde en steun die jullie mij in 
het verleden hebben gegeven. Lieve opa Klaas, ook u zou heel trots zijn geweest op deze prestatie. 
Esmee heeft mij nog steeds aardig onder de duim. Bedankt voor alle mooie momenten. Lieve oma 
Bep, wat geweldig dat u dit nog mee kunt maken. Uw eigen doctor in de familie!
Lieve Henny, bedankt voor alle steun en interesse tijdens de afgelopen jaren. Ik heb heel veel respect 
voor de manier waarop jij alles doet en in het verleden hebt gedaan. Ik ken geen vrouw die sterker is 
dan jij. Lieve Jerry, ik weet zeker dat jij het prachtig zou hebben gevonden om hier vandaag te zijn. 
Ook al was het ons niet gegund om elkaar heel goed te leren kennen, toch denk ik dat we in die korte 
tijd genoeg hebben opgebouwd voor de rest van het leven. Lieve Ronald, bedankt voor alle interesse 
en goede gesprekken. Met name de gesprekken over hoe om te gaan met het temperament van de 
Kuppens zijn verhelderend. Je bent een topvent! Lieve Chloé, ik ben ontzettend trots op mijn kleine 
zusje. Geweldig om te zien hoe jij door blijft leren, respect!
Lieve Anoek, wat ben ik trots op je en wat ben ik blij dat jij mijn zus bent. Dankjewel dat je altijd in-
teresse toont in alles wat ons bezighoudt. We hebben een geweldige tijd gehad in Toronto, waar ik 
met veel plezier aan terugdenk. Ik bewonder jouw doorzettingsvermogen en de manier waarop jij 
belangrijke keuzes maakt. Ik leer heel veel van je! Lieve David, ik had mij geen betere zwager kunnen 
bedenken. Jouw pragmatische manier van leven is een voorbeeld voor iedereen. Dankjewel voor de 
gezellige spelletjesavonden en de vele voortreffelijke maaltijden. Ik zou het je niet na kunnen doen!
  
Lieve papa en mama, bedankt voor alle steun en onvoorwaardelijke liefde die jullie mij geven. Jullie 
staan altijd voor ons klaar! Zonder jullie, zou ik niet alles uit het leven kunnen halen. Ik houd van jullie. 
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Lieve mama, jouw betrokkenheid is uniek. Altijd een luisterend oor, waarna vaak de juiste raad. Ik 
hoop dat we nog jaren van elkaar en alle mooie momenten mogen genieten. Lieve papa, wat ben ik 
blij dat jij er vandaag bent. Als er iemand is die altijd voor mij klaar staat dan bij jij het. Nooit te beroerd 
om mij op te halen van Schiphol om daarna door te rijden naar een willekeurig voetbalveld. In juni 
gaan we samen met David die kale berg op fietsen om daar het leven te vieren! 
Lieve Esmee, mijn allerliefste, ik weet niet hoe ik jou moet bedanken. Het geduld dat jij hebt gehad en 
de onvoorwaardelijke steun en liefde die je me hebt gegeven zijn niet in woorden uit te drukken. Jij 
stelde mij in staat om op de meest idiote tijden te kunnen werken en zonder jou was dit proefschrift 
er nooit gekomen. We kunnen nu ook deze mijlpaal aan al onze mooie en minder mooie momenten 
toevoegen. Vanaf vandaag gaan we onze grote dag voorbereiden. Ik kan niet wachten tot de dag 
komt, dat ik jou mijn vrouw mag noemen. 
Lieve Morris, wat ben jij een verrijking. Ons leven is nu nog mooier en leuker dan het al was. Door jou 
sta ik iedere dag met een grote glimlach op. De liefde die jij ons geeft, is niet te beschrijven. We gaan 
een mooie toekomst tegemoet.  
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CURRICULUM VITAE
Raoel Maan werd geboren op 3 december 1985 te Barendrecht. In 2004 behaalde hij zijn tweetalig 
VWO diploma aan het Wolfert van Borselen te Rotterdam. Hierna startte hij met zijn studie Genees-
kunde aan de medische faculteit van de Universiteit Leiden. Hij verkreeg zijn doctoraal in 2008 
nadat hij zijn afstudeeronderzoek naar de waarde van het electrocardiogram bij een myocard 
infarct had afgerond op de afdeling cardiologie van het Leids Universitair Medisch Centrum. Na 
het doorlopen van zijn coschappen, in onder andere het Tygerberg Ziekenhuis te Kaapstad, Zuid-
Afrika, behaalde hij in 2010 zijn artsexamen. Vervolgens werkte hij als basisarts op de afdeling Interne 
Geneeskunde van het Medisch Centrum Haaglanden te Den Haag. Anderhalf jaar later startte hij een 
promotieonderzoek naar de veiligheid van antivirale therapie voor chronische hepatitis C. Dit deed 
hij op de afdeling Maag-, Darm-, en leverziekten onder supervisie van prof.dr. H.L.A. Jannsen en dr. 
R.J. de Knegt. Tijdens deze periode heeft hij een half jaar gewerkt in het Toronto Western Hospital te 
Toronto, Canada, als research-fellow onder begeleiding van prof.dr. H.L.A. Janssen en J.J. Feld. Sinds 
juli 2016 is hij in opleiding tot Maag-, Darm-, en Leverarts in het Erasmus MC (opleider prof.dr. R.A. de 
Man).  Zijn vooropleiding Interne Geneeskunde volgt hij in het IJsselland Ziekenhuis, te Capelle aan 
den IJssel (opleider: dr. H.E. van der Wiel). Hij woont samen met Esmee Kuppen en hun zoon Morris 
in Rotterdam.    
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SUMMARY OF PHD TRAINING AND TEACHING
Name PhD student:   Raoel Maan
PhD period:  June 2012 – June 2016
Erasmus MC Department:  Gastroenterology and Hepatology
Promotor:  prof. dr. H.L.A. Janssen
Co-promotor:  dr. R.J. de Knegt 
      
1. PhD training Year Workload
Courses in Methodology and Biostatistics
Introduction to clinical research, Netherlands Institute for Health Sciences, 
Rotterdam, The Netherlands
2013 24 hours
Regression analysis for clinicians, Netherlands Institute for Health Sciences, 
Rotterdam, The Netherlands
2013 40 hours
10th Course on SNPs & Human Diseases, Molecular Medicine Postgraduate School 2013 40 hours
Research Integrity and Workshops
Basiscursus Regelgeving en Organisatie van Klinisch onderzoek, Erasmus MC, 
Rotterdam
2013 30 hours
UHN Good Clinical Practice – Principles, Toronto Western Hospital, Toronto, Canada 2015 24 hours
Scientific Writing course, Molecular Medicine Postgraduate School 2013 40 hours
Oral Presentations
Effect of thrombocytopenia on treatment tolerability and outcome in patients with 
chronic HCV infection and advanced hepatic fibrosis. Twice annual meeting of the 
Netherlands Association of Hepatology, Veldhoven, the Netherlands.
2013 12 hours
Assessment of noninvasive hepatic fibrosis markers among patients with chronic 
HCV infection and advanced liver disease. Twice annual meeting of the Netherlands 
Association of Hepatology, Veldhoven, the Netherlands. 
2014 24 hours
Liver biopsy for the diagnosis of disease severity among patients with chronic HCV 
infection. 2nd HCV Symposium, Amsterdam, the Netherlands
2014 12 hours
Benefit of attaining SVR. National Hepatitis Day, Amsterdam, the Netherlands. 2015 12 hours
New insights in the treatment of chronic HCV infection; relevance for Nephrology. 
25th Workshop Nephrology, Papendal, the Netherlands. 2015 36 hours
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Poster Presentations
Effect of thrombocytopenia on treatment tolerability and outcome in patients with 
chronic HCV infection and advanced hepatic fibrosis. 
64th Annual Meeting of the American Association for the Study of Liver Diseases 
(AASLD), Washington, DC, United States of America.
2013 32 hours
ITPA polymorphisms are associated with hemoglobin decline during pegylated 
interferon and ribavirin therapy in chronic hepatitis C. 64th  Annual Meeting of the 
American Association for the Study of Liver Diseases (AASLD), Washington, DC, 
United States of America.
2013 32 hours
Incidence and risk factors for infections during interferon-based treatment of chronic 
hepatitis C patients with advanced hepatic fibrosis. 49th Annual Meeting of the 
European Association for the Study of the Liver (EASL), London, United Kingdom.
2014 32 hours
DDRGK1 variants are associated with platelet decline during peginterferon and 
ribavirin therapy in Caucasian patients with chronic HCV infection. 65th Annual 
Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, 
MA, United States of America.
2014 32 hours
Assessment of noninvasive hepatic fibrosis markers among patients with chronic 
HCV infection and advanced liver disease. 65th Annual Meeting of the American 
Association for the Study of Liver Diseases (AASLD), Boston, MA, United States of 
America.
2014 32 hours
Epidemiological trends among patients with chronic HCV infection in a tertiary 
center in the Netherlands. 50th Annual Meeting of the European Association for the 
Study of the Liver (EASL), Vienna, Austria.
2015 32 hours
Hepatocellular carcinoma has a more aggressive disease course in patients with HCV 
genotype 3 compared to other genotypes. 66th Annual Meeting of the American 
Association for the Study of Liver Diseases (AASLD), San Francisco, CA, United States 
of America.
2015 32 hours
Safety of DAA-based therapy for the treatment of patients with chronic hepatitis C 
virus infection and cirrhosis: results from an international multicenter cohort study. 
51st Annual Meeting of the European Association for the Study of the Liver (EASL), 
Barcelona, Spain. 
2016 32 hours
HCV therapy selector webapp: an uniquely simple tool for evidence-based therapy 
selection for patients with chronic hepatitis C virus infection. 67th Annual Meeting of 
the American Association for the Study of Liver Diseases (AASLD), Boston, MA, United 
States of America.
2016 32 hours
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Attended (inter)national conferences
Twice annual meeting of the Dutch Association of Hepatology, Zeist, the 
Netherlands.
2012 12 hours
The Liver Meeting 2012, 63rd Annual Meeting of the American Association for the 
Study of Liver Diseases (AASLD). Boston, MA, United States of America.
2012 28 hours
48th Annual Meeting of the European Association for the Study of the Liver (EASL). 
Amsterdam, The Netherlands.
2013 28 hours
Twice annual meeting of the Dutch Association of Hepatology, Veldhoven, the 
Netherlands.
2013 12 hours
The Liver Meeting 2013, 64th Annual Meeting of the American Association for the 
Study of Liver Diseases (AASLD). Washington, DC, United States of America.
2013 28 hours
49th Annual Meeting of the European Association for the Study of the Liver (EASL). 
London, United Kingdom.
2014 28 hours
The 3rd world congress on controversies in the management of viral hepatitis. Berlin, 
Germany.
2014 20 hours
Twice annual meeting of the Dutch Association of Hepatology, Veldhoven, the 
Netherlands.
2014 12 hours
The Liver Meeting 2014, 65th Annual Meeting of the American Association for the 
Study of Liver Diseases (AASLD). Boston, MA, United States of America.
2014 28 hours
50th Annual Meeting of the European Association for the Study of the Liver (EASL). 
Vienna, Austria.
2015 28 hours
Twice annual meeting of the Dutch Association of Hepatology, Veldhoven, the 
Netherlands.
2015 12 hours
The Liver Meeting 2015, 66th Annual Meeting of the American Association for the 
Study of Liver Diseases (AASLD). San Francisco, CA, United States of America.
2015 28 hours
The Liver Meeting 2016, 67th Annual Meeting of the American Association for the 
Study of Liver Diseases (AASLD). Boston, MA, United States of America.
2016 28 hours
Attended seminars and workshops
4th Lagerhuisdebat Hepatitis B en C. Utrecht, The Netherlands 2012 3 hours
28th Erasmus Liver day. Rotterdam, The Netherlands 2013 6 hours
11th Post-AASLD symposium. Rotterdam, The Netherlands 2013 2 hours
5th Lagerhuisdebat Hepatitis B en C. Utrecht, The Netherlands 2013 3 hours
29th Erasmus Liver day. Rotterdam, The Netherlands 2014 6 hours
12th Post-AASLD symposium. Rotterdam, The Netherlands 2014 2 hours
6th Lagerhuisdebat Hepatitis B en C. Utrecht, The Netherlands 2015 3 hours
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30th Erasmus Liver day. Rotterdam, The Netherlands 2015 6 hours
3rd Post-EASL symposium, Amsterdam, The Netherlands 2016 3 hours
Reviewing for scientific journals
Including Hepatology, Journal of Hepatology, Liver International, AP&T, Drugs, PLoS 
One, Infectious Diseases, European Journal of Gastroenterology and Hepatology, 
Expert Review of Gastroenterology & Hepatology
40 hours
2. Teaching Year Workload
Lecturing
Diagnostics and treatment of chronic hepatitis C, Masterclass viral hepatitis, Erasmus 
Medical Center, Rotterdam, The Netherlands
2013 6 hours
Diagnostics and treatment of chronic hepatitis C, Masterclass viral hepatitis, Erasmus 
Medical Center, Rotterdam, The Netherlands
2015 6 hours
Chronic HCV infection, 2nd year curriculum Medicine, Erasmus University Rotterdam, 
Rotterdam, The Netherlands
2016 6 hours
Supervision
Supervision of graduation thesis of Esther Zoutendijk, Master of Health Sciences, 
Infectious Diseases and Public Health
2014 60 hours
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